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Abstract 
Colorectal cancer is the second most common cause of cancer death in the Western World.  
Although staging and prognosis is presently based on pathological assessment of primary 
tumour invasion and the presence of lymph node and distant metastases, it is increasingly 
recognised that other factors pertaining to both the tumour and host may similarly affect 
outcome. The local and systemic environment, encompassing host inflammatory responses 
and the tumour microenvironment, are examples of such.  However, how such measures 
may compliment present TNM-based staging are not clear.  Furthermore, tumour and host 
factors, both modifiable and non-modifiable, which may determine the local and systemic 
environment, remain to be fully determined.  
The present thesis examined the clinical and prognostic utility of assessment of the local 
and systemic environment, and potential tumour and host factors which may determine 
these responses. The following conclusions were drawn: 
Examining patients from the United Kingdom and Japan, Chapter 2 and 3 concluded that 
assessment of the systemic inflammatory response, utilising the modified Glasgow 
Prognostic Score, provides further prognostic stratification in addition to TNM stage.  
Although the proportion of patients exhibiting an elevated systemic inflammatory response 
differed between populations, the prognostic value was comparable.  
Chapter 4 validated assessment of the tumour stroma percentage as a prognostic factor 
independent of TNM stage and the local inflammatory cell infiltrate (cancer-specific 
survival HR 1.84, 95% CI 1.17-2.92, P=0.009).  Chapter 7 further confirmed the 
prognostic value of a combined tumour microenvironment score, based on assessment of 
the generalised inflammatory cell infiltrate and tumour stroma percentage, in patients with 
primary operable colorectal cancer.  This score, termed the Glasgow Microenvironment 
Score, was able to stratify patients into a good prognostic group, with five-year survival of 
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89%, an intermediate group with a two-fold increased risk of death and five-year survival 
of 75%, and a poor prognostic group, with a four-fold increased risk of death and five-year 
survival of 51%.   
Chapters 5 and 6 identified the presence of mismatch repair deficiency and activation of 
the JAK/STAT3 as two potential mechanisms which may determine host local and 
systemic inflammatory responses.  However, the prognostic value of such candidate 
mechanisms was weak, suggesting that other pathways and tumour characteristics are 
implicated, and that molecular heterogeneity is likely to play an important role in 
determining not only the local and systemic environment, but also outcome. 
Chapter 9 concluded that the Immunoscore, an immunohistochemistry-based assessment of 
T-lymphocyte density within the tumour microenvironment, held greater prognostic value 
than assessment of the generalised inflammatory cell infiltrate using the Klintrup-Mäkinen 
grade.  However, assessment of tumour stroma percentage provided additional prognostic 
value irrespective of the methodology employed to examine the local inflammatory cell 
infiltrate.  Furthermore, the results of Chapters 7, 8 and 9 together suggested that loss of 
the local, anti-tumour immune infiltrate was the primary event which allows continued 
tumour growth, development of a tumour-supportive microenvironment and propagation of 
a systemic inflammatory response. 
Chapter 10 concluded that pre-diagnosis use of aspirin but not statins was associated with a 
lower modified Glasgow Prognostic Score, despite strong associations with comorbidity 
and BMI.  This did not translate into an improvement in survival, potentially reflecting the 
underlying indication for use of these drugs primarily as cardiovascular secondary 
prevention medications. 
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Finally, Chapter 11 examined the clinical utility of assessment of the tumour 
microenvironment using colonoscopic biopsy specimens, concluding that the use of 
biopsy-derived specimens was feasible.  Furthermore, in addition to identifying patients 
who may benefit from therapies targeting the tumour microenvironment, assessment of a 
biopsy-derived Glasgow Microenvironment Score had comparable prognostic value to full 
section assessment of the tumour microenvironment.  
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Summary 
Colorectal cancer is common, with over 1 million cases each year globally.  Although 
advances in staging, surgical technique and chemotherapeutics have led to improvements 
in survival, approximately half of patients undergoing potentially curative resection die 
within five years.  Currently, staging, prognosis and need for adjuvant treatment is based 
on pathological assessment of the tumour using the TNM staging system.  In addition, 
other high-risk tumour characteristics, such as venous invasion, may predict increased risk 
of recurrence.  It is clear however that current staging is inadequate and may fail to stratify 
risk effectively.  As such, there is a need to identify other tumour and host characteristics 
which may be used to determine prognosis and guide treatment. 
One such approach is assessment of the local and systemic environment, encompassing 
amongst other things the host inflammatory response and the tumour microenvironment.  It 
is recognised that the presence of a conspicuous inflammatory cell infiltrate is a good 
prognostic factor independent of TNM staging.  Several measures of the local 
inflammatory response have been proposed; whereas the Klintrup-Mäkinen grade provides 
a measure of the generalised inflammatory infiltrate, the Immunoscore is a more detailed 
measure of the predominantly cytotoxic T-lymphocytic response.  Conversely, elevated 
systemic inflammatory responses, as measured by acute phase reactants and differential 
white cell count, are associated with poorer survival.  One such systemic inflammatory 
response-based score, the modified Glasgow Prognostic Score, has been validated and 
reported internationally as a stage-independent marker of poor prognosis. 
However, how such measures may be utilised in combination with current staging is not 
clear.  In addition, how other components of the tumour microenvironment, such as the 
tumour-associated stroma, may relate to the local and systemic inflammatory response, and 
outcome, is unknown.  Tumour and host characteristics, including anti-inflammatory drug 
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use, which may determine the local and systemic environment have not been fully 
determined.  Finally, the feasibility of pre-operative assessment of the tumour 
microenvironment has yet to be established.  The aim of the present thesis was to examine 
these questions. 
Chapter 2 examined the prognostic value of combined assessment of the modified Glasgow 
Prognostic Score and TNM stage in patients with non-metastatic colorectal cancer.  Using 
this combination, it was possible to identify patients with lymph node negative disease 
with poorer survival than those with lymph node positive disease.  Furthermore, in patients 
with stage III colon cancer, it was possible to identify patients less likely to benefit from 
adjuvant chemotherapy. 
Chapter 3 examined the prognostic value of the modified Glasgow Prognostic Score in two 
cohorts of patients from the United Kingdom and Japan.  When compared to a cohort of 
patients from Japan, it was found that patients from United Kingdom were more likely to 
be systemically inflamed, even after controlling for clinicopathological characteristics 
determined to be associated with the presence of a systemic inflammatory response.  Of 
interest however, the modified Glasgow Prognostic Score had similar prognostic value in 
both cohorts. 
In Chapter 4, the relationship between tumour stroma percentage, other components of the 
tumour microenvironment and survival was examined.  Although inversely associated with 
the local inflammatory cell infiltrate, tumour stroma percentage remained an independent 
prognostic factor, suggesting that it may be of complimentary value to measures of the 
local inflammatory cell infiltrate. 
In Chapter 5 and 6, the relationship between mismatch repair status, STAT3 expression 
and the local and systemic environment were examined.  It was found that both local and 
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systemic inflammatory responses were associated with mismatch repair deficiency, 
although both remained independently associated with survival irrespective of mismatch 
repair status.  STAT3 expression was associated with loss of the local inflammatory cell 
infiltrate and elevated systemic inflammatory responses, however STAT3 itself was not 
independently associated with survival.  These results again highlight the complex nature 
and multitude of factors underpinning the local and systemic environment. 
Chapter 7 examined the prognostic value of a novel tumour microenvironment-based 
score, encompassing the Klintrup-Mäkinen grade and tumour stroma percentage.  This 
score, termed the Glasgow Microenvironment Score was able to stratify survival greater 
than either measure alone.  Furthermore, the associations between the components of this 
score suggest that it is loss of the local anti-tumour immune response which allows 
subsequent development and expansion of a tumour-supporting stroma. 
Chapter 8 found that increasing tumour invasiveness, as measured by T stage, was 
associated with the development of a pro-tumour local and systemic environment.  Similar 
to the results of Chapter 6, it was found that loss of the local inflammatory cell infiltrate 
preceded tumour stroma expansion and development of a systemic inflammatory response, 
again suggesting that loss of the local immune response is an important driver of disease 
progression.  Furthermore, it was found that such measures at both a local and systemic 
level have similar if not greater prognostic value compared to current lymph node-based 
staging. 
In Chapter 9, two different measures of the local inflammatory cell infiltrate, the 
Immunoscore and Klintrup-Mäkinen grade, were compared.  It was found that the 
Immunoscore had greater fidelity with respect to determining prognosis of patients.  
Despite this, the addition of tumour stroma percentage still stratified survival greater than 
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either measure alone, again supporting the rationale for a comprehensive assessment of the 
tumour microenvironment as opposed to assessment of individual components alone. 
In Chapter 10, it was found that aspirin but not statin use was associated with lower levels 
of systemic inflammation at time of diagnosis.  Aspirin use was however not associated 
with improved survival.  As these drugs were primarily prescribed for cardiovascular 
secondary prevention, it is likely that any oncological benefit in this patient group will be 
underestimated due to the high level of comorbidity associated with aspirin and statin use. 
Chapter 11 examined the clinical utility of pre-operative assessment of the tumour 
microenvironment utilising colonoscopic biopsies.  Both the local inflammatory cell 
infiltrate and tumour stroma percentage could be measured using biopsy specimens, with 
diagnostic accuracy of the former improved by the use of digital automated pathology.  
Furthermore, a derived, biopsy-based Glasgow Microenvironment Score had similar 
prognostic value to more conventional, full section based assessment of the tumour 
microenvironment in patients with colorectal cancer. 
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1 Introduction 
1.1 Epidemiology of colorectal cancer 
Colorectal cancer is common, with an estimated 1.2 million cases worldwide in 2008 (1, 
2).  Globally, it is the second most common cancer in females with over 570,000 cases in 
2008, and the third most common cancer in males with over 663,000 cases.  It is more 
common in developed countries, with the highest incident rates in Europe, Australia and 
New Zealand and Northern America (1).  Although incidence is generally lower in 
developing countries, particularly Africa and South-Central Asia, rates of colorectal cancer 
are increasing in countries with historically low incidence rates.  In 2008 there was an 
estimated 608,700 deaths from colorectal cancer (1). 
In 2008, colorectal cancer was the most common cancer across Europe, with an estimated 
436,000 incident cases, accounting for 13.6% of all cases of cancer (2).  In 2009, it was 
estimated that the economic cost of colorectal cancer across the European Union was over 
EU €13 billion (3).  The incidence of colorectal cancer in Europe has increased over the 
past two decades, particularly in males and in Central Europe (4).  
In the United Kingdom, colorectal cancer is the fourth most common cancer overall, with 
37,600 cases registered in 2008 (2).  It is the third most common cancer in females behind 
breast and lung cancer, and the second most common cancer in males behind prostate 
cancer.  Similar to much of the rest of Europe, the incidence of colorectal cancer has 
increased over past decades (5), however even across the United Kingdom, there is 
significant geographical variation in the incidence of colorectal cancer, with the highest 
rates observed in Scotland and Northern Ireland and the lowest rates in England.  Whereas 
the age-standardised incidence rate across the United Kingdom is 47 cases per 100,000, 
this varies from approximately 53 cases per 100,000 in Scotland and Northern Ireland to 
46 cases per 100,000 in England (5).  Furthermore, incident rates for colorectal cancer are 
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greatest amongst more deprived areas, predominantly due to an increased incidence rate 
amongst males (6). 
The incidence of colorectal cancer also varies by sex and age.  Males have a higher 
incidence of colorectal cancer, predominantly due to an increase in the incidence of rectal 
cancers.  In 2012, females accounted for 18,160 registered cases of colorectal cancer with 
an age-standardised incidence rate of 37 cases per 100,00, compared to 22,600 cases and 
an age-standardised rate of 56 cases per 100,000 in males (7). Similar disparity in temporal 
trends for colorectal cancer incidence also exist; whereas the European age-standardised 
incidence rate for males has increased by 29% between 1975-1977 and 2009-2011, it has 
only increased by 7% in females over the same period (5).  In addition, the incidence of 
colorectal cancer is strongly associated with age, with 95% of colorectal cancers in the 
three years up to 2011 diagnosed in patients aged 50 and over (5).  Although between the 
ages of 45 and 85 the incidence of colorectal cancer is greater in males than females, above 
the age of 85 the incidence is greater in females due to the larger, at risk, female 
population. 
Overall, colorectal cancer is the second most common cause of cancer death in the United 
Kingdom (8).  It is the third most common cause of cancer death in females, with 7,470 
deaths in 2012 and an age-standardised mortality rate of 14 deaths per 100,000; similarly it 
is the third most common cause of cancer death in males, with 8,730 deaths in 2012 and a 
rate of 21 deaths per 100,000 (7).  Consistent with incidence, there is geographical 
variation in colorectal cancer mortality rates across the United Kingdom, with higher 
mortality rates in Scotland for both males and females compared to England (8); whereas 
the European age-standardised mortality rate across the United Kingdom is 16.3 per 
100,000, this varies from 19.2 to 15.9 deaths per 100,000 population in Scotland and 
England respectively.  Deprivation also influences mortality from colorectal cancer, with a 
30% higher mortality for males and 15% higher mortality for females from deprived areas 
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(8).  Mortality rates have improved over time, with an overall decrease since the 1970s (8).  
In the ten years leading up to 2012 for example, the mortality rate amongst females 
decreased by 15% and for males decreased by 12%.
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1.2 Colorectal carcinogenesis 
Rather than being one distinct entity, colorectal cancer is a heterogeneous disease arising 
from a number of different molecular and genetic pathways.  A prerequisite of 
carcinogenesis is the development of genetic instability, which is critical for the rapid 
accumulation of mutations required for cancer to develop (9).  The chromosomal 
instability pathway, described by Vogelstein and Fearon in 1988 (10), is now thought to be 
too simplistic and may only describe carcinogenesis in around 85% of cases of colorectal 
cancer.  Indeed, it is now recognised that at least three distinct molecular subtypes resulting 
in genetic instability exist; the chromosomal instability pathway (CIN), the microsatellite 
instability pathway (MSI), and the CpG island methylation pathway (CIMP).  Although in 
reality these pathways may co-exist in some cancers (11), they remain a useful backbone 
for the molecular characterisation of patients with colorectal cancer.  
1.2.1 Chromosomal instability pathway 
Invasive colorectal carcinoma develops from non-invasive, precursor adenomatous polyps, 
with an accumulation of specific mutations occurring in tandem with this pathway (Figure 
1.1).  This traditional ‘adenoma-carcinoma sequence’ as described by Vogelstein and 
Fearon, is characterised by aneuploidy and a number of common mutations which appear 
to occur at specific time points in the transition from adenoma to carcinoma (12, 13).  For 
example, loss of the adenomatous polyposis coli (APC) gene, either through mutation or 
loss of chromosome 5q, appears to occur at an early stage and can be observed in as many 
as 80% of early adenomata (14).  In addition to the deleterious effects of loss of its tumour 
suppressor function, APC loss also disrupts mitosis further contributing to CIN (15).  In 
contrast, loss of the tumour suppressor gene p53, usually through loss of chromosome 17p, 
is often a late event heralding the transition from a non-invasive to invasive lesion.  Indeed, 
whereas p53 loss may only be observed in less than a quarter of early adenomata, it has 
been observed in between 50-75% of colorectal carcinomas (13).  Intermediary steps have 
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been described by Vogelstein, including KRAS mutations and loss of chromosome 18q.  It 
has however been observed that these steps may not always occur in the same order, and 
indeed in some cases may not occur at all (9).  Although the above ‘traditional pathway’ 
does not fully explain the complexity of carcinogenesis arising through the CIN pathway, it 
is nonetheless thought that approximately 80% of colorectal cancers develop through this 
mechanism. 
 
Figure 1.1 The adenoma-carcinoma sequence in sporadic colorectal cancer, displaying key 
molecular and genetic events which occur in the transition from non-invasive lesion to 
invasive cancer.  Adapted from Walther, Johnstone et al. (11) 
 
1.2.2 Microsatellite instability pathway 
By the mid 1990s, it was recognised that up to 20% of tumours, including both hereditary 
and sporadic, arose via the MSI, or mutator, pathway (16).  The molecular hallmark of 
tumours arising through this pathway is loss of function of the mismatch repair (MMR) 
protein machinery which normally rectifies DNA replication errors.  These frameshift 
mutations commonly occur in repetitive nucleotide sequences known as microsatellites, 
many of which exist within key genes associated with carcinogenesis.  Loss of MMR 
protein function may be a result of germline mutations, as observed in Hereditary Non-
Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome, where hMSH2 and hMLH1 are 
the most commonly affected genes.  Approximately 15% of sporadic colorectal cancers 
may also arise through MSI, which usually occurs through epigenetic silencing of hMLH1, 
in turn leading to mutations within other MMR protein encoding genes (9). 
  38 
Tumours arising through the MSI pathway display a distinct phenotype; they are 
predominantly right-sided, poorly differentiated or displaying mucinous differentiation, 
and are often considered less likely to metastasise (17-19).  Furthermore, the tumour 
microenvironment of MSI tumours is often replete with tumour infiltrating lymphocytes 
(20).  Such characteristics may be used to identify tumours which should be further 
assessed for MSI. 
Detection of MSI may be performed by examining for instability within a panel of two 
mononucleotide (BAT25, BAT26) and three dinucleotide microsatellites (D2S123, 
D5S346, D17S250) known as the Bethesda panel (21).  Tumours are defined as MSI if 
mutations are identified in at least two of the specified sites, and defined as microsatellite 
stable (MSS) if no mutations are identified.  Tumours with a mutation within one site are 
termed as MSI-low, and are often categorised alongside MSS tumours, however may 
represent another distinct molecular entity.  As testing for MSI is expensive, screening for 
loss of mismatch repair proteins using immunohistochemistry (IHC) may be an acceptable 
alternative (22), with tumours found to be MMR deficient considered for subsequent 
genetic sequencing for MSI. 
1.2.3 CpG island methylation pathway 
Epigenetic silencing of gene transcription by DNA methylation is an important 
homeostatic mechanism.  It has been associated with the development of sporadic 
colorectal cancer in approximately 20% of cases (23), with hypermethylation of cytosine 
and guanine dinucleotide base pairs within gene promoter regions effectively ‘switching 
off’ tumour suppressor genes (9).  Identification of CIMP tumours can be performed 
through assessment of the methylation status of specific gene promoter regions (24).  
Hypermethylation is commonly associated with a number of other molecular 
characteristics, such as mutated BRAF status, and has been shown to overlap with the MSI 
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pathway, with hypermethylation of hMLH1 the driver event in the majority of sporadic 
MSI cases (25). 
Similar to the MSI pathway, CIMP-associated tumours display typical phenotypic 
characteristics, including proximal location and an improved prognosis (11).  Furthermore, 
whereas the precursor lesion in CIN and MSI-associated colorectal cancer is the 
adenomatous polyp, CIMP colorectal cancer is thought to arise from serrated hyperplastic 
polyps (23).
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1.3 Aetiology of colorectal cancer 
Colorectal cancer develops through an accumulation of genetic mutations over a prolonged 
period of time.  Approximately 80% of cases are sporadic, developing through a complex 
interaction of environmental, host and genetic factors.  Although 20% of patients will have 
a family history of colorectal cancer in a first-degree relative, an underlying inherited 
genetic condition is only identifiable in around 5% of all cases (26-28).  
1.3.1 Environmental factors 
It is now appreciated that environment plays an important role in the development of 
sporadic colorectal cancer.  The role of environmental factors in colorectal cancer 
aetiology is supported by the vast differences in disease incidence across different 
geographical regions (29).  In addition, migrants from regions with a low incidence of 
colorectal cancer moving to regions with a higher incidence experience an increase in risk 
within a generation (30, 31).  Many of these factors, such as diet and sedentary lifestyle, 
are commonly perceived as part of Western culture; adoption of such traits in transitioning 
nations is thought to be responsible for the sharp rise in incidence in these countries (29, 
32).  
Dietary fibre 
Burkitt first hypothesised an association between low dietary fibre intake and cancer risk in 
1971 (33).  The protective effect of dietary fibre is likely to be multifactorial, and in part 
may be due to decreased colonic transit time and dilution of carcinogenic compounds as a 
result of increased stool bulk (34).  Furthermore, fermentation of dietary starch to butyrate 
and other short-chain fatty acids may promote cell cycle arrest, apoptosis and 
differentiation of colonocytes (35). 
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The results of prospective cohort studies suggest a protective effect of fibre on colorectal 
cancer incidence.  The EPIC study, which included over 500,000 individuals over ten 
European countries, identified a 21% reduction in risk of colorectal cancer in those with 
the highest intake of dietary fibre compared to those with the lowest after controlling for 
folate intake (36).  Further follow-up of the EPIC study cohort, with a mean follow-up of 
11 years and accrual of 4,517 cases of colorectal cancer, further confirmed the protective 
benefit of dietary fibre, with an estimated 13% reduction in risk for every 10g increase in 
daily fibre intake (37).  Subsequent meta-analysis of prospective observational studies, 
performed in association with the Continuous Update Project of the World Cancer 
Research Fund, has confirmed a similar dose-response relationship, particularly for fibre 
derived from cereals and whole grains (38). 
Red and processed meat 
The Second Expert Report of the World Cancer Research Fund recognised that red meat 
and processed meat (preserved by smoking, curing, salting or chemical preservation) was 
associated with a significant increase in the risk of colorectal cancer (39).  The underlying 
mechanism is likely multifactorial, but involves exposure to carcinogenic compounds 
following cooking at high temperatures as well as following digestion.  Furthermore, free 
iron from haem can promote free radical synthesis. 
Following the Second Expert Report, additional prospective studies have further confirmed 
the association between both red and processed meats and colorectal cancer risk (40).  A 
recent meta-analysis of ten prospective studies found a relative increase in risk of 17% for 
every 100g/day of red meat and an increase in risk of 18% for every 50g/day of processed 
meat consumed (40). 
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Calcium and Vitamin D 
Increasingly calcium supplementation and, to a lesser extent, vitamin D supplementation, 
has been recognised as potentially protective against risk of colorectal cancer (41).  
Although this may reflect the importance of calcium as an intracellular second messenger 
and its role in the homoeostasis of proliferation and apoptosis, it has been hypothesised 
that the protective effects may be mediated by attenuation of tumour-associated 
inflammation (42).  Given their inextricable association, it is difficult to ascertain the 
independent effect of calcium and vitamin D supplementation on colorectal cancer risk, 
however it is likely that any effect of vitamin D is mediated by the protective effects of 
calcium (41).  Similarly, the perceived benefit of milk is likely due to dietary calcium 
supplementation. 
Alcohol 
Alcohol intake is associated with increased colorectal cancer risk.  The EPIC study 
estimated an 8% increase in risk for every 15g/day intake (36).  A differential effect may 
exist, with a higher risk for beer compared to wine.  Furthermore, the risk may be greater 
in males, however this may be a surrogate for greater alcohol intake and choice of 
beverage (39).  The relationship between alcohol intake and colorectal cancer risk displays 
a U-shaped curve, as it has previously been reported that moderate alcohol intake may 
reduce risk of colorectal cancer (42) 
1.3.2 Host Factors 
Age 
Age is the biggest single risk factor for the development of colorectal cancer, with 95% of 
cancers diagnosed in patients over the age 50 (5).  Increasing age allows for prolonged 
exposure to environmental and host risk factors.  Furthermore, older age is associated with 
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telomere attrition and the accumulation of epigenetic changes, both of which predispose to 
increased mutational burden and carcinogenesis (43, 44). 
Smoking 
Smoking is associated with an increased risk of colorectal adenoma and carcinoma (45-
48).  Follow-up from the Nurses’ Health Study and Health Professionals Follow-up Study 
suggested a 50% increased risk in females and almost two-fold increase in risk in males of 
colorectal cancer following a 35-year history of smoking, indicating the prolonged time 
taken for adenoma and carcinoma development (45, 46). 
Physical activity 
An increasingly sedentary lifestyle is a contributory factor to a number of common non-
communicable diseases, and physical inactivity is thought to be a causative factor in as 
much as 10% of the worldwide burden of colorectal cancer (49).  A meta-analysis of 21 
studies found a reduction of approximately 25% in the risk of both proximal and distal 
colon cancer in the most physically active subjects when compared to the least active (50), 
however it is unclear if physical activity reduces the risk of rectal cancer (41).  An increase 
in both recreational and total (i.e. occupational) physical activity has been found to be 
beneficial.  An increase in total physical activity to the equivalent of 5 metabolic 
equivalent tasks for an hour per day (comparable to moderate intensity gardening), is 
associated with a 3% reduction in risk of colorectal cancer (41).  The effect of physical 
activity on colorectal cancer risk is likely to be multifactorial; in addition to favourable 
effects on weight, body composition and gut motility, exercise also regulates insulin 
sensitivity and immune function. 
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Inflammatory bowel disease 
Colorectal cancer risk is increased in the presence of longstanding inflammatory bowel 
disease (IBD), accounting for approximately 1% of all reported cases (51).  The presence 
of ulcerative colitis is associated with a five to ten-fold increase in risk of colorectal cancer 
in comparison to age-matched controls (52), and risk is associated with cumulative 
exposure to colonic inflammation; whereas risk of colorectal cancer is 2% after 10 years 
duration of colitis, this increases to 18% following 30 years (51).  Patients with Crohn’s 
disease affecting the colon have a similar risk of colorectal cancer to those with ulcerative 
colitis (52). 
Given the association between increased duration of mucosal inflammation and colorectal 
cancer risk, it is thought that chronic inflammation is the predominant driver of 
carcinogenesis in patients with IBD-associated colorectal cancer (53), with several key 
inflammatory pathways implicated in the development of colitis-associated colorectal 
cancer (54).  Although a similar mutational burden can be seen in sporadic and IBD-
associated colorectal cancer, the timing of these events is often altered, with p53 mutations 
often occurring at a much earlier stage than in sporadic cancer (53). 
Given the increased risk of colorectal cancer, it is advised that patients with IBD undergo 
colonoscopic surveillance for neoplastic disease.  An initial colonoscopy should be offered 
after 10 years of disease activity (55), with the interval of subsequent examinations 
determined by risk stratification (53).  Colonoscopic surveillance identifies patients with 
colorectal cancer at an earlier disease stage, however it is unclear what benefit this may 
ultimately have on survival, with any perceived benefit presumed to be secondary to lead-
time bias (52).  More recent studies however have suggested a survival benefit for routine 
colonoscopic screening of patients with IBD (56). 
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Obesity and the metabolic syndrome 
Obesity is associated with increasing risk of colorectal neoplasia, including cancer.  
Whereas overall body fatness is associated with increasing risk (2% increase in risk per 
kg/m2 (41)), abdominal fatness is associated with an even greater risk, reflecting the higher 
metabolic activity of visceral fat (41).  The relationship between obesity and colorectal 
cancer risk is multifactorial, and in part reflects the pro-inflammatory state associated with 
obesity as well as the effect of adipocytes on sex hormone production.  
Visceral obesity is also recognised as a component of the metabolic syndrome, a spectrum 
of metabolic and physiological risk factors including obesity, insulin resistance, 
hypertension, and atherogenic dyslipidaemia (57, 58).  The metabolic syndrome is 
associated with increased risk of colorectal cancer, primarily through growth-promoting 
effects of insulin resistance and insulin-like growth factor-1 secretion, and the propagation 
of a pro-inflammatory state. 
Cardiovascular disease 
Patients with cardiovascular disease are at increased risk of colorectal neoplasia, including 
cancer, when compared to the general population.  In addition to patients with 
symptomatic coronary and peripheral arterial disease (59, 60), it has also been shown that 
the detection of asymptomatic, screen-detected coronary artery disease also confers 
increased risk of colorectal neoplasia (61).  Although this is likely due to shared risk 
factors for both diseases, the chronic inflammatory state associated with cardiovascular 
disease may also predispose to development of colorectal cancer.  
Systemic inflammation 
The presence of a chronic systemic inflammatory response is associated with increased risk 
of a number of cancers, including colorectal cancer.  Prolonged exposure to a chronic 
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inflammatory response may lead to tissue infiltration by innate immune cells, and 
predispose to cellular and DNA damage through the production of reactive nitrogen and 
oxygen species (62).  Furthermore, activated pro-inflammatory signalling pathways, such 
as nuclear factor ĸ-beta (NF-ĸB) are implicated in carcinogenesis (62).  For this reason, it 
is not surprising that elevated concentrations of acute phase reactants, such as serum C-
reactive protein (CRP) and inflammatory cytokines, has been associated with increasing 
risk of colorectal adenomata and cancer (63-65).  Furthermore, elevated serum cytokine 
concentrations may also predict response to chemoprophylactic agents such as aspirin and 
non-steroidal anti-inflammatory drugs (NSAIDs) (64). 
Aspirin and non-steroidal anti-inflammatory drug use 
Early evidence of a prophylactic effect of aspirin and NSAIDs in colorectal cancer 
originally arose out of studies of hereditary cancer syndromes.  The use of NSAIDs 
decreases the number and size of colonic polyps in patients with familial adenomatous 
polyposis (FAP) (66).  Similarly, aspirin also confers a protective effect on the colorectum 
in patients with Lynch syndrome (67).  Over the past two decades, accumulating evidence 
from epidemiological studies has identified a potential role in the prophylaxis of sporadic 
disease, with an approximate 30% risk reduction with aspirin and non-aspirin NSAIDs and 
a potentially greater reduction with cyclooxygenase-2 inhibitor (COXIB) use (68, 69).  A 
duration-dependent increase in risk reduction has been observed, with the greatest benefit 
seen after at least 10 years of continuous use.  Cessation of regular use results in a return to 
normal population risk for subsequent colorectal cancer development.  Secondary analyses 
of cardiovascular secondary prevention trials have found a significant benefit with aspirin 
doses commonly employed for cardiovascular disease prevention, rather than doses 
commonly associated with analgesic use (70).  Despite such convincing evidence, concerns 
regarding the safety profile of NSAIDs have discouraged their use as prophylactic agents 
in the general population, at least until the optimal target population is identified (71). 
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Statin use 
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
commonly known as statins, are primarily used in the treatment of hypercholesterolaemia 
and atherosclerotic cardiovascular disease and are known to have a number of pleiotropic 
effects on cell proliferation, angiogenesis, inflammation and endothelial cell function (72, 
73).  Although a reduction in the risk of several cancers has been found in epidemiological 
studies (74-76), the results of meta-analyses suggest only a modest effect, if any, on 
colorectal cancer incidence in the general population (73, 77).  Despite this, the results of 
in vivo studies and evidence of increased expression of HMG-CoA reductase in tumours 
arising from the left colon suggests a potential role for statins in the treatment of colorectal 
cancer (78). 
Reproductive history and hormone replacement therapy 
Although colorectal cancer is not considered hormone receptive, population level data has 
suggested a relationship between sex hormones and colorectal cancer risk.  Increased 
lifetime exposure to endogenous oestrogen increases risk of colorectal cancer in 
postmenopausal women (79).  Despite this, meta-analysis of data from observational 
studies suggests a reduced risk with both exogenous oestrogen and oestrogen-progestogen 
therapy (80).  The protective effect may be limited to distinct molecular subtypes, and in 
particular risk of MSS, CIMP-negative and BRAF-wildtype tumours (81).  Any potential 
benefit in reducing colorectal cancer risk may likely be offset by the increased risk of 
breast cancer with exogenous hormone therapy (80).  Furthermore, results of a randomised, 
placebo-controlled trial (Women’s Health Initiative) have suggested no clear benefit with 
combined hormone therapy, with a reduction in colorectal cancer incidence but increased 
disease stage at diagnosis in users of combined hormone treatment (82). 
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1.3.3 Hereditary colorectal cancer 
Familial Adenomatous Polyposis 
Familial adenomatous polyposis is associated with the development of hundreds of 
adenomatous polyps throughout the colon and rectum.  The incidence is 1:5000 to 
1:10000, accounting for less than 1% of all colorectal cancers (28),  Patients with classic 
FAP have a 100% lifetime risk of developing colorectal cancer, often by the end of the 
fourth decade of life (26).  Prophylactic colectomy is recommended when the affected 
carrier is in their teenage years.  In addition to colorectal polyps and cancer, FAP is 
associated with a high incidence of extracolonic tumours including duodenal and desmoid 
tumours, which are the second and third most common causes of death in those patients 
who have undergone prophylactic colectomy (83). 
Familial adenomatous polyposis displays an autosomal dominant pattern of inheritance, 
caused by germline mutations in the tumour suppressor APC gene.  Attenuated FAP has 
been identified as a separate polyposis syndrome, with affected patients exhibiting fewer 
polyps throughout the colon and a reduced, albeit still high, lifetime risk of colorectal 
cancer (28).  Whereas the underlying mutation in FAP results in a non-functioning protein, 
patients with attenuated FAP express a mutated but functioning form of APC.  A further 
polyposis syndrome with no germline APC mutation and a mutation within MUTYH has 
also been identified (28).  An autosomal recessive disorder, patients with MUTYH-FAP 
have a similar polyp burden to those with attenuated FAP and a lower lifetime risk of 
colorectal cancer.  
Hereditary Non-Polyposis Colorectal Cancer 
In the 1960s, Henry Lynch described a ‘cancer family syndrome’, with an increased 
predisposition to a number of cancers but primarily those affecting the colon and rectum 
(84).  The syndrome, known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), or 
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Lynch syndrome, has an incidence of approximately 1:1000 in the general population, and 
is the most common familial colorectal cancer syndrome, accounting for around 2-5% of 
all cases (85).  Affected carriers are at an increased risk of colorectal cancer in addition to 
stomach, small bowel, biliary, urothelial, ovarian, endometrial, skin appendage and brain 
tumours.  Compared to patients with sporadic colorectal cancer, those with Lynch 
syndrome have a younger age of onset, with diagnosis often in the fifth decade of life.  
Inheritance is autosomal dominant, with penetrance of around 80%, however this varies 
with the underlying germline mutation (26).  Although the precursor lesion is an 
adenomatous polyp, patients do not have extensive polyposis as observed in FAP. 
Lynch syndrome arises from a mutation affecting one of the MMR proteins responsible for 
repairing DNA replication errors, resulting in tumours arising through the MSI pathway as 
previously described.  These tumours exhibit many of the phenotypical characteristics 
associated with the MSI pathway.  Furthermore, tumours show a rapid progression through 
the process of carcinogenesis, and may be responsible for many ‘missed’ or interval 
cancers (26). 
International criteria have been established to identify Lynch syndrome patients and 
families (Table 1.1).  The Amsterdam criteria, first described in 1990, based likelihood of 
being a Lynch syndrome family on family history of colorectal cancer (86).  Subsequent 
updates of these criteria included other non-colorectal cancer cancers associated with 
Lynch syndrome, with increased sensitivity for the detection of affected families (87).  The 
Bethesda guidelines were subsequently established to identify colorectal cancers that 
should be tested for MSI, taking into consideration histopathological characteristics 
associated with MSI tumours (88).  Not all tumours fitting these guidelines will exhibit 
evidence of MMR deficiency.  Such tumours may fall into a separate category harbouring 
an as yet unknown mutation, and are termed Familial Colorectal Cancer Type X (28). 
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Table 1.1 Criteria for the diagnosis of Hereditary Non-Polyposis Colorectal Cancer 
Amsterdam II criteria (87) 
At least three relatives with hereditary HNPCC-associated cancer (tumours should be 
verified histologically whenever possible): 
1. One is a first-degree relative of the other two; 
2. At least two successive generations affected; 
3. At least one of the HNPCC-associated cancers diagnosed <50 years of age; 
4. Familial adenomatous polyposis has been excluded in colorectal cancer cases. 
Bethesda Guidelines (88) 
1. Colorectal cancer diagnosed in a patient <50 years of age; 
2. Presence of synchronous/ metachronous colorectal or other HNPCC-associated 
tumours, regardless of age; 
3. Colorectal cancer with MSI histology diagnosed in a patient <60 years of age; 
4. Colorectal cancer or other HNPCC-associated tumour diagnosed in at least one 
first-degree relative <50 years of age; 
5. Colorectal cancer or other HNPCC-associated tumour diagnosed in two first- or 
second-degree relatives at any age. 
 
Hamartomatous polyposis syndromes 
Hamartomas are benign overgrowths of cells arising from their tissues of origin.  A 
number of hamartomatous polyposis syndromes have been described, including Peutz-
Jeghers syndrome, juvenile polyposis syndrome and PTEN hamartoma tumour syndrome.  
In addition to a risk of colorectal cancer, these syndromes are commonly associated with 
extra-intestinal malignancies and manifestations.  The risk of colorectal cancer varies; for 
example, there is a 34-fold increased risk in patients with juvenile polyposis syndrome 
compared to a greater than 500-fold increased relative risk of colorectal cancer in patients 
with Peutz-Jeghers syndrome (89).  Overall, the hamartomatous polyposis syndromes 
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account for less than 1% of colorectal cancers.  The various hamartomatous polyposis 
syndromes display an autosomal dominant inheritance pattern, with a number of different 
mutations identified in key tumour suppressor genes, such as PTEN, SMAD4 and LKB1 
(90).  The underlying mechanism leading to the development of an invasive cancer is not 
entirely clear.  The presence of mesenchymal elements within associated polyps and 
cancers has led to the suggestion that mesenchymal overgrowth leads to ‘landscaping’ of 
the epithelium and carcinogenesis (91).  However, given that germline mutations also exist 
in the epithelium, it is likely that carcinogenesis may occur due to loss of tumour 
suppressor function as described above.  
1.3.1 Summary – aetiology of colorectal cancer 
The aetiology of colorectal cancer is complex, incorporating genetic alterations, host 
characteristics and exposure to environmental factors.  As colorectal cancer is sporadic in 
the majority (at least 80%) of cases, it is clear that the environment and host play an 
important role in carcinogenesis.  Many of these factors co-exist as part of the 
‘Westernised lifestyle’, hence the high incidence of colorectal cancer in developed 
countries and the increasing risk in developing countries adopting Western lifestyles.  
The presence of a chronic systemic inflammatory response is also associated with 
colorectal cancer risk.  Chronic inflammation links many of the host factors described 
above, including inflammatory bowel disease, obesity, the metabolic syndrome and 
atherosclerosis.  Given this, it would suggest that a chronic inflammatory response might 
be a potential target for colorectal cancer prevention and treatment.  The potential 
prophylactic effects of anti-inflammatory agents such as aspirin, NSAIDs and statins 
further ratify this.  Indeed, such drugs are likely to have a role in the chemoprophylaxis of 
colorectal cancer, however whether they may have a role in its treatment following 
diagnosis remains to be established. 
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1.4 Management principles of colorectal cancer 
1.4.1 Presentation 
Patients with colorectal cancer may commonly present with rectal bleeding, alteration of 
bowel habit or an abdominal mass.  The clinical presentation is often dictated by tumour 
location; whereas patients with colorectal cancer distal to the splenic flexure commonly 
present with rectal bleeding and alteration of bowel habit, patients with more proximally 
located tumours may present with an abdominal mass, iron deficiency anaemia or clinical 
evidence of intestinal obstruction.  Typically patients present with a combination of 
symptoms rather than a single symptom (92).  For example, patients presenting with rectal 
bleeding without alteration of bowel habit have a low risk of colorectal cancer (positive 
predictive value 2.5%), whereas those patients presenting with rectal bleeding and altered 
bowel habit but without any perianal symptoms have a much higher risk (positive 
predictive value 19.7%) (92).  Stratification on the basis of age and symptom profile may 
aid in the identification of those patients who would benefit from fast-track referral from 
primary to secondary care and expedited investigations (Figure 1.2) (55, 93). 
Up to one third of patients with colorectal cancer may present initially as an emergency 
(94), and often with locally advanced or distant metastatic disease.  Even when controlling 
for patient and tumour-related factors, such as age and disease stage, emergency surgical 
resection confers poorer survival compared to patients undergoing elective resection, with 
an almost two-fold increased risk of cancer-associated mortality (94). 
1.4.2 Population based screening 
Population based screening of asymptomatic patients for colorectal cancer has been 
incrementally introduced across Scotland since 2007, with the rationale of reducing 
mortality by identifying patient with earlier stage colorectal cancer.  On a biennial basis, 
individuals aged 50-74 are sent a guaiac-based faecal occult blood test and are 
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subsequently invited to attend for colonoscopy if the returned test is strongly positive (95).  
In patients with a weakly positive or spoilt test, a faecal immunochemical testing kit is 
sent; if positive, patients are again invited to attend for colonoscopy.  Although the positive 
predictive value of guaiac-based testing is low, meta-analysis has shown a reduction in 
cancer mortality of 25% when adjusted for screening uptake (96).  Furthermore, in addition 
to a decrease in the percentage of patients presenting as an emergency (97), a migration 
towards earlier stage disease has also been observed over subsequent rounds of screening 
(98). 
 
Figure 1.2 Guidelines for referral to secondary care for investigation of lower 
gastrointestinal symptoms. Adapted from SIGN guideline 126 (55) 
 
1.4.3 Investigation 
The investigation of patients with colorectal cancer aims to confirm a histological 
diagnosis.  This may not be possible for all patients; for example, in the patient presenting 
as an emergency with peritonitis or intestinal obstruction, both histological diagnosis and 
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complete disease staging will often occur following emergency surgery.  Likewise, 
although histological confirmation of colon cancer should ideally be performed prior to 
elective surgical resection, this may not always be feasible due to technical limitations of 
colonoscopy and biopsy technique.  In such cases it would be appropriate to proceed to 
surgery in a patient with a highly suspicious colonic lesion and signs or symptoms 
suggestive of colon cancer.  In patients with rectal cancer however, where neoadjuvant 
radiotherapy may be considered, or surgery may result in a permanent stoma or altered 
continence, histological confirmation of cancer is mandatory. 
Flexible sigmoidoscopy and colonoscopy 
Endoscopic assessment of the colon and rectum remains the gold standard for the diagnosis 
of colorectal cancer and should be offered to patients without major comorbidity (99).  In 
addition to direct visualisation of the tumour, it allows for biopsy of lesions for histological 
diagnosis and, in the case of early stage polyp cancers and pre-malignant adenomata, may 
allow complete endoscopic resection.  Direct visualisation of the distal colorectum from 
the anal verge to descending colon is possible at flexible sigmoidoscopy, and is likely to 
identify at least 70% of all cancers (100), without need for intravenous sedation or full 
mechanical bowel preparation.  However confirmation of a cancer at sigmoidoscopy 
necessitates the need for full colonoscopic assessment of the colon, as synchronous 
tumours can occur in approximately 5% of cases (101).  Colonoscopy requires full 
mechanical bowel preparation to allow for adequate visualisation of the colon, and patients 
often require intravenous sedation for comfort.  To ensure adequate standards for 
colonoscopy, endoscopists should aim for caecal intubation in at least 90% of patients 
(101), however multiple factors, including inadequate bowel preparation, patient 
discomfort and experience of endoscopy practitioners may influence this.  Both 
sigmoidoscopy and colonoscopy have an associated risk of perforation of around 0.1% 
(101). 
  55 
Barium enema 
Double-contrast barium enema examination is performed using rectal administration of 
barium and insufflation of air per rectum.  Barium enema has previously been 
recommended in patients with major comorbidity deemed not fit for colonoscopy as well 
as in patients who have had an incomplete colonoscopy (99).  The procedure however 
involves ionising radiation and requires complete bowel preparation and a similar level of 
patient mobility as would be expected during colonoscopy.  Furthermore, identification of 
a lesion at barium enema may necessitate an attempt at colonoscopy to obtain histological 
diagnosis.  Due to the presence of concomitant sigmoid diverticulosis in many patients, 
imaging of the distal colon and rectum is often suboptimal and additional flexible 
sigmoidoscopy is recommended to exclude a distal cancer (99).  The procedure has largely 
been superseded by the introduction of computed tomographic (CT) colonography. 
Computed tomographic colonography 
CT colonography has a higher detection rate for colorectal cancer and is better tolerated by 
patients than barium enema (102, 103).  Furthermore, in addition to assessment of the 
colon, it also allows for identification of extra-colonic pathology including metastatic 
disease.  Similar to barium enema and colonoscopy, full mechanical bowel preparation is 
ideally required, however minimal preparation with administration of oral contrast only 
(faecal tagging) may be performed in patients unable to tolerate full bowel preparation 
with acceptable sensitivity and specificity (104, 105).  Again, similar to barium enema, the 
procedure involves exposure to ionising radiation, and identification of a colonic lesion 
may require subsequent colonoscopy for histological diagnosis. 
1.4.4 Pre-operative assessment of disease stage 
Once a diagnosis of colorectal cancer has been histologically confirmed, further 
investigation is performed to stage the extent of disease both locally and with respect to 
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distant organ metastases.  Staging guides both operative and non-operative management, 
particularly in patients with rectal cancer where accurate staging will not only determine 
surgical technique, but also the need for pre-operative chemotherapy and radiotherapy. 
Computed tomography 
Pre-operative CT of thorax, abdomen and pelvis should be offered to all patients to assess 
the presence of pulmonary, hepatic and other distant organ metastases (55, 99, 101).  
Intravenous iodinated contrast is administered unless contraindicated due to risk of 
sensitivity or contrast-induced renal failure.  In such circumstances, a non-contrast 
enhanced CT can be performed, albeit with lower sensitivity.  Although primarily indicated 
for staging of metastatic spread, pre-operative CT may also inform local disease staging 
with respect to T and N stage, particularly when multiplanar reformatting is utilised (106). 
Magnetic resonance imaging 
The use of magnetic resonance imaging (MRI) is superior to contrast-enhanced CT for 
local staging of patients with rectal cancer (55, 99, 101).  Assessment of depth of tumour 
invasion, circumferential resection margin involvement, the presence of suspicious 
perirectal lymph nodes and extramural venous invasion using MRI can determine risk of 
local recurrence (Table 1.2), and aid in the selection of patients for primary resection or 
neoadjuvant chemoradiotherapy before surgery. 
Pre-operative MRI in rectal cancer is of greatest value in determining depth of primary 
tumour growth and involvement of the circumferential resection margin (107, 108).  
Patients with tumour present within 1mm of the mesorectal fascia on MRI should be 
considered as high risk for circumferential resection margin involvement and should be 
considered for preoperative therapy.  Furthermore, following neoadjuvant therapy, MRI 
assessment of tumour regression grade may be a useful prognostic marker prior to surgical 
resection (109). 
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Table 1.2 Rectal tumour characteristics as predicted by magnetic resonance imaging and 
risk of local recurrence.  Adapted from NICE guidelines (99) 
Local recurrence risk Tumour characteristic predicted by MRI 
High risk • Tumour <1mm from or breaching 
circumferential resection margin, or 
• Tumour encroaching inter-sphincteric plane, 
or 
• Involvement of levator ani complex 
Moderate risk • Radiological cT3b or greater without 
threatened resection margin, or 
• Suspicious lymph node not threatening 
resection margin, or 
• Presence of extramural venous invasion 
Low risk • Radiological cT1, cT2 or cT3a, and 
• No lymph node involvement 
 
Endoluminal ultrasound 
Endoluminal ultrasound (EUS) may be considered for patients in whom MRI is 
contraindicated or in whom local excision for an early tumour is being considered  (55, 
99).  Both T stage and N stage may be accurately determined (110, 111), however EUS 
may have greatest utility in identifying patients with carcinoma in situ who may be 
adequately treated by endoscopic excision only (112). 
Positron emission tomography 
Positron emission tomography-CT (PET-CT) combines functional assessment of abnormal 
tissue metabolism with anatomical detail derived from conventional CT imaging.  In 
patients with colorectal cancer, 18-fluoro-deoxy-glucose is commonly utilised as a 
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radiotracer which provides a measure of glucose uptake and tumour metabolism. Positron 
emission tomography-CT may be utilised in patients being considered for curative 
resection of hepatic and pulmonary metastases to identify occult metastatic disease (55).  
In a case series of 102 patients being considered for potentially curative resection of 
metastatic colorectal cancer, the use of PET-CT avoided unnecessary laparotomy in 16 
patients (113).  In addition, PET-CT may also be of use in patients undergoing surveillance 
following colorectal cancer resection with a rising carcinoembryonic antigen (CEA) and 
normal CT imaging, or in those patients with possible radiological evidence of pelvic 
recurrence following treatment of rectal cancer (55). 
Although the use of PET-CT is not routine in the staging of patients with colorectal cancer, 
colorectal neoplasms may occasionally be detected as an incidental finding on PET-CT 
performed in the staging of other cancers (55). 
1.4.5 The multidisciplinary team 
All patients with colorectal cancer should be discussed at the colorectal cancer MDT prior 
to the initiation of treatment, as well as following the completion of neoadjuvant therapy or 
surgical resection to determine the need for further treatment (101).  As a minimum, the 
colorectal cancer multidisciplinary team (MDT) should comprise of at least two specialist 
colorectal surgeons, gastrointestinal clinical oncologists, histopathologists and diagnostic 
radiologists with gastrointestinal expertise, and colorectal clinical nurse specialists, in 
addition to ancillary clerical staff. 
Implementation of the MDT process has led to improvements in the surgical and non-
surgical management of colorectal cancer, with a subsequent improvement in survival 
(114, 115).  For example, the management of locally advanced rectal cancer, with respect 
to increased use of neoadjuvant therapy and negative resections margins, has been shown 
to improve following introduction of routine MDT discussion (115).  Furthermore, patients 
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with potentially resectable hepatic or pulmonary metastases may benefit from review by 
specialist MDTs comprising of thoracic and liver surgeons with expertise in metastatic 
disease (55).  The development of standardised referral guidelines may aid in the 
identification of patients with metastatic disease likely to benefit from referral to such 
specialist MDTs (116). 
1.4.6 Treatment of primary operable colorectal cancer 
Surgery 
Surgery remains the mainstay of curative treatment for colorectal cancer at present.  The 
intent of curative surgery is twofold; resection of the tumour en bloc with a margin of 
healthy tissue to achieve macroscopically clear surgical margins, and resection of draining 
lymph nodes to remove potential lymph node metastases and allow proper pathological 
staging.  Resection can be performed by open, laparoscopic and robotic techniques, and the 
operation performed depends on the anatomical location of the tumour, with resection 
margins following the vascular supply to the bowel to ensure an adequate oncological 
resection of the vascular pedicle and draining lymph nodes.  Tumours within the caecum, 
ascending colon and hepatic flexure are resected by right hemicolectomy.  Tumours of the 
transverse colon and splenic flexure are resected by an extended right hemicolectomy 
which is perceived as a safer procedure compared to limited segmental resection (101).  
Left hemicolectomy and sigmoid colectomy are performed for tumours arising in the left 
and sigmoid colon respectively.   
Surgery for cancers arising within the lower two thirds of the rectum are resected either by 
anterior resection or abdominoperineal resection (APER), both of which have been 
revolutionised by the concept of total mesorectal excision (TME) (117).  The TME 
approach follows the plane encompassing the mesorectum below the peritoneal reflection; 
sharp dissection along the mesorectal plane under direct visions preserves the hypogastric 
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plexus, ensuring pelvic nerve function is maintained, whilst reducing the risk of involved 
margins and local recurrence. 
Comparing across trials, the introduction of this standardised surgical approach alone was 
shown to have similar effects on local recurrence rates as the introduction of neoadjuvant 
radiotherapy (118).  Numerous trials have examined the role of TME compared to standard 
resection of rectal cancer (119-121).  Such studies have benefited from standardisation of 
surgical technique, ensuring that involved surgeons adhere to the principles of TME.  
Similarly, a standardised approach to the reporting of rectal cancer resection specimens 
was also adopted.  However, despite employing such methodological rigour, TME trials 
did not initially report on measures of resection quality, such as circumferential resection 
margin or excision plane, and their subsequent effect on survival.  Indeed, retrospective 
reporting of the Dutch TME trial found an incomplete mesorectal excision had been 
performed in approximately one quarter of patients, with an associated increased risk of 
recurrence (122).  However, despite not controlling for such factors, TME trials overall 
have reported superior oncological outcome with this approach, and it is now accepted as a 
standard of care in the surgical management of rectal cancer. 
In patients with low rectal cancer, where the anal canal or levator ani muscle complex may 
be compromised, APER is required.  Although traditionally associated with a relatively 
high rate of circumferential margin involvement, adoption of a more radical, extralevator 
approach, whereby the levator muscles are resected with the surgical specimen, is 
associated with a lower rate of circumferential margin involvement (123-125). 
Minimally invasive surgery 
 The past two decades have seen significant advances in the operative and peri-operative 
management of patients undergoing resection of colorectal cancer.  In particular, the 
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adoption of minimally invasive techniques, such as laparoscopic resection, has led to 
significant improvements in short-term outcomes of patients undergoing surgery. 
Although potentially associated with an increased length of operation time, laparoscopic 
colonic resection has been shown to be associated with several short-term benefits; in 
addition to improved cosmesis from smaller wounds, the laparoscopic approach is 
associated with reduced post-operative analgesic requirements, reduced time to return of 
gastrointestinal function, and shorter time until discharge (126-128).  Despite this, initial 
reports doubted the oncological benefits of laparoscopic versus conventional open 
resection, particularly with respect to achievement of negative resection margins and a 
potentially increased risk of laparoscopic port site metastases (129).  However, several 
non-inferiority  randomised controlled trials comparing laparoscopic to open resection of 
colon cancer have suggested oncological equivalence between the two techniques.  The 
COSTS trial found laparoscopic resection not inferior to open resection for the primary 
outcome of disease recurrence (130).  Although the COLOR trial could not exclude a 
difference in three-year survival favouring open resection, any difference was felt 
clinically insignificant and likely outweighed by the recognised short-term benefits of 
laparoscopy (131).  Finally, the MRC CLASICC trial examined the clinical endpoint of 
resection margin positivity as an indicator of risk of local recurrence (128).  Both 
approaches were equivalent with regards to resection of colon cancer, however 
laparoscopy appeared to be inferior to open resection for circumferential margin positivity 
in patients undergoing anterior resection for rectal cancer; long-term survival was 
equivalent for patients with colon cancer (132).  Taken together, these results advocate the 
use of laparoscopic resection for patients with colon cancer, predominantly due to 
significant improvements in short-term outcomes and likely no difference in long-term 
survival.  
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The benefit of laparoscopic resection for patients with rectal cancer is not entirely clear.  
Although possibly suggesting a higher rate of circumferential margin involvement, long-
term follow-up of CLASICC suggested no difference in survival with open or laparoscopic 
rectal cancer resection, albeit this was without the standardised use of extralevator 
abdominoperineal resection and with relatively low rates of neoadjuvant therapy (132).  
Similarly, the COLOR II and COREAN trials found no significant differences in 
locoregional recurrence or survival (133, 134).  Conversely, the ALaCaRT and ACOSOG 
Z6051 randomised trials suggested a higher risk of margin positivity in patients undergoing 
laparoscopic resection (135, 136); however, although unable to recommend laparoscopic 
resection based on these pathological parameters, the effect on local recurrence and long-
term survival in these two studies remains to be determined. 
In addition to the advent of laparoscopic resection, the use of other minimally invasive 
techniques may significantly change the operative management of patients with colorectal 
cancer.  Robotic-assisted surgery may improve the outcome of rectal cancer resection, 
particularly with respect to preservation of pelvic nerve function (137).  However, both the 
oncological and cost benefit of robotic-assisted surgery remains to be determined. 
Similarly, local excision may be indicated for some early tumours (55).  This may be 
performed by either transanal endoscopic microsurgery for rectal cancers, or by 
polypectomy or endoscopic mucosal resection during colonoscopy for colon cancers.  
Generally, local excision is reserved for patients with T1 tumours and low risk 
characteristics on pathological assessment.  Evidence of extensive submucosal invasion, 
tumour present within 1mm of the resection margin, lymphovascular invasion or poorly 
differentiated tumour would be indications for further surgical resection, as each of these 
increases the risk of lymph node involvement.  The decision between local excision and 
surgical resection must be carefully considered with the patient, ensuring they are 
adequately informed regarding the risks of surgical morbidity versus the risks of 
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recurrence.  In patients with a high risk of surgical morbidity, local excision, even with the 
presence of high-risk pathological characteristics, may be the preferred option. 
Neoadjuvant radiotherapy 
Patients with rectal cancer have a relatively higher risk of local recurrence given the 
natural confines of the pelvis.  The addition of radiotherapy (either pre-operatively or post-
operatively) reduces the risk of local recurrence, however pre-operative radiotherapy has 
been shown to be superior to post-operative therapy (138).  Despite this, in patients with an 
involved surgical margin who did not receive pre-operative radiotherapy, post-operative 
chemoradiotherapy remains an acceptable salvage therapy.  Pre-operative radiotherapy 
may either be used as short course pre-operative radiotherapy (SCPRT) or as long course 
radiotherapy in combination with 5-fluorouracil-based chemotherapy.  Patients with 
moderate risk of local recurrence but without mesorectal fascial involvement on MRI may 
benefit from SCPRT in the week immediately prior to surgery; even with the introduction 
of total mesorectal excision, the addition of SCPRT reduces the risk of local recurrence at 
five years from 11.4% to 5.8% compared to surgery alone (139).  In patients with locally 
advanced disease at risk of mesorectal fascial involvement, chemoradiotherapy is utilised 
to downstage and shrink the tumour so that clear resection margins can be obtained.  
Chemoradiotherapy is given over a five-week period and then followed by an interval 
before proceeding to surgery.  Such a regime has been shown to be superior to post-
operative chemoradiotherapy in reducing local recurrence rates (140).  The addition of 
chemotherapy to pre-operative radiotherapy further reduces risk of local recurrence and 
increases likelihood of tumour regression and complete pathological response (141).  In 
patients with rectal cancer at low risk of local recurrence, radiotherapy may be avoided to 
avoid the potential toxic effects of radiotherapy. 
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Adjuvant chemotherapy 
In addition to improvements in pre-operative staging and surgical technique, refinement of 
chemotherapeutic drugs and treatment regimes has led to an increase in survival of patients 
with colorectal cancer.  Adjuvant chemotherapy is now a standard care for the management 
of patients with stage III (node positive) colorectal cancer.  Factors that may influence the 
decision to proceed to adjuvant chemotherapy however, include patient’s age, comorbidity 
status and patient preference.  Standard regimes consisting of a thymidylate synthase 
inhibitor, 5-fluorouracil (5-FU), given in combination with leucovorin, a folic acid 
derivative, for approximately six months have been shown to increase overall, disease-free 
and recurrence-free survival compared to surgery alone (142-144).  Oral, pro-drug 
equivalents of 5-FU, such as capecitabine, are now available, with similar long-term 
survival benefit as 5-FU but with less toxicity (145).  Combination regimes, with the 
addition of oxaliplatin, are superior to 5-FU/leucovorin alone (three-year disease-free 
survival 78.2% versus 72.9%), however carry an increased risk of treatment-associated 
toxicity (146, 147). 
The survival benefit conferred by adjuvant chemotherapy to patients with stage II (node 
negative) colorectal cancer is less clear, with randomised clinical trials showing little or no 
improvement in survival (148, 149).  For example, the QUASAR-1 trial, incorporating 
almost 3000 patients with stage II disease, found a modest, 3.6% absolute improvement in 
overall survival at five-years with the use of adjuvant chemotherapy (149).  As such, 
current guidelines do not recommend the routine administration of adjuvant chemotherapy 
for patients with stage II disease (55, 99, 150), instead recommending its use in patients 
with the presence of high-risk pathological characteristics, such as tumour perforation or 
venous invasion.  Increasingly, molecular characteristics, such as the absence of MSI, may 
be used as predictive biomarkers to identify patients with stage II disease likely to gain 
benefit from adjuvant therapy (151).
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1.5 Determining prognosis of patients with colorectal cancer  
Overall, survival following potentially curative resection remains relatively poor, with 
approximately 50% of patients suffering disease recurrence within five years of surgery 
(152, 153).  Pathological assessment of tumour characteristics is vital in determining 
prognosis and identifying patients likely to benefit from adjuvant therapy.  For example, it 
is now accepted that adjuvant chemotherapy may benefit those patients with lymphatic 
metastases, whereas adjuvant radiotherapy may be of use in patients with positive 
circumferential resection margins following rectal cancer resection.  Increasingly, other 
factors pertaining to the tumour, such as molecular characterisation and assessment of the 
tumour microenvironment, are recognised as having prognostic value in patients with 
colorectal cancer.  In addition, host characteristics, such as age, emergency presentation, 
burden of comorbidity and the presence of local and systemic inflammatory responses are 
now recognised as important predictors of survival. 
1.5.1 Tumour staging and prognosis of patients with colorectal cancer 
Dukes’ Stage 
Cuthbert Dukes originally described a standardised means of staging rectal cancer in 1932 
(154), which has since been validated for use in colon cancer.  Dukes’ staging is based on 
the previously held belief that lymphatic spread was not possible, or at least highly 
unlikely, in the absence of direct invasion though the bowel wall into extramural tissue.  
Using this staging system (Figure 1.3), tumours are classified as those without tumour 
growth through the bowel wall and without lymph node involvement (A), those extending 
through the bowel wall into surrounding tissues and without lymph node involvement (B), 
and those with lymph node metastases irrespective of extent of primary tumour growth (C).  
Three-year survival rates using this staging system were 80%, 73% and 7% for Dukes’ A, 
B and C rectal cancer respectively (154).  Since its original description, Dukes’ staging has 
been modified several times.  For example, Turnbull described a Dukes’ stage D in 1967 to 
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denote the presence of distant metastatic disease (155).  Presently, the Dukes and Bussey 
modification is recommended for routine pathological reporting by the Royal College of 
Pathologists (156).  This modification further subdivides patients with stage C disease into 
those with involved lymph nodes but sparing of the highest or apical node (C1), and those 
with involvement of the apical node (C2). 
 
Figure 1.3 Dukes’ staging of rectal cancer. Adapted from Dukes’ original description 
(154) 
 
TNM staging 
Although similar to the Dukes’ staging system, the tumour, nodes and metastases (TNM) 
system has largely replaced its use in clinical practice and research.  This more 
standardised staging system has allowed for more precise assessment of disease stage, with 
a view to better informing prognosis and need for adjuvant therapy.  Universal adoption of 
TNM staging allows for more meaningful dissemination of information in the literature.  
Dukes’ A Growth limited to 
wall of rectum 
Dukes’ B Extension of growth 
to extra-rectal tissues 
but no metastases in 
regional lymph nodes 
Dukes’ C Metastases in 
regional lymph nodes 
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Denoix initially described the TNM system in 1946 (157), with the publication of the first 
edition of the “TNM pocket book” in 1968 by the Union for International Cancer Control 
(UICC).  The American Joint Committee on Cancer (AJCC) also published TNM-based 
staging, however this differed from that of the UICC until 1987, when a unified staging 
system was proposed (158).  The TNM system describes the size and depth of invasion of 
the primary tumour into or through the bowel wall (T stage), the degree of involvement of 
regional lymph nodes (N stage), and the presence of distant metastatic disease (M stage).  
Pre-operative imaging may allow for assessment of TNM stage prior to surgery, 
particularly with respect to the presence of distant metastatic disease.  Although prognosis 
and need for adjuvant therapy will be determined by pathological assessment following 
surgical resection (pTNM stage), assessment of M stage is generally on the basis of 
radiological imaging rather than assessment of the resected specimen. 
The TNM staging system is regularly revised to incorporate new evidence, with the 7th 
edition published in 2009 (159).  This has, however, led to difficulties with respect to 
recruitment to and comparison of clinical trials due to differing criteria for each disease 
stage and subsequent stage migration over the recruitment period of clinical trials (160).  
Furthermore, recent revisions have been met with criticism due to a perceived lack of 
evidence with respect to many such changes (160).  Presently, in the United Kingdom, the 
5th edition of the TNM staging system (Table 1.3), published in 1997, is recommended by 
the Royal College of Pathologists for the routine reporting of colorectal cancer (101). 
Whereas the Dukes’ staging system was predicated on the hypothesis that lymphatic spread 
is uncommon without primary tumour growth through the bowel wall (154), the TNM 
classification accepts that lymphatic spread may occur even in the presence of an early 
primary tumour.  Taking this into consideration however, both staging systems are broadly 
comparable.  A comparison of Dukes’ staging, TNM staging and associated five-year 
survival rates is displayed in Table 1.4. 
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It is clear that good surgical technique is required not only to ensure an adequate 
oncological resection is performed, but also to allow for accurate pathological staging of 
the patient (161).  For example, a low yield of lymph nodes examined may result in under-
staging of patients, and it is recommended that a minimum of 12 lymph nodes are 
examined to allow for accurate staging (101).  Similarly, pathological assessment should 
follow rigorous protocols to ensure that resected specimens are examined and reported 
accurately and using reproducible methodologies.  In keeping with this, the Royal College 
of Pathologists have recommended a minimum dataset with respect to reporting of 
colorectal cancer and have set minimum audit standards for the detection of key tumour 
characteristics, such as venous invasion. 
1.5.2 Pathological characteristics and prognosis of patients with 
colorectal cancer 
Although both Dukes’ and TNM systems provide useful staging systems, it is increasingly 
appreciated that there is significant variation in prognosis within each staging group.  
Furthermore, an incremental increase in TNM stage does not necessarily translate into 
increased risk of recurrence, with some patients with stage II disease having a poorer 
outcome than those with stage III disease (162).  Therefore, other pathological 
characteristics, such as tumour differentiation, venous invasion, and margin involvement 
are routinely assessed to aid in further stratification of patients.  Such measures have been 
of greatest prognostic value in the assessment of patients with stage II disease, and may 
identify patients likely to benefit from adjuvant therapy (163). 
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Table 1.3 Summary of the 5th edition of the TNM classification of colorectal cancer 
pT 
pTx 
pT0 
pT1 
pT2 
pT3 
pT4 
Primary tumour 
Primary tumour cannot be assessed 
No evidence of primary tumour 
Tumour invades submucosa 
Tumour invades muscularis propria 
Tumour invades into subserosa or non-peritonealised/ perirectal tissues 
Tumour directly invades other organs or structures (pT4a) and/or perforates 
visceral peritoneum (pT4b) 
pN 
pNx 
pN0 
pN1 
pN2 
Regional lymph nodes 
Regional lymph nodes cannot be assessed 
No regional lymph node metastatic disease 
1-3 regional lymph nodes contain metastatic disease 
4 or more regional lymph nodes contain metastatic disease 
pM 
pMx 
pM0 
pM1 
Distant metastatic disease 
Distant metastatic disease cannot be assessed 
No distant metastatic disease 
Distant metastatic disease 
  
  70 
Table 1.4 A comparison between Dukes’ stage, TNM stage and five-year relative survival. 
Adapted from National Cancer Intelligence Network (164) 
Dukes’ stage TNM stage TNM classification 5-year relative survival 
A Stage I T1-2, N0, M0 93.2% 
B Stage II T3-4, N0, M0 77.0% 
C Stage III Any T, N1-2, M0 47.7% 
D Stage IV Any T, Any N, M1 6.6% 
 
Histological type 
The majority of colorectal cancers are adenocarcinomas, however other rare tumour types, 
such as medullary, primary squamous and neuroendocrine, have been reported.  
Adenocarcinomas may exhibit features suggestive of mucinous (>50% of tumour 
composed of extracellular mucin) or signet ring (>50% of tumour displaying signet ring 
cell morphology) differentiation.  Signet ring cell differentiation, in particular, is a stage-
independent predictor of poorer survival (165).  Mucin production may be induced by pre-
operative chemoradiotherapy, and as such its prognostic value is less clear (166, 167). 
Tumour differentiation 
Differentiation is based on microscopic assessment of the degree of gland formation and 
architecture within the tumour.  Tumours are graded as either well, moderately or poorly 
differentiated.  Poor tumour differentiation is identified by irregularly folded, distorted 
glands, or complete absence of gland formation.  Furthermore, tumours may be 
undifferentiated, bearing no resemblance to the underlying tissue architecture.  Tumours 
are often heterogeneous in appearance, and for that reason differentiation grade is based on 
the predominant pattern within the tumour (168). Assessment of differentiation is 
subjective and may be prone to significant inter-observer variability (169).  As such, in 
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clinical practice moderately- and well-differentiated tumours are often categorised together 
as low grade whereas poorly-differentiated and undifferentiated tumours are categorised as 
high grade (168).  High grade/ poor differentiation is associated with poorer survival (170). 
Peritoneal involvement 
Peritoneal or serosal involvement occurs when tumour breaches the visceral peritoneum 
with evidence of tumour cells on the peritoneal surface or present within the peritoneal 
cavity.  Using the 5th edition of TNM staging, this is defined as T4b disease.  Direct 
continuity with the primary tumour is evident in the presence of peritoneal involvement, 
and this must be differentiated from peritoneal metastatic deposits occurring separately 
from the primary tumour which are indicative of metastatic disease.  Peritoneal 
involvement is associated with an increased risk of intraperitoneal recurrence and reduced 
survival (171, 172). 
Tumour perforation 
A macroscopically visible defect through the tumour resulting in communication with the 
lumen is considered a tumour perforation, and is defined as T4b disease in the 5th edition of 
TNM.  Although perforation may occur spontaneously in T4 tumours, it may also be 
iatrogenic, particularly in rectal cancers (173).  The presence of tumour perforation is an 
adverse prognostic factor associated with increased risk of local recurrence and reduced 
survival (172, 173). 
Resection margins 
Resection margins include the resected ends of the specimen (longitudinal margins) as well 
as the circumferential resection margin.  In specimens where the primary tumour is at least 
30mm from either end of the specimen, longitudinal margins are not generally assessed for 
disease involvement.  Involvement of the circumferential margin is an important 
  72 
prognostic factor in patients with rectal cancer, associated with an increased risk of local 
recurrence (174, 175).  More recently however, it is recognised as an adverse characteristic 
in cancers of the colon (172).  Tumours that are completely excised are classified as R0, 
whereas those with microscopic involvement (£1mm from resection margin) are classified 
as R1, and those with macroscopic, visible tumour at the margin classified as R2 (176).  In 
addition to the presence of the primary tumour, the presence of tumour within 
lymphovascular channels and lymph nodes, as well as metastatic deposits in close 
proximity to the resection margin are also considered as evidence of an involved margin. 
Plane of excision and specimen quality 
Assessment of the plane of excision in patients undergoing TME surgery for rectal cancer 
is an important prognostic factor, with the risk of recurrence lowest in those patients with a 
complete mesorectal excision (122).  The plane of excision may be graded (Figure 1.4), 
with an increasing risk of local recurrence observed with decreasing quality of resection 
(177).  Similarly, performing a resection out with of the plane of the levator sling during 
APER (extralevator approach) reduces the risk of “waisting” of the specimen and risk of an 
involved resection margin (124).  Although the plane of resection may be influenced by 
several tumour and patient factors, such as depth of invasion, sex and body habitus, it is 
also a useful metric for quality of surgery (122, 178).  As such, plane of surgical resection 
should be routinely reported for patients undergoing resection of rectal cancer and 
discussed at MDT to aid in the improvement of surgical quality. 
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Mesorectal plane of excision 
 
 
Specimen exhibits shiny fascial covering 
with no defects and a good bulk to 
mesorectum anteriorly and posteriorly.  
 
Intramesorectal plane of excision 
 
 
Specimen exhibits minor irregularities in 
mesorectum with defects which do not 
extend into the muscularis propria.
Muscularis propria plane of excision 
 
 
Specimen exhibits significant defects in 
mesorectum which extend to muscularis 
propria.
Figure 1.4 Examples of planes of excision observed in anterior resection for rectal cancer. 
Adapted from Loughery et al. (179) 
  
 
Number of lymph nodes examined and lymph node ratio 
An increased number of lymph nodes examined following surgery is associated with 
improved survival of patients with node negative (stage I/II) colorectal cancer (180).  This 
may reflect more accurate staging, with a low lymph node yield effectively under-staging 
the patient.  For this reason, the Royal College of Pathologists recommend that a minimum 
of 12 lymph nodes are examined (101).  Similarly, the American Society of Clinical 
Oncology (ASCO) consider a low lymph node yield (£10) as an indication for adjuvant 
therapy in patients with stage II disease (150). 
  74 
In patients with stage III colorectal cancer, an increased number of lymph nodes examined 
is also associated with increased survival (180).  Furthermore, assessment of the ratio of 
number of positive lymph nodes compared to total number examined, or lymph node ratio 
(LNR), has been shown to be an independent prognostic characteristic, with an increasing 
LNR associated with poorer survival (181).  Inclusion of LNR has been suggested as a 
superior marker of lymph node metastases than pN stage (182).  However, several 
thresholds have been reported in the literature (182-185), with a lack of validation 
precluding the routine use of the LNR in clinical practice.  
Venous invasion 
Venous invasion is defined by the presence of tumour cells within an endothelial-lined 
space which either contains red blood cells or is surrounded by a rim of muscle (186).  The 
‘orphan artery’ sign, where an elongated tumour deposit is identified adjacent to an artery 
is also indicative of venous invasion.  The presence of venous invasion has been reported 
as a predictor of increased risk of systemic metastases and decreased survival in patients 
with rectal cancer (187), and has subsequently been validated as an independent prognostic 
marker in patients with colon cancer (172, 188, 189).  Although early reports suggested 
that only extramural venous was a prognostic factor, more recent studies have suggested 
that intramural venous invasion may also be associated with survival (172, 188, 189).  
Detection rates for venous invasion have been shown to vary between institutions (190), 
and are influenced by the number of blocks and sections examined and techniques used 
(191).  For example, in a single institution, the use of elastica staining in addition to 
haematoxylin and eosin (H&E) staining was shown to increase venous invasion detection 
rates from 18% to 58% (Figure 1.5), with a resultant increase in prognostic value (188). 
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Figure 1.5 Extramural venous invasion as evidenced by haemotoxylin & eosin (a)  and 
haemotoxylin & eosin and elastic staining (b). Figure from Roxburgh, McMillan et al. 
(188) 
 
Perineural invasion  
Perineural invasion is characterised by tumour invasion of nerve structures with spread 
along the nerve sheath (192).  The presence of perineural invasion is indicative of an 
aggressive tumour phenotype, and is an adverse prognostic characteristic associated with 
increased risk of locoregional recurrence and decreased survival (193-195).  Furthermore, 
the presence of perineural invasion is an independent predictor of lymph node metastases, 
and may be an indication for more radical surgery following local excision of T1/T2 
tumours (196).  Assessment of perineural invasion is not presently recommended by the 
Royal College of Pathologists as part of the minimum dataset for colorectal cancer 
reporting and is likely to be underreported in routine clinical practice.  In a retrospective 
re-review of 269 patients with colorectal cancer, perineural invasion was identified in 22% 
of patients compared to 0.5% in the original prospective reports (197).  
Determining prognosis of patients with Stage II colorectal cancer 
Whereas adjuvant chemotherapy is generally recommended for patients with stage III 
colorectal cancer, identifying patients with stage II disease who may benefit is more 
problematic.  In 2002, Petersen and colleagues described a scoring system based on the 
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presence of high-risk pathological characteristics to aid in the identification of patients 
with Dukes’ B/ stage II colon cancer at increased risk of recurrence (172).  Using this 
prognostic index, patients were allocated one point each for the presence of venous 
invasion, margin involvement and peritoneal involvement, and two points for the presence 
of tumour perforation.  A cumulative increase in score was associated with poorer survival 
(Table 1.5), and the authors recommended a cut-off of 2 or more to indicate high-risk, node 
negative disease.  Indeed, the survival of patients with low-risk disease is comparable to 
that of patients with Dukes’ A disease, whereas patients with a high-risk prognostic index 
disease have poorer survival than those with single node positive Dukes’ C colorectal 
cancer (163). 
Table 1.5 The relationship between Petersen Prognostic Index and five-year cancer 
specific survival of patients with Dukes’ B colon cancer. Adapted from (172) 
Prognostic Index Total patients 5 year cancer-specific 
survival (95% CI) 
0 82 94.2% (85.0-97.8) 
1 109 79.5% (69.9-86.3) 
2 63 54.3% (40.3-66.3) 
≥3 14 30.4% (7.8-57.4) 
All 268 76.1% (70.0-81.0) 
 
Similar guidelines for the identification of high-risk stage II disease have been published 
by ASCO (150).  Using these guidelines, low lymph node yield (less than 10 nodes), T4 
stage, tumour perforation or poor tumour differentiation are considered high-risk 
pathological characteristics which may be used to identify patients who may benefit from 
adjuvant therapy. 
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1.5.3 Molecular characteristics and prognosis of patients with colorectal 
cancer 
In addition to histopathological characterisation of the tumour, it is increasingly 
appreciated that molecular characterisation of the tumour may aid not only in determining 
prognosis, but also in predicting response to therapy.  Furthermore, assessment of tumour-
related proteins, such as carcinoembyronic antigen (CEA), may be useful adjuncts in the 
follow-up of patients following potentially curative resection. 
Microsatellite instability 
Approximately 15% of colorectal cancers arise through the MSI pathway, with both 
prognostic and therapeutic implications.  Two large meta-analyses, incorporating 32 and 
31 studies respectively (151, 198), each found that MSI was associated with an 
improvement in overall survival of around 40% compared to MSS tumours.  This survival 
benefit appeared to be greatest in patients with stage II/III disease.  Of interest however, 
MSI status appears to confer a poor response to standard, 5-FU-based chemotherapy 
regimens (199), potentially due to the increased tolerance of tumour cells lacking 
functional mismatch repair proteins to the cytotoxic, DNA-damaging effect of these agents 
(16). 
The favourable prognosis of patients with MSI colorectal cancer may  reflect the decreased 
preponderance for MSI tumours to metastasise.  It has however also been suggested that 
the rapid mutational rate associated with loss of MMR protein function leads to the 
development of multiple neo-antigens which may provoke a co-ordinated anti-tumour 
immune response as evidenced by the increased density of tumour-infiltrating lymphocytes 
within the tumour microenvironment.  It is not entirely clear if the favourable prognosis 
associated with the MSI pathway is independent of the local inflammatory cell infiltrate 
(200, 201). 
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Oncogene and tumour suppressor gene expression 
Given the importance of oncogene and tumour suppressor gene expression in the 
development of colorectal cancer, there exists a sound biological rationale to study the 
prognostic and predictive value of activating and de-activating mutations.  However, few 
of these have shown promise as candidate genes capable of informing prognosis and 
treatment decisions.  Many studies have failed to adopt standardised methodologies for the 
detections of mutations, such as is the case with p53 mutations (202).  Furthermore, the 
high frequency of some mutations in patients with colorectal cancer, such as APC 
mutations, limits their prognostic utility (11).   
A different approach has been the identification of gene expression profiles capable of 
predicting recurrence risk, particularly in the context of stage II disease (203).  One such 
profile is ColoPrint, an 18-gene expression classifier which may effectively identify 
patients at high and low risk, with reported five-year relapse-free survival of 67% and 88% 
respectively (204).  However, the practicalities of the assay employed, which requires fresh 
frozen tissue, in addition to high costs prohibits routine clinical use of such techniques. 
The proto-oncogene KRAS has been one of only a few gene assays to translate to routine 
clinical practice.  Activating mutations of KRAS have been associated with reduced 
survival of patients with metastatic colorectal cancer, and predict lack of therapeutic and 
radiological response to epidermal growth factor receptor (EGFR) inhibitors (205).  The 
clinical utility of KRAS mutations in patients with non-metastatic disease is unclear 
however, with some studies showing an association with reduced survival (206), and others 
showing no prognostic value (207).  Mutated BRAF and PIK3CA are also of increasing 
clinical value in determining patients with metastatic disease unlikely to benefit from 
EGFR inhibitors (205).  Furthermore PIK3CA mutations may predict benefit from aspirin 
(208). 
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1.5.4 Determining prognosis of patients with colorectal cancer – 
summary 
Although disease stage is primarily based on pathological assessment of the extent of 
disease spread, it is clear that other tumour characteristics may determine both disease 
stage and likely benefit from adjuvant therapy.  Many of these characteristics are based on 
pathological assessment of the resected tumour, with several now incorporated into routine 
assessment.  Others however, such as perineural invasion and LNR have yet to translate to 
clinical practice.  Furthermore, although it is clear that molecular and genetic analysis may 
similarly aid treatment decisions, lack of standardisation and high costs remain barriers to 
routine implementation.  
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1.6 The local and systemic environment in patients with colorectal 
cancer 
Rather than being a tumour cell autonomous process, sustained tumour growth and 
dissemination is reliant on the presence of a tumour-supporting environment.  Host 
inflammatory responses, at both the local and systemic level, play an important role in 
disease progression, as do other components of the tumour microenvironment.  Assessment 
of both the local and systemic environment may aid in determining prognosis of patients 
with colorectal cancer, and could potentially identify patients likely to benefit from 
adjuvant chemotherapy and novel therapies. 
1.6.1 Inflammation in cancer 
Cancer and inflammation have long been recognised as overlapping phenomena.  In the 
19th century, the pathologist Rudolf Virchow described the ‘lymphoreticular infiltrate’ 
identifiable within cancer tissues, recognising that this likely reflected the origin of cancer 
at sites of chronic inflammation (209).  Further supporting the link between inflammation 
and cancer is evidence that targeting chronic inflammation reduces cancer risk, as is 
evident in patients with longstanding IBD.  In addition, a number of anti-inflammatory 
agents, including aspirin and NSAIDs, have been associated with a reduction in the risk of 
cancer, including colorectal cancer (70). 
The recognition that inflammation is complicit in carcinogenesis is such that it is now 
considered a hallmark of cancer, with both tumour-initiating and enabling characteristics 
(210).  However, counterbalancing this is the host anti-tumour immune response, hindering 
continued tumour growth and dissemination.  Most if not all tumours elicit a combination 
of both responses, with amelioration of anti-tumour immunity responsible for tumour 
progression (211).   
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The host inflammatory response 
Immunity and inflammation is controlled by a number of cell types and is ultimately 
responsible for protecting the host from pathogenic agents and injury.  At its most basic 
level, the inflammatory and immune response can be considered as comprising of innate 
(non-specific) and adaptive (acquired or specific) cellular immune responses, connected 
and communicating via non-cellular, humoural immune responses (212).  In addition to 
being responsible for the detection and elimination of microbes, the host inflammatory 
response is also capable of detecting aberrant host cells, including cancer cells, through the 
detection of neo-antigens. 
The innate immune response is primarily comprised of phagocytic and granulocytic cells 
such as neutrophils (the most abundant leukocyte type), macrophages, eosinophils, 
dendritic cells and natural killer cells amongst others (212).  Trauma and pathogens 
activate these cell types through pattern recognition receptors, with release of 
inflammatory cytokines and chemokines eliciting an inflammatory response and recruiting 
further inflammatory cell types to the site of injury.  Although generally self-limiting, the 
innate immune response may persist as a chronic inflammatory response, as is observed in 
the tumour microenvironment of many tumours (213). 
Adaptive immunity may be triggered by innate immunity and recognises ‘non-self’ 
antigens on microbes and cancer cells to provoke an immune response (214).  In addition 
to eliminating pathogens, this immune response results in an immunological memory so 
that subsequent exposure to the same pathogen mounts a rapid response.  The main 
effector cells of the adaptive immune response are T-lymphocytes and B-lymphocytes, 
which are activated by antigen presentation by antigen presenting cells such as dendritic 
cells.  B-lymphocytes elicit a humoral response with the release of immunoglobulins 
(antibodies) which bind to pathogens to enable their recognition by other immune cells.  T-
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lymphocytes orchestrate a cell-mediated response, with a number of different subsets 
recognised, including helper, cytotoxic, memory and regulatory T-lymphocytes.   
The humoural immune response is comprised of soluble macromolecules and links cellular 
components of the innate and adaptive immune responses.  Innate components, such as 
complement, opsonins and pentraxins, including CRP, can induce destruction of 
pathogenic cells through osmotic lysis and facilitating phagocytic cell activity.  Adaptive 
components include antibodies; in addition to assisting in pathogen recognition, antibody 
binding facilitates opsonisation and phagocytosis of pathogenic cells. 
It is increasingly recognised that subsets of T-lymphocyte populations, particularly helper 
T-lymphocytes, may be polarised to have vastly different functions with both pro-tumour 
and anti-tumour properties (215).  Whereas it was previously hypothesised that host innate 
and adaptive responses were respectively pro- and anti-tumour, it is increasingly 
appreciated that tumour-associated inflammation is far more intricate (Table 1.6).  Indeed, 
a complex cascade of both adaptive and innate immune cells, inflammatory cytokine 
mediators and intracellular transcription factors are involved.  Furthermore, the plasticity 
of such components of the host immune response mean that it is not just immune cell type, 
but the inflammatory milieu in which it is found which ultimately determines the nature of 
the tumour-associated inflammatory response. 
Inflammation as a tumour-initiating factor  
Chronic inflammation predisposes to carcinogenesis by increasing the rate of mutations 
within precursor cells through a number of mechanisms (215).  DNA damage may be 
precipitated by the release of reactive oxygen and nitrogen species from chronic 
inflammatory mediators, such as neutrophils and macrophages.  Further genomic 
instability also arises as a result of epigenetic silencing of MMR genes or direct 
inactivation of MMR enzymes.  Furthermore, pro-inflammatory cytokine signalling  
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Table 1.6 Anti-tumour and tumour-promoting roles of cellular components of the innate 
and adaptive immune response. Adapted from Grivennikov, et al. (215) 
Cell Type Anti-tumour activity Tumour-promoting 
activity 
Innate Immune Cell Population 
Neutrophils Direct cytotoxicity, 
regulation of cytotoxic T-
cells 
Production of 
inflammatory cytokines, 
proteases, reactive 
oxygen/ nitrogen species 
Macrophages 
Myeloid-derived 
suppressor cells 
Dendritic cells 
M1 phenotype: 
Antigen presentation, anti-
tumour cytokines (IL-12, 
IFN) 
M2 phenotype: 
Immunosuppression, 
production of 
inflammatory cytokines, 
chemokines, growth and 
angiogenesis factors 
Natural killer cells Direct cytotoxicity, 
production of cytotoxic 
cytokines 
 
Mast cells  Production of 
inflammatory cytokine, 
chemokines 
Adaptive Immune Cell Population 
B-cells Tumour-specific antibody 
production 
Production of 
inflammatory cytokines, 
mast cell activation, 
immunosuppression 
Cytotoxic T-cells (CD8+) Direct cytotoxicity, 
production of cytotoxic 
cytokines 
 
Helper T-cells (CD4+) Th1 phenotype: 
Regulation of cytotoxic T-
cells, anti-tumour cytokines 
Th17 phenotype: 
Regulation of cytotoxic T-
cells 
Regulatory: 
Regulation of inflammation 
Th2 phenotype: 
Stimulation/ education of 
macrophages, production 
of inflammatory 
cytokines 
Th17 phenotype: 
Production of 
inflammatory cytokines 
Regulatory: 
Immunosuppression, 
production of 
inflammatory cytokines 
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promotes cell growth and the development of a ‘stem cell’ phenotype in pre-malignant 
cells.  An increase in mutational burden itself is pro-inflammatory, further promoting a 
local chronic inflammatory state and perpetuating genomic instability (Figure 1.6). 
 
 
Figure 1.6 The relationship between tumour inflammation and genomic instability 
 
Inflammation as a tumour-enabling factor 
Chronic inflammation promotes tumour cell survival and eventual dissemination through a 
number of mechanisms.  Activation of intracellular signal transduction pathways, such as 
Janus-activated kinase/ signal transduction and activator of transcription (JAK/STAT), 
nuclear factor kappa-B (NF-ĸB) and cyclo-oxygenase-2 (COX-2) have a multitude of pro-
oncogenic effects, including increasing cell survival and proliferation and inhibition of 
apoptosis (211, 216, 217).  In addition, activation of such pathways results in increased 
synthesis of pro-inflammatory cytokines, including interleukin-6 (IL-6) IL-17 and IL-22, 
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chemokines and growth-related factors.  This cascade has a number of pro-tumour effects, 
including recruitment of inflammatory cells to the tumour microenvironment.  Recruited 
neutrophils, M2-polarised macrophages and Th2-, Th17- and regulatory helper T-cells 
further promote ongoing tumour growth by release of inflammatory cytokines and 
prostaglandins, in addition to pro-angiogenic and growth factors such as vascular 
endothelial growth factor (VEGF) and transforming growth factor-B (TGFB) (215).  This 
inflammatory milieu down-regulates host anti-tumour immune responses, inhibiting 
effective tumour infiltration and destruction by cytotoxic T-cells and natural killer cells.  In 
tandem with neo-angiogenesis and recruitment and transformation of resident fibroblasts to 
cancer-associated fibroblasts, this produces a tumour microenvironment supportive of 
tumour establishment and ongoing growth (218). 
The inflammatory response also plays an integral role in the transition to disseminated 
disease and establishment of metastases. Activated inflammatory cells and secreted 
metalloproteinases and collagenases allow tumour cells to migrate through normal tissue 
barriers.  The above processes may promote the loss of normal cell adhesion and epithelial-
mesenchymal transitioning (EMT), a vital process required for tumour cells to ‘break free’ 
and disseminate (216).  Furthermore, increased vascular permeability, which allows 
migration of inflammatory cells to the tumour microenvironment, may also allow tumour 
cells to migrate into the systemic vasculature.  Finally, activated platelets aggregate around 
disseminated tumour cells, essentially ‘shielding’ them and facilitating the establishment of 
distant organ metastases (219). 
Chemokines in cancer 
Chemotactic cytokines, or chemokines, and their receptors play an important role in 
tumour survival, progression and dissemination.  Chemokines are small peptides that 
mediate leukocyte migration (chemotaxis), however also facilitate normal and malignant 
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cell homeostasis (220, 221).  Although chemokines represent a molecular superfamily with 
distinct structural similarities, they are classified into four subfamilies based on the 
location of the first two cysteine residues in their structure: CC, CXC, CX3C and C (X 
represents other amino acid residues within their structure).  Similarly, chemokine 
receptors are named on the basis of their chemokine ligands, although each ligand may 
activate numerous receptors, and each receptor may be activated by a number of ligands 
(220). 
Chemokine and chemokine receptor expression within the tumour microenvironment is 
observed not only on cancer epithelial cells, but also on surrounding fibroblasts and 
immune and inflammatory cells (220).  In addition to promoting leukocyte infiltration, 
activation of chemokine receptors by their respective ligands also induces signal 
transduction pathways with resultant effects on the cell cycle, proliferation, angiogenesis 
and cell adhesion.  Similar to cellular components of the inflammatory response, individual 
chemokines may elicit both pro-tumoural and anti-tumoural responses depending on both 
the underlying cell type involved as well as the surrounding inflammatory milieu.   
It is increasingly apparent that chemokine activity plays an integral role in not only 
facilitating EMT, but also in the development of distant organ metastases (221, 222).  
Indeed, rather than only shaping the tumour microenvironment, chemokine activity may 
also explain the tropism for metastatic cancer cells to specific organ sites.  For example, 
CXCL12 expression in liver, lung and lymph nodes may promote migration of CXCR4-
expressing colorectal cancer cells to these sites and initiation of metastases (222).  
Consistent with this, expression of CXCR4 in primary colorectal tumours is associated 
with increased risk of liver metastases and poorer survival (223).  Given their multifaceted 
role in tumour biology, targeting of chemokines and chemokine receptors present one 
potentially attractive therapeutic option in patients with colorectal cancer (224). 
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Immune surveillance and cancer immunoediting 
The recognition of tumour infiltrating lymphocytes as a favourable prognostic factor gives 
plausible evidence for the role of immune surveillance as an important host anti-tumour 
mechanism (225).  However, it is clear that tumour cells may circumvent competent host 
immune responses through a number of mechanisms, recognised as the process of cancer 
immunoediting (226).  This process is thought to comprise of three phases: elimination, 
equilibrium and escape.  In the elimination phase, adaptive and innate immune responses 
readily recognise and destroy developing tumour cells, generating a T-cell-mediated 
response with immunological memory (227).  However, as this process continues, 
selection pressure allows for the survival of cancer cells with reduced immunogenicity and 
capable of survival in an immunocompetent environment (immune equilibrium).  As this 
progresses, host immune responses may be suppressed by a number of mechanisms, 
including down-regulation of tumour expression of major histocompatibility complex 
(MHC) class I expression, immune checkpoint activation and activation of 
immunosuppressive regulatory T-cells (211).  In turn, immune escape allows for ongoing 
tumour growth and dissemination.  Indeed, evidence of early metastatic spread in the 
absence of tumour infiltrating memory T-cells highlights the importance of tumour cells 
overcoming adaptive anti-tumour immunity to allow sustained growth (227). 
Inflammation and signal transduction pathways in cancer 
Intracellular signal transduction pathways control many facets of tumour cell growth and 
metabolism, in addition to influencing the host inflammatory response to cancer.  Two of 
the most commonly studied pathways in the context of colorectal cancer are the 
JAK/STAT3 and NF-ĸB pathways.  Both may be constitutively activated in neoplastic 
cells, more commonly through upregulation of upstream signalling rather than gain-of-
function mutations (217).  Although both STAT3 and NF-ĸB control normal physiological 
functions, activation in cancer cells leads to deregulation of several pro-tumour pathways 
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complicit in cell cycle progression, resistance against apoptosis and hypoxia, and 
angiogenesis.  Likewise, tumour cell activation of STAT3 and NF-ĸB may impair host 
anti-tumour immunity. 
Significant interaction exists between the STAT3 and NF-ĸB pathways.  At the 
transcriptional level, there is overlap between the gene promoters which may be targeted 
by either pathway, and co-stimulation by both may result in even greater transcriptional 
activity of candidate genes (228).  Furthermore, STAT3 and members of the NF-ĸB family 
may interact with each other; for example, STAT3 may induce NF-ĸB pathway activation, 
whereas members of the NF-ĸB family may inhibit STAT3 transcriptional activity (217, 
218). 
It is not surprising that NF-ĸB and STAT3 have been shown to play a pertinent role in both 
the initiation and progression of cancer.  STAT3 is hypothesised to play a pivotal role in 
colitis-associated carcinogenesis (54), and tumour cell expression of STAT3 has been 
associated with poorer survival of patients with colorectal cancer.  Of interest however, the 
role of both pathways with respect to initiation of carcinogenesis and manipulation of host 
inflammatory responses differs according to the cell type in which it is activated (Figure 
1.7) (229).  For example, whereas studies have shown that STAT3 ablation in normal 
colonic epithelial cells inhibits carcinogenesis (54), ablation in myeloid-derived cells 
enhances inflammation and carcinogenesis (230).  Conversely, STAT3 inhibition in 
lymphocytes may enhance anti-tumour immune responses (231).  Similarly, NF-ĸB shows 
differential activity on tumourogenesis and host immunity dependent on the studied cell 
type (217). Both STAT3 and NF-ĸB may be potential therapeutic targets with effects not 
only on tumour cell growth, but also host anti-tumour immune responses.  However, given 
the plasticity of their effects on host immunity and tumour growth depending on the 
studied cell type, and the significant interaction between both pathways, further 
investigation of the effects of targeted inhibition is warranted. 
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Figure 1.7 Tumour and immune cell STAT3 and NF-ĸB activation and their effects on 
tumour cell survival. Figure from Grivennikov and Karin (217) 
 
Inflammation in cancer – summary 
Inflammation plays an integral role in not only the elimination, but also the initiation and 
progression of cancer.  Although host anti-tumour immune responses may identify and 
destroy nascent and established cancer cells, this may be circumvented by a number of 
mechanisms.  Furthermore, as the tumour progresses, host inflammatory responses may be 
recruited to promote sustained tumour growth and dissemination.  Underlying signal 
transduction pathways, such as STAT3 and NF-ĸB control numerous aspects of the host 
immune and inflammatory response to cancer, and ultimately may yield potential 
therapeutic targets. 
1.6.2 The local inflammatory response and prognosis of patients with 
colorectal cancer 
Given the above, it is not surprising that the local inflammatory infiltrate has been 
identified as a prognostic factor in patients with colorectal cancer.  Since initial reports 
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over 80 years ago, a multitude of studies have reported improved survival in association 
with the presence of a conspicuous inflammatory cell infiltrate (225).  Indeed, it is now 
clear that assessment of the inflammatory infiltrate may inform prognosis independent of 
TNM staging and molecular characterisation of colorectal cancer (201, 232). 
Early reports primarily considered the presence of the generalised inflammatory cell 
infiltrate, encompassing both adaptive and innate immune cells, utilising H&E-stained 
specimens.  As immunohistochemistry and molecular techniques have evolved, specific 
immune cell types, particularly T-lymphocyte subsets, and their location within the tumour 
microenvironment have been increasingly studied.  However, it is of considerable interest 
that reports have shown these differing approaches strongly correlate; as the generalised 
peritumoural inflammatory cell infiltrate increases in density, lymphocyte density also 
increases, whereas neutrophil and macrophage density decreases (233). 
Taken together, this would suggest that a conspicuous generalised inflammatory cell 
infiltrate signifies a co-ordinated anti-tumour response whereas an attenuated response 
represents a chronic, innate-driven pro-inflammatory response.  However, whether crude 
assessment of the generalised inflammatory cell infiltrate offers similar prognostic value to 
more refined assessment of immune cell type, density and location remains to be 
determined.  Furthermore, whether this information can be utilised to decide treatment is 
unclear.  Indeed, it has been suggested that patients with a conspicuous inflammatory cell 
infiltrate, and as such a good prognosis, may be more likely to respond to 5-FU-based 
chemotherapy, whereas those patients with a poor response, and as such deemed high risk, 
may be less likely to gain benefit from adjuvant chemotherapy (234). 
Despite reflecting the host anti-tumour immune response, several pathological 
characteristics may influence the density of the local inflammatory cell infiltrate, and as 
such may confound its clinical utility.  For example, the presence of extensive tumour 
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necrosis has been associated with loss of the local inflammatory cell infiltrate in colorectal 
cancer (235).  Similarly, stromal infiltration may result in ineffective immune cell 
infiltration of the tumour microenvironment (236, 237).  Although not previously 
examined in the context of colorectal cancer, peri-tumoural oedema has previously been 
shown to correlate with the density of the local inflammatory cell infiltrate (238), and may 
also influence the local tumour microenvironment of patients with colorectal cancer.  
Whether such factors influence only density and not the nature of the local inflammatory 
cell infiltrate, remains to be fully determined.  However, such factors may make 
assessment of the local inflammatory cell infiltrate more difficult, confounding its clinical 
utility. 
Assessment of the generalised inflammatory cell infiltrate 
Assessment of the generalised inflammatory cell infiltrate utilising H&E-stained 
specimens has shown considerable interest due to its reliance on routine specimens, and 
low associated costs.  To date however, these measures have failed to translate into routine 
clinical practice due to a number of reasons, including lack of standardisation and 
validation as well as concerns regarding reproducibility. 
Jass Criteria 
One of the earliest and most recognised assessments of the tumour inflammatory cell 
infiltrate in colorectal cancer was described by the pathologist Jeremy Jass in the 1980s.  
Jass first published on the inflammatory cell infiltrate of rectal cancers as an independent 
prognostic factor in 1986, describing the presence of a pronounced lymphocytic infiltrate 
at the invasive margin of the tumour (239).  Alongside this, he recognised the presence of a 
connective tissue lamina, resembling the lamina propria, which he hypothesised as a 
barrier to continued tumour growth.  Subsequently, in 1987, assessment of the 
inflammatory cell infiltrate was incorporated into a five-point pathological scoring system 
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for rectal cancer which was able to stratify survival at five years from 94% to 27% (240).  
Using Jass criteria (Figure 1.8), alongside growth limited to the bowel wall, a low burden 
of lymph node metastases and an expanding invasive margin, the presence of a “distinctive 
and delicate connective tissue mantle or cap at the invasive margin of the growth in which 
lymphocytes and other inflammatory cells were scattered” is recognised as a good 
prognostic feature. 
The Jass criteria has failed to translate into clinical practice, partly due to limited clinical 
utility when compared to other assessments of the local inflammatory cell infiltrate and 
even conventional Dukes’ staging (241-243).  Furthermore, difficulties with respect to 
reproducibility outside of specialist pathology units has limited its routine adoption (242, 
244). 
 
Figure 1.8 The Jass criteria for the prognostic classification of rectal cancer. Adapted from 
Jass, Love et al. (240) 
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TABLE I-VARIABLES SELECTED BY COX REGRESSION ANALYSIS
*Coding: lymph nodes (1)=0, (2) =1&mdash;4, (3)=>4; invasive margin
(1) = expanding (2) = infiltrating; lymphocytes (1) = conspicuous
(2) = "other"; spread (1) = none, (2) = slight, (3) = extensive.
The following stage-related variables were obtained from the
records of the pathology department:
Venous invasion.-cases were divided into those with
invasion of muscular extramural veins and those without such
invasion.
Lymph-node metastasis.-This was grouped as none, 1-4
nodes, and more than 4 nodes involved.
Metastasis within the apical lymph Mo<&.&mdash;The apical node is
that immediately beneath the ligature placed at the origin of the
inferior mesenteric artery.
Extent of direct spread.-This was described as none (limited
to the rectal wall), slight to moderate (spread beyond the rectal
wall), and extensive. Extent of spread beyond the bowel wall
was based on a subjective assessment made at the time of the
original dissection.
All cancers had been staged by the method of Dukes’ (A,
confined to the rectal wall, lymph nodes negative; B, extending
beyond the rectal wall, lymph nodes negative; Cl, lymph node(s)
invaded by tumour, irrespective of extent of spread; C2, apical
lymph node invaded by tumour).
Data relating to the eight discrete pathological variables were
entered into a mainframe computer and analysed by standard
univariate survival methods and by Cox regression analysis
(program BMDP2L) to identify variables influencing survival
independently.8,lo Patients who died within thirty days of surgery
were excluded from the analysis and only deaths attributable to
recurrent cancer were included as events. Appropriately weighted
scores (based on regression coefficients) were awarded to the
selected variables and the range of scores was divided to give four
groups of patients with differing prognosis.
A second set of 331 patients operated upon between 1965 and
1969 was selected and studied in exactly the same manner as the
first, except that long-term follow-up (in excess of 15 years) had
been less stringent. Because virtually no cancer deaths occurred
after 10 years the effect of this difference in follow-up was merely to
alter the ratio of patients who were known to be alive or dead from
unrelated causes. The patients were grouped into prognostic
categories by means of the previously derived model. 95 %
confidence bands for prognostic groups I-IV derived from the first
data set were calculated by Hall and Wellner’s method. Survival
curves for prognostic groups I-IV from the second data set were
drawn on the same graph. Finally the two data sets were combined
and the new system of prognostic grouping was compared with the
Dukes classification.
RESULTS
Four variables were selected by means of Cox regression
analysis as having an important and independent influence
upon survival-number of lymph nodes with metastatic
tumour, character of invasive margin, peritumoural
lymphocytic infiltration, and local spread (table l).
However, it was necessary only to grade spread as within or
Fig I-Scoring system for pathological variables selected by virtue
of their independent influence upon survival.
Key for converting the total score for each case into a prognostic group is
shown in the lower box.
beyond the rectal wall, since extent of spread beyond the
bowel wall (assessed subjectively as slight to moderate
versus extensive) did not contribute significantly to the
prognostic model. Histological type, grade of
differentiation, venous invasion, and metastatic spread to
the apical lymph node also had no additional influence upon
survival in the presence of the selected variables. The
scoring system for the four variables is depicted in fig 1
together with the derivation of the four prognostic groups.
Group I comprised 31 % of the patients, with a 96% 5-year
survival. Group II comprised a further 31% of patients,
with an 85% 5-year survival. 18% of the patients were in
group III and had a 67% 5-year survival. The remaining
20% of patients were placed in group IV with only 27%
survival at 5 years. When the scoring system was applied to
the second data set, similar survival results were obtained. In
fig 2 survival curves for the second data set are superimposed
on areas depicting the 95% confidence bands for survival
curves derived from the first data set. Details of the survival
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Crohn’s-like lymphoid reaction 
It is recognised that the host anti-tumour immune response may manifest as nodular 
lymphoid aggregates deep to the invasive margin of the tumour in patients with colorectal 
cancer (Figure 1.9).  Given its similarity to histopathological features identified in patients 
with Crohn’s disease, Graham and Appelman termed this the Crohn’s-like lymphoid 
reaction (CLR), and reported its semi-quantitative assessment as a potential good 
prognostic factor (245).  Subsequent reports confirmed the presence of a conspicuous CLR 
as a prognostic factor, independent of both pathological and molecular characteristics of 
the tumour (201, 246).  In addition, several groups have reported assessment of the CLR as 
a useful method for identifying MSI tumours, recommending further testing for those with 
a dense CLR (246, 247).  However, similar to Jass criteria, difficulties with respect to its 
subjective nature and reproducibility have prevented mainstream acceptance. 
 Klintrup-Mäkinen grade 
A more recently reported assessment of the peritumoural generalised inflammatory cell 
infiltrate is the Klintrup-Mäkinen (KM) grade (248).  Based on semi-quantitative 
assessment, it describes not only the density of inflammatory cells at the invasive margin, 
but also the presence of active destruction of cancer cell islets by immune cells (Table 1.7, 
Figure 1.9).  Detailed studies of the components of a weak and high KM grade have found 
an increase in the abundance of lymphocytes with increasing density (233), suggesting that 
it may be a useful surrogate for more detailed studies of the local inflammatory cell 
infiltrate and its nature. 
The presence of a high KM grade has been validated as a predictor of improved survival in 
patients with node negative and node positive colorectal cancer (233, 243, 248, 249), and 
has been identified as a prognostic factor in a number of other solid organ cancers, 
including oesophageal and breast cancer (250, 251).  In addition, assessment of KM grade 
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has been shown to have acceptable inter-operator variability (248).  Given this, its reliance 
on routinely available tumour specimens, and its informative nature with respect to both 
the density and activity of the inflammatory cell infiltrate, it provides a useful tool which 
may be readily applied in routine clinical practice.  Further prospective validation studies, 
particularly in the context of adjuvant therapy clinical trials are warranted. 
Table 1.7 Klintrup-Mäkinen score and grade for the assessment of the generalised local 
inflammatory infiltrate at the invasive margin of colorectal cancer 
Klintrup-Mäkinen 
score 
Description Grade 
0 No increase in inflammatory cells at invasive margin Low 
grade 1 Mild/patchy increase in inflammatory cells at invasive 
margin 
2 Prominent inflammatory reaction forming a band at the 
invasive margin 
High 
grade 
3 Florid cup-like infiltrate at the invasive edge with 
destruction of cancer cell islands evident 
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Figure 1.9 Examples of the generalised inflammatory cell infiltrate in colorectal cancer as examined using haematoxylin & eosin stained sections of the 
invasive margin. (A) Crohn’s-like lymphoid reaction, (B) high Klintrup-Mäkinen grade displaying florid cup-like infiltrate at the invasive edge with 
destruction of cancer cell islands, and (C) low Klintrup-Mäkinen grade displaying no increase in inflammatory cells at the invasive margin. (A) adapted 
from Ueno, Hashiguchi et al. (252) 
A 
B C 
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Assessment of the T-lymphocyte inflammatory infiltrate 
Advances in immunohistochemistry and molecular techniques have led to increasing 
interest in the assessment of immune cell subsets within the local inflammatory cell 
infiltrate of patients with colorectal cancer (225).  Of these, one of the most studied cell 
types has been tumour infiltrating T-lymphocytes.  Composite scores, based on 
immunohistochemistry-based assessment of multiple T-lymphocyte subtypes, their density 
and their location within the tumour microenvironment have been proposed and have been 
reported as having superior prognostic value when compared to conventional TNM-based 
staging. 
CD3+ T-lymphocytes 
Mature T-lymphocytes express CD3, and as such it has been one of the most widely 
reported markers of T-lymphocyte density in patients with colorectal cancer (225).  
Generally, CD3+ T-cell density has been associated with increased survival and decreased 
disease recurrence.  Several studies have identified associations between decreasing 
density of CD3+ T-cells and the presence of adverse pathological characteristics such as 
increasing T stage, the presence of lymph node metastases, and venous, lymphatic and 
perineural invasion (227, 253).  Furthermore, MSI status is strongly associated with CD3+ 
density within the tumour microenvironment (254).  Despite these associations, CD3+ T-
cell density has been shown to have prognostic value independent of such characteristics. 
CD8+ cytotoxic T-lymphocytes 
Cytotoxic T-lymphocytes express CD8 and are an important mediator of the host cytotoxic 
response to pathogens and tumour cells.  Multiple studies have identified the density of 
CD8+ T-cells as an independent prognostic factor in patients with both localised and 
metastatic disease (225).  In addition, several groups have reported the prognostic value of 
assessment of CD8+ T-cell density in combination with other components of the tumour 
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microenvironment.  For example, Lugli and colleagues reported that combined assessment 
of CD8+ T-cells and tumour budding was an independent prognostic factor, and provided a 
more comprehensive representation of pro-tumour and anti-tumour characteristic than 
either measure alone (255). 
CD45RO+ memory T-lymphocytes 
Once an immunological response to an antigen has occurred, immunological memory of 
the encounter is maintained by memory T-lymphocytes.  These T-lymphocytes undergo a 
conformational change, expressing CD45RO and are able to mount a cytotoxic immune 
response much more rapidly on re-exposure.  As such, their presence within the 
microenvironment is of considerable interest.  Similar to other T-lymphocyte subsets, 
memory T-cell density is strongly associated with MSI status (256), likely due to the 
increased burden of tumour neo-antigens capable of eliciting immunological memory.  
Furthermore, an increased density of CD45RO+ T-cells within the tumour 
microenvironment is associated with favourable pathological characteristics, such as less 
frequent lymphatic, perineural and venous invasion (227).  Several studies have reported 
memory T-lymphocyte density as an independent prognostic factor in patients with 
colorectal cancer (225). 
 The Immunoscore 
Although individual T-lymphocyte subsets have shown varying prognostic value in 
patients with colorectal cancer, it is increasingly apparent that assessment of a single 
immune cell type fails to encompass the complex immune and inflammatory milieu present 
within the tumour microenvironment.  For this reason, several groups have proposed 
assessment of multiple immune cell types to provide more comprehensive characterisation.  
One such score is the Immunoscore proposed by Galon and Pagès (257), and based on the 
premise that it is not only immune cell type, but density and location within the tumour 
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microenvironment which are important determinants of the host anti-tumour immune 
response and therefore outcome. 
Genomic studies of the tumour microenvironment by this group identified that the presence 
of a Th1-polarised adaptive immune response was associated with favourable outcome of 
patients with colorectal cancer (232).  Furthermore, the presence of T-lymphocytes 
associated with a Th1-type response, namely those expressing CD3+, CD8+, CD45RO+ and 
granzyme B+, was associated with increased survival.  Interestingly, combined assessment 
of multiple immune cell types and at different locations within the tumour 
microenvironment stratified survival greater than individual immune cell assessment 
within a single region, and had greater prognostic utility than conventional TNM-based 
staging.  Indeed, the authors subsequently postulated that assessment of the ‘immune 
contexture’ as they termed it provides a comprehensive assessment of effective anti-
tumour immunity, and therefore may more accurately predict patients at high risk of 
disease recurrence (258). 
Further validation studies have confirmed the Immunoscore as a stage-independent 
prognostic marker in patients with colorectal cancer, including in the context of node 
negative disease (259, 260).  Although originally proposed as an assessment of the density 
of cytotoxic and memory T-cells, difficulties with respect to staining and assessment of 
CD45RO+ T-lymphocytes has led to subsequent revisions (257).  The Immunoscore now 
reflects the density of CD3+ and CD8+ T-lymphocytes within the tumour core and invasive 
margin, providing five prognostic groups (Figure 1.10).  A standardised protocol for the 
assessment of Immunoscore has been proposed and is now the subject of an ongoing, 
international validation study (257).  
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Figure 1.10 The Immunoscore – an assessment of CD3+ and CD8+ T-lymphocyte density 
within the tumour core (CT) and invasive margin (IM). Figure from Galon, Pagès, et al. 
(257) 
 
The local inflammatory response and prognosis of patients with colorectal 
cancer – summary 
Multiple studies have confirmed the local inflammatory cell infiltrate as a predictor of 
survival of patients with colorectal cancer. To this effect, numerous scoring systems, based 
on both assessment of the generalised inflammatory cell infiltrate as well specific immune 
cell subsets, have been proposed.  However, the validity and reproducibility of these scores 
as well as their clinical utility in the routine staging of patients with colorectal cancer 
remain in question. The Immunoscore, an assessment of immune cell type, density and 
location, is currently the subject of an international validation study.  However, whether 
such a score, reliant on immunohistochemistry with its inherent complications and added 
costs is superior to more comprehensive assessment of the generalised inflammatory cell 
infiltrate using routine pathological specimens, remains to be determined.  
1.6.3 The systemic inflammatory response and prognosis of patients with 
colorectal cancer         
The systemic inflammatory response is a normal physiological reaction, occurring as a 
rapid non-specific response to tissue injury.  Complement and pentraxin activation, 
leukotriene and prostaglandin and pro-inflammatory cytokine release may all stimulate the 
Figure 1
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systemic inflammatory response as a result of tissue trauma or infection. What follows is a 
complex cascade of changes in circulating inflammatory cytokines and inflammatory and 
immune cell activity, with a number of local and systemic effects targeted at containing 
and eliminating the injuring stimuli and initiating tissue repair.  In addition to initiating a 
stress response, with an increase in heart rate, blood pressure and catecholamine and 
steroid release, a number of other key physiological effects occur as part of the systemic 
inflammatory response (261) (Table 1.8).  Although normally self-limiting due to 
endogenous anti-inflammatory cytokines, such as IL-10 (262), a chronic systemic 
inflammatory response may occur.  In such circumstances, many of the physiological 
effects occurring are detrimental to host immune competence and may impact on recovery 
from both surgery and chemotherapy. 
Table 1.8 Physiological effects of the systemic inflammatory response. Adapted from 
Gabay and Kushner (261) 
System Effects 
Neuroendocrine Fever, somnolescence, anorexia 
Increased secretion of endogenous steroids, vasopressin and 
catecholamines 
Decreased synthesis of insulin-like growth factor I 
Haematopoietic Anaemia 
Leukocytosis 
Thrombocytosis 
Metabolic Muscle loss 
Decrease gluconeogenesis 
Osteoporosis 
Cachexia 
Hepatic Changes in hepatic acute phase protein synthesis 
Changes in drug metabolism 
 
The systemic inflammatory response in cancer 
The systemic inflammatory response in malignancy is multifactorial in origin (263), 
involving tumour cell secretion of pro-inflammatory cytokines and activation of 
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inflammatory cells.  Furthermore, tissue hypoxia is a common feature of many solid organ 
tumours and an important precipitant of the systemic inflammatory response in patients 
with cancer (264).  In such circumstances, systemic inflammation favours tumour growth 
and dissemination by a number of mechanisms.  As described above, these include 
promotion of tumour growth and angiogenesis through pro-inflammatory cytokine and 
growth factor secretion, subversion of host anti-tumour immunity, and facilitating tumour 
dissemination throughout the systemic circulation (263).  
The presence of a measurable systemic inflammatory response is a marker of poor 
prognosis in patients with cancer and may drive many of the characteristics associated with 
advanced disease.  Studies in patients with advanced malignancy identified the presence of 
an elevated systemic inflammatory response as being strongly associated with poor 
functional status, weight loss and reduced survival (265-267).  Indeed, it is increasingly 
appreciated that chronic inflammation is a key component of the cancer cachexia syndrome 
(268), and may be a potential therapeutic target in its management (266). 
Even in the context of non-metastatic disease, systemic inflammation is now recognised as 
an important determinant of survival.  Independent of disease stage, the presence of a 
systemic inflammatory response has been associated with poorer survival (269).  
Furthermore, many of the physiological effects of inflammation may have detrimental 
effects following treatment, such as increased risk of complications following surgery, and 
impaired response to and tolerance of chemotherapy (270, 271). 
Measuring the systemic inflammatory response in patients with colorectal 
cancer 
Changes in circulating protein concentrations, known as the acute phase response, occur 
rapidly in the hours and days following initiation of the systemic inflammatory response 
(261) (Figure 1.11).  The pro-inflammatory cytokine, IL-6, is the primary mediator of 
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many of these changes, influencing hepatic synthesis of acute phase reactants (272).  In 
addition, changes in circulating immune cell numbers, particularly an increase in 
neutrophils and decrease in lymphocytes, are also evident.  Such changes in inflammatory 
cell numbers and acute phase protein concentrations may be utilised to examine and 
monitor the systemic inflammatory response (271). 
 
Figure 1.11 Changes in acute phase protein concentrations following initiation of a 
systemic inflammatory response. Figure from Gabay and Kushner (261) 
 
Based on our knowledge of these biochemical and haematological parameters, a number of 
scores have been proposed to measure the cancer-associated systemic inflammatory 
response and predict survival (Table 1.9).  One such score is the Glasgow Prognostic Score 
(GPS), a cumulative score derived from serum CRP and albumin concentrations (267).  
The prototypical acute phase protein, CRP, is a sensitive and routinely available marker of 
the systemic inflammatory response with demonstrable changes in serum concentrations 
(273).  Similarly, serum albumin displays a clear change in circulating levels in the 
presence of a systemic inflammatory state.  As such, the GPS offers a routinely available 
and simply calculated measure of the systemic inflammatory response with prognostic 
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Post-translational changes in the glycosylation of plas-
ma proteins during inflammatory states include al-
terations in oligosaccharide branching,
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sialylation of orosomucoid,
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 and decreased galactos-
ylation of IgG.
 
25
 
 Changes in oligosaccharide branch-
ing are induced by inflammation-associated cytokines,
independently of their effects on the production of
acute-phase proteins. Finally, the efficiency of secre-
tion of C-reactive protein, a process distinct from its
synthesis, is greatly increased during the acute-phase
response.
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Regulation of Other Acute-Pha  Chang s 
by Inflammation-Associated Cytokines
 
Fever is representative of the neuroendocrine
changes that characterize the acute-phase response.
Although several cytokines may induce fever, inter-
leukin-6 produced in the b ain stem is required for
the final steps leading to fever.
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 However, cytokines
are not the sole inducers of fever; the recent finding
that subdiaphragmatic vagotomy blocks fever after
intraperitoneal (but not intramuscular) injection of
lipopolysaccharide implicates neural transmis ion in
the febrile response.
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 Other neuroendocrine chang-
es reflect complex interactions among cytokines, the
hypothalamic–pituitary–adrenal axis, and other com-
ponents of the neuroendocrine system.
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 For exam-
ple, inflammation-associated cytokines stimulate the
production of corticotropin-releasing hormone, with
consequent stimulation of corticotropin and cortisol
production, and also directly stimulate the adrenal
gland. Stimulation of the production of arginine
vasopressin by interleukin-6 can explain the hypo-
natremia that occurs during some inflammatory dis-
orders.
The behavioral changes that often accompany in-
flammation, including anorexia, somnolence, and
lethargy, are similarly induced by cytokines. Neural
mechanisms have also been implicated in anorexia;
as with fever, vagal afferents are required for the in-
duction of anorexia after intraperitoneal injection of
interleukin-1
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 and lipopolysaccharide. Increased plas-
ma leptin concentrations occur in inflammation,
probably in response to stimulation of adipocytes by
cytokines, and may also contribute to anorexia.
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Inflammation-associated cytokines have been im-
plicated in the pathogenesis of anemia in chronic
disease; examples of their involvement include the
decreased responsiveness of erythrocyte precursors
to erythropoietin, decreased production of erythro-
poietin, and impaired mobilization of iron from mac-
rophages.
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 Hypoferremia results largely from the
sequestration of iron in macrophages by apoferritin
produced in response to the inflammation-associat-
ed cytokines interleukin-4 and interleukin-13.
 
32 
 
The
thrombocytosis of inflammation appears to be caused
by interleukin-6.
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 Finally, cachexia, the loss of body
mass that occurs in severe chronic inflammatory dis-
ease, results from decreases in skeletal muscle, fat tis-
sue, and bone mass. Interleukin-1
 
b
 
, interleukin-6,
tumor necrosis factor 
 
a
 
, and interferon 
 
g
 
 all contrib-
ute to these processes.
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Inflammation-associated cytokines also alter many
intracellular hepatic constituents, including induc-
ible nitric oxide synthase, manganese superoxide dis-
mutase, and microsomal heme oxygenase. Interleu-
kin-6 increases the production of the metal-binding
protein metallothionein, with consequent increased
zinc binding and hypozincemia. Interleukin-1
 
b 
 
and
tumor necrosis factor 
 
a
 
 decrease the expression of
growth-hormone receptors on hepatocytes, with sub-
sequent decreased responsiveness to growth hormone
and low plasma concentrations of insulin-like growth
factor I.
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Transgenic mice that overexpress interleu-
kin-6 have low plasma concentrations of insulin-like
growth factor I and are smaller than normal mice.
This finding suggests that increased production of
inflammation-associated cytokines may explain, at
least in part, impaired growth in children with chron-
ic inflammatory conditions.
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POSTULATED FUNCTION OF THE 
ACUTE-PHASE RESPONSE
 
The assumption that the changes in plasma con-
centrations of acute-phase proteins are beneficial is
based largely on the known functional capabilities of
the proteins and on logical speculation as to how
these might serve useful purposes in inflammation,
 
Figure 1.
 
 Characteristic Patterns of Change in Plasma Concen-
trations of Some Acute-Phase Proteins after a Moderate Inflam-
matory Stimulus.
Modified from Gitlin and Colten
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 with the permission of the
publisher.
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value.  This score was later revised to reflect the fact that hypoalbuminaemia in the 
absence of an elevated CRP did not reflect a chronic inflammatory state and was not 
associated with survival (269).  Using the modified GPS (mGPS) it was possible to stratify 
cancer-specific survival of patients undergoing potentially curative resection of colorectal 
cancer from over 90% to approximately 50% at three years (269).  Prognostic scores based 
on components of the differential white cell count have also been proposed.  For instance, 
the neutrophil: lymphocyte ratio (NLR) (274), and the platelet: lymphocyte ratio (PLR) 
(275), have been proposed as inflammation-based prognostic scores in patients with 
cancer. 
Table 1.9 Systemic inflammation-based prognostic scores in patients with cancer 
Prognostic score Components Score 
Modified Glasgow 
Prognostic Score 
C-reactive protein ≤ 10mg/l and albumin ≥ 35g/l 
C-reactive protein > 10mg/l  
C-reactive protein > 10mg/l and albumin < 35g/l 
0 
1 
2 
Neutrophil: 
Lymphocyte 
Ratio 
Neutrophil count : lymphocyte count < 5:1 
Neutrophil count : lymphocyte count ≥ 5:1 
0 
1 
Platelet: 
Lymphocyte 
Ratio 
Platelet count : lymphocyte count < 150:1 
Platelet count : lymphocyte count 150-300:1 
Platelet count : lymphocyte count > 300:1 
0 
1 
2 
 
The systemic inflammatory response and prognosis of patients with colorectal 
cancer – summary 
The systemic inflammatory response represents one way by which the tumour may utilise 
normal, physiological host inflammatory responses to facilitate disease progression.  In 
addition to underpinning many of the mechanisms responsible for tumour growth and 
dissemination, it is clear that a chronic systemic inflammatory response is also a key 
mediator of functional and nutritional decline in patients with advanced cancer.  
Furthermore, even in the context of potentially curative disease, assessment of systemic 
inflammatory profiles may aid in determining prognosis. 
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1.7 Local and systemic inflammatory responses as therapeutic targets in 
patients with colorectal cancer 
Given the observed prognostic value of the host local and systemic inflammatory response 
in patients with colorectal cancer, therapeutic targeting presents an intriguing concept, 
particularly in patients with an “unfavourable” inflammatory profile.  Immunotherapeutics, 
targeting host immunity to promote an effective anti-tumour immune response through 
several mechanisms, have been investigated in patients with colorectal cancer.  Despite 
this, most studies to date have been in the context of metastatic, non-chemotherapy naïve 
patients, and have largely been limited to Phase II clinical trials with limited benefit. 
However, it is increasingly apparent that other drugs, currently licensed for non-cancer 
indications, may have potentially favourable effects on cancer-associated inflammation, 
and thus may be repurposed for use in patients with cancer.  Indeed, compared to novel 
agents, such drugs, including aspirin, NSAIDs, statins and histamine-2 receptor antagonists 
(H2RAs), provide an attractive option given their extensive safety profiles and relatively 
cheap cost.  Furthermore, the wealth of data available from historical clinical trials as well 
as population-level studies has allowed post-hoc exploration of their potential 
chemotherapeutic role in patients with colorectal cancer. 
Aspirin and NSAIDs, including COXIBs, have been identified as potential 
chemotherapeutic drugs which may favourably manipulate the inflammatory response in 
colorectal cancer.  Despite convincing evidence from epidemiological studies and 
cardiovascular secondary prevention trials of a chemoprophylactic effect in reducing 
colorectal cancer incidence and mortality (276, 277), it is relatively recently that a potential 
benefit in patients with established disease has been realised, with NSAID users less likely 
to present with advanced or metastatic disease at diagnosis or follow-up (278, 279).  
Emerging evidence of as much as a 40% reduction in mortality in patients undergoing 
curative treatment makes the concept of the use of NSAIDs as adjuvant treatment in high 
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risk disease more compelling (70, 280-285).  In such circumstances, the potential survival 
benefits may outweigh the risks which have so far precluded their use in CRC prevention 
(71).  
Similarly, statins and H2RAs have also been identified as drugs with a potential benefit in 
improving survival and reducing risk of recurrence in patients with established colorectal 
cancer.  A direct effect on tumour biology has been proposed through manipulation of 
several key signalling pathways, with a resultant effect on several of the key hallmarks of 
carcinogenesis, including proliferative and anti-apoptotic capacity as well tumour-
mediated angiogenesis and invasiveness (210).  Furthermore, these drugs have also been 
identified as potential agents capable of manipulating the host systemic and local 
inflammatory response to colorectal cancer (Table 1.10).  Although the use of such drugs 
to manipulate the tumour and local and systemic environment in colorectal cancer presents 
an attractive concept, most evidence to date arises from in vitro and in vivo investigations, 
with little confirmation from clinical studies. In particular, there has been no attempt to 
stratify the use of anti-inflammatory agents and subsequent benefit in patients according to 
the presence of a systemic inflammatory response. 
1.7.1 Immunotherapy 
Efforts to employ immunotherapy in patients with colorectal cancer have concentrated on 
upregulating the host anti-tumour immune response.  Over the past three decades, 
numerous treatment strategies have been employed; although cytokine therapy and toll-like 
receptor agonists have been investigated, most studies to date have examined cancer 
vaccines, adoptive cell transfer and immune checkpoint inhibition (286). 
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Vaccines 
Cancer vaccines aim to upregulate anti-tumour immunity and cancer cell destruction by 
promoting the host’s natural immune response to altered self-antigens, as loss of this 
normal physiological process is thought to contribute to immune evasion by cancer cells.  
Vaccines can be generated using several techniques which have shown varying success.  
Autologous vaccines utilise tumour cells removed from the patient to ensure that all 
potential tumour-associated antigens are included (286).  However, tumour cells also share 
numerous normal self-antigens which are present on non-malignant cells, thereby limiting 
efficacy.  Other techniques to establish vaccines have been investigated, such as the use of 
specific short chain peptides, including CEA (287), to target tumour-specific antigens.  
Similarly, dendritic cell vaccines and viral or bacterial vectors have been utilised to 
increase immunogenicity (286).  Most studies to date have been performed in patients with 
metastatic disease, with varying results.  Of interest however, two phase III studies 
investigated the use of autologous cell vaccines in patients with stage II and stage III colon 
cancer.  The results were conflicting; whereas Vermorken and colleagues found a reduced 
risk of recurrence in the study group, particularly in patients with stage II disease (288), the 
study by Harris and colleagues found no significant difference in survival (289).  However, 
sub-group analysis of patients in the Harris study suggested a potential, albeit not 
statistically significant, improved survival in patients with a pronounced delayed cutaneous 
hypersensitivity reaction following repeated vaccination.  It was suggested that this may 
reflect heterogeneity in vaccine quality within the study; however taking the presence of a 
cutaneous reaction as a surrogate for vaccine quality, the study did propose a benefit in 
patients who had been effectively immunised. 
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Adoptive cell transfer 
Adoptive cell transfer utilises autologous T-lymphocytes which have been harvested from 
the tumour.  These are then activated and the cell population expanded before transfusion.  
By activating the T-lymphocytes ex vivo, in vivo immune inhibition can be circumvented 
(290).  Other techniques to enhance immunogenicity include genetically modifying cells to 
increase affinity for T-lymphocyte receptors, or depletion of regulatory T-lymphocytes 
with cyclophosphamide before cell transfusion to inhibit host immunosuppression.  
Although early phase I/II studies identified treatment toxicity as a significant concern 
(286), a more recent study of patients with metastatic colorectal cancer found good 
tolerability and a significant improvement in survival in treated patients (291). 
Immune checkpoint inhibition 
Immune checkpoint activation is one means by which the immune system confers 
tolerance against self-antigens (292).  Recent studies of immunotherapy in patients with 
colorectal cancer have been founded on the premise that activation of these checkpoints by 
the tumour may circumvent host anti-tumour immunity.   
Inhibition of two specific T-lymphocyte checkpoint receptors – CTLA-4, which prevents 
immune stimulation, and PD-1, which induces T-lymphocyte anergy, have been 
investigated in patients with colorectal cancer.  Initial studies of a CTLA-4 inhibitor, 
tremelimumab, have shown little response (293).  Conversely, a phase II study of 
pembrolizumab, a PD-1 inhibitor, observed improved progression-free survival in patients 
with MMR deficient metastatic colorectal cancer, but not those with MMR competent 
disease (294).  This is consistent with studies which have identified immune checkpoint 
activation as a consistent feature of patients with MMR deficient tumours (295).  Although 
suggesting a role for immune checkpoint inhibition in the treatment of patients with MMR 
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deficient colorectal, whether a subset of patients with MMR competent tumours will 
similarly benefit remains to be determined. 
1.7.2 Aspirin, NSAIDs and COX-2 inhibitors 
Recent evidence has suggested a potential beneficial effect of NSAIDs on colorectal cancer 
progression, with as much as a 40% reduction in cancer-specific mortality with regular 
aspirin and NSAID use (70, 282-285).  Rothwell and co-workers suggested that the 
observed reduction in mortality apparent on secondary analysis of cardiovascular disease 
prevention trials was greater than what would be expected as a result of a NSAID-mediated 
decrease in cancer incidence alone (70).  In addition, evidence that NSAID users are less 
likely to present with advanced or metastatic disease at diagnosis or follow-up further 
supports a direct effect on progression of established disease (278, 279). 
Given such compelling evidence of an NSAID-mediated effect on established colorectal 
cancer, it is not surprising that their potential utility as adjuvant agents is currently being 
considered (281).  Analysis of pre- and post-diagnosis NSAID usage further confirms a 
potential role for aspirin in addition to potentially curative surgery and adjuvant 
chemotherapy,  with an almost 50% reduction in cancer mortality in patients who 
commence regular aspirin use following diagnosis (296).  Interestingly, no significant 
survival benefit was seen in patients continuing pre-diagnosis aspirin use, suggesting that 
cancers arising in these circumstances may be aspirin-resistant (296, 297). 
Surprisingly, there have been few trials of aspirin or NSAIDs as adjuvant agents in 
colorectal cancer.  Sub-analysis of a randomised trial of 5-fluorouracil and leucovorin with 
or without irinotecan in patients with stage III colon cancer examined the effect of aspirin 
and COXIBs on recurrence and survival (298).  Even after controlling for treatment arm, 
NSAID use was associated with a 50% reduction in disease recurrence or death.  Two 
further clinical trials of adjuvant COXIB following curative resection in patients with stage 
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II/III disease ceased recruitment early following concerns regarding the cardiovascular 
safety profile of prolonged COXIB use (299, 300). The VICTOR trial, which randomised  
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Table 1.10 Direct tumour, local and systemic inflammatory effects of nonsteroidal anti-inflammatory drugs, statins and histamine-2 receptors antagonists 
in patients with colorectal cancer 
Drug/Class Direct tumour effects Effects on local inflammatory 
response 
Effects on systemic inflammatory response 
NSAID Up-regulated: 
• differentiation 
• apoptosis 
• cellular adhesion 
• radiosensitivity 
• susceptibility to oxidative 
stress 
 
 
Down-regulated: 
• proliferation 
• angiogenesis 
• motility/migration 
Up-regulated: 
• MHC class II expression 
• anti-tumour cytokines 
• inflammatory infiltrate 
• Th1/M1 response 
 
 
 
 
Down-regulated:  
• pro-tumour cytokines 
• COX-2 expression 
• Treg activity 
Up-regulated: 
• lymphocyte and NK cell activity 
 
 
 
 
 
 
 
Down-regulated: 
• platelet activation 
• serum acute phase proteins 
Statin Up-regulated: 
• apoptosis 
• cell cycle arrest 
• susceptibility to oxidative 
stress 
• differentiation 
Down-regulated: 
• proliferation 
• angiogenesis 
Unknown effect on inflammatory 
infiltrate 
 
 
 
 
Down-regulated: 
• NOS expression 
• COX-2 expression 
 
 
 
 
 
 
Down-regulated: 
• circulating cytokines 
H2 receptor antagonist Up-regulated:  
• cellular adhesion 
• proliferation 
• angiogenesis 
Up-regulated: 
• inflammatory infiltrate 
• anti-tumour cytokine 
• Treg activity 
Up-regulated: 
• lymphocyte and NK cell activity 
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patients who had undergone surgery and adjuvant treatment for stage II/III disease to daily 
rofecoxib or placebo, was terminated early with only 33% of patients receiving active 
treatment for at least one year (299). Interestingly however, despite no significant 
difference in cancer-specific mortality and recurrence-free survival, a statistically 
significant reduction in recurrence within the first year was found with regular COXIB use.  
Given that most adenoma prevention trials exposed patients to at least two years of regular 
COXIB use, the early termination of VICTOR likely precluded the investigators from 
finding any significant survival benefit. 
Given the observed effects on tumour biology and microenvironment, the use of NSAIDs 
concomitant with neoadjuvant chemoradiotherapy has also been investigated.  Indeed, 
decreased synthesis of protective prostaglandins via inhibition of COX-2 has been shown 
to increase tumour radiosensitivity (301).  To date however, only phase II feasibility 
studies have shown a potential increase in tumour response and clinicopathological 
downstaging with the addition of COXIBs (302).  Certainly such time-restricted use may 
be promising and favour the risk-benefit ratio of COXIB use.  Regardless, although trials 
of adjuvant aspirin use are currently recruiting (303), it is clear that further, adequately 
powered trials are required to fully ascertain the benefit of aspirin, NSAIDs and COXIBS, 
both in the adjuvant and neoadjuvant setting.	
 Direct tumour effects 
Pre-clinical investigations have found an increase in tumour cell apoptosis in association 
with a decrease in cell proliferation, angiogenesis and metastatic potential (304, 305).  
Although limited, mechanistic studies in patients with colorectal cancer have again 
suggested similar effects, with an NSAID-mediated decrease in primary and metastatic 
tumour blood flow and microvessel density even with short courses of NSAIDs (306, 307).  
Of further interest, NSAID administration has also been shown to facilitate tumour cell 
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differentiation, with a loss of cancer cell stemness and down-regulation of gene expression 
associated with increased metabolic turnover and resistance to oxidative stress (308, 309). 
 Cyclooxygenase-dependent effects 
Several potential mechanistic pathways have been implicated in the anti-tumour effects of 
aspirin and other NSAIDs. The most studied mechanism is their inhibitory effect on COX-
mediated synthesis of prostanoids, and in particular prostaglandin E2 (PGE2) (304, 305, 
310, 311).  Increased synthesis of PGE2 by COX-2, the inducible form of the enzyme, has 
been shown to have several pro-tumour and immunosuppressant effects in vitro and in 
vivo, including an increase in tumour cell proliferation, decreased apoptosis, increased 
angiogenesis and increased chemo- and radio-resistance.  Indeed, COX-2 is overexpressed 
in some but not all colorectal neoplasia, particularly those arising in the distal colon and 
rectum (312, 313), where its expression is associated with tumour invasiveness, metastatic 
potential and poorer survival (304, 310, 314).  Furthermore, epidemiological evidence 
suggests a prominent role for COX-2 inhibition, with a reduced risk of COX-2 
overexpressing tumours in long-term aspirin users and a modification of their anti-tumour 
effects observed in patients with common COX-2 gene polymorphisms (315, 316).  
Similarly, an increase in tumour cell apoptosis and decrease in tumour vascularity has also 
been confirmed in human subjects in response to NSAID administration, mediated by a 
reduction in COX-2 expression and tissue PGE2 (306, 317). 
Aspirin, particularly at low doses employed in cardiovascular disease, is a weak inhibitor 
of COX-2 whereas it remains a strong inhibitor of the constitutively expressed enzyme 
COX-1, particularly in anucleated cells such as platelets (318).  As such, inhibition of 
COX-1 has also been suggested as another potential mechanism for the anti-tumour effects 
of NSAIDs by inhibiting platelet activation, facilitating immunosurveillance and 
preventing haematogenous spread. Indeed, aspirin can abrogate the increase in platelet 
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activation demonstrated in patients with colorectal cancer, even after only five days 
administration (319). 
Cyclooxygenase-independent effects 
Although many of the anti-proliferative effects of NSAIDs may be explained by their 
inhibitory effects on PGE2 synthesis, several COX-independent actions have also been 
identified (320).  Many of the effects of NSAIDs on proliferation and apoptosis have also 
been identified in cancer cell lines known not to express COX-2 (321).  Several signal 
transduction pathways, including Wnt/β-catenin, NF-ĸB and the phosphatidylinositol 3-
kinase/AKT/mammalian target of rapamycin pathway have been identified as potential 
targets for the non-COX mediated effects of NSAIDs, with limited clinical evidence 
suggesting an NSAID-mediated effect on associated signalling and transcription pathways 
(208, 321, 322).  Epidemiological data again suggests these as valid targets of NSAID 
therapy in colorectal cancer, with increased survival associated with aspirin use in patients 
with PIK3CA mutated cancers (208), and a reduced risk of cancer with NSAIDs in patients 
with mutations within the NF-ĸB pathway (323). 
Effects on cancer-related inflammation 
The anti-inflammatory properties of aspirin and non-aspirin NSAIDs have identified them 
as likely candidates in the manipulation of cancer-associated inflammation; evidence of a 
NSAID-mediated attenuation of the acute phase response and weight loss in advanced 
cancer suggests a potential role in the management of the cancer cachexia syndrome.  
Furthermore, the chemoprophylactic effects of NSAIDs appear to be greater in patients 
with evidence of a systemic inflammatory response (64), although unfortunately, so do the 
cardiovascular risks of long-term COXIB use (324). 
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Local inflammation 
The effects of aspirin, non-selective NSAIDs and COXIBs on the local inflammatory 
response have been investigated in a number of solid cancers, with significant anti-tumour 
responses identified in gastrointestinal, breast, bladder and head and neck cancers (325) 
(Table 1.11).  A decrease in the levels of pro-tumour, immune-suppressing cytokines 
including PGE2, has been identified in the colon and in colorectal hepatic metastases, 
likely mediated at a gene transcription level (306, 308, 317).  Furthermore, NSAIDs have 
been shown to induce expression of MHC class II molecules on the surface of colorectal 
cancer cells (326).  Such changes within the tumour microenvironment may in turn allow 
for the recruitment and propagation of a co-ordinated, effective anti-tumour lymphocytic 
response.  Indeed, Lönnroth and colleagues have shown an increase in tumour infiltration 
of activated T-lymphocytes and a decrease in immunosuppressive regulatory T-
lymphocytes following a short course of pre-operative indomethacin or celecoxib in 
patients with colorectal cancer (326).  Similarly, indomethacin augmented the anti-CEA 
immune response ex vivo through inhibition of COX-2 and regulatory T-cell activity (327).  
The authors concluded that COX-2 inhibition could attenuate the inhibitory activity of 
regulatory T-cells identified in tumour tissue and regional lymph nodes, promoting an 
effective anti-tumour immune response.  However, the longterm oncological benefits of 
NSAID-mediated manipulation of the local inflammatory response remain to be 
elucidated.	
Systemic inflammation 
The administration of NSAIDs has been shown to abrogate suppression of systemic 
lymphocyte and natural killer cell activity in patients undergoing major surgery (328, 329) 
and in patients with colorectal cancer (330, 331) (Table 1.12).  NSAIDs attenuate the acute 
phase response in patients with advanced cancer, with a decrease in serum CRP identified 
in tandem with an improvement in weight and quality of life (266).  Furthermore, the effect 
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of NSAIDs on reducing risk of colorectal cancer appears to be greatest in patients with 
evidence of systemic inflammation as measured by soluble tumour necrosis factor (TNF)  
receptor-2 (64). Interestingly however, in a polyp prevention study utilising low dose 
aspirin with or without folic acid, aspirin 325mg daily did not decrease CRP but did 
stabilise it over a three year period whereas patients receiving placebo experienced a 
significant increase (332).  Regardless, CRP did not predict the chemoprophylactic effects 
of aspirin use.  Despite this, the role of NSAIDs in patients with cancer-associated 
systemic inflammation undergoing potentially curative surgical resection remains largely 
unknown.  In patients with rectal cancer, the use of celecoxib has been shown to decrease 
elevated circulating levels of TNFα and IL-8, potentially through a direct effect on tumour 
cells and NF-ĸB activity (333).  Similarly, in patients with colorectal cancer and an 
elevated CRP, ibuprofen decreases circulating CRP, cortisol and IL-6 (334).  Whether 
attenuation of the systemic inflammatory response by NSAIDs in patients with colorectal 
cancer undergoing curative surgery translates into a benefit in recurrence rates and survival 
however remains unknown, and must be addressed by future trials of neoadjuvant and 
adjuvant NSAID use.	
1.7.3 Statins 
Despite an unclear effect on the incidence of colorectal cancer, statins may influence the 
progression of established disease, with regular statin use being associated with earlier 
stage at diagnosis in three case-control studies (74, 335, 336).  Siddiqui and co-workers, in 
a case-control study of 326 male users with colorectal cancer and regular statin use of at 
least three years, found a lower mean stage and lower frequency of metastases (28.4% vs. 
38.8%, P<0.01) at presentation, with a higher prevalence of right-sided tumours in statin 
users (336).  Furthermore, statin users had superior five-year survival (37% vs. 33%, 
P=0.03).  Coogan and colleagues also found a significant reduction in the risk of stage IV 
disease (odds ratio (OR) 0.18, 95% confidence interval(CI) 0.05-0.62) with regular use of 
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statins for at least 3 months (335).  Similarly, a modest reduction of stage III/IV disease 
was also observed by Poynter, however this failed to reach statistical significance (OR 
0.90, 95% CI 0.54 to 1.50).  In contrast however, despite finding a reduced risk of 
colorectal cancer with statin use, a recent case-control study from Scotland with 
prescription data linkage found no difference in stage at diagnosis or survival (76), 
although the study was underpowered to identify any significant survival benefit.  Of more 
interest, a prospective observational study of statin use within a randomised trial of 
adjuvant chemotherapy in stage III colon cancer found no survival benefit with statin use, 
irrespective of duration of use or presence of KRAS mutations (337).  These conflicting 
results may in part be explained by population-based genetic variation in HMG-CoA 
reductase, as the presence of single nucleotide polymorphisms have previously been 
hypothesised  to modify the protective effect of statins on colorectal cancer risk (338). 
It is clear that the benefit of statins in the treatment of colorectal cancer has not yet been 
defined and that further clinical trials are required.  Recruitment for the National Surgical 
Adjuvant Breast and Bowel Project: Statin Polyp Prevention Trial is currently underway 
with the aim of investigating the effects of rosuvastatin on polyp/cancer recurrence and 
metachronous cancer development in patients who have undergone resection for stage I/II 
colon cancer (339)(335)(335)(325)(325)(313)(309)(307)(303)(298)(294)(294).  This and 
further trials may in time define the role statins may play in treatment of colorectal cancer. 
Direct tumour effects 
Mevalonate, the end product of HMG-CoA reductase metabolism and its isoprenoid 
metabolites are required for the activation of the Ras superfamily of small GTPases by 
prenylation (340).  In turn, these GTPases are crucial for downstream activity of several 
signal transduction pathways (341); inhibition of mevalonate synthesis by statins 
subsequently has indirect and direct effects on cell survival and growth.  Such inhibition 
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has been shown to have a pleiotropy of effects, including a reduction in cell proliferation 
(78, 342), induction of apoptosis (78, 342), increased susceptibility to oxidative stress 
(343) and inhibition of metastatic transformation and angiogenesis (344). A role for non 
HMG-CoA reductase-mediated pathways has also been suggested, particularly in tumours 
exhibiting the CIMP phenotype.  Hypermethylation of the bone morphogenic protein 
(BMP) pathway is common in CIMP tumours (345), and statin-mediated demethylation of 
the BMP2 promoter region and subsequent BMP pathwa has previously been shown to 
increase apoptosis and promote cell differentiation in cell line studies (346).  Indeed, such 
an effect may suggest a pertinent role for statins in patients with CIMP-associated tumours. 
Of further interest, statin therapy has been shown to augment the activity of a number of 
chemotherapeutic agents, even in resistant cell lines (340, 347, 348).  The activity of 
epidermal growth factor receptor inhibitors, including cetuximab, also appears to be 
potentiated in vitro and in vivo, even in cell lines with known KRAS mutations and 
resistance (349).  Furthermore, statin therapy may also increase the likelihood of 
pathological complete response following neoadjuvant chemoradiotherapy(347, 350). 
Effects on cancer-related inflammation 
Cardiovascular disease prevention trials have identified a clear anti-inflammatory effect of 
statins, with down-regulation of pro-inflammatory cytokines and increased cardiovascular 
risk reduction in patients with elevated serum inflammatory markers (351).  Furthermore, 
favourable effects on organ rejection following heart and renal transplant suggest a potent 
immunomodulatory effect, potentially through a direct effect on MHC class II expression 
and subsequent T-cell activation (352).  Similar effects on the inflammatory response may 
also be expected in patients with colorectal cancer, and certainly evidence from clinical 
trials of a 90% reduction in risk of inflammatory bowel disease-related colorectal cancer is 
compelling (353). 
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Local inflammation 
To date, no clinical evidence exists to support the role of statins in influencing the local 
inflammatory response in patients with colorectal cancer, although pre-clinical data 
suggests a direct inhibitory effect on NF-ĸB activation, with subsequent down-regulation 
of COX-2 and pro-inflammatory cytokine expression (354-356).  A cohort study of 
patients undergoing radical prostatectomy found that statin use was associated with a 
reduced tumour inflammatory infiltrate (357); in contrast to colorectal cancer, however, a 
minimal local inflammatory response is associated with reduced recurrence and improved 
survival.  Whether similar effects on the tumour inflammatory infiltrate in colorectal 
cancer can be expected remains to be seen.  
 Systemic inflammation 
Despite a clear benefit on the systemic inflammatory response in cardiovascular disease 
and in patients following transplant, the clinical application of these effects in patients with 
colorectal cancer is less clear (Table 1.12).  In an interventional study of patients 
undergoing curative resection, Malicki and co-workers found a significant reduction in pre-
operative serum IL-6 in patients receiving statins (358).  In contrast however, a recent 
study of the systemic inflammatory response to neoadjuvant chemoradiotherapy in patients 
with oesophageal and rectal cancer found that concomitant statin use did not attenuate the 
systemic inflammatory response or treatment-associated symptoms (359).  Further 
clarification of the effects of statins on cancer-related systemic inflammation is required, 
and such measures should be incorporated in to future studies of the chemotherapeutic 
benefits of statins.	
1.7.4 Histamine-2 receptor antagonists 
Since early reports of a survival advantage in patients with gastric cancer (360), there has 
been interest in the potential use of H2RAs in the treatment of colorectal cancer.  Aside 
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from potentially beneficial effects on the local and immune responses, pre-clinical data 
suggests direct anti-tumour effects, including inhibition of histamine as a growth factor and 
inhibition of tumour-endothelial cell adhesion and motility.  Furthermore, prolonged 
H2RA use has been shown to increase the systemic bioavailability of 5-FU (361).  
The first reports of a survival advantage for H2RAs in patients with colorectal were in the 
early 1990s, when Adams and co-workers reported a non-significant increase in three-year 
survival with peri-operative cimetidine in patients with Dukes’ A to C disease (93% vs. 
59%, P=0.17) (362).  In 1995, Matsumoto and co-workers reported the survival analysis of 
a multicentre, randomised controlled trial of the effects of cimetidine on adjuvant 5-FUl-
induced appetite loss and oesophagitis (363).  Interestingly, they found a significant 
increase in survival for both colonic and rectal cancers at almost four years.  A ten-year 
analysis from the same patient cohort further confirmed increased survival and reduced 
risk of recurrence with cimetidine, with greatest benefit seen in Dukes’ C patients (364). 
Further studies of differing doses and types of H2RAs given either prior to surgery or as 
adjuvant treatment have only shown a non-significant trend towards improved survival 
(365-368), particularly in patients with Dukes’ C disease (365).  Subgroup analyses have 
identified potential patient groups who may be more likely to benefit from H2RA 
treatment, such as those with MSS tumours or tumours with a low peritumoural 
lymphocytic infiltrate (366).  As such patients with MSS tumours may represent a 
subgroup of patients likely to benefit from H2RA use, however no large scale studies have 
examined these relationships and therefore further investigation is necessary.  In addition, 
patients who did not receive perioperative blood transfusion or develop post-operative 
infectious complications have similarly been identified as groups who may benefit 
oncologically (367).  Differences in type and dose of drug used as well as inclusion of 
patients with metastatic disease at enrolment may have precluded finding significant 
results in these studies.  The consistency of trend towards improved survival however does 
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suggest that further, standardised studies are required.  A recent Cochrane Collaboration 
review of H2RAs as adjuvant treatment following colorectal cancer resection found overall 
a significant improvement in survival for cimetidine only (combined hazard ratio (HR) 
0.53; 95% CI 0.32 to 0.87) (369).  Given that most of the included trials were performed 
before the routine use of diagnostic cross-sectional imaging, total mesenteric excision 
surgery and contemporary chemoradiotherapy regimes, the authors advised caution 
regarding the applicability of these trials and advised the need for further studies 
incorporating current “best practice” treatment. 
Direct tumour effects 
Histamine acts as an autocrine tumour growth factor and has been shown to increase 
colorectal cancer cell proliferation and growth in vitro and in vivo (370).  Indeed, 
expression of histamine and histidine decarboxylase, the enzyme responsible for histamine 
synthesis, is increased in cancer epithelium when compared to normal colorectal mucosa 
(371, 372); increasing expression has been associated with the presence of nodal and 
distant metastases as well as increased microvessel density, suggesting a potential role in 
the transformation to invasive and metastatic disease.  Furthermore, histamine has also 
been shown to increase expression of COX-2 and PGE2 as well as vascular endothelial 
growth factor in cell lines constitutively expressing COX-2 (371). Celecoxib has been 
shown to abrogate the histamine-induced increase in vascular endothelial growth factor 
expression, suggesting that at least some of the pro-tumour effects of histamine may be 
mediated by COX-2 and prostaglandin activity (371). 
Although several histamine receptors have been identified with H2 and H4 receptor 
stimulation both being implicated in tumour growth (371), only H2 receptors appear to be 
preserved in colorectal cancer tissue with loss of H1 and H4 receptors when compared to 
normal mucosa (373).  The use of H2RAs in both cell line and animal studies has been 
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associated with a decrease in histamine-induced tumour growth, proliferation and increase 
in apoptosis in vitro (370, 374).  The use of H2RAs may also reduce the metastatic 
potential of colorectal tumour cells by inhibition of E-selectin expression, endothelial cell 
adhesion and a decrease in tumour microvessel density (364, 371).  
Effects on cancer-related inflammation 
Local inflammation 
Activation of histamine receptor-2 on regulatory T-lymphocytes inhibits the cell-mediated 
immune response (375).  Amelioration of this immunosuppressant effect by H2RA use has 
been shown to subsequently increase tumour infiltration of activated lymphocytes (Table 
1.11).  Adams and co-workers, using quantitative assessments of peri-tumoural 
lymphocytic infiltration such as the presence of a Crohn’s-like reaction or Jass criteria, 
found an increased conspicuous lymphocytic infiltration with peri-operative cimetidine use 
(362, 376).  Qualitative assessment of the lymphocytic infiltrate using 
immunohistochemistry have been equivocal, with one study suggesting that H2RA use 
increases tumour infiltration of CD3+ T-lymphocytes, particularly in patients with late 
stage disease (377), whereas another study examining the dose-response of cimetidine 
suggested that H2RAs may exert their effects through other, non-CD3+ cellular 
components (366).  Interestingly, Kapoor et al. found that pre-operative use of the H2RA 
famotidine led to a significant increase in tumour lymphocyte infiltration in colon cancer 
rather than rectal cancer, with the largest effect seen in those patients with a normal pre-
operative CEA (368).	
 Systemic inflammation 
Histamine attenuates the systemic immune response in patients with colorectal cancer.  
Similarly, the exaggerated post-operative immune suppression experienced in patients with 
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colorectal cancer is in part mediated by histamine release (377).  The use of H2RAs has 
been shown to abrogate tumour-associated systemic immune suppression, with restoration 
of circulating levels and activity of T-lymphocyte and natural killer cell subsets (378), 
potentially via augmentation of IL-2 and interferon activity (Table 1.13).  Furthermore, 
peri-operative H2RA use restores normal cell-mediated immunity following surgery (377, 
379).  Although shown to decrease post-operative CRP in patients without cancer (380), 
the effects of H2RA use on systemic cytokine profiles and biomarkers of the systemic 
inflammatory response in patients with colorectal cancer remains unknown. 
1.7.5 Local and systemic inflammatory responses as therapeutic targets 
– summary 
Several strategies for targeting of the tumour-associated inflammatory response and host 
anti-tumour immunity have been investigated in patients with colorectal cancer. Early 
phase clinical trials have investigated the role of novel immunotherapy agents, including 
vaccines and monoclonal antibodies targeting immune checkpoints, with varying results.  
Such an approach is expensive, and significant drug toxicities have often hampered 
translation into phase III trials.  Attempts to appropriately stratify patients, such as by 
MMR status, may aid in the identification of patients likely to benefit from novel therapies. 
In spite of convincing epidemiological evidence, the role of statins, H2RAs and 
particularly NSAIDs in the management of patients with colorectal cancer has yet to be 
defined.  Although shown to have a direct effect not only on tumour biology but also on 
the host systemic and local inflammatory response, most evidence has arisen from pre-
clinical investigations in vitro and in vivo.  The few clinical investigations described above 
have been limited in their clinical applicability, and the long-term oncological outcomes 
have not yet been fully explored.  
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The use of these agents is an attractive option not only because of their low cost, but also 
due to their relatively well-defined long-term safety profiles.  Clinical trials of adjuvant 
aspirin and statins in patients with colorectal cancer are currently recruiting.  Furthermore, 
their relatively common use in patients undergoing resection of colorectal cancer would 
allow for retrospective analysis to examine their effect on inflammatory profiles and 
outcome.  It is clear however, that further studies are required to identify the role of anti-
inflammatory agents in the management of patients with colorectal cancer, and particularly 
those patients identified at high risk due to the presence of an “unfavourable” 
inflammatory profile.
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Table 1.11 The effects of nonsteroidal anti-inflammatory drugs and H2 receptor antagonists on the local inflammatory cell infiltrate of patients with 
colorectal cancer 
↑ increased activity or expression in response to drug, ↓decreased activity or expression in response to drug, CRC – colorectal cancer, TIL – tumour infiltrating lymphocytes, PTL – 
peritumoural lymphocytes, CEA –carcinoembryonic antigen 
Drug Class 
 
Drug Patient Group 
(n) 
Study 
Type 
Duration Outcome Measure Outcome Comment 
NSAID 
• Lönnroth (2008) 
 
 
 
• Yaqub (2008) 
 
Indomethacin, 
Celecoxib 
 
 
Indomethacin 
 
CRC (28) (1 Dukes D) 
 
 
 
CRC  (12) (5 Dukes D) 
 
Randomised, 
controlled trial 
 
 
Ex vivo and 
histopathologica
l study 
 
3 days pre-op 
 
 
 
N/A 
 
TILs, 
 
 
 
Tumour and lymph node Treg 
infiltration 
 
↑CD4+, CD8+ tumour 
infiltration 
↓ Treg tumour infiltration 
 
↑tumour and lymph node 
infiltration by Treg, COX-2 
expression by lymph node  
Treg 
↓ Treg activity ex vivo 
 
 
 
 
 
NSAIDs may improve systemic and 
local immune responses by 
inhibiting circulating Treg activity 
and COX-2 expressing  Treg cells 
identified in regional lymph nodes 
H2 Receptor antagonist 
• Adams (1994) 
 
 
 
 
• Adams (1997) 
 
 
 
 
 
• Kelly (1999) 
 
 
 
 
 
 
• Lin (2004) 
 
 
 
 
 
• Kapoor (2005) 
 
Cimetidine 
 
 
 
 
Cimetidine 
 
 
 
 
 
Cimetidine 
(400mg and 
800mg) 
 
 
 
 
Cimetidine 
 
 
 
 
 
Famotidine 
 
CRC (not given) 
 
 
 
 
CRC (42) (8 Dukes D) 
 
 
 
 
 
CRC (112) (22 Dukes D) 
 
 
 
 
 
 
Gastrointestinal cancers 
(38 CRC) 
 
 
 
 
CRC (23) (2 Dukes D) 
 
Randomised, 
controlled trial 
 
 
 
Randomised, 
controlled trial 
 
 
 
 
Randomised, 
controlled trial 
 
 
 
 
 
Randomised, 
controlled trial 
 
 
 
 
Randomised, 
controlled trial 
 
7 days peri-op 
 
 
 
 
5 days pre-op, 2 
days post-op 
 
 
 
 
5 days pre-op 
 
 
 
 
 
 
7 days pre-op, 
10 days post-op 
 
 
 
 
7 days pre-op 
 
TILs 
 
 
 
 
Presence of “Crohn’s-like 
reaction”, Jass criteria, 
quantative assessment of 
“conspicuous lymphocyte 
response” 
 
Presence of “Crohn’s-like 
reaction”, Jass criteria, 
quantitatice assessment TILs, 
PTLs, CD3+, CD8+ 
 
 
 
TILs, PTL, CD3+, CD20+ 
 
 
 
 
 
TILs 
 
↑tumour lymphocyte 
infiltration 
 
 
 
↑tumour lymphocyte 
infiltration using all measures 
 
 
 
↑ trend towards peritumoural 
lymphocytic infiltration in 
patients treated with 
cimetidine 800mg, no 
difference in  CD3+, CD8+ 
between groups 
 
↑tumour/peri-tumoural 
lymphocyte infiltration, 
predominantly  CD3+ with 
few CD20+ 
 
 
↑in tumour lymphocyte 
infiltration 
 
Increased 3-year survival in 
cimetidine-treated patients (93% vs. 
59%) associated with presence of 
lymphocytic infiltration  
 
Presence of lymphocytic infiltrate 
associated with improved survival 
 
 
 
 
Trend towards increased survival in 
group treated with cimetidine 
800mg 
 
 
 
 
Increase in TILs/PTLs even in 
patients with advanced stage 
disease (less likely to have 
pronounced inflammatory infiltrate) 
 
Greatest benefit seen in patients 
with colonic tumour and normal 
pre-operative CEA 
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Table 1.12 The effects of nonsteroidal anti-inflammatory drugs and statins on the systemic inflammatory response of patients with colorectal cancer 
↑ increased activity or expression in response to drug, ↓decreased activity or expression in response to drug, CRC – colorectal cancer, MILPR – mitogen-induced lymphocyte 
proliferative response, CRT- chemoradiotherapy, CEA- carcinoembryonic antigen 
  
Drug Class 
 
Drug Patient Group 
(n) 
Study Type Duration Outcome Measure Outcome Comment 
NSAID 
• Han (1983) 
 
 
• Balch (1984) 
 
• McMillan (1995) 
 
 
 
 
 
• Sciulli (2005) 
 
 
 
• Konturek (2006) 
 
 
• Yaqub (2008) 
 
 
Indomethacin 
 
 
Indomethacin 
 
Ibuprofen 
 
 
 
 
 
Aspirin 
 
 
 
Celecoxib 
 
 
 
Indomethacin 
 
 
CRC (29) (11 patients 
Dukes C) 
 
CRC (57) 
 
CRC (9) (3 Dukes D) 
 
 
 
 
 
CRC (10) 
 
 
 
Rectal (10) 
 
 
 
CRC  (12) (5 Dukes D) 
 
Ex vivo 
 
 
Ex vivo 
 
Non-randomised, 
controlled study 
 
 
 
 
Non-randomised, 
controlled study 
 
 
Non-randomised, 
age- and sex-
matched controls 
 
Ex vivo 
 
N/A 
 
 
N/A 
 
8-11 days 
 
 
 
 
 
5 days pre-op 
 
 
 
14 days pre-op 
 
 
 
N/A 
 
MILPR 
 
 
MILPR 
 
Acute phase reactants 
 
 
 
 
 
Platelet activation 
 
 
 
Acute phase reactants, 
gastrin and progastrin 
 
 
Anti-CEA immune response 
 
Increase in MILPR  
 
 
Increase in MILPR 
 
↓ CRP, IL-6, cortisol, platelet 
count  
No change in albumin, 
insulin, CEA, WCC 
 
 
↓ COX-1 activity, platelet 
activity 
 
 
↓ TNFα, IL-8 serum and 
tumour gastrin, serum 
progastrin 
 
↑anti-CEA immune response 
by inhibition of Treg activity 
 
MILPR impaired in up to 52% of 
CRC patients  
 
MILPR impaired in CRC patients 
compared to controls; 
 
 
 
 
 
 
Increase in platelet activation in 
CRC patients compared to controls 
 
Effects mediated by NFkB 
inhibition, increase in tumour COX-
2 expression 
 
 
 
Statin 
• Malicki (2009) 
 
 
 
• Wang (2012) 
 
Simvastatin 
 
 
 
N/A 
 
CRC (9) 
 
 
 
CRC undergoing CRT 
(50) (28% receiving 
statin) 
 
Non-randomised, 
controlled study 
 
 
Cohort study 
 
14 days 
 
 
 
N/A 
 
Serum IL-6, IL-8 
 
 
 
Acute phase reactants, 
treatment-associated 
symptoms 
 
↓ IL-6, IL-8 (n.s.) 
 
 
 
Statin use did not influence 
acute phase reactants or 
symptom severity 
 
Elevated serum and tumour IL-6 
and IL-8 in CRC patients compared 
to age-matched healthy controls.  
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Table 1.13 The effects of H2-receptor antagonists on the systemic inflammatory response of patients with colorectal cancer 
↑ increased activity or expression in response to drug, ↓decreased activity or expression in response to drug, CRC – colorectal cancer, MILPR – mitogen-induced lymphocyte 
proliferative response, CRT- chemoradiotherapy, CEA- carcinoembryonic antigen 
 
Drug Class 
 
Drug Patient Group 
(n) 
Study Type Duration Outcome Measure Outcome Comment 
H2 Receptor antagonist 
• Adams (1994) 
 
 
 
 
 
 
• Nielsen (1995) 
 
 
 
 
• Lin (2004) 
 
Cimetidine 
 
 
 
 
 
 
Ranitidine 
 
 
 
 
Cimetidine 
 
CRC (50) 
 
 
 
 
 
 
CRC (12 Dukes D) 
 
 
 
 
CRC (38) 
 
Randomised, 
controlled study 
 
 
 
 
 
Ex vivo  
 
 
 
 
Randomised, 
controlled study 
 
5 days pre-op,  
2 days post-op 
 
 
 
 
 
N/A 
 
 
 
 
7 days pre-op,       
10 days post-op 
 
MILPR, CMI, lymphocyte 
subsets 
 
 
 
 
 
NK cell activity  
 
 
 
 
Peripheral blood lymphocyte 
subsets (pre-op and post-op) 
 
No fall in MILPR or CMI 
compared to controls, 
No fall in B-cells in 
treatment group 
↓ T-cells, NK cells in both 
groups. 
 
Increased NK cell activity 
insignificantly, however 
augmented effect of IL-2 on 
NK cell activity 
 
↑ CD3+, CD4+ and CD4+/ 
CD8+ ratio pre-operatively 
Improvement of post-op 
suppression of  CD3+,  CD4+ 
and  CD57+ 
 
 
 
 
 
 
 
 
NK cell activity decreased in CRC 
compared to healthy volunteers 
(greater decrease in metastatic 
patients) 
 
Peripheral blood CD3+,  CD4+,  
CD57+ and  CD4+/CD8+ratio 
decreased in CRC patients 
compared to healthy controls and  
CD8+ increased 
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1.8 Summary and Aims 
1.8.1 Summary 
Colorectal cancer is the second most common cause of cancer death in the United 
Kingdom and Western World.  Although the landscape of diagnosis, treatment and 
ultimately prognosis has improved over the past few decades, it still remains the case that 
around half of patients undergoing potentially curative resection die within five years of 
diagnosis.  Indeed, it is clear that further work is required to identify novel prognostic 
factors that may be utilised alongside current TNM-based staging.  The local and systemic 
environment, encapsulating the host inflammatory response to cancer, represents two 
potential characteristics which may aid in the prognosis of patients with colorectal cancer. 
It is increasingly appreciated that an elevated systemic inflammatory response is associated 
with poorer survival in a number of cancers, including colorectal cancer.  Numerous 
inflammation-based prognostic scores, derived from acute phase reactants and components 
of the differential white cell count, have been proposed.  The mGPS is one such measure 
and has been validated extensively in the literature as having stage-independent prognostic 
value in patients with colorectal cancer.  However, it has not been established how this 
may be utilised alongside current TNM-based staging of patients undergoing potentially 
curative resection.  Furthermore, although the mGPS has been validated internationally, it 
is not clear how the combination of TNM stage and a systemic inflammation-based score 
may stratify survival of patients from distinct geographical locations.  Indeed, given that 
the systemic inflammatory response may influence response to chemotherapy, differences 
in systemic inflammatory profiles across distinct populations would be of considerable 
importance. 
The local tumour environment is also of importance in determining both disease 
progression and outcome of patients with colorectal cancer.  Numerous studies have 
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confirmed the value of measures of the local inflammatory cell infiltrate in determining 
prognosis, using both assessments of the generalised inflammatory cell infiltrate and the 
adaptive, T-lymphocytic response.  It is now realised, however, that other components of 
the tumour microenvironment may similarly determine tumour biology and outcome.  
Despite this, it is not clear how these other components, such as the tumour-associated 
stroma, may relate to the local inflammatory cell infiltrate and other pathological features 
in patients undergoing resection of colorectal cancer.  Furthermore, whether assessment of 
the tumour-associated stroma may determine survival independent of the local 
inflammatory response and other high-risk pathological characteristics remains to be 
determined. 
Despite our understanding of the prognostic value of measures of the local and systemic 
environment, it is not fully understood what mechanisms underpin and potentially link 
them.  Multiple tumour and host factors have previously been hypothesised, including age, 
comorbidity status, and the presence of tumour necrosis.  Increasing tumour size and depth 
of invasion has previously been associated with the presence of a systemic inflammatory 
response and amelioration of the local inflammatory cell infiltrate.  In keeping with this, it 
is not clear if such measures are simply reflective of increasing tumour invasiveness and its 
association with survival. 
At the level of the cancer cell, it is known that molecular characteristics may determine 
host inflammatory responses and the local and systemic environment.  With respect to the 
local inflammatory cell infiltrate, it is known that tumours arising via MMR deficiency/ 
MSI pathway elicit a pronounced local inflammatory cell infiltrate.  However, the 
relationship between these tumour characteristics and the systemic inflammatory response 
has not yet been defined.  In addition, whether the improved prognosis observed in patients 
with MSI colorectal cancers is truly independent of the local and systemic environment has 
not yet been established. 
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Activation of pro-inflammatory signal transduction pathways may also be responsible for 
determining the nature of the local and systemic environment.  Indeed, numerous 
signalling pathways have been implicated not only in tumour-associated inflammation, but 
also in determining other tumour characteristics such as degree of invasiveness.  One such 
pathway is the JAK/STAT3 pathway which is activated by the pro-inflammatory cytokine 
IL-6.  However, although JAK/STAT3 activation has been associated with suppression of 
anti-tumour immune response in pre-clinical studies, it is not clear how cancer cell STAT3 
expression may affect the local and systemic inflammatory response in patients with 
colorectal cancer. 
Whereas the local inflammatory cell infiltrate and tumour-associated stroma have been 
shown to determine prognosis of patients with colorectal cancer when examined 
individually, it would be expected that a combined approach to assessment would be of 
greater value.  Indeed, such an approach would provide a more holistic overview of the 
nature of the tumour microenvironment and would be expected to stratify survival greater 
than either measure alone.  Given that both the generalised inflammatory cell infiltrate and 
tumour-associated stroma may be assessed using H&E-stained sections, this would be a 
compelling concept given its use of routine pathological specimens.  
Although assessment of the generalised local inflammatory cell infiltrate using H&E-
stained sections is attractive due to reliance on routine specimens and low associated costs, 
it is not yet clear how the prognostic value of more detailed measures of the inflammatory 
infiltrate compare.  The Immunoscore, for instance, may provide more granularity with 
respect to survival, despite the inherent costs and complexities associated with 
immunohistochemistry.  As such it remains imperative that these two differing techniques 
are compared, particularly in the context of assessment of other components of the local 
and systemic environment. 
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To date, most reported measures of the tumour microenvironment are performed using full 
sections following surgical resection of the tumour en bloc.  Although this allows for 
comprehensive assessment, particularly at the invasive margin, it does preclude targeting 
of the tumour microenvironment in the neoadjuvant setting.  Indeed, by identifying patients 
with an ‘unfavourable’ tumour microenvironment before surgery, it may be possible to 
target and ‘re-educate’ both the local inflammatory cell infiltrate and the tumour-associated 
stroma in the neoadjuvant setting.  Nearly all patients undergoing potentially curative 
resection of colorectal cancer will undergo colonoscopy and biopsy, thus providing an 
ideal opportunity to obtain pre-operative specimens for assessment of the tumour 
microenvironment.  Whether biopsy-derived specimens are suitable, however, remains to 
be determined. 
Finally, it is now accepted that anti-inflammatory drugs, such as aspirin, NSAIDs and 
statins, are associated with improved outcome of patients with colorectal cancer.  
Numerous mechanisms have been proposed, however given their intrinsic anti-
inflammatory properties, it is likely that the favourable effect on tumour biology and 
outcome is in part due to mediation of the host inflammatory response.  As such, it could 
be expected that patients receiving such drugs at the time of diagnosis would be less likely 
to exhibit evidence of a systemic inflammatory response.  Indeed, it would be of interest to 
examine the potential role of the systemic inflammatory response as a potential predictive 
biomarker of response to anti-inflammatory drugs such as aspirin.   
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1.8.2 Hypothesis and aims 
To address the above areas of uncertainty, two main hypotheses were proposed: 
1. The local and systemic environment, as measured using components of the tumour 
microenvironment and systemic inflammatory responses, could provide additional 
prognostic value complimentary to present day, TNM-based staging of patients 
undergoing potentially curative resection of stage I-III colorectal cancer. 
2. A number of tumour and host factors determine the local and systemic environment 
in patients undergoing potentially curative resection of stage I-III colorectal cancer, 
some of which may be potential therapeutic targets. 
To examine these hypotheses, studies were performed in patients undergoing potentially 
curative resection of stage I-III colorectal cancer to achieve the following aims: 
1. To examine the relationship between measures of the systemic inflammatory 
response, using the mGPS, TNM-based staging and survival. 
2. To examine differences in the host and tumour characteristics associated with the 
mGPS in two geographically distinct populations. 
3. To examine the relationship between the tumour-associated stroma, the local 
inflammatory response, host and tumour characteristics and survival. 
4. To examine the relationship between MMR status, the local and systemic tumour 
environment and survival. 
5. To examine the relationship between tumour cell STAT3 expression and the local 
and systemic tumour environment and survival. 
6. To examine the clinical utility of a combined tumour microenvironment-based 
score, comprised of measures of the generalised inflammatory cell infiltrate and 
tumour-associated stroma. 
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7. To compared the prognostic value of measures of the generalised inflammatory 
cell infiltrate and T-lymphocytic infiltrate and tumour-associated stroma. 
8. To examine the relationship between tumour invasiveness, the local and systemic 
environment and survival. 
9. To examine the feasibility of pre-operative, colonoscopic biopsy-based assessment 
of the tumour microenvironment. 
10. To examine the relationship between pre-operative aspirin and statin use, systemic 
inflammatory responses and host and tumour characteristics. 
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2 Colorectal cancer, systemic inflammation and outcome: 
staging the tumour and staging the host 
2.1 Introduction 
Colorectal cancer is the third most common cancer in the Western World and the second 
most common cause of cancer death (381).  Prognosis and the need for adjuvant therapy is 
primarily based on pathological staging of the resected tumour using TNM criteria (382).  
However, such a scheme may fail to accurately distinguish patients at high risk of disease 
recurrence and death, particularly in the context of lymph node negative disease (383).  
Characteristics pertaining to the host are also associated with outcome.  For example, the 
presence of an elevated systemic inflammatory response, as evidenced by changes in 
circulating acute phase proteins or myeloid cells, is an important unifying host 
characteristic and has been consistently associated with reduced survival independent of 
stage across a number of cancers including colorectal cancer (384, 385).  Systemic 
inflammation-based prognostic scores, such as the mGPS and the NLR have been validated 
to have prognostic value in a variety of operable cancers (384, 385).  Of these, the mGPS, 
a cumulative score based on the presence of an elevated serum CRP and decreased serum 
albumin, has been reported to have superior prognostic value compared to the NLR in 
patients with operable colorectal cancer (386-389). 
Although the prognostic value of the mGPS has been widely reported, how it might be 
incorporated into the existing TNM-based staging of colorectal cancer, and how it might be 
implemented into routine clinical practice is not clear.  Therefore, the aim of the present 
study was to examine the clinical utility of the pre-operative mGPS in a large cohort of 
patients from a single institution undergoing potentially curative resection of colorectal 
cancer. 
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2.2 Patients and Methods 
Patients from a single surgical unit at Glasgow Royal Infirmary (GRI) were identified from 
a prospectively collected and maintained database of elective and emergency colorectal 
cancer resections.  Consecutive patients who had pre-operative measurement of serum 
CRP and serum albumin within 30 days prior to surgery and, who on the basis of 
preoperative abdominal computed tomography and laparotomy findings were considered to 
have undergone potentially curative resection of stage I-III colorectal adenocarcinoma 
between January 1997 and May 2013 were included.  Patients with IBD-associated cancer, 
or cancer arising from the vermiform appendix were excluded.  In addition, patients who 
underwent resection with palliative intent or local resection only were excluded. 
Tumours were staged using the fifth edition of the TNM classification (382), with 
additional data taken from pathological reports issued following resection.  Following 
surgery, all patients were discussed at a colorectal multidisciplinary meeting involving 
surgeons, oncologists, radiologists and pathologists with a colorectal cancer special 
interest; patients with stage III disease or high-risk stage II disease and no significant 
comorbidities precluding chemotherapy were offered primarily 5-FU-based adjuvant 
chemotherapy on the basis of current guidelines at the time.  
Pre-operative serum CRP and albumin were recorded prospectively.  Patients undergoing 
elective resection had CRP and albumin concentrations measured routinely within 30 days 
prior to elective surgery.  In patients undergoing emergency resection, CRP and albumin 
measured on admission were recorded.  The mGPS was calculated as follows: patients with 
a CRP ≤10mg/L were allocated a score of 0, a CRP >10mg/L a score of 1, and a CRP 
>10mg/L and albumin <35g/L a score of 2. 
Patients were routinely followed up for five years following surgery with outpatient clinic 
review at three months, six months and then yearly until five years following resection.  
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Surveillance computed tomography was performed yearly during this period with regular 
colonoscopic surveillance.  Date and cause of death was crosschecked with the cancer 
registration system and the Registrar General (Scotland).  Death records were complete 
until 31st March 2014 that acted as the censor date.  Cancer-specific survival was measured 
from date of surgery until date of death from recurrent or metastatic colorectal cancer.  
Overall survival was measured until the date of death from any cause. 
Statistical Analysis 
The relationship between mGPS and clinicopathological characteristics was examined 
using the χ2 method for linear trend.  The relationship between clinicopathological 
characteristics, pre-operative mGPS and survival was examined using Kaplan-Meier log-
rank survival analysis and univariate Cox proportional hazards regression to calculate HRs 
and 95% CIs.  Variables with a P-value ≤0.1 on univariate analysis were subsequently 
entered into a multivariate model using a backwards conditional method.  Five and ten-
year survival was presented as percentage of patients surviving (standard error (SE)).  A P-
value ≤0.05 was considered statistically significant for all analyses.  All analyses were 
performed using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).  The West of Scotland 
Research Ethics Committee approved the study.
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2.3 Results 
One thousand patients who underwent potentially curative resection of colorectal cancer 
were studied.  Clinicopathological characteristics are shown in Table 2.1.  Data on 
neoadjuvant therapy, adjuvant therapy and tumour differentiation were missing in 19, two 
and 10 patients respectively.  Two-thirds of patients were older than 65 at time of surgery, 
55% were male and over 90% of patients underwent elective resection.  Two thirds of 
patients underwent resection of colon cancer.  Ninety-four patients with rectal cancer and 
five patients with colon cancer received neoadjuvant therapy prior to surgery; of these, 
thirteen patients with rectal cancer had complete pathological response (subsequently 
termed stage 0 disease).  Overall, 15% of patients had stage I disease, 46% had stage II 
disease and 38% had stage III disease.  A quarter of patients received adjuvant 
chemotherapy following surgery; 16% of patients with stage II disease and 45% of patients 
with stage III disease received adjuvant therapy.  	
Thirty-seven percent of patients had CRP >10mg/L and 26% had an albumin <35g/L prior 
to surgery.  Almost two thirds of patients were mGPS=0, whereas 21% and 16% were 
mGPS=1 and mGPS=2 respectively.  An elevated mGPS was associated with advancing 
age, emergency presentation (both P≤0.001), less frequent use of neoadjuvant therapy 
(P<0.05), colonic primary, advancing T stage, advancing TNM stage, poor tumour 
differentiation, surgical margin involvement, peritoneal involvement and tumour 
perforation (all P≤0.001) (Table 2.1). 
The median follow-up of survivors was 56 months (range 10-206 months; interquartile 
range 28-107 months), with 242 colorectal cancer-related deaths and 193 non-cancer 
deaths.  Cancer-specific survival at five and ten years was 75% and 67% respectively, and 
overall survival at five and ten years was 64% and 43%.  The following clinicopathological 
characteristics were associated with reduced cancer-specific survival on univariate analysis 
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(Table 2.2): mGPS (P<0.001), advancing age (P<0.01), emergency presentation (P<0.01), 
T stage (P<0.001), N stage (P<0.001), poor differentiation (P<0.01), venous invasion 
(P<0.001), margin involvement (P<0.001) and peritoneal involvement (P<0.001).  Tumour 
perforation showed a trend towards poorer cancer-specific survival (P<0.1).  On 
multivariate survival analysis, mGPS was associated with reduced cancer-specific survival 
(HR 1.30, 95%CI 1.10-1.53, P=0.002), independent of age (P<0.01), T stage (P<0.001), N 
stage (P<0.001) and margin involvement (P<0.001).  Poor differentiation and venous 
invasion showed a trend towards reduced survival on multivariate analysis (P=0.086 and 
P=0.084, respectively), whereas emergency presentation, peritoneal involvement and 
tumour perforation were not associated with survival.   
The following clinicopathological characteristics were associated with reduced overall 
survival on univariate analysis (Table 2.2): mGPS (P<0.001), advancing age (P<0.001), 
emergency presentation (P<0.05), no adjuvant therapy (P<0.05), T stage (P<0.001), N 
stage (P<0.001), poor differentiation (P=0.001), venous invasion (P<0.01), margin 
involvement (P<0.001) and peritoneal involvement (P<0.001).  On multivariate analysis 
mGPS was associated with reduced overall survival (HR 1.28, 95%CI 1.13-1.45, 
P<0.001), independent of age (P<0.001), adjuvant therapy use (P<0.05), T stage (P<0.05), 
N stage (P<0.001), differentiation (P<0.05) and margin involvement (P<0.001).  Venous 
invasion showed a trend towards reduced overall survival (P=0.066), whereas emergency 
presentation, peritoneal involvement and tumour perforation were not associated with 
survival. 
The relationship between pre-operative mGPS, TNM stage and cancer-specific survival is 
displayed in Table 2.3.  Cancer-specific survival at five years varied from 100% in patients 
with stage 0 colorectal cancer to 61% in patients with stage III disease, and from 80% in 
patients with mGPS=0 to 61% in patients with mGPS=2 (Figure 2.1).  When TNM stage 
and mGPS were combined, cancer-specific survival at five years varied from 100% in 
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patients with stage 0 disease and mGPS=0, to 32% in patients with stage III disease and 
mGPS=2 (P<0.001).  A similar relationship between TNM stage, mGPS and ten-year 
cancer-specific survival was also observed; whereas survival ranged from 100% to 52% 
and from 70% to 52% with TNM stage or mGPS alone, the combination of TNM and 
mGPS stratified ten-year survival from 100% (TNM 0, mGPS=0) to 32% (TNM III, 
mGPS=2).  The nature of the relationship between TNM stage and mGPS is shown for 
patients with TNM stage III disease in Figure 2.2 (P<0.001).  
The relationship between pre-operative mGPS, TNM stage and overall survival is 
displayed in Table 2.4.  TNM stage stratified survival at five years from 92% to 51%, and 
mGPS stratified survival from 70% to 46% (Figure 2.3).  Ten year overall survival varied 
from 92% (stage 0) to 35% (stage III) and from 49% (mGPS=0) to 30% (mGPS=2).  
Combining TNM stage and mGPS, five-year overall survival ranged from 92% (TNM 0, 
mGPS=0) to 26% (stage III, mGPS=2) and ten-year overall survival ranged from 92% 
(TNM 0, mGPS=0) to 17% (TNM III, mGPS=2) (P<0.001).  The effect of the combination 
of TNM stage and mGPS on overall survival is shown for patients with stage III disease in 
Figure 2.4 (P<0.001).  
As mGPS was associated with emergency resection and a colonic primary, to control for 
any confounding of these variables the relationship between TNM stage, mGPS and 
survival was examined for 579 patients undergoing elective resection of colon cancer.  In 
patients undergoing elective resection of colon cancer, an elevated mGPS was associated 
with advancing age, advancing T stage and TNM stage, poor differentiation, surgical 
margin and peritoneal involvement and tumour perforation (Table 2.5).  The median 
follow-up of survivors was 58 months (range 10-206 months; interquartile range 28-107 
months), with 122 cancer-related deaths and 124 non-cancer deaths.  Cancer-specific and 
overall survival was 79% and 66% respectively at five years and 71% and 44% at ten 
years.  On multivariate analysis, mGPS was associated with reduced cancer-specific 
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survival (HR 1.58, 95% CI 1.25-1.99, P<0.001), independent of age (P<0.01), T stage, N 
stage (both P<0.001) and margin involvement (P<0.05), and reduced overall survival (HR 
1.53, 95% CI 1.30-1.81, P<0.001), independent of age (P<0.001), no adjuvant therapy 
(P<0.05), N stage (P<0.001) and margin involvement (P<0.01) (Table 2.6).  Venous 
invasion, peritoneal involvement and tumour perforation were not associated with cancer-
specific or overall survival on multivariate analysis.	
In patients undergoing elective resection of colon cancer, cancer-specific survival at five 
years ranged from 96% in patients with stage I disease to 63% in patients with stage III 
disease and from 86% in patients with mGPS=0 to 65% in patients with mGPS=2 (Figure 
2.5).  Cancer-specific survival at ten years ranged from 96% (stage I) to 54% (stage III) 
and from 77% (mGPS=0) to 50% (mGPS=2).  The combination of TNM stage and mGPS 
stratified both five and ten-year cancer-specific survival from 100% (stage I, mGPS=0) to 
37% (stage III, mGPS=2) (P<0.001; Table 2.7).  
The overall survival of patients undergoing elective resection of colon cancer was stratified 
by TNM stage from 79% to 53% at five years and from 46% to 38% at ten years, whereas 
mGPS stratified survival from 75% to 47% at five years, and from 54% to 24% at ten years 
(Figure 2.6).  The combination of TNM stage and mGPS stratified overall survival at five 
years from 87% (stage I, mGPS=0) to 30% (stage III, mGPS=2) and at ten years from 55% 
(stage I, mGPS=0) to 17% (stage III, mGPS=2 (P<0.001; Table 2.8). 
Subgroup analysis was subsequently performed to examine the relationship between 
mGPS, use of adjuvant chemotherapy and cancer-specific survival of 208 patients 
undergoing elective resection of stage III colon cancer.  Use of adjuvant chemotherapy in 
patients with stage III colon cancer was associated with younger age (P<0.001), less 
advanced T stage and a lower mGPS (both P<0.05) but no other clinicopathological 
characteristics.  The median follow-up of survivors was 62 months (range 11-205 months; 
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interquartile range 31-107 months), with 73 cancer-related deaths.  Cancer-specific 
survival was 78% at five years and 63% at ten years for patients with stage III colon cancer 
who received adjuvant chemotherapy, compared to 51% and 47% respectively for patients 
who did not receive adjuvant therapy (P=0.003; Table 2.9).  The mGPS stratified survival 
of patients with stage III colon cancer irrespective of adjuvant therapy status; for example, 
five-year survival varied from 91% (mGPS=0) to 57% (mGPS=1) for patients who 
received adjuvant therapy (P=0.002), and varied from 60% (mGPS=0) to 34% (mGPS=2) 
for patients who did not receive adjuvant therapy (P=0.117).  Furthermore, whereas use of 
adjuvant therapy was associated with increased survival in patients with mGPS=0 
(P=0.003), it was not associated with improved survival in patients with an elevated mGPS 
(P=0.431). 
Finally, subgroup analysis was performed to examine the relationship between mGPS, 
ASCO high-risk pathological criteria (presence of a T4 tumour, lymph node yield <10 
nodes, poor tumour differentiation, tumour perforation or venous invasion) and cancer-
specific survival of 238 patients undergoing elective resection of stage II colon cancer 
without subsequent adjuvant therapy.  The median follow-up of survivors was 64 months 
(range 10-205 months; interquartile range 28-111 months), with 39 cancer-related deaths.  
Five and ten-year survival of patients with no high-risk pathological characteristics was 
91% and 85% respectively, compared to 85% and 72% for patients with one or more high-
risk characteristic (P=0.212; Table 2.10).  An elevated mGPS was associated with reduced 
survival of patients with both low and high-risk stage II colon cancer; ten-year survival of 
patients with low-risk disease was stratified from 88% (mGPS=0) to 68% (mGPS=2) 
(P=0.035), and ten-year survival of patients with high-risk disease varied from 72% to 
53% (P=0.062). 
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2.4 Discussion 
The results of the present study show how the combination of TNM and mGPS effectively 
stratifies outcome in patients undergoing potentially curative resection of colorectal cancer.  
These data support the routine staging of both the tumour and the host systemic 
inflammatory response in patients with colorectal cancer. 
In the present study, an increasing mGPS was associated with the presence of high-risk 
clinicopathological characteristics pertaining to both the host and the tumour.  Even so, the 
pre-operative mGPS was prognostic independent of TNM stage and routinely reported 
adverse tumour characteristics, such as peritoneal involvement and tumour perforation.  
Furthermore, although associated with emergency presentation and a colonic primary, 
which may potentially reflect site-specific tumour heterogeneity (390), it was of interest 
that the mGPS retained independent prognostic utility in the context of elective resection 
of colon cancer.  The combination of TNM stage and mGPS increased the range of 
survival compared to either measure alone.  For example, whereas five-year cancer-
specific survival of all patients undergoing elective resection of stage III colon cancer was 
63%, the addition of mGPS stratified survival from 75% to 37%.  Furthermore, within 
stage II disease, it was possible to identify a fifth of patients undergoing resection at higher 
risk than that afforded by TNM criteria alone. 
The present study was able to provide further insight regarding the relationship between 
systemic inflammatory responses and use of adjuvant chemotherapy for stage III colon 
cancer.  Patients with an elevated mGPS prior to elective resection were less likely to 
receive adjuvant therapy.  At the time of data collection, however, it was unlikely to have 
been a factor in the multidisciplinary team’s decision to recommend chemotherapy.  
Furthermore, although an elevated mGPS was associated with advancing age, over 40% of 
patients who did not receive chemotherapy were younger than 75 at time of surgery.  With 
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such observational studies, there is a concern that one might be examining a population 
with an associated but unrelated (to cancer) chronic inflammatory state, which may also be 
associated with a lower rate of adjuvant therapy.  However, the common chronic 
inflammatory conditions, such as rheumatoid arthritis, do not normally preclude adjuvant 
chemotherapy.  It is therefore of interest that an elevated mGPS has previously been 
associated with co-morbid status and the presence of post-operative infectious 
complications (391-393).  However, although both may preclude use of adjuvant 
chemotherapy and explain the present inverse association between mGPS and use of 
adjuvant therapy (394), it is important to note that the relationship between mGPS and 
oncological outcome has previously been shown to be independent of underlying patient 
comorbidity (392, 395). 
Of interest, the mGPS stratified the survival of patients who received adjuvant 
chemotherapy following resection of stage III colon cancer.  Although the present analysis 
must be interpreted with caution, it is consistent with previous reports (384).  Although 
patients with mGPS=0 had a 50% relative increase in survival at five years with adjuvant 
therapy, patients with mGPS≥1 appeared to derive no benefit.  The underlying mechanism 
responsible for this lack of benefit is unclear, however may be orchestrated by 
inflammation-induced alterations in cytochrome-P450-mediated metabolism of 
chemotherapeutic drugs (396).  Whereas it may be indicative of reduced tolerance to 
chemotherapy leading to subsequent dose reduction or cessation of treatment (397), it may 
also simply represent a lack of efficacy in the systemically inflamed patient.  Certainly, 
although secondary analyses of reported trials of adjuvant chemotherapy may provide 
further insight, it is clear that future studies of adjuvant therapies should incorporate 
assessment of the pre-operative systemic inflammatory response. 
Although there is clear rationale for the use of adjuvant chemotherapy in patients with 
stage III colon cancer, the post-operative management of lymph node negative disease is 
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problematic.  Other high-risk pathological characteristics, such as the presence of venous 
invasion, have been shown to effectively stratify outcome within the confines of TNM 
staging, and may predict need for adjuvant therapy (179).  However, the recent inclusion of 
venous invasion, alongside other high risk pathological characteristics as additional 
prognostic factors in tumour staging does not negate the utility of host characteristics, such 
as the mGPS, in the effective stratification of outcome.  Indeed, in the present study, 
patients with mGPS=2 undergoing elective resection for otherwise low-risk stage II colon 
cancer had five and ten-year survival comparable to that of patients with stage III disease.  
Whereas assessment of pathological characteristics are often subjective and may be 
underreported (163), the components of the mGPS are objectively measured and routinely 
available.  Although the small number of patients receiving adjuvant therapy for stage II 
colon cancer precluded meaningful analysis in the present study, whether the mGPS may 
aid in the selection of patients with stage II colon cancer likely to benefit from adjuvant 
therapy would be of considerable interest.  
This study was limited by its single-centre nature; however, this was a large, prospectively 
collected cohort of patients.  Although a population whose mGPS reverted to normal 
following surgery would be of interest, the majority of patients do not appear, in terms of 
their mGPS, to change their inflammatory state.  Indeed of those patients with an elevated 
mGPS, up to 80% may remain systemically inflamed following potentially curative 
resection of colorectal cancer (388).  As such, any changes to the operative and peri-
operative management of patients over the time period studied, for example the 
introduction of enhanced recovery protocols to our centre in 2011, are unlikely to have had 
a significant effect on an elevated mGPS.  Furthermore, the small number of patients 
undergoing resection for stage I colon cancer and patients with rectal cancer precluded 
meaningful analysis within these subsets.  Finally, as mGPS was only recorded prior to 
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surgery, it was not possible to examine the impact of neoadjuvant chemoradiotherapy on 
the mGPS of patients with rectal cancer.  This would also be of considerable interest. 
Although representing only “the tip of a far larger iceberg” in inflammation-associated 
tumour progression and dissemination (398), the use of routinely available biomarkers, 
such as the mGPS, allows us to utilise our current understanding of the systemic 
inflammatory responses in patients with cancer.  This has several far-reaching implications 
for clinical practice.  As demonstrated, alongside guiding long-term prognosis, the 
incorporation of the mGPS into routine assessment may also identify patients less likely to 
tolerate, or benefit from, adjuvant systemic therapy.  Furthermore, routine use of the mGPS 
may also direct future therapeutic strategies, targeted at the systemic inflammatory 
response itself.  Indeed, it is now appreciated that systemic inflammation is complicit in 
cancer cachexia (399), and may be attenuated by the use of non-steroidal anti-
inflammatory drugs (NSAIDs) (266).  A similar scheme may also be applied to patients 
undergoing potentially curative surgery.  For example, in patients with stage III disease, 
those with mGPS=0 may benefit from adjuvant chemotherapy alone, whereas those with 
an elevated mGPS may also benefit from the addition of an anti-inflammatory agent, such 
as aspirin or other NSAID (400).  Certainly, it is clear that randomised controlled trials, 
incorporating both routine assessment of the systemic inflammatory response and use of 
anti-inflammatory agents, are required. 
In conclusion, the mGPS provides complimentary prognostic information to current TNM-
based staging and may also aid in directing future therapeutic strategies, targeting the 
systemic inflammatory response.  Given that the combination of TNM stage and the mGPS 
are routinely available worldwide, this staging system for patients undergoing potentially 
curative resection of colorectal cancer has much to commend it. 
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Figure 2.1 Ten-year cancer-specific survival of patients undergoing potentially curative resection of stage I-III colorectal cancer stratified by (A) TNM 
stage (log-rank P<0.001), and (B) modified Glasgow Prognostic Score (log-rank P<0.001) 
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Figure 2.2 The relationship between modified Glasgow Prognostic Score and ten-year 
cancer-specific survival of patients undergoing potentially curative resection of stage III 
colorectal cancer (log-rank P<0.001) 
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Figure 2.3 Ten-year overall survival of patients undergoing potentially curative resection of stage I-III colorectal cancer stratified by (A) TNM stage 
(log-rank P<0.001), and (B) modified Glasgow Prognostic Score (log-rank P<0.001)	
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Figure 2.4 The relationship between modified Glasgow Prognostic Score and ten-year 
overall survival of patients undergoing potentially curative resection of stage III colorectal 
cancer (log-rank P<0.001) 
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Figure 2.5 Ten-year cancer-specific survival of patients undergoing elective, potentially curative resection of stage I-III colon cancer stratified by (A) 
TNM stage (log-rank P<0.001), and (B) modified Glasgow Prognostic Score (log-rank P<0.001) 
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Figure 2.6 Ten-year overall survival of patients undergoing elective, potentially curative resection of stage I-III colon cancer stratified by (A) TNM stage 
(log-rank P<0.001), and (B) modified Glasgow Prognostic Score (log-rank P<0.001)
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Table 2.1 The relationship between modified Glasgow Prognostic Score and 
clinicopathological characteristics of patients undergoing potentially curative resection of 
stage 0-III colorectal cancer 
Data analysed using χ2 analysis for linear trend.
   All  mGPS=0  mGPS=1  mGPS=2  
Clinicopathological Characteristics  
(n when data missing) 
 n=1000 
(%) 
 n=635 
(%) 
 n=207 
(%) 
 n=158 
(%) 
P 
Age  
<65 
65-74 
>75 
  
330 (33) 
347 (35) 
323 (32) 
  
218 (34) 
238 (38) 
179 (28) 
  
66 (32) 
73 (35) 
68 (33) 
  
46 (29) 
36 (23) 
76 (48) 
0.001 
Sex  
Female 
Male 
  
452 (45) 
548 (55) 
  
274 (43) 
361 (57) 
  
102 (49) 
105 (51) 
  
76 (48) 
82 (52) 
0.137 
Presentation  
Elective 
Emergency 
  
913 (91) 
87 (9) 
  
610 (96) 
25 (4) 
  
174 (84) 
33 (16) 
  
129 (82) 
29 (18) 
<0.001 
Neoadjuvant therapy 
(981) 
 
No 
Yes  
  
883 (88) 
98 (10) 
  
544 (88) 
77 (12) 
  
199 (97) 
7 (3) 
  
140 (91) 
14 (9) 
0.020 
Adjuvant therapy 
(998) 
 
No 
Yes  
  
750 (75) 
248 (25) 
  
483 (76) 
151 (24) 
  
145 (70) 
62 (30) 
  
122 (78) 
35 (22) 
0.805 
Tumour site  
Colon 
Rectum 
  
661 (66) 
339 (34) 
  
381 (60) 
254 (40) 
  
157 (76) 
50 (24) 
  
123 (78) 
35 (22) 
<0.001 
T stage   
0 
1 
2 
3 
4 
  
13 (1) 
66 (7) 
112 (11) 
550 (55) 
259 (26) 
  
13 (2) 
56 (9) 
95 (15) 
354 (56) 
117 (18) 
  
0 (0) 
7 (3) 
11 (5) 
111 (54) 
78 (38) 
  
0 (0) 
3 (2) 
6 (4) 
85 (54) 
64 (41) 
<0.001 
N stage  
0 
1 
2 
  
618 (62) 
274 (27) 
108 (11) 
  
396 (62) 
182 (29) 
57 (9) 
 
 
 
118 (57) 
58 (28) 
31 (15) 
  
104 (66) 
34 (22) 
20 (13) 
0.470 
TNM stage  
0 
I 
II 
III 
 
 
 
13 (1) 
148 (15) 
457 (46) 
382 (38) 
  
0 (0) 
126 (20) 
257 (41) 
239 (38) 
  
0 (0) 
14 (7) 
104 (50) 
89 (43) 
  
0 (0) 
8 (5) 
96 (61) 
54 (34) 
0.001 
Less than 10 lymph 
nodes retrieved 
 
No 
Yes 
  
824 (82) 
176 (18) 
  
518 (82) 
117 (18) 
  
171 (83) 
36 (17) 
  
135 (85) 
23 (15) 
0.267 
Tumour 
differentiation 
(990) 
 
Mod/well 
Poor 
  
894 (89) 
96 (10) 
  
584 (93) 
42 (7) 
  
181 (87) 
26 (13) 
  
129 (82) 
28 (18) 
<0.001 
Venous invasion  
No 
Yes 
  
493 (49) 
507 (51) 
  
312 (49) 
323 (51) 
  
108 (52) 
99 (48) 
   
73 (46) 
85 (54) 
0.747 
Margin involvement  
No 
Yes 
  
929 (93) 
71 (7) 
  
605 (95) 
30 (5) 
  
183 (88) 
24 (12) 
  
141 (89) 
17 (11) 
0.001 
Peritoneal 
involvement 
 
No 
Yes 
  
773 (77) 
227 (23) 
  
531 (84) 
104 (16) 
  
138 (67) 
69 (33) 
  
104 (66) 
54 (34) 
<0.001 
Tumour perforation  
No 
Yes 
  
973 (97) 
26 (3) 
  
630 (99) 
5 (1) 
  
195 (94) 
11 (6) 
  
148 (94) 
10 (6) 
<0.001 
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Table 2.2 The relationship between clinicopathological characteristic and survival of patients undergoing potentially curative resection of stage 0-III 
colorectal cancer 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
 Cancer-specific survival  Overall survival 
Clinicopathological 
characteristics 
Univariate 
analysis 
P Multivariate 
analysis 
P  Univariate 
analysis 
P Multivariate 
analysis 
P 
Age (<65/ 65-74/ >75) 1.28 (1.09-1.50) 0.002 1.25 (1.07-1.47) 0.005  1.69 (1.50-1.91) <0.001 1.57 (1.39-1.79) <0.001 
Sex (Female/ male) 1.08 (0.84-1.40) 0.534 - -  1.14 (0.94-1.37) 0.189 - - 
Presentation (Elective/ 
emergency) 
1.75 (1.20-2.55) 0.004 - 0.974  1.37 (1.01-1.88) 0.046 - 0.654 
Neoadjuvant therapy (No/ yes) 1.16 (0.76-1.78) 0.485 - -  0.84 (0.58-1.21) 0.349 - - 
Adjuvant therapy (No/ yes) 1.08 (0.81-1.44) 0.617 - -  0.75 (0.59-0.96) 0.020 0.73 (0.56-0.95) 0.017 
Tumour site (Colon/ rectum) 1.15 (0.89-1.95) 0.294 - -  0.96 (0.82-1.22) 0.960 - - 
T stage (0/ 1/ 2/ 3/ 4) 1.98 (1.63-2.40) <0.001 1.49 (1.21-1.83) <0.001  1.37 (1.20-1.56) <0.001 1.16 (1.01-1.33) 0.042 
N stage (0/ 1/ 2) 1.88 (1.60-2.21) <0.001 1.58 (1.33-1.88) <0.001  1.42 (1.25-1.62) <0.001 1.39 (1.21-1.60) <0.001 
Less than 10 lymph nodes 
retrieved (No/ yes) 
1.28 (0.95-1.72) 0.110 - -  1.15 (0.92-1.44) 0.227 - - 
Tumour differentiation (Mod-
well/ poor) 
1.81 (1.25-2.63) 0.002 - 0.086  1.63 (1.22-2.17) 0.001 1.36 (1.02-1.82) 0.038 
Venous invasion (No/ yes) 1.69 (1.31-2.19) <0.001 - 0.084  1.36 (1.12-1.65) 0.002 - 0.066 
Margin involvement (No/ yes) 3.74 (2.67-5.23) <0.001 2.61 (1.84-3.70) <0.001  2.51 (1.87-3.36) <0.001 2.06 (1.52-2.80) <0.001 
Peritoneal involvement (No/ yes) 2.12 (1.63-2.76) <0.001 - 0.646  1.51 (1.22-1.86) <0.001 - 0.733 
Tumour perforation (No/ yes) 1.75 (0.93-3.29) 0.084 - 0.990  1.48 (0.88-2.47) 0.138 - - 
mGPS (0/ 1/ 2) 1.51 (1.29-1.76) <0.001 1.30 (1.10-1.53) 0.002  1.43 (1.27-1.61) <0.001 1.28 (1.13-1.45) <0.001 
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Table 2.3 The relationship between modified Glasgow Prognostic Score, TNM stage and five and ten-year cancer-specific survival of patients 
undergoing potentially curative resection of stage 0-III colorectal cancer 
 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0 
 
 mGPS = 1 
 
 mGPS = 2 
 
 n  5-yr CSS % (SE)     n 5-yr CSS % (SE)  n 5-yr CSS % (SE)  n 5-yr CSS % (SE) 
Stage 0 13 100 (0)     13 100 (0)  0 -  0 - 
Stage I 148 94 (2)     126  97 (2)  14  72 (14) 0.008  8  - 
Stage II 457 82 (2)     257  83 (3)  104 84 (4)   96 76 (5) 0.009 
Stage III 382 61 (3) <0.001     239  68 (4) <0.001  89  56 (6) 0.001  54  32 (8) <0.001/<0.001 
 
Stage 0-III 
 
1000 
 
75 (2) 
     
635 
 
80 (2) 
  
207 
 
71 (3) 
  
158 
 
61 (5) <0.001 
 n  10-yr CSS % (SE)     n 10-yr CSS % (SE)  n 10-yr CSS % (SE)  n 10-yr CSS % (SE) 
Stage 0 13 100 (0)     13 100 (0)  0 -  0 - 
Stage I 148 83 (5)     126  86 (5)  14  57 (17) 0.008  8  - 
Stage II 457 73 (3)     257  75 (3)  104 76 (5)  96 61 (8) 0.0009 
Stage III 382 52 (3) <0.001     239  56 (4) <0.001  89  53 (6) 0.001  54  32 (8) <0.001/<0.001 
 
Stage 0-III 
 
1000 
 
67 (2) 
     
635 
 
70 (2) 
  
207 
 
65 (4) 
  
158 
 
52 (6) <0.001 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying cancer-specific survival within each TNM stage (rows) and 
prognostic value of TNM stage stratifying cancer-specific survival within each mGPS group (columns). CSS – cancer-specific survival, SE – standard 
error. Survival not calculated if n<10. 
Table 2.3 displays the prognostic value of the combination of TNM stage and mGPS in determining five and ten-year cancer-specific survival relative to 
either measure alone in patients undergoing resection of stage 0-III colorectal cancer. For example, whereas five-year cancer-specific survival of patients 
with stage III disease was 61%, the addition of mGPS stratified survival from 68% to 32% (P<0.001). Similarly, whereas five-year cancer-specific 
survival of  patients with mGPS=0 was 80%, the addition of stage stratified survival from 100% to 68% (P<0.001).
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Table 2.4 The relationship between modified Glasgow Prognostic Score, TNM stage and five and ten-year overall survival in patients undergoing 
potentially curative resection of stage 0-III colorectal cancer 
 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS = 1  mGPS = 2 
 n  5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE)  n 5-yr OS % (SE) 
Stage 0 13 92 (7)     13 92 (7)  0 -  0 - 
Stage I 148 80 (4)     126  87 (4)  14  59 (14) 0.006  8  - 
Stage II 457 70 (2)     257  74 (3)  104 74 (5)  96 57 (6) 0.003 
Stage III 382 51 (3)<0.001     239  59 (4)0.002  89  45 (5)0.013  54  26 (7) <0.001/ 0.011 
 
Stage 0-III 
 
1000 
 
64 (2) 
     
635 
 
70 (2) 
  
207 
 
60 (4) 
  
158 
 
46 (5) <0.001 
 n  10-yr OS % (SE)     n 10-yr OS % (SE)  n 10-yr OS % (SE)  n 10-yr OS % (SE) 
Stage 0 13 92 (7)     13 92 (7)  0 -  0 - 
Stage I 148 49 (7)     126  56 (8)  14  16 (14) 0.006  8  - 
Stage II 457 48 (3)     257  53 (4)  104 44 (6)  96 38 (7) 0.003 
Stage III 382 35 (3) <0.001     239  40 (4) 0.002  89  33 (5) 0.013  54  17 (7) <0.001/ 0.011 
 
Stage 0-III 
 
1000 
 
43 (2) 
     
635 
 
49 (3) 
  
207 
 
38 (4) 
  
158 
 
30 (5) <0.001 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying overall survival within each TNM stage (rows) and prognostic 
value of TNM stage stratifying overall survival within each mGPS group (columns). OS - overall survival, SE – standard error. Survival not calculated if 
n<10. 
Table 2.4 displays the prognostic value of the combination of TNM stage and mGPS in determining five and ten-year overall survival relative to either 
measure alone in patients undergoing resection of stage 0-III colorectal cancer. For example, whereas five-year overall survival of patients with stage III 
disease was 51%, the addition of mGPS stratified survival from 59% to 26% (P<0.001). Similarly, whereas five-year overall survival of  patients with 
mGPS=0 was 70%, the addition of stage stratified survival from 92% to 59% (P=0.002).
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Table 2.5 The relationship between modified Glasgow Prognostic Score and 
clinicopathological characteristics of patients undergoing elective, potentially curative 
resection of stage I-III colon cancer 
Data analysed using χ2 analysis for linear trend. 
   mGPS=0  mGPS=1  mGPS=2  
Clinicopathological Characteristic 
(n when data missing) 
  n=358 
(%) 
 n=126 
(%) 
 n=95 
(%) 
P 
Host characteristics         
Age  
<65 
65-74 
>75 
  
111 (31) 
130 (36) 
117 (33) 
  
36 (29) 
42 (33) 
48 (38) 
  
24 (25) 
24 (25) 
47 (50) 
0.016 
Sex  
Female 
Male 
  
166 (46) 
192 (54) 
  
64 (51) 
62 (49) 
  
47 (50) 
48 (50) 
0.455 
Neoadjuvant therapy 
(569) 
 
No 
Yes 
  
348 (99) 
2 (1) 
  
124 (98) 
2 (2) 
  
92 (99) 
1 (1) 
0.456 
Adjuvant therapy  
No 
Yes 
  
271 (76) 
87 (24) 
  
93 (74) 
33 (26) 
  
75 (79) 
20 (21) 
0.663 
Tumour characteristics         
T stage   
1 
2 
3 
4 
  
33 (9) 
53 (15) 
195 (55) 
77 (22) 
  
2 (2) 
6 (5) 
70 (56) 
48 (38) 
  
2 (2) 
3 (3) 
53 (56) 
37 (39) 
<0.001 
N stage  
0 
1 
2 
  
231 (65) 
99 (28) 
28 (8) 
 
 
 
75 (60) 
35 (28) 
16 (13) 
  
65 (68) 
21 (22) 
9 (9) 
0.831 
TNM stage  
I 
II 
III 
 
 
 
77 (22) 
154 (43) 
127 (36) 
  
8 (6) 
67 (53) 
51 (41) 
  
4 (4) 
61 (64) 
30 (31) 
0.017 
Less than 10 lymph nodes retrieved  
No 
Yes 
  
294 (82) 
64 (18) 
  
98 (78) 
28 (22) 
  
84 (88) 
11 (12) 
0.374 
Tumour differentiation 
(566) 
 
Mod/well 
Poor 
  
332 (93) 
24 (7) 
  
109 (87) 
17 (14) 
  
71 (76) 
23 (25) 
<0.001 
Venous invasion  
No 
Yes 
  
186 (52) 
172 (48) 
  
67 (53) 
59 (47) 
  
47 (50) 
48 (51) 
0.765 
Margin involvement  
No 
Yes 
  
349 (98) 
9 (3) 
  
117 (93) 
9 (7) 
  
88 (93) 
7 (7) 
0.012 
Peritoneal involvement  
No 
Yes 
  
287 (80) 
71 (20) 
  
83 (66) 
43 (34) 
  
66 (70) 
29 (31) 
0.004 
Tumour perforation  
No 
Yes 
  
356 (99) 
2 (1) 
  
120 (95) 
6 (5) 
  
90 (95) 
5 (5) 
0.001 
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Table 2.6 The relationship between clinicopathological characteristics and survival of patients undergoing potentially curative, elective resection of stage 
I-III colon cancer 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
 Cancer-specific survival  Overall survival 
Clinicopathological characteristics Univariate 
analysis 
P Multivariate 
analysis 
P  Univariate 
analysis 
P Multivariate 
analysis 
P 
Age (<65/ 65-74/ >75) 1.41 (1.12-1.76) 0.003 1.39 (1.10-1.75) 0.005  1.87 (1.58-2.21) <0.001 1.73 (1.46-2.06) <0.001 
Sex (Female/ male) 0.93 (0.65-1.33) 0.696 - -  1.03 (0.80-1.32) 0.849 - - 
Neoadjuvant therapy (No/ yes) 0.87 (0.12-6.24) 0.891 - -  0.41 (0.06-2.91) 0.371 - - 
Adjuvant therapy (No/ yes) 1.16 (0.75-1.67) 0.595 - -  0.64 (0.46-0.89) 0.007 0.67 (0.46-0.97) 0.032 
T stage (0/ 1/ 2/ 3/ 4) 2.48 (1.85-3.34) <0.001 1.80 (1.30-2.49) <0.001  1.38 (1.15-1.65) 0.001 - 0.339 
N stage (0/ 1/ 2) 2.14 (1.70-2.69) <0.001 1.88 (1.47-2.40) <0.001  1.43 (1.20-1.72) <0.001 1.63 (1.34-1.98) <0.001 
Less than 10 lymph nodes retrieved 
(No/ yes) 
1.01 (0.65-1.57) 0.955 - -  0.96 (0.71-1.31) 0.803 - - 
Differentiation (Mod-well/ poor) 1.59 (0.95-2.66) 0.075 - 0.668  1.59 (1.11-2.27) 0.012 - 0.226 
Venous invasion (No/ yes) 1.83 (1.27-2.63) 0.001 - 0.256  1.29 (1.00-1.68) 0.050 - 0.335 
Margin involvement (No/ yes) 4.18 (2.39-7.31) <0.001 1.88 (1.05-3.48) 0.035  3.20 (1.99-4.99) <0.001 2.16 (1.32-3.54) 0.002 
Peritoneal involvement (No/ yes) 2.53 (1.77-3.62) <0.001 - 0.988  1.45 (1.11-1.90) 0.007 - 0.275 
Tumour perforation (No/ yes) 3.31 (1.46-7.54) 0.004 - 0.121  2.57 (1.32-5.02) 0.006 - 0.052 
mGPS (0/ 1/ 2) 1.76 (1.42-2.18) <0.001 1.58 (1.25-1.99) <0.001  1.63 (1.40-1.91) <0.001 1.53 (1.30-1.81) <0.001 
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Table 2.7 The relationship between modified Glasgow Prognostic Score, TNM stage and five and ten-year cancer-specific survival of patients 
undergoing elective, potentially curative resection of stage I-III colon cancer 
 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS = 1  mGPS = 2 
 n  5-yr CSS % (SE)     n 5-yr CSS % (SE)  n 5-yr CSS % (SE)  n 5-yr CSS % (SE) 
Stage I 89 96 (3)     77 100 (0)  8 -  4 - 
Stage II 282 86 (2)     154 90 (3)  67 86 (5)  61 79 (6) 0.004 
Stage III 208 63 (4) <0.001     127 75 (4) <0.001  51 52 (8) 0.001  30 37 (10) <0.001/0.005 
 
Stage I-III 
 
579  
 
79 (2) 
     
358 
 
86 (2) 
  
126 
 
71 (4) 
  
95 
 
65 (6) <0.001 
 n  10-yr CSS % (SE)     n 10-yr CSS % (SE)  n 10-yr CSS % (SE)  n 10-yr CSS % (SE) 
Stage I 89 96 (3)     77 100 (0)  8 -  4 - 
Stage II 282 77 (3)     154 80 (4)  67 81 (5)  61 55 (11) 0.001 
Stage III 208 54 (4) <0.001     127 62 (6) 0.063  51 48 (8) 0.007  30 37 (10) <0.001/0.041 
 
Stage I-III 
 
579  
 
71 (3) 
     
358 
 
77 (3) 
  
126 
 
67 (5) 
  
95 
 
50 (8) <0.001 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying cancer-specific survival within each TNM stage (rows) and 
prognostic value of TNM stage stratifying cancer-specific survival within each mGPS group (columns). CSS – cancer-specific survival, SE – standard 
error. Survival not calculated if n<10. 
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Table 2.8 The relationship between modified Glasgow Prognostic Score, TNM stage and five and ten-year overall survival of patients undergoing 
elective, potentially curative resection of stage I-III colon cancer 
 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS = 1  mGPS = 2 
 n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE)  n 5-yr OS % (SE) 
Stage I 89 79 (5)     77 87 (5)  8 -  4 - 
Stage II 282 73 (3)     154 78 (4)  67 73 (6)  61 58 (7) 0.001 
Stage III 208 53 (4) 0.001     127 66 (5) 0.063  51 39 (7) 0.007  30 30 (9) <0.001/0.041 
 
Stage I-III 
 
579  
 
66 (2) 
     
358 
 
75 (3)  
  
126 
 
58 (5) 
  
95 
 
47 (6) <0.001 
 n  10-yr OS % (SE)     n 10-yr OS % (SE)  n 10-yr OS % (SE)  n 10-yr OS % (SE) 
Stage I 89 46 (9)     77 55 (12)  8 -  4 - 
Stage II 282 47 (4)     154 56 (5)  67 43 (7)  61 30 (9) 0.001 
Stage III 208 38 (4) 0.001     127 50 (6) 0.063  51 25 (7) 0.007  30 17 (9) <0.001/0.041 
 
Stage I-III 
 
579  
 
44 (3) 
     
358 
 
54 (4) 
  
126 
 
33 (5) 
  
95 
 
24 (7) <0.001 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying overall survival within each TNM stage (rows) and prognostic 
value of TNM stage stratifying overall survival within each mGPS group (columns). OS – overall survival, SE – standard error. Survival not calculated if 
n<10. 
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Table 2.9 The relationship between modified Glasgow Prognostic Score, adjuvant chemotherapy use and five and ten-year cancer-specific survival of 
patients undergoing elective, potentially curative resection of stage III colon cancer 
 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS = 1  mGPS = 2 
 n 5-yr CSS % (SE)     n 5-yr CSS % (SE)  n 5-yr CSS % (SE)  n 5-yr CSS % (SE) 
Adjuvant therapy 96 78 (5)     64 91 (4)  24 57 (11) 0.002  8 - 
No adjuvant therapy 112 51 (5) 0.003     63 60 (7) 0.003  27 47 (11) 0.798  22 34 (11) 0.117/0.591 
 
All  
 
208 
 
63 (4) 
     
127 
 
75 (4) 
  
51 
 
52 (8) 
  
30 
 
37 (10) <0.001 
 n 10-yr CSS % (SE)     n 10-yr CSS % (SE)  n 10-yr CSS % (SE)  n 10-yr CSS % (SE) 
Adjuvant therapy 96 63 (7)     64 72 (9)  24 51 (12) 0.002  8 - 
No adjuvant therapy 112 47 (6) 0.003     63 53 (8) 0.003  27 47 (11) 0.798  22 34 (11) 0.117/0.591 
 
All 
 
208 
 
54 (4) 
     
127 
 
62 (6) 
  
51 
 
48 (8) 
  
30 
 
37 (10) <0.001 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying cancer-specific survival within each adjuvant therapy group 
(rows) and prognostic value of adjuvant therapy use stratifying cancer-specific survival within each mGPS group (columns). CSS – cancer-specific 
survival, SE – standard error. Survival not calculated if n<10. 
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Table 2.10 The relationship between modified Glasgow Prognostic Score, American Society of Clinical Oncology high-risk pathological criteria and five 
and ten-year cancer specific survival of patients undergoing elective, potentially curative resection of stage II colon cancer 
 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS = 1  mGPS = 2 
 n  5-yr CSS % (SE)     n 5-yr CSS % (SE)  n 5-yr CSS % (SE)  n 5-yr CSS % (SE) 
ASCO Criteria               
Low risk 91 91 (3)     48 93 (4)  30 100 (0)  13 68 (13) 0.035 
High riska 147 85 (4) 0.212     83 87 (5) 0.293  28 84 (7) 0.647  36 80 (8) 0.062/0.783 
 
All 
 
238 
 
87 (2) 
     
131 
 
89 (3) 
  
58 
 
92 (4) 
  
49 
 
77 (7) 0.002 
 n  10-yr CSS % (SE)     n 10-yr CSS % (SE)  n 10-yr CSS % (SE)  n 10-yr CSS % (SE) 
Low risk 91 85 (5)     48 88 (6)  30 89 (7)  13 68 (13) 0.035 
High risk 147 72 (5) 0.212     83 72 (7) 0.293  28 84 (7) 0.647  36 53 (14) 0.062/0.783 
 
All  
 
238 
 
77 (4) 
     
131 
 
79 (5) 
  
58 
 
87 (5) 
  
49 
 
56 (12) 0.002 
a High-risk stage II colon cancer denoted by presence of one or more of the following: T4 tumour, lymph node yield <10 nodes, poor tumour 
differentiation, tumour perforation or venous invasion. Log-rank P-value provided for the differential prognostic value of mGPS in stratifying cancer-
specific survival within each ASCO risk group (rows) and prognostic value of ASCO risk group stratifying cancer-specific survival within each mGPS 
group (columns). CSS – cancer-specific survival, SE – standard error. Survival not calculated if n<10.
 
 
3 A comparison of the combination of TNM and the modified 
Glasgow Prognostic Score, and its association with survival 
of patients with colorectal cancer from United Kingdom and 
Japan  
3.1 Introduction 
In Chapter 2, it was observed that the mGPS held complimentary prognostic value to 
routine TNM-based staging of patients undergoing resection of TNM stage I-III colorectal 
cancer.  Furthermore, the mGPS appeared to select for patients with stage III colon cancer 
less likely to derive benefit from adjuvant therapy.  Therefore, it is of interest that the 
mGPS has been validated internationally in patients with colorectal cancer (384).  Given its 
objectivity and potential role as a prognostic and predictive marker, the mGPS would be a 
useful adjunct to the routine staging of patients with colorectal cancer.  Furthermore, 
similar to TNM-based staging, it offers the opportuinity to compare outcomes across the 
world by not only staging the tumour, but also the host. 
However, systemic inflammation is determined by a number of host factors, including 
ethnicity; population studies have found those of Black and South Asian origin to have 
higher CRP concentrations than those of Caucasian descent (401-403), whereas individuals 
of East Asian heritage have consistently been reported as having significantly lower 
concentrations (404-406).  Although studied in healthy subjects and cardiovascular disease 
screening programmes, it is not clear whether the presence of a cancer-associated systemic 
inflammatory response differs with ethnicity.  Therefore, the aim of the present study was 
to examine the combination of TNM staging and the mGPS, and survival of patients from 
the United Kingdom (UK) and Japan undergoing potentially curative resection of TNM 
stage I-III colorectal cancer.
 
 
3.2 Patients and Methods 
UK cohort 
Patients from a single surgical unit at GRI, UK who underwent potentially curative 
resection of stage I-III colorectal adenocarcinoma from January 1997 to May 2013 without 
neoadjuvant chemoradiotherapy were identified from a prospectively collected database of 
elective and emergency colorectal cancer resections.  Inclusion and exclusion criteria, 
pathological assessment of resected specimens, measurement of pre-operative CRP and 
albumin, and follow-up protocols are described in Chapter 2. 
Patients were routinely followed up for five years following surgery, with surveillance 
computed tomography performed yearly with regular surveillance colonoscopy.  Death 
records were complete until 30th May 2015 that acted as the censor date.  Overall survival 
was measured from date of surgery until date of death from any cause.  The West of 
Scotland Research Ethics Committee approved the study 
 Japanese cohort 
Patients were identified retrospectively from a database of elective and emergency 
colorectal cancer resections performed by a single surgical team in the Department of 
Gastroenterological Surgery, Dokkyo Medical University, Japan (DMU).  For the present 
study, patients who underwent potentially curative resection of TNM stage I-III colorectal 
cancer without neoadjuvant therapy between November 2005 to December 2015 were 
included.  Exclusion criteria were identical to those applied to the GRI cohort, with pre-
operative measurement of CRP and albumin performed on day of admission.  
Patients were staged according to the seventh edition of the TNM classification (19).  After 
discussion at colorectal multidisciplinary meetings, patients with stage III disease and 
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high-risk stage II disease were considered for 5-FU-based chemotherapy in accordance 
with current treatment guidelines. 
Patients were routinely followed up for five years following surgery, with yearly 
surveillance computed tomography and regular surveillance colonoscopy (407).  Deaths up 
until 30th April 2016 were included.  Overall survival was measured from date of surgery 
until date of death from any cause, with survival censored at last clinic follow-up.  The 
local institutional review board approved the study. 
The mGPS for both cohorts was calculated as described in Chapter 2. 
Statistical analysis 
The relationship between study cohort, mGPS and clinicopathological characteristics was 
examined using the χ2 method for linear trend.  The relationship between mGPS and 
overall survival was examined using Kaplan-Meier log-rank analysis to calculate five-year 
survival percentage (SE).  A P-value ≤0.05 was considered statistically significant.  All 
analyses were performed using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).
 
 
3.3 Results 
The study included 882 patients from GRI and 597 patients from DMU with stage I-III 
colorectal cancer.  Data on American Society of Anesthesiologists (ASA) grade and 
adjuvant therapy use were missing for 298 and two patients respectively from GRI.  Data 
on ASA grade, adjuvant therapy, lymph node yield, venous invasion, margin involvement 
and tumour perforation were missing for 38, 14, 6, 10 and 2 patients respectively from 
DMU. 
A comparison of characteristics of the two cohorts is displayed in Table 3.1.  Patients from 
GRI were more likely to be female, have a high ASA grade and present as an emergency, 
whereas patients from DMU were more likely to receive adjuvant chemotherapy and 
undergo resection for rectal cancer.  Patients from GRI were likely to have more advanced 
disease than patients from DMU as measured by T stage, peritoneal and margin 
involvement, however patients from DMU were more likely to have evidence of venous 
invasion and tumour perforation.  Lymph node yield and N stage were similar between 
groups.  Patients from GRI were more likely to show evidence of an elevated mGPS 
(mGPS³1: 39% vs. 16%, P<0.001).  For subsequent analyses, only patients undergoing 
elective resection were included. 
The relationship between mGPS and clinicopathological characteristics of patients 
undergoing elective resection of colorectal cancer is displayed in Table 3.2.  In patients 
from GRI, mGPS was associated with advancing age and ASA grade, colonic primary, 
advancing T stage and TNM stage, peritoneal involvement and tumour perforation, and 
showed a trend towards an association with margin involvement.  In patients from DMU, 
mGPS was associated with advancing age and ASA grade, colonic primary, advancing T 
stage and peritoneal involvement, and showed a trend towards an association with margin 
involvement.  Although a similar trend between mGPS and TNM stage was observed in 
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patients from DMU, this did not reach statistical significance.  The mGPS was not 
associated with use of adjuvant therapy, lymph node status, lymph node yield nor venous 
invasion in either cohort. 
Comparison of the proportion of patients with an elevated mGPS in each cohort was 
subsequently performed after controlling for clinicopathological characteristics (Table 3.3).  
After controlling for age, sex, ASA grade and tumour location, patients from GRI were 
more likely to have an elevated mGPS compared to patients from DMU.  Patients from 
GRI with T2-4 but not T1 disease were more likely to have an elevated mGPS than 
comparable patients from DMU.  After controlling for N stage, TNM stage, venous 
invasion, lymph node yield and tumour perforation, patients from GRI were again more 
likely to have an elevated mGPS than patients from DMU. 
The relationship between TNM stage, the mGPS and overall survival was examined (Table 
3.4).  The median follow-up of survivors from GRI was 76 months with 375 deaths and 
five-year overall survival of 65%.  The median follow-up of survivors from DMU was 29 
months with 53 deaths and five-year overall survival of 85%.  TNM stage stratified five-
year survival of patients from GRI from 80% to 53% (P<0.001) and patients from DMU 
from 94% to 84% (P=0.11); mGPS stratified survival of patients from GRI and DMU from 
71% to 57% and 88% to 73% respectively (both P£0.001).  In the GRI cohort, the 
combination of TNM stage and mGPS stratified survival at five years from 85% (TNM 
stage I, mGPS=0) to 40% (TNM stage III, mGPS³1) (P<0.001); in the DMU cohort, the 
combination of TNM stage and mGPS stratified survival at five years from 95% (TNM 
stage I, mGPS=0) to 68% (TNM stage III, mGPS³1) (P<0.001). 
As overall survival of patients from GRI was consistently lower than patients from DMU 
with comparable disease stage and systemic inflammatory profile, the relationship between 
TNM stage, mGPS and ASA grade was examined (Table 3.5).  Even after controlling for 
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stage and mGPS, patients from GRI were likely to be ASA grade III/IV compared to 
patients from DMU.  
To control for potential discrepancies in staging due to differences between the 5th and 7th 
edition of TNM staging, the relationship between T stage, the mGPS and survival was 
examined (Table 3.6).  As there were few events in patients with T1 disease, patients with 
T1 and T2 disease were combined into one group.  T stage stratified survival of patients 
from GRI from 79% to 52% (P<0.001) and patients from DMU from 93% to 71% 
(P=0.009).  The combination of T stage and mGPS stratified survival of patients from GRI 
from 82% (T1-2, mGPS=0) to 46% (T4, mGPS³1) (P<0.001), and patients from DMU 
from 95% (T1-2, mGPS=0) to 59% (T4, mGPS³1) (P=0.002). 
The relationship between mGPS and five-year overall survival of patients receiving 
adjuvant chemotherapy for TNM stage III colorectal cancer was examined (Table 3.7).  An 
elevated mGPS was present in 37% of patients from GRI compared to only 11% of patients 
from DMU (P<0.001).  The presence of an elevated mGPS stratified overall survival of 
patients from GRI from 75% to 51% (P=0.002), and patients from DMU from 85% to 68% 
(P=0.028).
 
 
3.4 Discussion 
In the present study, systemic inflammatory profiles differed markedly in patients with 
colorectal cancer from distinct geographical locations, even after controlling for clinical 
and pathological characteristics.  However, the combination of TNM stage and mGPS 
effectively stratified survival of patients with colorectal cancer in both cohorts.  Within 
such TNM/mGPS-based stratification, there were significant differences in survival, with 
the Japanese cohort having superior overall survival.  Therefore, the results of the present 
study not only show the clinical utility of TNM/mGPS-based staging, but also give an 
insight into the variation in outcomes for primary operable colorectal cancer worldwide. 
What might explain the differences in survival between the UK and Japan? The basis of 
the differences in survival even after stratifying by TNM/mGPS may in part reflect 
differences in staging, with patients from the UK being effectively “understaged” 
compared to those from Japan.  However, migration from the 5th to 7th edition would 
account for an upstaging from node negative to node positive disease in less than 3% of 
cases, with little prognostic implication (408, 409).  Furthermore, differences in survival 
were still evident when patients were stratified by T stage, the definition of which has 
remained relatively stable through updates of TNM staging (410).   
Another explanation is that patients from GRI were more likely to exhibit adverse host 
characteristics, including a higher burden of comorbidity as evidenced by ASA grade.  
Comorbidity and physiological status are independent determinants of survival, and may 
explain the differences observed in a cohort of patients otherwise comparable by TNM 
stage and systemic inflammatory profiles (391).  Although it would be of interest to 
examine more objective measures of comorbidity (392), the present results highlight the 
importance of assessment of not only tumour, but also host characteristics when comparing 
outcomes. 
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Even after controlling for clinicopathological characteristics, patients from the UK were 
more likely to exhibit an elevated mGPS.  This is consistent with previous studies which 
have identified lower circulating CRP concentrations in healthy individuals of East Asian 
origin compared to those of European descent (404-406, 411).  Although the increased 
prevalence of an elevated systemic inflammatory response may be explained by 
differences in socioeconomic and lifestyle characteristics, markers of inflammation differ 
widely in individuals of different ethnicity resident in the same geographical location, 
thereby limiting the role of environmental factors and implicating other, intrinsic, factors 
(403, 411). 
Circulating CRP levels are partly determined by genetic polymorphisms (412).  Several 
associated single nucleotide polymorphisms (SNPs) have been identified (413-415), with a 
difference in not only their prevalence, but also their subsequent effect on CRP 
concentrations across different ethnic populations (415).  A number of these SNPs have 
been confirmed as potential determinants of CRP concentrations in individuals of Asian 
descent (414), and the differences observed presently may reflect such underlying genetic 
polymorphisms.  However, previous studies have generally considered mean population 
CRP concentrations in the region of 1-5mg/L, rather than >10mg/L as in the present study.  
Furthermore, in a prior study of patients with advanced cancer, no relationship between a 
number of candidate SNPs associated with inflammation and elevated CRP concentrations 
in the context of the cancer cachexia syndrome were identified (416). 
Other factors therefore may be responsible for the differences observed.  Comorbidity 
burden is associated with the presence of a systemic inflammatory response in patients 
with cancer (391, 392), however differences persisted even after controlling for ASA 
grade.  Other factors, unmeasured in the present study, are as such likely to be implicated.  
One such factor is obesity, which is recognised as an important contributor to the systemic 
inflammatory response (417).  Indeed, it is estimated that almost one quarter of males aged 
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20 or older are obese in the UK, compared to less than 5% in Japan (418).  Therefore, it is 
likely that obesity and other uncontrolled factors, such as smoking, have contributed to the 
differing prevalence of elevated mGPS observed. 
Despite differences in prevalence, the mGPS was associated with overall survival of 
patients from both the UK and Japan.  The mGPS provided complimentary prognostic 
value to standard, TNM-based staging; it was possible to stratify survival of patients from 
both centres with node negative and node positive disease into low- and high-risk groups.  
Similarly, when utilising T stage alone, the mGPS again provided additional prognostic 
utility.  Given its objectivity and reliance on routinely available serum markers, the results 
of the present study would further support the routine reporting of the mGPS as a 
prognostic marker in patients with primary operable colorectal cancer.  
Consistent with the results of Chapter 2, an elevated mGPS was associated with reduced 
survival of patients receiving adjuvant chemotherapy for TNM stage III disease, however it 
was not possible to gain further insight into the mechanisms underlying this relationship.  
The present study only identified whether patients were commenced on adjuvant therapy, 
and did not consider either treatment duration or subsequent dose reductions.  Such factors, 
and their relationship to systemic inflammation and outcome, are of considerable interest, 
and worthy of further study. 
The present study has a number of limitations.  Due to differences in cancer follow-up and 
attainment of mortality data, it was only possible to robustly report overall survival rather 
than cancer-specific or disease-free survival.  However, reporting of overall survival 
provides a pragmatic measure of relevance to patients, and is increasingly recognised as a 
valuable metric for measuring outcome (419).  In addition, the present study did not 
consider tumour molecular characteristics, such as mismatch repair deficiency (dMMR).  
However, few molecular characteristics, except for dMMR, KRAS/BRAF status have 
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translated into routine practice.  Furthermore, in patients with non-metastatic disease, such 
measures are not used in the determination of prognosis or treatment in either institution.  
Finally, although the present study has examined two patient cohorts from geographically 
distinct locations, the ethnicity of individual patients was not considered.  However, the 
population covered by GRI is predominantly European, with a small non-White population 
(420).  Similarly, Japan has a predominantly East Asian population (421).  Therefore, this 
is unlikely to have confounded results.  Further confirmation of the results of the present 
study, particularly with respect to the differing prevalence of elevated systemic 
inflammatory responses in distinct geographical populations is required. 
The results of the present study identify two intriguing points for further consideration.  
Firstly, the difference in systemic inflammatory profiles between geographically distinct 
populations raises issue with respect to the reporting of colorectal cancer outcomes.  
Whereas TNM staging has been standardised internationally to aid in the recruitment to 
and reporting of clinical trials, it is clear that similar must now occur with respect to the 
systemic inflammatory response.  Second, given the perceived lack of efficacy of adjuvant 
chemotherapy in the systemically inflamed patient, such measures should be routinely 
reported to allow appropriate interpretation of clinical trial data. 
In conclusion, using two geographically distinct populations, the results of the present 
study confirm the validity of the mGPS as a prognostic and potential predictive marker.  
Alongside tumour characteristics, such measures should be considered in future studies 
reporting outcome of patients undergoing resection of primary operable colorectal cancer. 
 
 
 
  171 
Table 3.1 Comparison of clinicopathological characteristics of patients from Glasgow 
Royal Infirmary and Dokkyo Medical University undergoing potentially curative resection 
of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Data analysed using χ2 analysis for linear trend.
  GRI cohort  DMU cohort  
Clinicopathological Characteristics 
(n when data missing) 
(n=882) (%)   (n=597) (%) P 
Host characteristics      
Age  
<65 
65-74 
>75 
 
279 (32) 
293 (33) 
310 (35) 
  
219 (36) 
176 (30) 
202 (34) 
0.146 
Sex  
Female 
Male 
 
402 (46) 
480 (54) 
  
226 (38) 
371 (62) 
0.003 
ASA grade 
(1143) 
 
I/II 
III/IV 
 
315 (54) 
269 (46) 
  
490 (88) 
69 (12) 
<0.001 
Presentation  
Elective 
Emergency 
 
796 (90) 
86 (10) 
  
584 (98) 
13 (2) 
<0.001 
Adjuvant therapy 
(1463) 
 
No 
Yes  
 
668 (76) 
212 (24) 
  
376 (64) 
207 (36) 
<0.001 
Tumour characteristics      
Tumor site  
Colon 
Rectum 
 
645 (73) 
237 (27) 
  
383 (64) 
214 (36) 
<0.001 
T stage   
1 
2 
3 
4 
 
59 (7) 
100 (11) 
479 (54) 
244 (28) 
  
96 (16) 
77 (13) 
324 (54) 
100 (17) 
<0.001 
N stage  
0 
1 
2 
 
549 (62) 
245 (28) 
88 (10) 
  
367 (62) 
169 (28) 
60 (10) 
0.831 
TNM stage  
I 
II 
III 
 
135 (15) 
414 (47) 
333 (38) 
  
153 (26) 
213 (36) 
231 (39) 
0.016 
Venous invasion 
(1473) 
 
No 
Yes 
 
430 (49) 
452 (51) 
  
161 (27) 
430 (73) 
<0.001 
Less than 12 lymph nodes retrieved 
(1475) 
 
No 
Yes 
 
644 (73) 
238 (27) 
  
421 (71) 
172 (29) 
0.396 
Margin involvement  
(1469) 
 
No 
Yes 
 
829 (94) 
53 (6) 
  
568 (97) 
19 (3) 
0.016 
Peritoneal involvement  
No 
Yes 
 
663 (75) 
219 (25) 
  
565 (95) 
32 (5) 
<0.001 
Tumour perforation 
(1477)   
 
No 
Yes 
 
859 (97) 
23 (3) 
  
559 (94) 
36 (6) 
0.001 
mGPS  
0 
1 
2 
 
543 (61) 
199 (23) 
140 (16) 
  
502 (84) 
29 (5) 
66 (11) 
<0.001 
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Table 3.2 The relationship between modified Glasgow Prognostic Score and clinicopathological characteristics of patients undergoing potentially 
curative, elective resection of stage I-III colorectal cancer in Glasgow Royal Infirmary and Dokkyo Medical University 
 
 
 
 
 
 
 
 
Data analysed using χ2 analysis for linear trend.
   Glasgow Royal Infirmary   Dokkyo Medical University  
   mGPS=0  mGPS=1  mGPS=2   mGPS=0  mGPS=1  mGPS=2  
Clinicopathological Characteristics 
(n when data missing) 
 n=519 (%)  n=166 (%)  n=111 (%) P  n=497 (%)  n=28 (%)  n=59 (%)  
Host characteristics               
Age  
<65 
65-74 
>75 
  
167 (32) 
186 (36) 
166 (32) 
  
52 (31) 
57 (34) 
57 (34) 
  
29 (26) 
25 (23) 
57 (51) 
0.007   
190 (38) 
154 (31) 
153 (31) 
  
13 (46) 
8 (29) 
7 (25) 
 
 
 
10 (17) 
12 (20) 
37 (63) 
<0.001 
Sex  
Female 
Male 
  
227 (44) 
292 (56) 
  
83 (50) 
83 (50) 
  
56 (50) 
55 (55) 
0.105   
195 (39) 
302 (61) 
 
 
 
4 (14) 
24 (86) 
  
22 (37) 
37 (63) 
0.322 
ASA grade 
(1080) 
 
I/II 
III/IV 
  
199 (59) 
136 (41) 
  
62 (51) 
60 (49) 
 
 
 
33 (43) 
44 (57) 
0.005   
415 (89) 
49 (11) 
  
26 (93) 
2 (7) 
  
42 (78) 
12 (22) 
0.026 
Adjuvant therapy 
(1365) 
 
No 
Yes  
  
400 (77) 
118 (23) 
 
 
 
120 (72) 
46 (28) 
  
88 (79) 
23 (21) 
0.933   
311 (64) 
175 (36) 
  
16 (57) 
12 (43) 
  
42 (75) 
14 (25) 
0.184 
Tumour characteristics               
Tumour site  
Colon 
Rectum 
  
348 (67) 
171 (33) 
  
124 (75) 
42 (25) 
  
92 (83) 
19 (17) 
<0.001   
306 (62) 
191 (38) 
  
17 (61) 
11 (39) 
  
48 (81) 
11 (19) 
0.005 
T stage   
1 
2 
3 
4 
  
51 (10) 
83 (16) 
292 (56) 
93 (18) 
  
5 (3) 
11 (7) 
93 (56) 
57 (34) 
  
2 (2) 
5 (4) 
63 (57) 
41 (37) 
<0.001   
89 (18) 
72 (15) 
266 (53) 
70 (14) 
  
5 (18) 
1 (3) 
14 (50) 
8 (29) 
  
2 (3) 
4 (7) 
37 (63) 
16 (27) 
<0.001 
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Table 3.2 (continued) The relationship between modified Glasgow Prognostic Score and clinicopathological characteristics of patients undergoing 
potentially curative, elective resection of stage I-III colorectal cancer in Glasgow Royal Infirmary and Doyyko Medical University 
 
 
 
 
 
 
 
                 
Data analysed using χ2 analysis for linear trend. 
   Glasgow Royal Infirmary   Dokkyo Medical University  
   mGPS=0  mGPS=1  mGPS=2   mGPS=0  mGPS=1  mGPS=2  
Clinicopathological Characteristics 
(n when data missing) 
 n=519 (%)  n=166 (%)  n=111 (%) P  n=497 (%)  n=28 (%)  n=59 (%) P 
N stage  
0 
1 
2 
  
331 (64) 
152 (29) 
36 (7) 
  
95 (57) 
47 (28) 
24 (15) 
  
77 (69) 
23 (21) 
11 (10) 
0.572   
303 (61) 
143 (29) 
50 (10) 
  
15 (53) 
8 (29) 
5 (18) 
  
43 (73) 
14 (24) 
2 (3) 
0.115 
TNM stage  
I 
II 
III 
 
 
 
16 (22) 
215 (41) 
188 (36) 
 
 
 
13 (8) 
82 (49) 
71 (43) 
  
6 (5) 
71 (64) 
34 (31) 
0.011   
143 (29) 
159 (32) 
195 (39) 
  
5 (18) 
10 (36) 
13 (46) 
  
5 (9) 
36 (64) 
16 (27) 
0.307 
Less than 12 lymph nodes retrieved 
(1376) 
 
No 
Yes 
  
371 (71) 
148 (29) 
  
122 (73) 
44 (27) 
  
85 (77) 
26 (23) 
0.262   
353 (71) 
141 (29) 
  
19 (70) 
8 (30) 
 
 
 
42 (71) 
17 (29) 
0.941 
Venous invasion 
(1368) 
 
No 
Yes 
  
257 (50) 
262 (50) 
  
87 (52) 
79 (48) 
  
58 (52) 
53 (48) 
0.492   
138 (28) 
354 (72) 
  
2 (30) 
19 (70) 
  
13 (22) 
46 (78) 
0.382 
Margin involvement 
(1370) 
 
No 
Yes 
  
499 (96) 
20 (4) 
  
150 (90) 
16 (10) 
  
104 (94) 
7 (6) 
0.051   
478 (98) 
11 (2) 
  
24 (89) 
3 (11) 
  
55 (95) 
3 (5) 
0.060 
Peritoneal involvement  
No 
Yes 
  
434 (84) 
85 (16) 
  
114 (69) 
52 (31) 
  
77 (69) 
34 (31) 
<0.001   
483 (97) 
14 (3) 
  
25 (89) 
3 (11) 
  
47 (80) 
12 (20) 
<0.001 
Tumour perforation 
(1378) 
 
No 
Yes 
  
517 (99) 
2 (1) 
  
160 (96) 
6 (4) 
  
107 (96) 
4 (4) 
<0.001   
472 (95) 
23 (5) 
  
24 (86) 
4 (14) 
  
57 (97) 
2 (3) 
0.825 
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Table 3.3 Comparison between clinicopathological characteristics and the modified 
Glasgow Prognostic Score of patients undergoing potentially curative, elective resection of 
stage I-III colorectal cancer in Glasgow Royal Infirmary and Dokkyo Medical University 
Data analysed using χ2 analysis for linear trend. 
Table 3.3 displays the difference in prevalence of an elevated mGPS after controlling for 
clinicopathological characteristics. Even after controlling for such factors (except tumour 
perforation and peritoneal involvement), patients from GRI were more likely to exhibit an 
elevated mGPS.
Clinicopathological 
Characteristics  
(n when data missing) 
  GRI  DMU  
  mGPS=0 mGPS³1  mGPS=0 mGPS³1 P 
Host characteristics        
Age  
<65 
65-74 
>75 
  
167 (67) 
186 (69) 
166 (59) 
 
81 (33) 
82 (31) 
114 (41) 
  
190 (89) 
154 (88) 
153 (78) 
 
23 (11) 
20 (12) 
44 (22) 
 
<0.001 
<0.001 
<0.001 
Sex  
Female 
Male 
  
227 (62) 
292 (68) 
 
139 (38) 
138 (32) 
  
195 (88) 
302 (83) 
 
26 (12) 
61 (17) 
 
<0.001 
<0.001 
ASA grade  
I/ II 
III/ IV 
  
199 (68) 
136 (57) 
 
95 (32) 
104 (43) 
  
415 (86) 
49 (78) 
 
68 (14) 
14 (22) 
 
<0.001 
0.002 
Adjuvant therapy  
No 
Yes  
  
400 (66) 
118 (63) 
 
208 (34) 
69 (37) 
  
311 (84) 
175 (87) 
 
58 (16) 
26 (13) 
 
<0.001 
<0.001 
Tumour characteristics         
Tumour site  
Colon 
Rectum 
  
348 (62) 
171 (74) 
 
216 (38) 
61 (26) 
  
306 (82) 
191 (90) 
 
65 (18) 
22 (10) 
 
<0.001 
<0.001 
T stage   
1 
2 
3 
4 
  
51 (88) 
83 (84) 
292 (65) 
93 (49) 
 
7 (12) 
16 (16) 
156 (35) 
98 (51) 
 
 
 
89 (93) 
72 (93) 
266 (84) 
70 (74) 
 
7 (7) 
5 (7) 
51 (16) 
24 (26) 
 
0.319 
0.05 
<0.001 
<0.001 
N stage  
0 
1 
2 
 
 
 
331 (66) 
152 (68) 
36 (51) 
 
172 (34) 
70 (32) 
35 (49) 
  
303 (84) 
143 (87) 
50 (88) 
 
58 (16) 
22 (13) 
7 (12) 
 
<0.001 
<0.001 
<0.001 
TNM stage  
I 
II 
III 
 
 
 
116 (86) 
215 (58) 
188 (64) 
 
19 (14) 
153 (42) 
105 (36) 
  
143 (93) 
159 (77) 
195 (87) 
 
10 (7) 
48 (23) 
29 (13) 
 
0.034 
<0.001 
<0.001 
Venous invasion  
No 
Yes 
  
257 (64) 
262 (67) 
 
145 (36) 
132 (33) 
  
138 (87) 
354 (84) 
 
21 (13) 
65 (16) 
 
<0.001 
<0.001 
Less than 12 lymph nodes 
retrieved 
 
No 
Yes 
  
371 (64) 
148 (68) 
 
207 (36) 
70 (32) 
  
353 (85) 
141 (85) 
 
61 (15) 
25 (15) 
 
<0.001 
<0.001 
Margin involvement  
No 
Yes 
  
499 (66) 
20 (47) 
 
254 (34) 
23 (53) 
  
478 (86) 
11 (65) 
 
79 (14) 
6 (35) 
 
<0.001 
0.208 
Peritoneal involvement  
No 
Yes 
  
434 (69) 
85 (50) 
 
191 (31) 
86 (50) 
  
483 (87) 
14 (48) 
 
72 (13) 
15 (52) 
 
<0.001 
0.887 
Tumour perforation  
No 
Yes 
  
517 (66) 
2 (17) 
 
267 (34) 
10 (83) 
  
472 (85) 
23 (79) 
 
81 (15) 
6 (21) 
 
<0.001 
<0.001 
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Table 3.4 The relationship between modified Glasgow Prognostic Score, TNM stage and five-year overall survival of patients undergoing potentially 
curative, elective resection of stage I-III colorectal cancer in Glasgow Royal Infirmary and Dokkyo Medical University 
 
 
 
 
 
 
 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying overall survival within each TNM stage (rows) and prognostic 
value of TNM stage stratifying overall survival within each mGPS group (columns) for patients from GRI and DMU. OS – cancer-specific survival, SE – 
standard error. Survival not calculated if n<20. 
 
Table 3.4 displays the prognostic value of the combination of TNM stage and mGPS in patients from both GRI and DMU undergoing elective resection 
of stage I-III colorectal cancer. Whereas five-year overall survival of patients from GRI with stage III disease was 53%, mGPS further stratified survival 
from 60% to 40% (P<0.001). Similarly, whereas five-year overall survival of patients from DMU with stage III disease was 84%, mGPS further stratified 
survival from 86% to 68% (P=0.004). 
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS ≥ 1 
GRI n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE) 
Stage I 135 80 (4)     116 85 (4)  19 - 
Stage II 368 72 (2)     215 75 (3)  153 69 (4) 0.016 
Stage III 
 
293 53 (3) <0.001     188 60 (4) 0.003  105 40 (5) <0.001/0.001 
Stage I-III 796 66 (2)     519 71 (2)  277 57 (3) <0.001 
DMU n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE) 
Stage I 153 94 (2)     143 95(2)  10 - 
Stage II 207 82 (4)     159 84 (4)  48 73 (10) 0.057  
Stage III 
 
224 84 (3) 0.110     195 86 (3) 0.222  29 68 (12) 0.004/0.643 
Stage I-III 584 86 (2)     497 88 (2)  87 73 (8) <0.001 
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Table 3.5 The relationship between modified Glasgow Prognostic Score, TNM stage and 
American Society of Anaesthesiologists grade in patients undergoing potentially curative, 
elective resection of stage I-III colorectal cancer in Glasgow Royal Infirmary and Dokkyo 
Medical University 
 
 
 
 
 
 
 
Data analysed using χ2 analysis for linear trend. P-value compared to patients from GRI 
with similar TNM stage and mGPS. 
 
 
 mGPS = 0  mGPS ≥ 1 
GRI n ASA 
I-II/ III-IV (%) 
 n ASA 
I-II/ III-IV (%) 
Stage I 60 37 (62)/ 23 (38)  13 6 (46)/ 7 (54) 
Stage II 143 84 (59)/ 59 (41)  116 54 (47)/ 62 (53) 
Stage III 132 78 (59)/ 54 (41)  70 35 (50)/ 35 (50) 
DMU n ASA 
I-II/ III-IV (%) 
 n ASA 
I-II/ III-IV (%) 
Stage I 131 119 (91)/ 12 (9) <0.001  9 7 (78)/ 2 (22) 0.147 
Stage II 152 132 (87)/ 20 (13) <0.001  44 35 (79)/ 9 (21) <0.001 
Stage III 181 164 (91)/ 17 (9) <0.001  29 26 (90)/ 3 (10) <0.001 
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Table 3.6 The relationship between modified Glasgow Prognostic Score, T stage and five-year overall survival of patients undergoing potentially 
curative, elective resection of stage I-III colorectal cancer in Glasgow Royal Infirmary and Dokkyo Medical University 
 
 
 
 
 
 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying overall survival within each T stage (rows) and prognostic value 
of T stage stratifying overall survival within each mGPS group (columns) for patients from GRI and DMU. OS – cancer-specific survival, SE – standard 
error. Survival not calculated if n<20.
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS ≥ 1 
GRI n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE) 
T1-2 157 79 (4)     134 82 (4)  23 62 (11) 0.020 
T3 448 68 (2)     292 71 (3)  156 62 (4) 0.002 
T4 
 
191 52 (4) <0.001     94 58 (5) 0.013  98 46 (5) 0.029/0.184 
T1-4 796 66 (2)     519 71 (2)  277 57 (3) <0.001 
DMU n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE) 
T1-2 173 93 (2)     161 95 (2)  12 - 
T3 317 85 (3)     266 87 (3)  51 79 (9) 0.172 
T4 
 
94 71 (8) 0.007     70 76 (9) 0.097  24 59 (14) 0.019/0.297 
T1-4 584 86 (2)     497 88 (2)  87 73 (8) <0.001 
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Table 3.7 The relationship between modified Glasgow Prognostic Score and five-year overall survival of patients undergoing potentially curative, 
elective resection of stage III colorectal cancer with adjuvant chemotherapy in Glasgow Royal Infirmary and Dokkyo Medical University 
 
 
 
 
Log-rank P-value provided for the differential prognostic value of mGPS in stratifying overall survival of patients receiving adjuvant therapy for patients 
from GRI and DMU. OS – cancer-specific survival, SE – standard error..
 All mGPS 
(mGPS = 0-2) 
    mGPS = 0  mGPS ≥ 1 
GRI n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE) 
Adjuvant therapy 130 70 (4)     89 77 (5)  41 55 (8) 0.002 
DMU n 5-yr OS % (SE)     n 5-yr OS % (SE)  n 5-yr OS % (SE) 
Adjuvant therapy 153 82 (4)     137 85 (4)  16 66 (15) 0.028 
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4 The tumour stroma percentage as a determinant of disease 
progression and prognosis in patients with primary operable 
colorectal cancer 
4.1 Introduction 
In addition to the intrinsic properties of the tumour cell, there is increasing appreciation of 
the importance of components of the tumour microenvironment, including tumour necrosis 
and host local inflammatory responses, as important determinants of oncological outcome 
(225, 235).  Of more recent interest has been the role of the tumour-associated stroma itself 
as an important determinant of disease progression and survival in a number of solid 
cancers (422).  The stroma, comprised of cancer-associated fibroblasts and supporting 
extracellular matrix, may facilitate survival and proliferation of neoplastic cells and 
promote EMT (423), local invasion and metastatic dissemination (424).  In addition, in 
patients with colorectal cancer, characteristics of the stroma may contribute towards 
chemoresistance to 5-FU-based chemotherapy (425), and increased recurrence following 
neoadjuvant radiotherapy for rectal cancer (426). 
Therefore it is of interest that an increase in the proportion of tumour-associated stroma 
within the tumour microenvironment has been associated with poorer survival in a number 
of solid cancers, including breast (427), oesophageal (428) and colon cancer (429-431).  
Given the above, it may be hypothesised that assessment of the ratio of stroma to tumour, 
or tumour stroma percentage (TSP), may act as a surrogate for stromal activity and its 
subsequent effect on disease progression, chemoresistance and oncological outcome. 
It is not clear, however, whether the effect of an expanded stroma on survival is 
independent of other components of the tumour microenvironment, and in particular the 
host local inflammatory cell infiltrate.  Furthermore, the relationship between TSP, host 
and tumour characteristics remains unknown.  Therefore, the aim of the present study was 
to examine the relationship between the tumour-associated stroma using TSP, 
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clinicopathological and tumour microenvironment characteristics, and survival of patients 
undergoing elective, potentially curative resection of colorectal cancer. 
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4.2 Patients and Methods 
Clinicopathological characteristics 
Patients were identified from a prospectively collected and maintained database of elective 
and emergency colorectal cancer resections undertaken in a single surgical unit at GRI.  
For the purposes of the present study, patients who on the basis of preoperative computed 
tomography and laparotomy findings were considered to have undergone elective, 
potentially curative resection of stage I-III colorectal adenocarcinoma between January 
1997 and May 2008 were included.  Patients with IBD-associated cancer, cancers arising 
from the vermiform appendix, and those who received neoadjuvant therapy, or who had 
undergone emergency resection, local resection or resection with palliative intent were 
excluded.  Patients who died within 30 days of surgery were excluded. 
Tumours were staged using the fifth edition of the TNM classification (382), with 
additional data taken from pathological reports issued following resection.  Venous 
invasion was routinely identified using elastica staining as previously described (432).  
Patient demographics and pre-operative serum CRP and albumin concentrations were 
collected prospectively, and the systemic inflammatory response was assessed using the 
mGPS as described in Chapter 2.   
Multi-disciplinary team review, indications for adjuvant therapy and patient follow-up 
have previously been described in Chapter 2.  Date and cause of death was crosschecked 
with the cancer registration system and the Registrar General (Scotland).  Death records 
were complete until 1st December 2011 that served as the censor date.  Cancer-specific 
survival was measured from the date of surgery until the date of death from colorectal 
cancer. 
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Assessment of the tumour microenvironment 
Assessment of the inflammatory cell infiltrate using the KM grade, tumour necrosis and 
TSP were all performed using original H&E-stained sections retrieved from the NHS 
Greater Glasgow & Clyde pathology archive.  Sections were selected from areas of the 
tumour most representative of the deepest point of tumour invasion. 
Klintrup-Mäkinen grade 
Assessment of the generalised inflammatory cell infiltrate at the invasive margin using the 
(KM) grade has previously been performed in this cohort (249).  Briefly, the density of the 
generalised inflammatory cell infiltrate at the invasive margin was graded semi-
quantitatively using a four-point scale as described in Table 1.7.  For the purpose of further 
analysis, KM grade was subsequently categorised as low grade or high grade. 
T-lymphocyte subsets 
On the basis of a previous systematic review (225), the adaptive local inflammatory 
response within the tumour microenvironment was examined using immunohistochemistry 
for mature (CD3+), cytotoxic (CD8+), memory (CD45R0+) and regulatory (FOXP3+) T-
lymphocyte subsets in a cohort of patients as previously described (433).  The density of 
each T-lymphocyte subset within the invasive margin and intraepithelial (cancer cell nests) 
compartments was graded semi-quantitatively using a four-point scale (absent/ low/ 
moderate/ high).  For the purposes of analysis, T-lymphocyte density was subsequently 
graded as low (absent/ low) or high (moderate/ high).  
Tumour necrosis 
Assessment of tumour necrosis has previously been performed in this cohort using 
methodology described by Pollheimer and colleagues (235, 434).  Briefly, necrosis was 
semi-quantitatively graded as absent, focal (<10% of tumour area), moderate (10–30% of 
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tumour area) or extensive (> 30% per cent of tumour area).  For the purpose of analysis, 
tumours were subsequently graded as either low grade (absent/ focal) or high grade 
(moderate/ extensive). 
Tumour stroma percentage 
Assessment of TSP was performed using methodology previously described by Mesker 
and colleagues (429).  Tumour sections were scanned using a Hamamatsu NanoZoomer 
(Welwyn Garden City, Hertfordshire, UK) at x20 optical magnification and visualisation 
was carried out using Slidepath Digital Image Hub, version 4.0.1, (Slidepath, Leica 
Biosystems, Milton Keynes, UK).  At x5 magnification, an area representative of the 
tumour invasive margin was selected.  Using x10 magnification, a single field was 
examined, ensuring that tumour cells were present at all four sides of the image.  The area 
of stroma was calculated as a percentage (to the nearest 5%) of the visible field.  Areas of 
necrosis or mucin were excluded from the field for purposes of analysis, and in tumours 
with a heterogeneous appearance, the area with the highest tumour stromal volume was 
measured, consistent with the method described by Mesker.  Where multiple sections were 
available, each section was scored and an average value calculated for each tumour.  All 
tumours were scored by a single investigator blinded to clinicopathological data and 
clinical outcomes (JHP), with co-scoring of 35 patients performed by another investigator 
(CSDR) to ensure consistency. 
Statistical analysis 
To identify a threshold for subsequent analysis, patients were split into quartiles on the 
basis of TSP and survival analysed between each group using Kaplan-Meier log rank 
(Mantel-Cox) pairwise comparisons.  This was subsequently used to categorise patients as 
low TSP or high TSP.  Subsequent analysis was performed to examine the relationship 
between TSP group and survival using Kaplan-Meier log rank analysis to calculate five-
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year survival (SE).  Univariate Cox proportional hazards regression was used to calculate 
HRs and 95% CIs.  To identify clinicopathological characteristics independently associated 
with survival, variables with P-value <0.1 were then entered in to a multivariable model 
using a backwards conditional method.  For the purposes of survival analysis, only the KM 
grade was entered into the multivariate model as a measure of the local inflammatory cell 
infiltrate as this has previously been shown to have similar prognostic value to assessment 
of T-lymphocyte subsets (433).  The relationship between TSP and other 
clinicopathological characteristics was examined using the χ2 test for linear trend. A P-
value <0.05 was considered statistically significant. All analyses were performed using 
SPSS version 22.0 for Mac (IBM SPSS, IL, USA). 
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4.3 Results 
Three hundred and thirty-one patients who underwent elective resection of Stage I-III 
colorectal cancer were included.  Clinicopathological characteristics are displayed in Table 
4.1.  Data on adjuvant therapy and systemic inflammatory responses was missing for one 
patient.  Two thirds of patients were older than 65 years at time of surgery and 52% were 
male.  Over two thirds of patients (70%) underwent colonic resection, with pathological 
confirmation of stage I disease in 25 patients (8%), stage II in 184 patients (56%) and 
Stage III disease in 122 patients (37%).  Eighty-two patients (25%) received adjuvant 
chemotherapy; one patient with stage I disease, 22 patients with stage II disease and 59 
patients with stage III disease received adjuvant chemotherapy. 
The median number of slides scored per patients was 2 (range 1-8).  Tumour stroma 
percentage ranged from 5% to 95%.  The interobserver intraclass correlation coefficient 
was 0.783 for assessment of TSP (>0.7 is considered good).  On univariate Cox 
proportional regression, an incremental increase in TSP was associated with reduced 
cancer-specific survival (HR 1.02, 95%CI 1.01-1.03, P<0.001).  When split into quartiles 
(Figure 4.1), the survival of patients in the first, second and third quartiles did not differ 
significantly, however the survival of patients in the fourth quartile (TSP>50%) was 
significantly worse (quartile 1 (TSP 5%-22%) P=0.001; quartile 2 (TSP 23%-35%) 
P=0.021; quartile 3 (TSP 36%-50%) P=0.018).  As such, patients were classified as low 
TSP (TSP≤50%) and high TSP (>50%).  The interobserver intraclass correlation 
coefficient for TSP group was 0.813, indicating excellent concordance.  Examples of low 
TSP and high TSP tumours are displayed in Figure 4.2. 
The relationship between TSP and clinicopathological characteristics is displayed in Table 
4.1.  Tumour stroma percentage was not associated with age, sex, or mGPS, however 
patients with a high TSP were more likely to receive adjuvant chemotherapy (P<0.01).  A 
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high TSP was associated with the presence of adverse pathological characteristics; TSP 
was associated with increasing T stage (P<0.05), N stage, TNM stage (both P<0.01), 
margin involvement and peritoneal involvement (both P<0.05).  In addition, patients with a 
high TSP tumour showed a trend towards increased presence of venous invasion 
(P=0.066).  There was no relationship between TSP and tumour location, differentiation or 
tumour perforation. 
The relationship between TSP and characteristics of the tumour microenvironment is 
displayed in Table 4.2.  A high TSP was inversely associated with the presence of tumour 
necrosis and associated with the presence of an infiltrative invasive margin (both P≤0.001).  
TSP was inversely associated with the density of CD3+ and CD8+ T-cells within the cancer 
cell nests (P<0.01 and P<0.05 respectively) but not CD45R0+ or FOXP3+ T-cells.  Tumour 
stroma percentage showed a trend towards an inverse association with KM grade 
(P=0.069), but was not associated with the density of any T-lymphocyte subset at the 
invasive margin.  
The median follow-up of survivors was 107 months (range 44-179 months) and five-year 
cancer-specific survival was 75%.  There were 95 cancer-associated deaths and 66 non-
cancer deaths.  The relationship between TSP and cancer-specific survival of patients 
undergoing resection of stage I-III colorectal cancer is displayed in Figure 4.3.  A high 
TSP was significantly associated with poorer five-year cancer-specific survival (81% (3) 
vs.64% (6), P<0.001). 
The relationship between TSP, clinicopathological and tumour microenvironment 
characteristics and cancer-specific survival is shown in Table 4.3.  On univariate Cox 
regression survival analysis, high TSP was associated with shorter cancer-specific survival 
(P<0.001).  On multivariate analysis, high TSP was associated with reduced cancer-
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specific survival (HR 1.84, 95% CI 1.17-2.92, P=0.009), independent of age (P<0.05), 
mGPS, N stage (both P<0.001), venous invasion (P<0.05) and K-M grade (P=0.001). 
The relationship between TSP and cancer-specific survival of patients undergoing elective 
resection of node negative colorectal cancer is displayed in Figure 4.3.  A high TSP 
showed a trend towards poorer five-year cancer-specific survival (87% (3) vs. 80% (7), 
P=0.069).  On multivariate survival analysis (Table 4.4), a high TSP was independently 
associated with reduced cancer-specific survival (HR 2.14, 95% CI 1.01-4.54, p=0.048), 
independent of mGPS and K-M score (both P<0.05). 
The relationship between TSP and cancer-specific survival of 82 patients receiving 
adjuvant chemotherapy following resection was subsequently examined (Figure 4.3).  A 
high TSP was associated with poorer five-year cancer-specific survival following adjuvant 
chemotherapy (83% (5) vs. 55% (9), P=0.009).  On multivariate analysis (Table 4.5), a 
high TSP was associated with reduced cancer-specific survival (HR 2.83, CI 1.23-6.53, 
P=0.015), independent of mGPS, venous invasion, tumour perforation and K-M score (all 
P<0.05). 
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4.4 Discussion 
In the present study of patients undergoing elective, potentially curative resection of Stage 
I-III colorectal cancer without neoadjuvant therapy, a high TSP was associated with 
reduced cancer-specific survival, independent of clinicopathological and tumour 
microenvironment characteristics.  Furthermore, the present threshold of a TSP of 50% is 
consistent with, and externally validates, previous reports by Mesker and colleagues (429, 
430).  This simple, rapid assessment of the tumour-associated stroma, using routine 
pathological specimens, may improve risk stratification of patients undergoing curative 
resection of colorectal cancer. 
Despite being associated with increasing T stage, TSP was inversely associated with 
tumour necrosis.  The basis of this observation was not clear, however stromal expansion 
may obviate the development of tumour necrosis through increased angiogenesis (435) and 
resistance to tissue hypoxia (436).  Furthermore the tumour-associated stroma may 
reciprocate in tumour cell metabolism by facilitating the recycling of products of anaerobic 
metabolism for further use by tumour cells (437).  Moreover, the inverse association 
between TSP and necrosis may also explain the lack of any perceived effect of TSP on the 
host systemic inflammatory response, as necrosis has been shown to promote systemic 
inflammation through interleukin-6 and other circulating pro-inflammatory cytokines 
(438).  
The present results suggest that an expanded tumour-associated stroma may influence 
disease progression through a direct effect on tumour growth and invasive capabilities.  
Indeed, the presence of a tumour-supporting stroma may overcome barriers to sustained 
tumour growth and invasion, such as a lack of suitable energy substrate and build-up of 
metabolic waste (437), tissue hypoxia (436) and host-tissue integrity (424).  It was of 
interest that the proportion of T1-2 and T3 tumours with a high TSP was similar (21% and 
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19% respectively), whereas 38% of T4 tumours had a high TSP.  Therefore, although a 
high TSP may be identified in earlier stage tumours, expansion of the stromal compartment 
may predominantly be a characteristic of more locally advanced, aggressive disease, 
perhaps facilitating tumour budding and host tissue infiltration (439). 
Indeed, the present study found an association between TSP and the presence of an 
infiltrative invasive margin.  Furthermore, lymph node metastases and venous invasion 
were also more likely in patients with a high TSP.  Consistent with this, the tumour-
associated stroma has previously been shown to facilitate EMT (424, 440) and tumour cell 
migration into normal tissue at the host-tumour interface, characteristic of an infiltrative 
invasive margin (439).  Similarly, the presence of an immature stroma and a high density 
of stromal myofibroblasts have both been associated with tumour budding (237, 441).  
Therefore, the present findings further support a pertinent role for the tumour-associated 
stroma in facilitating tumour cell de-differentiation and dissemination. 
Although the interrelationships between the tumour-associated stroma, tumour 
microenvironment and gross pathological characteristics are likely complex, TSP remained 
independently associated with cancer-specific survival in patients undergoing elective, 
potentially curative resection of colorectal cancer.  Furthermore, alongside host local and 
systemic inflammatory responses, TSP was more strongly associated with reduced cancer-
specific survival than pathological characteristics currently used to identify high-risk, node 
negative disease (172).  Indeed, the present results further confirm the importance of both 
tumour-based factors, such as the tumour microenvironment, and host factors, such as the 
systemic inflammatory response, in determining oncological outcome. 
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Consistent with previous reports of the role of the tumour-associated stroma as a 
determinant of chemoresistance (425), survival was significantly shorter in patients 
undergoing adjuvant therapy for high TSP tumours.  In addition to identifying high risk 
patients, TSP may also select patients less likely to benefit from standard adjuvant therapy 
and who should be considered for additional adjunctive treatment, potentially targeted at 
the stroma itself (442). Indeed, given the potential role of the tumour-associated stroma in 
promoting angiogenesis (435), TSP may well be a biomarker of response to antiangiogenic 
therapies.  However, such agents are not currently licensed for use in patients with non-
metastatic colorectal cancer in the UK.  Furthermore, relatively few patients in the present 
study received adjuvant chemotherapy, with less than 50% of patients with Stage III 
undergoing adjuvant treatment.  Therefore, the role of TSP as a prognostic and predictive 
biomarker remains to be investigated in a larger cohort of patients undergoing adjuvant 
chemotherapy for high-risk colorectal cancer. 
Despite recognition of the importance of the tumour-associated stroma in cancer 
progression, its relationship with other components of the tumour microenvironment has 
yet to be fully characterised.  In the present study, the presence of a high TSP appeared to 
preclude infiltration of cancer cell nests by mature (CD3+) and cytotoxic (CD8+) T-
lymphocytes.  Furthermore, although not reaching statistical significance, TSP displayed 
an inverse association with the density of the peritumoural inflammatory cell infiltrate as 
measured by K-M grade but not by T-lymphocyte subsets.  Indeed, it has previously been 
proposed that the tumour-associated stroma may prevent effective tumour infiltration by 
adaptive immune cells (236, 237, 443).  Of interest however, the effect of TSP on survival 
in the present study remained independent of local inflammatory responses, suggesting that 
the tumour-associated stroma may influence survival through a number of mechanisms 
rather than just through a direct effect on adaptive, T-lymphocyte-mediated immunity.  
Furthermore, although the T-lymphocyte markers examined in the present study were 
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chosen on the basis of a recent systematic review confirming their relevance in colorectal 
cancer (225), the relationship between TSP and other cellular components of both the 
adaptive and innate local inflammatory responses remains to be examined.  Indeed, the 
tumour-associated stroma may promote the development of a pro-tumour rather than anti-
tumour immune infiltrate (444).  Therefore, further characterisation of the inflammatory 
infiltrate and its association with the tumour stroma is warranted.  
The present study is limited by the small number of patients with stage I disease (25 
patients).  As such, it was not possible to examine the effect of TSP on clinicopathological 
characteristics and survival separately in patients with stage I and stage II colorectal 
cancer, and therefore gain further insight into the natural history and development of the 
tumour-associated stroma.  Despite this limitation, the present study provides 
comprehensive assessment of the associations between TSP and the tumour 
microenvironment and, in a cohort of patients with mature survival data, further confirms 
the prognostic relevance of assessment of the tumour microenvironment in patients 
undergoing resection. 
In summary, the present study further confirms the importance of the tumour 
microenvironment, and in particular the tumour-associated stroma, in determining 
oncological outcome in patients with colorectal cancer.  Due to its relatively simple 
assessment, TSP may be readily incorporated into routine clinical pathological reporting to 
improve risk stratification following potentially curative resection of stage I-III colorectal 
cancer.
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Figure 4.1 The relationship between tumour stroma percentage quartile and cancer-
specific survival of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer (log-rank P<0.001) 
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Figure 4.2 Tumour stroma percentage of patients with colorectal cancer as assessed using haematoxylin and eosin-stained sections of the invasive 
margin. (A) and (B) an example of low tumour stroma percentage at x20 and x100 magnification, and (C) and (D) an example of high tumour stroma 
percentage at x20 and x100 magnification
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Figure 4.3 The relationship between tumour stroma percentage and cancer-specific 
survival of patients undergoing elective, potentially curative resection in (A) stage I-III 
colorectal cancer (P<0.001), (B) node negative (stage I-II) colorectal cancer (P=0.069), 
and (C) patients receiving adjuvant chemotherapy (log-rank P=0.009). All P-values 
calculated using log-rank analysis 
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Table 4.1 The relationship between tumour stroma percentage and clinicopathological 
characteristics of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer 
 
Data analysed using χ2 analysis for linear trend. 
 
   All Low TSP  High 
TSP 
  
Clinicopathological Characteristics 
(n when data missing) 
 n=331 
(%) 
n=250 
(%) 
 n=81 (%)  P 
Host characteristics         
Age  
<65 
65-74 
>75 
  
112 (34) 
110 (33) 
109 (33) 
 
82 (33) 
80 (32) 
88 (35) 
  
30 (37) 
30 (37) 
21 (26) 
 0.197 
Sex  
Female 
Male 
  
160 (48) 
171 (52) 
 
126 (50) 
124 (50) 
  
34 (42) 
47 (58) 
 0.188 
Modified Glasgow Prognostic 
Score 
(330) 
 
0 
1 
2 
  
194 (59) 
90 (27) 
46 (14) 
 
143 (57) 
67 (27) 
39 (16) 
  
51 (64) 
23 (28) 
7 (9) 
 0.177 
Adjuvant therapy 
(330) 
 
No 
Yes  
  
248 (75) 
82 (25) 
 
196 (79) 
53 (21) 
  
52 (64) 
29 (36) 
 0.009 
Tumour characteristics         
Tumour site  
Colon 
Rectum 
  
232 (70) 
99 (30) 
 
179 (72) 
71 (28) 
  
53 (65) 
28 (35) 
 0.293 
T stage   
1-2 
3 
4 
  
33 (10) 
208 (63) 
90 (27) 
 
26 (11) 
168 (67) 
56 (22) 
  
7 (9) 
40 (49) 
34 (42) 
 0.027 
N stage  
0 
1 
2 
  
209 (63) 
95 (279 
27 (8) 
 
171 (69) 
61 (24) 
18 (7) 
  
38 (47) 
34 (42) 
9 (11) 
 0.002 
TNM stage  
I 
II 
III 
  
25 (8) 
184 (56) 
122 (37) 
 
20 (8) 
151 (60) 
79 (32) 
  
5 (6) 
33 (41) 
43 (53) 
 0.002 
Tumour differentiation  
Mod/well 
Poor 
  
292 (88) 
39 (12) 
 
222 (89) 
28 (11) 
  
70 (86) 
11 (14) 
 0.564 
Venous invasion  
No 
Yes 
  
216 (65) 
115 (35) 
 
170 (68) 
80 (32) 
  
46 (57) 
35 (43) 
 0.066 
 
Margin involvement  
No 
Yes 
  
310 (94) 
22 (6) 
 
239 (96) 
11 (4) 
  
71 (88) 
10 (12) 
 0.011 
Peritoneal involvement  
No 
Yes 
  
249 (75) 
82 (25) 
 
196 (78) 
54 (22) 
  
53 (65) 
28 (35) 
 0.019 
Tumour perforation  
No 
Yes 
  
324 (98) 
7 (2) 
 
244 (98) 
6 (2) 
  
80 (99) 
1 (1) 
 0.527 
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Table 4.2 The relationship between tumour stroma percentage and components of the 
tumour microenvironment of patients undergoing elective, potentially curative resection of 
stage I-III colorectal cancer 
 
Data analysed using χ2 analysis for linear trend. 
 
 
  Low TSP  High 
TSP 
  
Tumour microenvironment characteristics 
(n when data missing) 
n=244 
(%) 
 n=87 (%)  P 
Tumour necrosis  
(297) 
 
Low grade 
High 
grade 
 
115 (51) 
109 (49) 
  
54 (74) 
19 (26) 
 0.001 
Character of margin  
(312) 
 
Expansile 
Infiltrative 
 
152 (64) 
84 (36) 
  
26 (34) 
50 (66) 
 <0.001 
Klintrup-Mäkinen grade  
(307) 
 
High 
grade 
Low grade 
 
84 (36) 
147 (64) 
 
 
 
19 (25) 
57 (75) 
 0.069 
CD3+ margin density  
(249) 
 
High 
Low 
 
80 (57) 
80 (43) 
  
28 (44) 
36 (56) 
 0.944 
CD3+ cancer cell nest density  
(259) 
 
High 
Low 
 
76 (39) 
119 (61) 
  
12 (19) 
52 (81) 
 0.003 
CD8+ margin density  
(226) 
 
High 
Low 
 
70 (42) 
96 (58) 
  
24 (40) 
36 (60) 
 0.771 
CD8+ cancer cell nest density  
(226) 
 
High 
Low 
 
53 (32) 
113 (68) 
  
11 (18) 
49 (82) 
 0.046 
CD45R0+ margin density  
(222) 
 
High 
Low 
 
77 (47) 
87 (53) 
  
26 (45) 
32 (55) 
 0.781 
CD45R0+ cancer cell nest 
density  
(223) 
 
High 
Low 
 
51 (31) 
114 (69) 
  
12 (21) 
46 (79) 
 0.138 
FOXP3+ margin density  
(219) 
 
High 
Low 
 
68 (42) 
93 (58) 
  
22 (38) 
36 (62) 
 0.569 
FOXP3+ cancer cell nest density 
(219) 
 
High 
Low 
 
84 (52) 
77 (48) 
  
25 (43) 
33 (57) 
 0.237 
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Table 4.3 The relationship between clinicopathological characteristics, components of the tumour microenvironment and cancer-specific survival of 
patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
  
Cancer-specific survival 
Clinicopathological characteristics Univariate analysis P Multivariate analysis P 
Age (<65/ 65-74/ >75) 1.38 (1.07-1.77) 0.013 1.42 (1.08-1.85) 0.011 
Sex (Female/ male) 0.81 (0.54-1.20) 0.291 - - 
mGPS (0/ 1/ 2) 1.75 (1.35-2.27) <0.001 1.73 (1.29-2.31) <0.001 
Adjuvant therapy (No/ yes) 1.15 (0.73-1.80) 0.548 - - 
Tumour site (Colon/ rectum) 1.18 (0.77-1.81) 0.456 - - 
T stage (1-2/ 3/ 4) 1.43 (1.07-1.92) 0.016 - 0.814 
N stage (0/ 1/ 2) 2.19 (1.67-2.88) <0.001 1.75 (1.29-2.38) <0.001 
Tumour differentiation (Mod-well/ poor) 1.59 (0.90-2.80) 0.110 - - 
Venous invasion (No/ yes) 2.37 (1.58-3.55) <0.001 1.78 (1.13-2.78) 0.012 
Margin involvement (No/ yes) 2.88 (1.54-5.42) 0.001 - 0.580 
Peritoneal involvement (No/ yes) 1.86 (1.22-2.84) 0.004 - 0.148 
Tumour perforation (No/ yes) 2.69 (0.85-8.55) 0.094 - 0.061 
Character of margin (Expansile/ infiltrative) 1.69 (1.11-2.56) 0.014 - 0.883 
Tumour necrosis (Low grade/ high grade) 1.42 (0.92-2.19) 0.112 - - 
Klintrup-Mäkinen grade (Low grade/ high grade) 0.32 (0.18-0.57) <0.001 0.37 (0.21-0.66) 0.001 
Tumour stroma percentage (≤50%/ >50%) 2.10 (1.38-3.19) <0.001 1.84 (1.17-2.92) 0.009 
  198 
Table 4.4 The relationship between clinicopathological characteristics, components of the tumour microenvironment and cancer-specific survival of 
patients undergoing elective, potentially curative resection of node negative colorectal cancer 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis.
  
Cancer-specific survival 
Clinicopathological characteristics Univariate analysis P Multivariate analysis P 
Age (<65/ 65-74/ >75) 1.41 (0.95-2.08) 0.089 - 0.087 
Sex (Female/ male) 0.97 (0.52-1.80) 0.912 - - 
mGPS (0/ 1/ 2) 1.61 (1.08-2.38) 0.018 1.71 (1.11-2.64) 0.016 
Adjuvant therapy (No/ yes) 1.00 (0.36-2.82) 0.996 - - 
Tumour site (Colon/ rectum) 1.38 (0.71-2.69) 0.337 - - 
T stage (1-2/ 3/ 4) 0.92 (0.64-1.32) 0.639 - - 
Tumour differentiation (Mod-well/ poor) 0.96 (0.29-3.10) 0.939 - - 
Venous invasion (No/ yes) 1.96 (1.03-3.74) 0.041 - 0.079 
Margin involvement (No/ yes) 1.55 (0.37-6.44) 0.547 - - 
Peritoneal involvement (No/ yes) 1.32 (0.65-2.71) 0.443 - - 
Tumour perforation (No/ yes) 1.82 (0.25-13.43) 0.557 - - 
Character of margin (Expansile/ infiltrative) 1.50 (0.78-2.89) 0.225 - - 
Tumour necrosis (Low grade/ high grade) 1.11 (0.56-2.18) 0.770 - - 
Klintrup-Mäkinen grade (Low grade/ high grade) 0.39 (0.17-0.89) 0.025 0.41 (0.18-0.93) 0.034 
Tumour stroma percentage (≤50%/ >50%) 1.88 (0.94-3.78) 0.074 2.14 (1.01-4.54) 0.048 
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Table 4.5 The relationship between clinicopathological characteristics, components of the tumour microenvironment and cancer-specific survival of 
patients receiving adjuvant chemotherapy following elective, potentially curative resection of colorectal cancer 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
  
Cancer-specific survival 
Clinicopathological characteristics Univariate analysis P Multivariate analysis P 
Age (<65/ 65-74/ >75) 1.16 (0.66-2.02) 0.613 - - 
Sex (Female/ male) 0.8 (0.38-1.81) 0.645   
mGPS (0/ 1/ 2) 1.99 (1.19-3.32) 0.009 1.95 (1.11-3.43) 0.020 
Tumour site (Colon/ rectum) 1.06 (0.47-2.37) 0.895 - - 
T stage (1-2/ 3/ 4) 1.55 (0.81-2.96) 0.181 - - 
N stage (0/ 1/ 2) 1.49 (0.80-2.77) 0.210 - - 
Tumour differentiation (Mod-well/ poor) 1.14 (0.39-3.30) 0.814 - - 
Venous invasion (No/ yes) 3.01 (1.31-6.96) 0.010 3.31 (1.33-8.24) 0.010 
Margin involvement (No/ yes) 4.77 (1.98-11.49) 0.001 - 0.195 
Peritoneal involvement (No/ yes) 2.13 (0.98-4.64) 0.056 - 0.392 
Tumour perforation (No/ yes) 5.82 (1.33-25.44) 0.019 6.95 (1.16-41.51) 0.034 
Character of margin (Expansile/ infiltrative) 0.85 (0.39-1.84) 0.684 - - 
Tumour necrosis (Low grade/ high grade) 1.19 (0.51-2.76) 0.682 - - 
Klintrup-Mäkinen grade (Low grade/ high grade) 0.17 (0.04-0.70) 0.015 0.21 (0.05-0.88) 0.033 
Tumour stroma percentage (≤50%/ >50%) 2.71 (1.25-5.91) 0.012 2.83 (1.23-6.53 0.015 
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5 Mismatch repair status in patients with colorectal cancer: 
association with phenotypic features of the tumour and the 
host 
5.1 Introduction 
In Chapters 2 and 4, assessment of the local and systemic environment of the tumour was 
shown to determine the prognosis of patients undergoing potentially curative resection of 
stage I-III colorectal cancer.  In particular, systemic and local inflammatory responses, in 
addition to TSP, held prognostic value independent of conventional, TNM-based staging.  
However, the characteristics of the tumour that may determine these components of the 
local and systemic environment remain to be elicited. 
One such tumour characteristic is loss of MMR protein activity.  Approximately 15-18% of 
tumours arise through genomic instability as a result of loss of MMR competency; whereas 
2% of MMR deficient (dMMR) tumours occur through inherited germline mutations, the 
remaining 13-15% account for sporadic cases of colorectal cancer, often as a result of 
hypermethylation-induced silencing of the hMLH1 promoter region (16).  Tumours arising 
through dMMR activity accumulate mutations at an exponential rate, particularly within 
repeating microsatellite regions, and are characterised by the presence of MSI as well as 
distinct phenotypic characteristics, such as proximal tumour location and poor or mucinous 
differentiation (17-19).  Furthermore, dMMR status is associated with improved survival, 
particularly in patients with Stage II/III colorectal cancer (151, 198, 420). 
In addition to such characteristics, dMMR colorectal cancer is associated with a typical 
tumour microenvironment phenotype; in particular, the presence of a high density of 
tumour infiltrating lymphocytes has been consistently reported (17, 19, 20, 445).  
Furthermore, the presence of a low proportion of tumour-associated stroma has similarly 
been associated with dMMR status (430).  Indeed, the improved prognosis attributed to 
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dMMR status may not be entirely independent of such favourable characteristics within the 
tumour microenvironment (200, 201, 430). 
Despite extensive characterisation of the tumour microenvironment, it is of interest that the 
relationship between MMR status and the systemic environment remains to be fully 
defined.  Given the favourable prognosis associated with dMMR status, it would be 
expected that patients with tumours arising through this pathway would be less likely to 
exhibit evidence of a cancer-associated systemic inflammatory response at diagnosis.  
Therefore, the aim of the present study was to characterise the relationships between MMR 
status, the local and systemic environment and survival of patients undergoing elective, 
potentially curative resection of colorectal cancer.  
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5.2 Patients and Methods 
Clinicopathological characteristics 
Patients were identified from a prospectively collected and maintained database of elective 
and emergency colorectal cancer resections undertaken in a single surgical unit at GRI.  
For the purposes of the present chapter, patients who had undergone elective, primary 
resection of stage I-III colorectal adenocarcinoma between January 1997 and May 2007, 
and who had tumour tissue included in a previously constructed colorectal cancer tissue 
microarray (TMA) were included (446).  In addition to exclusion criteria described in 
Chapter 4, patients with a known or suspected hereditary colorectal cancer syndrome were 
excluded.  Clinicopathological staging, multi-disciplinary team review, indications for 
adjuvant chemotherapy and clinical follow-up have previously been described in Chapter 
2. 
Date and cause of death was crosschecked with the cancer registration system and the 
Registrar General (Scotland).  Death records were complete until 31st March 2014 that 
served as the censor date.  Cancer-specific survival was measured from the date of surgery 
until the date of death from colorectal cancer. 
Assessment of the tumour microenvironment 
The KM grade and TSP were both assessed using routine H&E-stained sections of the 
deepest point of tumour invasion as previously described in Chapter 4.  The KM grade was 
categorised as low grade or high grade, and TSP was categorised as low (≤50%) or high 
(>50%). 
Full sections of the invasive margin were stained for mature (CD3+), cytotoxic (CD8+), 
memory (CD45R0+) and regulatory (FOXP3+) T-lymphocyte subsets as previously 
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described in Chapter 4.  The density of each T-lymphocyte subset within the invasive 
margin or cancer cell nests was graded as either high or low density. 
Assessment of the systemic inflammatory responses 
Pre-operative serum C-reactive protein (CRP), albumin and the mGPS were measured as 
previously described in Chapter 2.  In addition, the differential white cell count measured 
at the same time was also recorded prospectively.  The NLR was calculated by dividing the 
absolute neutrophil count by the absolute lymphocyte count.  On the basis of previously 
derived thresholds, neutrophil count>7.5x109, platelet count>400x109/L and NLR>5were 
considered elevated (385, 447). The neutrophil:platelet score (NPS) was calculated as 
described by Watt and colleagues (448): patients with a normal platelet count and 
neutrophil count were allocated a score of 0, either an elevated neutrophil count or platelet 
count a score of 1, and those with both an elevated neutrophil and platelet count a score of 
2. 
Assessment of mismatch repair status 
Previously constructed TMAs, comprising of four 0.6mm cores of formalin-fixed paraffin-
embedded cancer tissue per patient, were utilised to assess MMR status (446).  TMA slides 
were placed in a ThermoFisher pH 9 PT module solution (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) at room temperature.  Slides were then heated in the PT module to a 
temperature of 96oC for 20 minutes and allowed to cool.  Using the ThermoFisher 
autostainer, slides were incubated in peroxidase block for 5 minutes and rinsed with TBS 
before incubating in UV protein blocker for 5 minutes and rinsing once again with TBS 
solution.  Slides were incubated in primary antibody for 20 minutes at a concentration of 
1:100 for MLH1 and MSH6 and 1:50 for MSH2 and PMS2 (product codes: M3640, 
M3646, M3639 and M3647 respectively; Dako UK Ltd, Cambridgeshire, UK).  Following 
this incubation period, slides were rinsed with TBS and Quanto Amplifier (Thermo Fisher 
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Scientific Inc.) was applied to slides for 10 minutes followed by a further wash with TBS.  
Quanto Polymer was then added for 10 minutes followed by a TBS wash.  DAB Quanto 
substrate was then added for 5 minutes, slides washed in TBS, counterstained in 
haematoxylin, blued in Scotts’ tap water, and dehydrated through a series of graded 
alcohols before applying cover slips with distrene, plasticizer and xylene (DPX) mounting 
medium. 
The expression of MMR proteins was established by a single observer (AGP) blinded to 
clinical outcomes using UK NEQAS scoring guidelines (22).  Appendix and normal colon 
were used as positive controls and positive staining within intratumoural immune cells 
served as an internal positive control.  An example of positive and negative staining for 
MLH1 protein expression is displayed in Figure 5.1.  One observer blinded to clinical 
outcome (JHP) scored 10% of cores.  Expression was reported as MMR proficient (tumour 
cell nuclear expression with positive immune cell expression) or MMR deficient (absent 
tumour nuclear expression with normal immune cell expression).  The use of multiple 
TMA cores per patient has been shown to be comparable to the use of full sections, even in 
the presence of known intratumoural heterogeneity of protein expression (449).  In the 
present study, four cores were examined per patient for each MMR protein; TMA 
assessment of MLH1 and MSH2 using three cores per patient has previously been shown 
to be comparable to use of full section analysis (450). 
Statistical analysis 
The relationship between MMR status, clinicopathological characteristics and 
characteristics of the local and systemic environment was examined using the χ2 method 
for linear trend for categorical variables and Mann-Whitney U test for continuous 
variables. The relationship between MMR status, local and systemic environment 
characteristics associated with MMR status and survival was examined by Kaplan-Meier 
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log-rank survival analysis and Cox proportional hazards regression using a multivariate 
backwards conditional model to calculate HRs and 95% CIs.  A P-value ≤0.05 was 
considered statistically significant.  All analyses were performed using SPSS version 22.0 
for Mac (IBM SPSS, IL, USA).  The West of Scotland Research Ethics Committee 
approved the study and tissue for analysis of MMR status was obtained from the NHS 
Greater Glasgow & Clyde Tissue Biorepository. 
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5.3 Results 
A total of 228 patients who underwent elective, potentially curative resection of stage I-III 
colorectal cancer were included.  Clinicopathological characteristics of the cohort are 
displayed in Table 5.1.  Almost two thirds of patients were older than 65 at time of surgery 
and 53% were male.  Pathological assessment confirmed Stage I disease in 16 patients 
(7%), stage II disease in 111 patients (49%) and stage III disease in 101 patients (44%).  
Sixty-six patients (29%) received adjuvant therapy; 1 patient with stage I disease, 15 
patients with stage II disease and 50 patients with stage III disease received adjuvant 
therapy.  Mismatch repair deficiency was identified in 35 patients (15%); the frequency of 
aberrant MMR protein expression in patients with dMMR colorectal cancer is displayed in 
Table 5.2.	
The relationship between mismatch repair status and clinicopathological 
characteristics 
The relationship between MMR status and clinicopathological characteristics is displayed 
in Table 5.1.  Patients with dMMR colorectal cancer were more likely to have a colonic 
primary and exhibit poor tumour differentiation (both P<0.05).  In addition, although not 
associated with T stage, dMMR status was associated with an increased rate of peritoneal 
involvement (P<0.05).  Detection of dMMR did not differ with year of diagnosis 
(P=0.290).  Furthermore, the age of patients with dMMR colorectal cancer did not differ 
significantly from those with MMR competent cancer (P=0.707).  As such, it is unlikely 
that a significant proportion of included patients had Lynch syndrome-associated cancer. 	
The relationship between mismatch repair status and the tumour 
microenvironment 
The relationship between MMR status and the tumour microenvironment is displayed in 
Table 5.3.  Patients with dMMR colorectal cancer had an increased density of CD3+ 
(P<0.01), CD45R0+ (P<0.05) and CD8+ (P=0.071) T-lymphocytes within the cancer cell 
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nests.  Although not reaching statistical significance, patients with dMMR colorectal 
cancer were less likely to have a high TSP (15% vs. 28%, P=0.118).  The density of 
FOXP3+ T-lymphocytes within the cancer cell nests, density of T-lymphocytes at the 
invasive margin, nor the KM grade, showed significant association with MMR status.  
The relationship between mismatch repair status and systemic inflammatory 
responses 
The relationship between MMR status and systemic inflammatory responses is displayed 
in Figure 5.2 and Table 5.4.  Patients with dMMR colorectal cancer had a higher median 
pre-operative CRP (P<0.001) and neutrophil count (P<0.05), and showed a trend towards a 
higher median platelet count (P=0.091).  Serum albumin concentrations and circulating 
lymphocyte count did not differ with MMR status.  Patients with dMMR colorectal cancer 
were more likely to have a neutrophil count>7.5x109/L (P<0.01) and platelet count 
>400x109/L (P<0.05). In addition, both the mGPS and NPS were more likely to be 
elevated in patients with dMMR colorectal cancer (both P<0.01). 
The relationship between mismatch repair status, the local and systemic 
environment and survival 
The relationship between MMR status, characteristics of the local and systemic 
inflammatory responses significantly associated with MMR status, and cancer-specific 
survival was subsequently examined (Table 5.5).  The median follow-up of survivors was 
143 months (range 87-206 months) with 66 cancer-specific deaths and five-year cancer-
specific survival of 76%.  On multivariate survival analysis, dMMR was not significantly 
associated with cancer-specific survival (P=0.790), whereas the density of CD3+ T-
lymphocytes within the cancer cell nests (P<0.001), mGPS (P<0.01) and NPS (P<0.05) 
were independently associated with survival.  When analysis was restricted to patients with 
stage II/III disease only, cancer cell nest CD3+ T-lymphocyte density (P<0.001), mGPS 
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and NPS (both P<0.05) remained associated with survival independent of MMR status 
(P=0.833). 
As cancer cell nest density of CD3+ T-lymphocytes, mGPS and NPS were all associated 
with survival independent of MMR status, the relationship between these characteristics 
and cancer-specific survival of patients with MMR competent colorectal cancer was 
subsequently examined (Figure 5.3).  Five-year cancer specific survival was stratified from 
94% to 67% by cancer cell nest CD3+ T-lymphocyte density (P<0.001), from 83% to 46% 
by mGPS (P=0.002) and from 78% to 60% by NPS (P=0.054). 
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5.4 Discussion 
The results of the present study describe the distinct tumour and host phenotypic 
characteristics associated with MMR deficiency in patients undergoing elective, potentially 
curative resection of colorectal cancer.  Patients with dMMR colorectal cancer were more 
likely to have a high density of T-lymphocytes within the tumour microenvironment and 
evidence of an elevated host systemic inflammatory response as evidenced by components 
of the differential white cell count and serum acute phase proteins.  Furthermore, these 
characteristics were associated with cancer-specific survival independent of MMR status.  
Taken together with the previous literature (201, 254, 430, 451), this provides further 
evidence that the prognostic benefit associated with dMMR colorectal cancer is not 
necessarily independent of such characteristics. 
Patients with dMMR colorectal cancer were more likely to have a high density of 
intratumoural CD3+, CD8+ and CD45R0+ T-lymphocytes, however dMMR status did not 
appear to influence FOXP3+ T-regulatory lymphocyte density.  Furthermore, it was of 
interest that the inflammatory cell infiltrate at the invasive margin, as measured by either 
T-lymphocyte density or KM grade, did not differ with MMR status.  Given that the KM 
grade is reflective of components of both adaptive and innate local immune responses 
(452), the present study would favour an association between dMMR status and 
development of a primarily co-ordinated, adaptive intratumoural immune response.  
Indeed, this is consistent with recent work addressing the nature of the immune 
microenvironment in patients with dMMR colorectal cancer (445, 453).  De Smedt and 
colleagues recently reported that MSI-associated colon cancers primarily elicited an 
intratumoural, lymphocytic inflammatory response with little change in the peritumoural 
generalised inflammatory infiltrate (445).  Secondly, Maby and co-workers reported that 
an increased burden of MSI-associated frameshift mutations predominantly favoured 
tumour infiltration by CD8+ T-lymphocytes but not FOXP3+ T-lymphocytes (453).  Taken 
  210 
together with these prior studies, the present results further support the role of dMMR in 
promoting tumour infiltration by a co-ordinated, adaptive, anti-tumour lymphocytic 
response (295). 
An unexpected finding was an association between dMMR status and the presence of an 
elevated systemic inflammatory response.  In particular, dMMR status was associated with 
an elevated CRP, neutrophil count and platelet count, as well prognostic scores derived 
from these markers.  Of interest however, and consistent with recent work by Pine and 
colleagues (454), neither circulating lymphocyte count nor NLR were associated with 
MMR status.  Although Pine and colleagues hypothesised that the peritumoural 
lymphocytosis associated with dMMR colorectal cancer may translate into an increase in 
circulating lymphocyte count, the results of the present study more closely reflect our 
understanding of the nature of the cancer-associated systemic inflammatory response.  
Whereas the presence of a conspicuous inflammatory cell infiltrate within the tumour 
microenvironment reflects the presence of an adaptive, anti-tumour immune response, it is 
increasingly appreciated that an elevated systemic inflammatory response primarily 
reflects up-regulation of mediators of innate immunity, which in turn promote tumour 
progression and dissemination (398).  As such, it would be expected that any association 
between tumour characteristics and the systemic inflammatory response would be reflected 
by changes in markers of innate immunity, such as circulating CRP concentrations and 
neutrophil and platelet counts. 
The mechanism underlying an association between systemic inflammation and MMR 
status is not clear.  Although dMMR tumours may be more likely to express an 
“inflammatory response”-type gene signature (455), another possible explanation is that 
the presence of a chronic systemic inflammatory response may predispose patients to 
sporadic development of dMMR tumours (16, 456).  For example, the pro-inflammatory 
cytokine IL-6 has previously been implicated in the initiation of mismatch repair defects in 
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colon cancer cell lines (457), and a similar relationship between systemic inflammation 
and MMR status has been observed in patients with gynaecological malignancies (456).  
Furthermore, despite dMMR tumours eliciting a profound anti-tumour lymphocytic 
immune response, it has recently been shown that this is counterbalanced by up-regulation 
of multiple immune checkpoints (295).  Indeed, whether the systemic inflammatory 
response reflects underlying immune checkpoint activation, or may be indicative of an 
activated common upstream precursor, such as the JAK/STAT3 pathway, would be of 
considerable interest (458).  
Characterisation of host local and systemic inflammatory responses was a stronger 
predictor of survival than assessment of MMR status on multivariate survival analysis, and 
also showed prognostic value in patients with MMR competent colorectal cancer, 
consistent with previous reports (201, 451, 452, 459, 460).  Furthermore, a considerable 
proportion of patients with MMR competent colorectal cancer had a high density of 
intraepithelial T-lymphocytes. Given that assessment of MMR status alone would have 
failed to identify these patients, it is clear that combined assessment of host local and 
systemic inflammatory responses, in conjunction with MMR status and standard 
pathological staging, could potentially lead to better risk stratification than each of these 
measures used individually. 
The results of the present chapter are perhaps limited by the use of immunohistochemistry 
to identify loss of MMR activity rather than genetic sequencing for microsatellite 
instability.  Not all MSI pathway tumours will be identifiable by loss of MMR proteins 
(461), however immunohistochemistry-based detection of MLH1 and MSH2 has an 
acceptable sensitivity and specificity for microsatellite instability screening (462), and this 
is further improved by the use of the additional markers PMS2 and MSH6 as utilised in the 
present study (461).  In addition, previous studies have found that immunohistochemistry-
based assessment of MMR status utilising TMA sections is comparable to full-section 
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analysis (450, 463).  Whereas prior studies have recommended the use of three cores per 
tumour (450), the present analysis was performed using four cores for each protein.  
Furthermore, although the use of older, archival tissue can influence the results of 
immunohistochemistry, there was no difference in the frequency of detection of MMR 
deficiency with year of surgery, suggesting that this was not an issue in the present study.  
Finally, manual semi-quantitative assessment of the local inflammatory cell infiltrate was 
presently employed rather than automated assessment.  However, this has been shown to 
have excellent inter-operator agreement (433), and correlates strongly with automated 
digital assessment (445, 464). 
In summary, the results of the present study further highlight the complexities of the 
relationship between the local and systemic tumour environment and MMR status in 
patients with colorectal cancer.  Furthermore, these results further confirm the importance 
of the local and systemic environment, in addition to the intrinsic properties of tumour 
cells, in determining outcome of patients with colorectal cancer. 
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Figure 5.1 Example of mismatch repair protein expression of patients with colorectal cancer (x200 magnification). (A) positive MLH1 expression within 
tumour epithelium, and (B) lack of MLH1 expression within tumour epithelium. Positive staining of intratumoural lymphocytes provides a positive 
internal control
A B
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Figure 5.2 The relationship between mismatch repair status and host systemic 
inflammatory responses in patients undergoing elective, potentially curative resection of 
stage I-III colorectal cancer. (A) serum C-reactive protein (P<0.001), (B) serum albumin 
(P=0.258), (C) circulating neutrophil count (P=0.032), (D) circulating lymphocyte count 
(P=0.669), (E) circulating platelet count (P=0.091), (F) modified Glasgow Prognostic 
Score (P=0.007), (G) neutrophil: platelet score (P=0.001), and (H) neutrophil: lymphocyte 
ratio (P=0.145). All P-values calculated using Mann-Whitney U test 
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Figure 5.3 The relationship between tumour and host characteristics associated with 
survival independent of mismatch repair status and cancer-specific survival of patients 
undergoing elective, potentially curative resection of mismatch repair competent, stage I-
III colorectal cancer. (A) cancer cell nest CD3+ T-lymphocyte density (P<0.001), (B) 
modified Glasgow Prognostic Score (P=0.002), and (C) neutrophil: platelet score 
(P=0.054). All P-values calculated using log-rank analysis
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Table 5.1 The relationship between mismatch repair status and clinicopathological 
characteristics of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer 
Data analysed using χ2 analysis for linear trend.
  All  MMR competent  MMR deficient   
Clinicopathological Characteristics n=228  
(%) 
 n=193  
(%) 
 n=35  
(%) 
 P 
Host characteristics         
Age  
<65 
65-74 
>75 
 
83 (36) 
73 (32) 
72 (32) 
  
71 (37) 
62 (32) 
60 (31) 
  
12 (34) 
11 (32) 
12 (34) 
 0.707 
Sex  
Female 
Male 
 
108 (47) 
120 (53) 
  
92 (48) 
101 (52) 
  
16 (46) 
19 (54) 
 0.832 
Diagnosis Year  
1997-2002 
2003-2007 
 
142 (62) 
86 (38) 
  
123 (64) 
70 (36) 
  
19 (54) 
16 (46) 
 0.290 
Adjuvant therapy  
No 
Yes  
 
162 (71) 
66 (29) 
  
135 (70) 
58 (30) 
  
27 (77) 
8 (23) 
 0.389 
Tumour characteristics         
Tumour location  
Colon 
Rectum 
 
151 (66) 
77 (34) 
  
122 (63) 
71 (37) 
  
29 (83) 
6 (17) 
 0.024 
T stage   
1-2 
3 
4 
 
25 (11) 
141 (62) 
62 (27) 
  
21 (11) 
124 (64) 
48 (25) 
  
4 (11) 
17 (49) 
14 (40) 
 0.365 
N stage  
0 
1 
2 
 
127 (55) 
77 (34) 
24 (11) 
  
105 (54) 
65 (34) 
23 (12) 
  
22 (63) 
12 (34) 
1 (3) 
 0.160 
TNM stage  
I 
II 
III 
 
16 (7) 
111 (49) 
101 (44) 
  
14 (7) 
91 (47) 
88 (46) 
  
2 (6) 
20 (57) 
13 (37) 
 0.539 
Tumour differentiation  
Mod/well 
Poor 
 
200 (88) 
28 (12) 
  
173 (90) 
20 (10) 
  
27 (77) 
8 (23) 
 0.039 
Venous invasion  
No 
Yes 
 
148 (65) 
80 (35) 
  
123 (64) 
70 (36) 
  
25 (71) 
10 (29) 
 0.381 
Margin involvement  
No 
Yes 
 
215 (94) 
13 (6) 
  
182 (94) 
11 (6) 
  
33 (94) 
2 (6) 
 0.997 
Peritoneal involvement  
No 
Yes 
 
165 (72) 
63 (28) 
  
145 (75) 
48 (25) 
  
20 (57) 
15 (43) 
 0.029 
Tumour perforation  
No 
Yes 
 
223 (98) 
5 (2) 
  
188 (97) 
5 (3) 
  
35 (100) 
0 (0) 
 0.337 
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Table 5.2 Patterns of aberrant mismatch repair protein expression in patients undergoing 
elective, potentially curative resection of mismatch repair deficient, stage I-III colorectal 
cancer 
 
 
 
 
Table 5.2 displays the observed patterns of MMR deficiency in the present cohort of 
patients undergoing elective resection of stage I-III colorectal cancer. The high prevalence 
of aberrant MLH1/PMS2 expression suggests that this cohort is likely to predominantly be 
comprised of patients with sporadic MMR deficient colorectal cancer.
Aberrant protein 
expression 
Number of patients 
MLH1/PMS2 17 
MSH6/MSH2 8 
PMS2 7 
MSH6 1 
PMS2/MSH6 1 
PMS/MSH6/MSH2 1 
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Table 5.3 The relationship between mismatch repair status and tumour microenvironment 
of patients undergoing elective, potentially curative resection of stage I-III colorectal 
cancer 
Data analysed using χ2 analysis for linear trend 
  All  MMR 
competent 
 MMR 
deficient 
  
Tumour microenvironment 
(n when data missing) 
 
n=228  
(%) 
 n=193  
(%) 
 n=35  
(%) 
 P 
Klintrup-Mäkinen grade  
Low 
High 
 
77 (34) 
151 (66) 
  
63 (33) 
130 (67) 
  
14 (40) 
21 (60) 
 0.398 
CD3+ margin density  
(215) 
 
Low 
High 
 
118 (55) 
97 (45) 
  
100 (55) 
83 (45) 
  
18 (56) 
14 (44) 
 0.867 
CD3+ cancer cell nest density  
(224) 
 
Low 
High 
 
146 (65) 
78 (35) 
  
130 (69) 
59 (31) 
  
16 (46) 
19 (54) 
 0.009 
CD8+ margin density  
(216) 
 
Low 
High 
 
127 (59) 
89 (41) 
  
105 (57) 
78 (43) 
  
22 (67) 
11 (33) 
 0.319 
CD8+ cancer cell nest density  
(222) 
 
Low 
High 
 
161 (72) 
61 (28) 
  
140 (75) 
47 (25) 
  
21 (60) 
14 (40) 
 0.071 
CD45R0+ margin density  
(217) 
 
Low 
High 
 
112 (52) 
105 (48) 
  
96 (53) 
87 (47) 
  
16 (47) 
18 (53) 
 0.564 
CD45R0+ cancer cell nest density 
(224) 
 
Low 
High 
 
160 (71) 
64 (29) 
  
141 (75) 
48 (25) 
  
19 (54) 
16 (46) 
 0.015 
FOXP3+ margin density  
(216) 
 
Low 
High 
 
126 (58) 
90 (42) 
  
104 (57) 
78 (43) 
  
22 (65) 
12 (35) 
 0.413 
FOXP3+ cancer cell nest density 
(219) 
 
Low 
High 
 
110 (50) 
109 (50) 
  
92 (50) 
93 (50) 
  
18 (53) 
16 (47) 
 0.731 
Tumour stroma percentage  
(225) 
 
Low 
High 
 
166 (74) 
59 (26) 
  
138 (72) 
54 (28) 
  
28 (85) 
5 (15) 
 0.118 
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Table 5.4 The relationship between mismatch repair status and systemic inflammatory 
responses of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer 
 
Categorical data analysed using χ2 analysis for linear trend. Continuous data analysed using 
Mann-Whitney U test. IQR – interquartile range. 
  All  MMR 
competent 
 MMR 
deficient 
  
Systemic environment 
(n when data missing)x 
n=228  
(%) 
 n=193  
(%) 
 n=35  
(%) 
 P 
CRP (mg/L) Median 
(IQR) 
8 (6-20)  7 (5-18)  21 (7-48)  <0.001 
Albumin (g/L) Median 
(IQR) 
40 (36-42)  40 (37-42)  39 (34-43)  0.258 
Modified Glasgow 
Prognostic Score 
 
0 
1 
2 
 
131 (58) 
71 (31) 
26 (11) 
  
117 (61) 
58 (30) 
18 (9) 
  
14 (40) 
13 (37) 
8 (23) 
 0.007 
Neutrophil count 
(x109/L) 
Median 
(IQR) 
5.4 (4.3-6.7)  5.3 (4.2-6.6)  6.4 (4.6-7.7)  0.032 
Lymphocyte count 
(x109/L) 
Median 
(IQR) 
1.5 (1.2-2.1)  1.5 (1.2-2.1)  1.6 (1.2-2.1)  0.891 
Platelet count (x109/L) Median 
(IQR) 
300 (245-369)  296 (242-360)  352 (251-441)  0.091 
Neutrophil count  
(227) 
 
 
≤7.5x109/L 
>7.5x109/L 
 
192 (85) 
35 (15) 
  
168 (87) 
24 (13) 
  
24 (69) 
11 (31) 
 0.004 
Lymphocyte count  
(227) 
 
 
≤4x109/L 
>4x109/L 
 
226 (99) 
1 (0) 
  
191 (99) 
1 (1) 
  
35 (100) 
0 (0) 
 0.669 
Platelet count  
(207) 
 
≤400x109/L 
>400x109/L 
 
171 (83) 
36 (17) 
  
150 (85) 
26 (15) 
  
21 (68) 
10 (32) 
 0.018 
Neutrophil:lymphocyte 
ratio 
(227) 
 
≤5 
>5 
 
177 (78) 
50 (22) 
  
153 (80) 
39 (20) 
  
24 (69) 
11 (31) 
 0.145 
Neutrophil:platelet 
score (207) 
 
0 
1 
2 
 
149 (72) 
47 (23) 
11 (5) 
  
132 (75) 
39 (22) 
5 (3) 
  
17 (55) 
8 (26) 
6 (19) 
 0.001 
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Table 5.5 The relationship between local and systemic environment characteristics 
associated with mismatch repair status and cancer-specific survival of patients undergoing 
elective, potentially curative resection of stage I-III colorectal cancer 
 
Data analysed using Cox proportional hazards regression using a backwards conditional 
method to calculate hazard ratios and 95% confidence intervals. 
 
 
  
Cancer-specific survival 
All patients (n=228) Multivariate analysis P 
CD3+ cancer cell nest density (Low/ high) 0.28 (0.14-0.57) <0.001 
CD45R0+ cancer cell nest density (Low/ high) 0.69 (0.28-1.72) 0.430 
Modified Glasgow Prognostic Score (0/ 1/ 2) 1.59 (1.12-2.27) 0.010 
Neutrophil: platelet score (0/ 1/ 2) 1.47 (1.01-2.14) 0.042 
Mismatch repair status (Competent/ deficient) 0.69 (031-1.54) 0.367 
Stage II/Stage III only (n=212)   
CD3+ cancer cell nest density (Low/ high) 0.30 (0.15-0.61) 0.001 
CD45R0+ cancer cell nest density (Low/ high) 0.77 (0.30-1.95) 0.578 
Modified Glasgow Prognostic Score (0/ 1/ 2) 1.52 (1.06-2.19) 0.023 
Neutrophil: platelet score (0/ 1/ 2) 1.46 (1.01-2.13) 0.047 
Mismatch repair status (Competent/ deficient) 0.71 (0.32-1.58) 0.399 
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6 Signal Transduction and Activator of Transcription-3 in 
patients with colorectal cancer: association with phenotypic 
features of the tumour and the host 
6.1 Introduction 
Another potential mechanism linking local and systemic inflammatory responses in 
patients with colorectal cancer is activation of the JAK/STAT3 pathway by IL-6.  
Circulating IL-6 is commonly elevated in a number of cancers, including colorectal cancer 
(438, 465, 466), and is the predominant stimulus for the hepatic synthesis of acute phase 
proteins, including CRP (261).  Cancer-associated fibroblasts and inflammatory cells 
contribute to high levels of IL-6 within the tumour microenvironment (467, 468), with 
subsequent tumour cell activation of the soluble IL-6 receptor/ glycoprotein 130 complex 
(469).  Interleukin-6 trans-signalling regulates JAK activity within the tumour cell to 
promote phosphorylation of the tyrosine 705 residue of STAT3.  Phosphorylated STAT3 
(pSTAT3) translocates to the nucleus where it is a key transcription factor for numerous 
Th2-type cytokines, including IL-6 (466, 467), in turn promoting a pro-tumour, 
immunosuppressive environment and attenuating host anti-tumour immune responses (218, 
468).  Indeed, given its role in not only de-regulation of the host anti-tumour immune 
response, but also in orchestrating numerous pro-oncogenic processes (229, 468, 470), it is 
not surprising that STAT3 expression and activation has previously been associated with 
reduced survival in a number of gastrointestinal cancers, including colorectal cancer (471).  
Given the above, it can be hypothesised that the host systemic and local inflammatory 
responses in patients with colorectal cancer may be linked by STAT3.  As such, the aim of 
the present study was to examine the relationship between tumour cell STAT3 expression, 
the local and systemic environment and survival in a cohort of patients undergoing 
potentially curative, elective resection of stage I-III colorectal cancer. 
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6.2 Patients and Methods 
Patients who had undergone elective, primary resection of stage I-III colorectal 
adenocarcinoma without neoadjuvant chemoradiotherapy and who had tumour tissue 
included in a previously constructed colorectal cancer TMA were included as previously 
described in Chapter 5.  Routine follow-up of patients following surgery has previously 
been described in Chapter 2.  Mismatch repair status was determined as described in 
Chapter 5.  Date and cause of death was crosschecked with the cancer registration system 
and the Registrar General (Scotland).  Death records were complete until 31st March 2014 
that served as the censor date.  Cancer-specific survival was measured from the date of 
surgery until the date of death from colorectal cancer. 
Assessment of the tumour microenvironment 
The KM grade and TSP were both assessed using routine H&E-stained sections of the 
deepest point of tumour invasion as previously described in Chapter 4; KM grade was 
categorised as low grade or high grade, and TSP was categorised as low (≤50%) or high 
(>50%).  Full sections of the invasive margin were stained for mature (CD3+), cytotoxic 
(CD8+), memory (CD45R0+) and regulatory (FOXP3+) T-lymphocyte subsets as 
previously described in Chapter 4.  The density of each T-lymphocyte subset within the 
invasive margin or cancer cell nests was graded as either high or low density. 
Assessment of the systemic inflammatory responses 
Pre-operative serum CRP, albumin and the mGPS were measured as previously described 
in Chapter 2.  The NLR and NPS were calculated as described in Chapter 5.  
Assessment of STAT3 expression 
Immunohistochemical assessment of STAT3 activity was performed using a previously 
constructed colorectal cancer TMA as described in Chapter 5 (446).  In addition to total 
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STAT3 expression, phosphorylated STAT3Tyr705 (pSTAT3) expression was measured as a 
marker of activation of STAT3 by IL-6/JAK.  Sections were dewaxed in xylene before 
being rehydrated using graded alcohols.  Antigen retrieval was performed using a citrate 
buffer at 96oC for 20 minutes for STAT3, and using a Tris-EDTA buffer at high pressure in 
a microwave for 5 minutes for pSTAT3.  Endogenous peroxidase activity was blocked 
using 3% hydrogen peroxide for 10 minutes before rinsing in water.  Casein and 5% horse 
serum in TBS were applied for 20 minutes at room temperature as a blocking agent for 
STAT3 and pSTAT3 respectively.  Sections were then incubated overnight at 4oC with the 
primary antibody (STAT3: product code 9132, Cell Signaling Technologies; pSTAT3: 
product code 9131, Cell Signaling Technologies) at a concentration of 1:100 and 1:50 for 
STAT3 and pSTAT3 respectively before washing in TBS for ten minutes.  Envision 
(Dako) was then added to the sections for 30 minutes at room temperature before washing 
in TBS for ten minutes.  DAB substrate was added for five minutes until colour developed 
before washing in running water for ten minutes.  Slides were counterstained in 
haematoxylin for 60 seconds and blued with Scotts’ tap water before dehydration through 
graded alcohols.  Cover slips were applied using DPX.  
Sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, UK) at x20 magnification and visualization was carried out using Slidepath 
Digital Image Hub (Slidepath, Leica Biosystems, Milton Keynes, UK).  Assessment of 
STAT3 and pSTAT3 expression within the cancer cell cytoplasm and nucleus was 
performed at x20 magnification by a single examiner (JHP) blinded to clinical data using 
the weighted histoscore (472).  To ensure reproducibility of scoring, 15% of tumours were 
co-scored by a second investigator (JC); the intraclass correlation coefficient was 0.826 
and 0.837 respectively.  For the purposes of the present study, cytoplasmic localisation of 
STAT3 expression was considered representative of total STAT3 expression, whereas 
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nuclear localisation of STAT3 and pSTAT3 expression was considered representative of 
STAT3 transcriptional activation. 
Statistical analysis 
Patients were divided into tertiles (low/ moderate/ high) on the basis of cytoplasmic and 
nuclear STAT3 and pSTAT3 expression.  The relationship between clinicopathological 
characteristics and cytoplasmic and nuclear STAT3 expression was examined using the χ2 
method for linear trend.  The relationship between STAT3 expression and five-year 
cancer-specific survival was examined using Kaplan-Meier log-rank analysis and 
displayed as percentage surviving (SE).  The relationship between STAT3 expression, 
clinicopathological characteristics and cancer-specific survival was examined using Cox 
proportional hazards regression; variables with a P≤0.1 on univariate analysis were entered 
into a multivariate model using a backwards conditional model to calculate HRs and 95% 
CIs.  A P-value £0.01 was considered statistically significant for Chi-square analysis of 
categorical variables to compensate for multiple comparisons, whereas a P-value £0.05 
considered statistically significant for survival analysis.  All analyses were performed 
using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).  The West of Scotland Research 
Ethics Committee approved the study and tissue for analysis of STAT3 expression was 
obtained from the National Health Service Greater Glasgow & Clyde Tissue Biorepository. 
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6.3 Results 
A total of 196 patients who underwent elective, potentially curative resection of stage I-III 
colorectal cancer were included.  Clinicopathological characteristics are displayed in Table 
6.1.  Almost two thirds of patients were older than 65 at time of surgery and 52% were 
male.  Pathological assessment confirmed Stage I disease in 16 patients (8%), stage II 
disease in 94 patients (48%) and stage III disease in 86 patients (44%).  Fifty-four patients 
(28%) received adjuvant therapy; 1 patient with stage I disease, 14 patients with stage II 
disease and 39 patients with stage III disease received adjuvant therapy.  Mismatch repair 
deficiency was identified in 27 patients (14%).  Expression of STAT3 was observed in 
both the cytoplasm and nucleus, whereas pSTAT3 expression was only observed in the 
nucleus.  An example of tumour epithelial expression of STAT3 and pSTAT3 is displayed 
in Figure 6.1.	
Tumour cytoplasmic expression of STAT3 was associated with nuclear expression of 
STAT3 (Spearman’s r=0.363, P<0.001) but not pSTAT3 (r=0.111, P=0.121).  Nuclear 
STAT3 expression showed a trend towards an association with nuclear pSTAT3 
expression (r=0.130, P=0.068).  Normal, non-cancer epithelium expression of STAT3 was 
available for 10 patients.  Although this precluded meaningful statistical analysis, it was of 
interest that 7 patients showed similar or higher expression of cytoplasmic STAT3, nuclear 
STAT3 and nuclear pSTAT3 in normal tissue compared to cancer tissue.  The remaining 
three patients showed heterogeneous expression of each of the studied markers. 
The relationship between STAT3 expression and clinicopathological 
characteristics 
The relationship between STAT3 and pSTAT3 expression tertiles and clinicopathological 
characteristics is displayed in Table 6.1.  Cytoplasmic expression of STAT3 was not 
associated with any clinicopathological characteristics.  Although failing to reach statistical 
significance (P£0.01), nuclear STAT3 expression showed an inverse association with use 
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of adjuvant chemotherapy (P=0.038), whereas pSTAT3 expression was associated with 
younger age (P=0.026) and an increased prevalence of lymph node positive disease (low 
pSTAT3 expression – 35% vs. high pSTAT3 expression – 52%, P=0.039).	
The relationship between STAT3 expression and the tumour 
microenvironment 
The relationship between STAT3 and pSTAT3 expression and components of the tumour 
microenvironment is displayed in Table 6.2.  Cytoplasmic STAT3 expression was 
inversely associated with the cancer cell nest density of CD8+ and FOXP3+ T-lymphocytes 
(both P<0.01) and showed a trend towards a similar relationship with CD3+ density 
(P=0.012) but was not associated with TSP or the local inflammatory cell density at the 
invasive margin as measured by Klintrup-Mäkinen grade or T-lymphocyte density.  
Nuclear expression of STAT3 showed no statistically significant association with 
characteristics of the tumour microenvironment, however a lower density of CD8+ 
(P=0.039) and CD3+ (P=0.055) T-lymphocytes was observed in patients with high nuclear 
STAT3 expression.  There were no statistically significant associations between nuclear 
pSTAT3 expression and tumour microenvironment characteristics; patients with high 
nuclear pSTAT3 expression however were observed to have a lower density of CD45R0+ 
T-lymphocytes (P=0.037).	
When analysis was restricted to patients with MMR competent colorectal cancer, the 
observed trends between cytoplasmic STAT3 and cancer cell nest density of CD3+ 
(P=0.061) CD8+ (P<0.05) and FOXP3+ (P<0.01) T-lymphocytes remained.  Nuclear 
STAT3 was no longer associated with CD8+ density within cancer cell nests but was 
associated with CD3+ density within the invasive margin (P<0.05).  Nuclear pSTAT3 
expression again showed a non-significant trend towards low cancer cell nest density of 
CD45R0+ T-lymphocytes.  Although the small number of patients limited statistical power, 
when analysis was restricted to patients with MMR deficient colorectal cancer, the 
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relationship between cytoplasmic STAT3 expression and cancer cell nest density of CD3+ 
(P<0.05) and CD8+ (P<0.01) T-cells, and nuclear STAT3 expression and cancer cell nest 
density of CD8+ T-cells (P<0.05) remained.  Nuclear pSTAT3 expression, however, was 
not associated with T-lymphocyte density of patients with MMR deficient colorectal 
cancer. 
The relationship between STAT3 expression and systemic inflammatory 
responses 
The relationship between STAT3 and pSTAT3 expression and systemic inflammatory 
responses is displayed in Table 6.3.  Cytoplasmic STAT3 expression was associated with 
the systemic inflammatory response as measured by mGPS; this was predominantly due to 
an increase in the number of patients with mGPS=2 (high expression – 19% vs. low 
expression 4%, P=0.004).  Similarly, nuclear STAT3 expression showed a similar trend in 
the number of patients with mGPS=2, however this failed to reach statistical significance 
(18% vs. 8%, P=0.244).  Neither cytoplasmic nor nuclear STAT3 expression were 
associated with the systemic inflammatory response as measured by circulating platelets or 
components of the differential white cell count.  Nuclear pSTAT3 expression was not 
associated with the systemic inflammatory response.	
The relationship between STAT3 expression and survival 
The median follow-up of survivors was 143 months (range 101-204) with 57 cancer-
associated deaths and 64 non-cancer deaths.  For the purposes of survival analysis, low and 
moderate expression of each marker was combined to form one group (low expression).  
The relationship between cytoplasmic STAT3, nuclear STAT3 and nuclear pSTAT3 and 
cancer-specific survival is displayed in Figure 6.2 and in Table 6.4.  High nuclear STAT3 
expression was associated with poorer cancer-specific survival (P<0.05).  High expression 
of both cytoplasmic STAT3 expression and nuclear pSTAT3 expression showed a non-
significant trend towards poorer survival (P=0.068 and P=0.116 respectively). 
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To examine the relationship between expression and activation of STAT3 and survival, the 
cumulative prognostic value of cytoplasmic STAT3, nuclear STAT3 and nuclear pSTAT3 
was examined with respect to five-year cancer-specific survival (Table 6.4).  Three models 
were examined: model 1 (cytoplasmic STAT3/ nuclear STAT3) stratified survival from 
81% (low expression of both) to 63% (high expression of both) (P=0.022), model 2 
(cytoplasmic STAT3/ nuclear pSTAT3) stratified survival from 81% to 54% (P=0.018), 
and model 3 (nuclear STAT3/ nuclear pSTAT3) stratified survival from 81% to 62% 
(P=0.012).  When the three models were entered into a multivariate model using a 
backwards conditional method, only model 3 (nuclear STAT3/ nuclear pSTAT3) remained 
independently associated with cancer-specific survival (HR 1.63, 95%CI 1.14-2.34 
P=0.008, Figure 6.2). 
The relationship between combined nuclear STAT3/pSTAT3 expression, 
tumour characteristics and survival 
The relationship between combined assessment of nuclear STAT3/pSTAT3 expression and 
tumour characteristics was subsequently examined (Table 6.5).  Combined nuclear STAT3 
and pSTAT3 expression was inversely associated with the density of CD3+ and CD45R0+ 
T-lymphocytes within the invasive margin and cancer cell nests.  Furthermore, increasing 
nuclear expression of STAT3/ pSTAT3 showed a trend towards a decrease in the density 
of CD8+ T-lymphocytes within the cancer cell nests (P=0.153) and an increase in TSP 
(P=0.056).  No significant association with the systemic inflammatory response was 
identified.  
Finally, the relationship between combined nuclear STAT3 and pSTAT3 expression and 
cancer-specific survival was examined on multivariate analysis.  As the prognostic value of 
the KM grade has previously been shown to be similar to assessment of individual T-
lymphocyte subsets (433), only KM grade was entered into the multivariate model.  On 
multivariate survival analysis (Table 6.6), combined nuclear STAT3/ pSTAT3 expression 
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showed a trend towards reduced cancer-specific survival (HR 1.39, 95%CI 0.94-2.06, 
P=0.102).  Venous invasion (HR 2.82, 95%CI 1.58-5.04, P<0.001), mGPS (HR 1.79, 
96%CI 1.18-2.70, P=0.006), KM grade (HR 2.23, 95%CI 1.04-4.81, P=0.04) and TSP (HR 
2.75, 95%CI 1.55-4.89, P=0.001) were all independently associated with survival. 
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6.4 Discussion 
In the present study of patients undergoing potentially curative colorectal cancer resection, 
STAT3 was not strongly associated with clinicopathological characteristics of the tumour 
but was associated with adverse host inflammatory responses.  In particular, increased 
tumour cell STAT3 expression was associated with down-regulation of the local 
inflammatory cell infiltrate.   
Although in keeping with previous clinical studies of colorectal and pancreatic 
adenocarcinoma (473, 474), the present study is to our knowledge the first to examine the 
relationship between tumour STAT3 expression and the density of the local adaptive 
immune infiltrate as evidenced by T-lymphocytes in the clinical context of patients with 
gastrointestinal cancer.  Whereas previous studies found a decrease in the density of the 
generalised inflammatory cell infiltrate or tumour-infiltrating lymphocytes using H&E-
based assessments (473, 474), the present study utilised immunohistochemistry and found 
a decrease in the density of tumour-associated T-lymphocyte populations.  This would 
suggest a direct effect of STAT3 activation on adaptive, T-lymphocyte-mediated anti-
tumour immunity.  Furthermore, the relationship between STAT3 expression and the local 
inflammatory cell infiltrate would appear to be independent of MMR status. 
Although assessment of both cytoplasmic STAT3 expression and combined nuclear 
STAT3 and pSTAT3 expression were both significantly associated with the density of T-
lymphocytes, it was of interest that the KM grade, an assessment of the generalised 
inflammatory cell infiltrate, did not differ with STAT3 expression.  This may reflect the 
ability of STAT3 to simultaneously suppress anti-tumour immune responses whilst 
promoting pro-tumour immunity (218, 475).  Whereas anti-tumour, adaptive, Th1-polarised 
immune responses are down-regulated (476, 477), STAT3-dependent transcription and 
release of Th2-type cytokines favours recruitment of tumour-promoting macrophages and 
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myeloid-derived cells (218).  Furthermore, STAT3 activation may additionally favour the 
differentiation of naïve T-lymphocytes into tumour-promoting lymphocytic subsets (218).  
Consistent with such a hypothesis, Morikawa and colleagues found that although 
intratumoural lymphocyte density decreased, the density of the peritumoural inflammatory 
cell infiltrate increased with increasing STAT3 activity in a cohort of patients with stage I-
IV colorectal cancer (473).  Furthermore, it has been shown in some tumours, such as 
ependymomas, that STAT3 immunosuppression is mediated by up-regulation of myeloid-
derived cell activity, with a deleterious effect on T-lymphocytic, anti-tumour activity 
(478).  As such, future studies of STAT3 activation in patients with gastrointestinal cancers 
should also consider the nature and density of local innate immune responses.  
Although failing to reach statistical significance, it was of interest that the density of 
tumour-associated stroma, as measured by TSP, appeared to be associated with both 
pSTAT3 and combined nuclear STAT3/pSTAT3 activation.  Given that an increase in TSP 
primarily reflects an increased population of cancer-associated fibroblasts within the 
tumour microenvironment, this would further support the importance of IL-6 secretion by 
fibroblasts in the activation of the JAK/STAT3 pathway in tumour cells (467, 468).  
Indeed, the present results suggest that the JAK/STAT3 pathway may be an important 
mechanism by which the tumour influences the composition of the tumour 
microenvironment and deregulates host anti-tumour immune responses. 
Increased tumour cytoplasmic STAT3 expression was associated with elevated systemic 
inflammatory responses as measured using the mGPS, a cumulative score based on serum 
CRP and albumin concentrations.  Such routinely measured biomarkers of the systemic 
inflammatory response represent only “the tip of a far larger iceberg” of cancer-associated 
systemic inflammation, whereby circulating cytokines, growth factors and myeloid-derived 
cells promote cancer progression and dissemination (398).  One such cytokine, IL-6, is 
commonly elevated in colorectal cancer (438, 465), and is the main determinant of hepatic 
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synthesis of CRP and responsible for the acute phase reduction in hepatic albumin 
synthesis (261).  Given the importance of IL-6 as both an activator of the JAK/STAT3 
pathway and as an end product of its activation, the present results are not surprising, and 
suggest that STAT3 may play a role in the systemic inflammatory response in colorectal 
cancer. 
However, although cytoplasmic STAT3 expression was associated with an elevated mGPS, 
it was not associated with measures of the differential white cell count.  This is in keeping 
with previous work from Guthrie and colleagues, whereby serum IL-6 concentration 
correlated strongly with the mGPS but not the NLR in patients with colorectal cancer 
(438).  However, other groups have found contradictory results, with a positive association 
between serum IL-6 concentrations and the NLR in patients with colorectal cancer.  This 
disparity may be explained by differences in the groups studied; whereas the patients in the 
present analysis, and that of Guthrie and colleagues were undergoing potentially curative 
resection of stage I-III colorectal cancer, the groups studied by Kantola and Chen included 
patients with stage I-IV colorectal cancer at varying stages of treatment (465, 479).  
Therefore, it would appear that at least in patients with non-metastatic colorectal cancer, 
the effects of the IL-6/JAK/STAT3 pathway on the systemic inflammatory response may 
not be modulated by an effect on circulating innate and adaptive immune cells. 
Of interest, only total cytoplasmic STAT3 expression and not nuclear STAT3/ pSTAT3 
activation was associated with the systemic inflammatory response as measured by mGPS.  
The reason for this is not clear, however may represent the dynamic nature of JAK/STAT3 
activation and translocation.  Although activation of the IL-6 receptor leads to rapid 
accumulation of STAT3, mechanistic studies have shown that less than 30% of total 
cytoplasmic STAT3 translocates to the nucleus on cytokine stimulation (480).  
Furthermore, STAT3 also exhibits transcription-independent activity within the cytoplasm 
without nuclear translocation (480, 481).  Another plausible hypothesis is that rather than 
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being directly causative, the presently observed associations between the mGPS and 
tumour cell STAT3 expression may represent separate down-stream events of a common 
precursor, such as elevated systemic IL-6 concentrations.  Finally, given the lack of a 
consistent relationship across different measures of the systemic inflammatory response, 
the present results may simply represent a Type-I statistical error.  Indeed, rather than the 
tumour itself, other end organs, such as liver or skeletal muscle, may be the predominant 
drivers of the systemic inflammatory response in such patients (482).  As such, the present 
observations should be regarded as hypothesis-generating, and remain to be further 
investigated by mechanistic and clinical studies. 
Consistent with previous reports in patients with gastrointestinal cancers, (471), increased 
tumour cell STAT3 expression and activitation was associated with reduced survival.  The 
importance of the pleiotropic nature of STAT3 activation is reflected in the fact that 
combined assessment of total STAT3 and pSTAT3 held greater prognostic value than 
either measure alone.  Whereas the present analysis investigated IL-6/JAK-mediated 
activation of STAT3 by phosphorylation of tyrosine residue 705, mitogen-activated protein 
kinase-dependent activation results in phosphorylation of the serine 727 residue, with 
differing results on transcriptional activity (483).  Furthermore, STAT3 may also undergo 
nuclear import without phosphorylation (484).  In addition to its role in mediating host 
immune responses, STAT3 activation plays an integral role in many key tumour cell 
pathways, including proliferation, EMT and promotion of cancer cell stemness (485).  As 
such, rather than targeting upstream activation of STAT3, future therapeutic strategies may 
benefit from targeting STAT3 itself and its subsequent activation.  
In the present study, assessment of the local and systemic environment held greater 
prognostic value than STAT3 and pSTAT3 expression or activation.  Rather than being 
defined by one mechanism such as the JAK/STAT3 pathway, characteristics within the 
tumour microenvironment and the systemic inflammatory response are multifactorial in 
  234 
origin.  Therefore, it would be expected that such phenotypic characteristics would be of 
greater prognostic value than a single, contributory pathway.  Indeed, it would be of 
considerable interest to examine and compare similar inflammatory pathways, such as the 
NF-kB pathway (486, 487), in future studies. 
The present study provides further clinical evidence of the potential role of the IL-
6/JAK/STAT3 pathway in the amelioration of host anti-tumour immune responses, and 
raises two interesting points that remain to be investigated.  Firstly, it would suggest a role 
for inhibitors of the IL-6/JAK/STAT3 pathway in restoring anti-tumour immune responses 
in patients with colorectal cancer (488, 489).  Secondly, it would support the hypothesis 
that routine markers of the systemic inflammatory response, and in particular the mGPS, 
may act as predictive biomarkers for patients likely to benefit from such targeted therapies 
(490).  In keeping with such a scheme, one recent clinical trial of a JAK inhibitor in 
patients with metastatic pancreatic cancer found an increase in overall survival only in 
those patients with an elevated CRP or mGPS (491).  Therefore, it is clear that markers of 
the host inflammatory response should be incorporated into future studies of agents 
targeting the IL-6/JAK/STAT3 pathway in cancer.  
Given the increasing appreciation of distinct molecular subtypes of colorectal cancer (492), 
the results of the present study are perhaps limited by the lack of molecular 
characterisation of the tumours studied.  Although not associated with MMR status in the 
present cohort, the relationship between STAT3 and other characteristics, such as KRAS 
and BRAF status, would be of interest.  However, a previous comprehensive study by 
Morikawa and colleagues found no association between STAT3, a number of molecular 
characteristics and survival in a cohort of over 700 patients (473).  Furthermore, it has also 
been suggested that STAT3 may have a role in not only induction of KRAS mutated 
tumours (493), but also in conferring chemoresistance in patients with KRAS wild-type 
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tumours (494).  Indeed, this would suggest that STAT3 is independent of such 
characteristics.  A further limitation is the relatively small sample size, precluding 
meaningful subgroup analysis.  Analysis was restricted to a previously constructed TMA, 
and only patients who had complete staining for both STAT3 and pSTAT3 were included.  
However, post-hoc power calculation shows that the present study has adequate power to 
examine the relationship between STAT3 and the local and systemic environment.  For 
example, post-hoc analysis suggests that the present study holds 84% power to determine a 
difference in cancer cell nest CD8+ T-lymphocyte density between those with low and high 
cytoplasmic STAT3 expression.  Finally, although immunohistochemistry is useful for 
assessment of protein expression and localisation, other techniques may be more useful for 
examining STAT3 activation.  For instance, the use of gel shift assays would yield more 
information regarding the transcriptional activity of STAT3 (495). 
In conclusion, the results of the present study suggest a relationship between tumour cell 
STAT3 expression and activation and local and systemic inflammatory responses, and may 
be one potential mechanism whereby the tumour promotes an environment amenable to 
tumour growth and dissemination.  Further studies are required to confirm such a 
relationship, and whether therapeutic targeting of the IL-6/JAK/STAT3 may be utilised in 
the treatment of patients with colorectal cancer and elevated systemic inflammatory 
responses. 
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Figure 6.1 An example of STAT3 and phosphorylated STAT3 expression in patients with 
colorectal cancer (x200 magnification). (A) exhibits low tumour epithelial cell expression 
of STAT3, whereas (B) exhibits high tumour epithelial cell expression of STAT3. (C) 
exhibits low tumour epithelial cell expression of pSTAT3, whereas (D) exhibits high 
tumour epithelial cell expression of pSTAT3
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Figure 6.2 The relationship between STAT3 and pSTAT3 expression and cancer-specific 
survival of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer. (A) cytoplasmic STAT3 expression (P=0.068), (B) nuclear STAT3 
expression (P=0.012), (C) nuclear pSTAT3 expression (P=0.116), and (D) combined 
nuclear STAT3/pSTAT3 expression (P=0.012). All P-values calculated using log-rank 
analysis 
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Table 6.1 The relationship between STAT3 and pSTAT3 expression and clinicopathological characteristics of patients undergoing elective, potentially 
curative resection of stage I-III colorectal cancer 
   Cytoplasmic STAT3 Nuclear STAT3 Nuclear pSTAT3 
Clinicopathological characteristics All 
N=196 
(%) 
Low 
n=76 
(%) 
Moderate 
n=56 (%) 
High 
n=64 
(%) 
P Low 
n=75 
(%) 
Moderate 
n=66 (%) 
High 
n=55 
(%) 
P Low 
n= 72 
(%) 
Moderate 
n=61 (%) 
High 
n=63 
(%) 
P 
Host characteristics              
Age  
<65 
65-74 
>75 
 
72 (37) 
61 (31) 
63 (32) 
 
23 (30) 
29 (38) 
24 (32) 
 
22 (39) 
18 (32) 
16 (29) 
 
27 (42) 
14 (22) 
23 (36) 
0.571  
29 (39) 
25 (33) 
21 (28) 
 
25 (37) 
22 (33) 
10 (29) 
 
18 (33) 
14 (26) 
23 (41) 
0.199  
19 (26) 
23 (32) 
30 (42) 
 
26 (43) 
19 (31) 
16 (26) 
 
27 (43) 
19 (30) 
17 (27) 
0.026 
Sex  
Female 
Male 
 
94 (48) 
102 (52) 
 
40 (53) 
36 (47) 
 
21 (37) 
35 (63) 
 
33 (52) 
31 (48) 
0.833  
35 (47) 
40 (53) 
 
31 (47) 
35 (53) 
 
28 (51) 
27 (49) 
0.647  
38 (53) 
34 (47) 
 
23 (38) 
38 (62) 
 
33 (52) 
30 (48) 
0.906 
Adjuvant 
therapy 
 
No 
Yes  
 
142 (72) 
54 (28) 
 
55 (72) 
21 (28) 
 
44 (79) 
12 (21) 
 
43 (67) 
21 (33) 
0.532  
48 (64) 
27 (36) 
 
50 (76) 
16 (24) 
 
44 (80) 
11 (20) 
0.038  
56 (78) 
16 (22) 
 
41 (67) 
20 (33) 
 
45 (71) 
18 (29) 
0.389 
Tumour characteristics              
Tumour 
location 
 
Colon 
Rectum 
 
130 (66) 
66 (34) 
 
48 (63) 
28 (37) 
 
37 (66) 
19 (34) 
 
45 (70) 
19 (30) 
0.375  
47 (63) 
28 (37) 
 
43 (65) 
23 (35) 
 
40 (73) 
15 (27) 
0.242  
49 (68) 
23 (32) 
 
37 (61) 
24 (39) 
 
44 (70) 
19 (30) 
0.860 
T stage   
1-2 
3 
4 
 
25 (13) 
121 (61) 
50 (26) 
 
10 (13) 
49 (65) 
17 (22) 
 
9 (16) 
34 (61) 
13 (23) 
 
6 (9) 
38 (59) 
20 (31) 
0.288  
10 (13) 
46 (61) 
19 (25) 
 
10 (15) 
41 (62) 
15 (23) 
 
5 (9) 
34 (62) 
16 (29) 
0.480  
10 (14) 
43 (60) 
19 (26) 
 
8 (13) 
39 (64) 
14 (23) 
 
7 (11) 
39 (62) 
17 (27) 
0.694 
N stage  
0 
1 
2 
 
110 (56) 
68 (35) 
18 (9) 
 
47 (61) 
24 (32) 
5 (7) 
 
30 (53) 
20 (36) 
6 (11) 
 
33 (51) 
24 (38) 
7 (11) 
0.183 
 
 
34 (45) 
34 (45) 
7 (10) 
 
46 (70) 
16 (24) 
4 (6) 
 
30 (54) 
18 (33) 
7 (13) 
0.470  
47 (65) 
21 (29) 
4 (6) 
 
33 (54) 
21 (34) 
7 (12) 
 
30 (48) 
26 (41) 
7 (11) 
0.039 
TNM stage  
I 
II 
III 
 
16 (8) 
94 (48) 
86 (44) 
 
6 (8) 
41 (54) 
29 (38) 
 
7 (13) 
23 (41) 
26 (46) 
 
3 (5) 
30 (47) 
31 (48) 
0.211  
6 (8) 
28 (37) 
41 (55) 
 
8 (12) 
38 (58) 
20 (30) 
 
2 (4) 
28 (50) 
25 (46) 
0.494  
7 (10) 
40 (55) 
25 (35) 
 
5 (8) 
28 (46) 
28 (46) 
 
4 (6) 
26 (41) 
33 (52) 
0.051 
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 Table 6.1 (continued) The relationship between STAT3 and pSTAT3 expression and clinicopathological characteristics of patients undergoing elective, 
potentially curative resection of stage I-III colorectal cancer 
Data analysed using χ2 analysis for linear trend.
   Cytoplasmic STAT3 Nuclear STAT3 Nuclear pSTAT3 
Clinicopathological characteristics All 
N=196 
(%) 
Low 
n=76 
(%) 
Moderate 
n=56 (%) 
High 
n=64 
(%) 
P Low 
n=75 
(%) 
Moderate 
n=66 (%) 
High 
n=55 
(%) 
P Low 
n= 72 
(%) 
Moderate 
n=61 (%) 
High 
n=63 
(%) 
P 
Tumour characteristics              
Tumour 
differentiation 
 
Mod/well 
Poor 
 
174 (89) 
22 (11) 
 
69 (91) 
7 (9) 
 
49 (87) 
7 (13) 
 
56 (87) 
8 (13) 
0.530  
63 (84) 
12 (16) 
 
60 (91) 
6 (9) 
 
51 (93) 
4 (7) 
0.108  
60 (83) 
12 (17) 
 
57 (93) 
4 (7) 
 
57 (91) 
6 (10) 
0.174 
Venous invasion  
No 
Yes 
 
129 (66) 
67 (34) 
 
51 (67) 
25 (33) 
 
39 (70) 
17 (30) 
 
39 (61) 
25 (39) 
0.465  
46 (61) 
29 (39) 
 
45 (68) 
21 (32) 
 
38 (69) 
17 (31) 
0.337  
51 (71) 
21 (29) 
 
39 (64) 
22 (36) 
 
39 (62) 
24 (38) 
0.271 
Margin 
involvement 
 
No 
Yes 
 
187 (95) 
9 (5) 
 
72 (95) 
4 (5) 
 
54 (96) 
2 (4) 
 
61 (95) 
3 (5) 
0.856  
70 (93) 
5 (7) 
 
65 (98) 
1 (2) 
 
52 (94) 
3 (6) 
0.649  
70 (97) 
2 (3) 
 
57 (93) 
4 (7) 
 
60 (95) 
3 (5) 
0.562 
Peritoneal 
involvement 
 
No 
Yes 
 
144 (3) 
52 (27) 
 
57 (75) 
19 (25) 
 
43 (77) 
13 (23) 
 
44 (69) 
20 (31) 
0.423  
55 (73) 
20 (27) 
 
50 (76) 
16 (24) 
 
39 (71) 
16 (29) 
0.794  
53 (74) 
19 (26) 
 
46 (75) 
15 (25) 
 
45 (71) 
18 (29) 
0.787 
Tumour 
perforation 
 
No 
Yes 
 
192 (98) 
4 (2) 
 
74 (97) 
2 (3) 
 
55 (98) 
1 (2) 
 
63 (98) 
1 (2) 
0.652  
73 (97) 
2 (3) 
 
66 (100) 
0 (0) 
 
53 (96) 
2 (4) 
0.799  
69 (96) 
3 (4) 
 
60 (98) 
1 (2) 
 
63 (100) 
0 (0) 
0.087 
Mismatch 
repair status 
 
Competent 
Deficient 
 
169 (86) 
27 (14) 
 
65 (85) 
11 (15) 
 
48 (86) 
8 (14) 
 
56 (87) 
8 (13) 
0.741  
62 (83) 
13 (17) 
 
59 (89) 
7 (11) 
 
48 (87) 
7 (13) 
0.406  
61 (85) 
11 (15) 
 
52 (85) 
9 (15) 
 
56 (89) 
7 (11) 
0.491 
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Table 6.2 The relationship between STAT3 and pSTAT3 expression and tumour microenvironment characteristics of patients undergoing elective, 
potentially curative resection of stage I-III colorectal cancer 
 
  Cytoplasmic STAT3 Nuclear STAT3 Nuclear pSTAT3 
Tumour microenvironment 
(n when data missing) 
Low 
n=76 (%) 
Moderate 
n=56 (%) 
High 
n=64 (%) 
P Low 
n=75 (%) 
Moderate 
n=66 (%) 
High 
n=55 (%) 
P Low 
n= 72 (%) 
Moderate 
n=61 (%) 
High 
n=63 (%) 
P 
Klintrup-Makinen 
grade 
 
Weak 
Strong 
 
28 (37) 
48 (63) 
 
20 (36) 
36 (64) 
 
17 (27) 
47 (73) 
0.208  
25 (33) 
50 (67) 
 
24 (36) 
42 (64) 
 
16 (29) 
30 (71) 
0.657  
26 (36) 
46 (64) 
 
19 (31) 
42 (69) 
 
20 (32) 
43 (68) 
0.582 
Tumour stroma 
percentage  
(195) 
 
Low 
High 
 
59 (78) 
17 (22) 
 
43 (78) 
12 (22) 
 
44 (69) 
20 (31) 
0.241  
56 (75) 
19 (25) 
 
51 (77) 
15 (23) 
 
39 (72) 
15 (28) 
0.794  
55 (78) 
16 (22) 
 
50 (82) 
11 (18) 
 
40 (64) 
22 (36) 
0.090 
CD3+ margin density  
(184) 
 
Low 
High 
 
36 (49) 
37 (51) 
 
30 (60) 
20 (40) 
 
35 (57) 
26 (43) 
0.332  
37 (51) 
35 (49) 
 
28 (46) 
33 (54) 
 
36 (71) 
15 (29) 
0.055  
34 (54) 
29 (46) 
 
31 (52) 
28 (48) 
 
36 (58) 
26 (42) 
0.648 
CD3+ cancer cell nest 
density  
(192) 
 
Low 
High 
 
38 (51) 
37 (49) 
 
42 (79) 
11 (21) 
 
45 (70) 
19 (30) 
0.012  
47 (64) 
27 (37) 
 
38 (59) 
26 (41) 
 
40 (74) 
14 (26) 
0.262  
43 (62) 
26 (38) 
 
35 (58) 
25 (42) 
 
47 (75) 
16 (25) 
0.150 
CD8+ margin density  
(184) 
 
Low 
High 
 
41 (59) 
29 (41) 
 
34 (64) 
19 (36) 
 
33 (54) 
28 (46) 
0.630  
38 (53) 
34 (47) 
 
37 (61) 
25 (39) 
 
33 (65) 
18 (35) 
0.177  
38 (59) 
26 (41) 
 
33 (55) 
27 (45) 
 
37 (62) 
23 (38) 
0.806 
CD8+ cancer cell nest 
density  
(190) 
 
Low 
High 
 
41 (57) 
31 (43) 
 
45 (83) 
9 (17) 
 
51 (80) 
13 (20) 
0.003  
47 (63) 
27 (37) 
 
47 (76) 
15 (24) 
 
43 (80) 
11 (20) 
0.039  
50 (72) 
19 (28) 
 
41 (68) 
19 (32) 
 
46 (75) 
15 (25) 
0.730 
CD45R0+ margin 
density  
(186) 
 
Low 
High 
 
38 (52) 
35 (48) 
 
27 (51) 
26 (49) 
 
31 (52) 
29 (48) 
0.960  
33 (47) 
38 (54) 
 
31 (48) 
33 (52) 
 
32 (63) 
19 (37) 
0.089  
32 (48) 
38 (52) 
 
29 (50) 
29 (50) 
 
37 (57) 
26 (43) 
0.282 
CD45R0+ cancer cell 
density  
(192) 
 
Low 
High 
 
48 (64) 
27 (36) 
 
43 (80) 
11 (20) 
 
44 (70) 
19 (30) 
0.408  
48 (67) 
24 (33) 
 
46 (70) 
20 (30) 
 
41 (76) 
13 (24) 
0.268  
46 (64) 
26 (36) 
 
39 (67) 
19 (33) 
 
50 (81) 
12 (19) 
0.037 
FOXP3+ margin 
density  
(186) 
 
Low 
High 
 
37 (51) 
36 (49) 
 
29 (56) 
23 (44) 
 
38 (62) 
23 (38) 
0.180  
39 (53) 
34 (47) 
 
34 (54) 
29 (46) 
 
31 (62) 
19 (38) 
0.373  
40 (60) 
27 (40) 
 
32 (54) 
27 (46) 
 
32 (53) 
28 (47) 
0.466 
FOXP3+ cancer cell 
nest density  
(188) 
 
Low 
High 
 
26 (36) 
47 (64) 
 
26 (49) 
27 (51) 
 
39 (63) 
23 (37) 
0.002  
39 (53) 
34 (47) 
 
25 (39) 
39 (61) 
 
27 (53) 
24 (47) 
0.807  
38 (56) 
30 (44) 
 
26 (44) 
33 (56) 
 
27 (44) 
34 (56) 
0.181 
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Table 6.2 (continued) The relationship between tumour cell STAT3 and pSTAT3 expression and T-lymphocyte density of patients undergoing elective, 
potentially curative resection of stage I-III mismatch repair competent colorectal cancer 
Data analysed using χ2 analysis for linear trend. 
  Cytoplasmic STAT3 h-score Nuclear STAT3 h-score Nuclear pSTAT3 h-score 
Tumour microenvironment 
(n when data missing) 
Low 
n=76 (%) 
Moderate 
n=56 (%) 
High 
n=64 (%) 
P Low 
n=75 (%) 
Moderate 
n=66 (%) 
High 
n=55 (%) 
P Low 
n= 72 (%) 
Moderate 
n=61 (%) 
High 
n=63 (%) 
P 
CD3+ margin 
density  
(157) 
 
Low 
High 
 
32 (50) 
32 (50) 
 
26 (63) 
15 (37) 
 
29 (56) 
23 (44) 
0.495  
31 (51) 
30 (49) 
 
23 (44) 
29 (56) 
 
33 (75) 
11 (25) 
0.024  
27 (51) 
26 (49) 
 
27 (53) 
24 (47) 
 
33 (62) 
20 (38) 
0.243 
CD3+ cancer cell 
nest density  
(161) 
 
Low 
High 
 
36 (55) 
29 (45) 
 
36 (86) 
6 (14) 
 
38 (70) 
16 (30) 
0.061  
42 (69) 
19 (31) 
 
33 (61) 
21 (39) 
 
35 (76) 
11 (24) 
0.498  
37 (66) 
19 (34) 
 
31 (61) 
20 (39) 
 
42 (78) 
12 (22) 
0.193 
CD8+ margin 
density  
(155) 
 
Low 
High 
 
36 (59) 
25 (41) 
 
28 (67) 
14 (33) 
 
29 (56) 
23 (44) 
0.759  
34 (57) 
26 (43) 
 
30 (59) 
21 (41) 
 
29 (66) 
15 (34) 
0.355  
30 (57) 
23 (43) 
 
29 (57) 
22 (43) 
 
34 (67) 
17 (33) 
0.299 
CD8+ cancer cell 
nest density  
(159) 
 
Low 
High 
 
38 (61) 
24 (39) 
 
38 (88) 
5 (12) 
 
42 (78) 
12 (22) 
0.035  
42 (69) 
19 (31) 
 
40 (77) 
12 (23) 
 
36 (78) 
10 (22) 
0.255  
42 (75) 
14 (25) 
 
35 (69) 
16 (31) 
 
41 (79) 
11 (21) 
0.666 
CD45R0+ margin 
density  
(156) 
 
Low 
High 
 
35 (56) 
28 (44) 
 
23 (55) 
19 (45) 
 
27 (53) 
24 (47) 
0.783  
28 (48) 
30 (52) 
 
28 (52) 
26 (48) 
 
29 (66) 
15 (34) 
0.085  
28 (51) 
27 (49) 
 
24 (49) 
25 (51) 
 
33 (63) 
19 (37) 
0.199 
CD45R0+ cancer 
cell density  
(161) 
 
Low 
High 
 
45 (69) 
20 (31) 
 
35 (81) 
8 (19) 
 
37 (70) 
16 (30) 
0.882  
41 (69) 
18 (31) 
 
41 (73) 
15 (27) 
 
35 (76) 
11 (24) 
0.449  
40 (68) 
19 (32) 
 
33 (67) 
16 (33) 
 
44 (83) 
9 (17) 
0.077 
FOXP3+ margin 
density  
(156) 
 
Low 
High 
 
33 (52) 
30 (48) 
 
20 (49) 
21 (51) 
 
31 (60) 
21 (40) 
0.463  
33 (55) 
27 (45) 
 
26 (49) 
27 (51) 
 
25 (58) 
18 (42) 
0.819  
31 (56) 
24 (44) 
 
26 (52) 
24 (48) 
 
27 (53) 
24 (47) 
0.720 
FOXP3+ cancer cell 
nest density  
(158) 
 
Low 
High 
 
23 (36) 
41 (64) 
 
19 (45) 
23 (55) 
 
32 (61) 
20 (39) 
0.006 
 
 
32 (52) 
29 (48) 
 
19 (35) 
35 (65) 
 
23 (53) 
20 (47) 
0.910  
31 (55) 
25 (45) 
 
20 (40) 
30 (60) 
 
23 (44) 
29 (56) 
0.239 
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Table 6.3 The relationship between STAT3 and pSTAT3 expression and systemic inflammatory responses of patients undergoing elective, potentially 
curative resection of stage I-III colorectal cancer 
Data analysed using χ2 analysis for linear trend.
  Cytoplasmic STAT3 Nuclear STAT3 Nuclear pSTAT3 
Systemic inflammatory response 
(n when data missing) 
Low 
n=76 
(%) 
Moderate 
n=56 (%) 
High 
n=64 
(%) 
P Low 
n=75 
(%) 
Moderate 
n=66 (%) 
High 
n=55 
(%) 
P Low 
n= 72 
(%) 
Moderate 
n=61 (%) 
High 
n=63 
(%) 
P 
Modified Glasgow Prognostic 
Score 
 
0 
1 
2 
 
53 (70) 
20 (26) 
3 (4) 
 
33 (59) 
18 (32) 
5 (9) 
 
33 (51) 
19 (30) 
12 (19) 
0.004  
46 (61) 
23 (31) 
6 (8) 
 
42 (64) 
20 (30) 
4 (6) 
 
31 (56) 
14 (26) 
10 (18) 
0.244  
44 (61) 
20 (28) 
8 (11) 
 
36 (59) 
17 (28) 
8 (13) 
 
39 (62) 
20 (32) 
4 (6) 
0.651 
Neutrophil count  
(195) 
 
≤7.5x109/L 
>7.5x109/L 
 
67 (88) 
9 (12) 
 
47 (85) 
8 (15) 
 
54 (84) 
10 (16) 
0.515  
63 (85) 
11 (15) 
 
60 (91) 
6 (9) 
 
45 (82) 
10 (18) 
0.676  
60 (85) 
11 (16) 
 
52 (85) 
9 (15) 
 
56 (89) 
7 (11) 
0.470 
Lymphocyte count  
(195) 
 
>4x109/L 
≤4x109/L 
 
76 (100) 
0 (0) 
 
54 (98) 
1 (2) 
 
64 (100) 
0 (0) 
0.942  
74 (100) 
0 (0) 
 
66 (100) 
0 (0) 
 
54 (98) 
1 (2) 
0.174   
71 (100) 
0 (0) 
 
61 (100) 
0 (0) 
 
62 (98) 
1 (2) 
0.209 
Platelet count  
(176) 
 
≤400x109/L 
>400x109/L 
 
58 (87) 
9 (13) 
 
44 (86) 
7 (14) 
 
48 (83) 
10 (17) 
0.557  
55 (85) 
10 (15) 
 
49 (83) 
10 (17) 
 
46 (88) 
6 (12) 
0.587  
57 (85) 
10 (15) 
 
44 (85) 
8 (15) 
 
49 (86) 
8 (14) 
0.895 
Neutrophil: lymphocyte ratio 
(195) 
 
≤5 
>5 
 
62 (82) 
14 (18) 
 
45 (82) 
10 (18) 
 
48 (75) 
16 (25) 
0.350  
61 (82) 
13 (18) 
 
55 (83) 
11 (17) 
 
39 (71) 
16 (29) 
0.131  
56 (79) 
15 (21) 
 
45 (74) 
16 (26) 
 
54 (86) 
9 (14) 
0.352 
Neutrophil: platelet score  
(176) 
 
0 
1 
2 
 
52 (78) 
13 (19) 
2 (3) 
 
40 (78) 
7 (14) 
5 (8) 
 
40 (69) 
17 (29) 
1 (2) 
0.441  
47 (72) 
16 (25) 
2 (3) 
 
46 (78) 
10 (17) 
3 (5) 
 
39 (75) 
11 (21) 
2 (4) 
0.831  
49 (73) 
15 (22) 
3 (5) 
 
39 (75) 
11 (21) 
2 (4) 
 
44 (77) 
11 (19) 
2 (4) 
0.602 
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Table 6.4 The relationship between STAT3 and pSTAT3 expression and cancer-specific survival of patients undergoing elective, potentially curative 
resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
      
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. CSS – cancer-specific survival, SE – standard error, HR – hazard ratio, 95% CI – 95% confidence interval  
Table 6.4 displays the relationship between markers of STAT3 expression and cancer-specific survival of patients undergoing elective resection of stage 
I-III colorectal cancer as measured by five-year survival and hazard ratios and 95% confidence intervals. The combination of nuclear STAT3 and 
pSTAT3 expression showed greatest prognostic value.
 N 5-year CSS % 
(SE)  
Univariate HR (95% CI) P Multivariate HR (95% CI) P 
Cytoplasmic STAT3 
Low expression 
High expression 
 
132 
64 
 
81 (3) 
67 (6) 
 
 
1.62 (0.96-2.65) 
 
 
0.072 
 
- 
- 
 
Nuclear STAT3 
Low expression 
High expression 
 
141 
55 
 
78 (4) 
70 (6) 
 
 
1.89 (1.12-3.22) 
 
 
0.018 
 
- 
- 
 
Nuclear pSTAT3 
Low expression 
High expression 
 
133 
63 
 
80 (4) 
69 (6) 
 
 
1.52 (0.90-2.57) 
 
 
0.119 
 
- 
- 
 
Combined cytoplasmic STAT3/ nuclear STAT3 (Model 1) 
Both low 
One high 
Both high 
 
106 
61 
29 
 
81 (4) 
73 (6) 
63 (9) 
 
 
1.56 (1.20-2.17) 
 
 
 
0.009 
 
 
- 
 
 
0.221 
Combined cytoplasmic STAT3/ nuclear pSTAT3 (Model 2) 
Both low 
One high 
Both high 
 
95 
75 
26 
 
80 (4) 
79 (5) 
54 (10) 
 
 
1.50 (1.06-2.13) 
 
 
0.024 
 
 
- 
 
 
0.526 
Combined nuclear STAT3/ nuclear pSTAT3 (Model 3) 
Both low 
One high 
Both high 
 
100 
74 
22 
 
81 (4) 
74 (5) 
62 (11) 
 
 
1.63 (1.14-2.34) 
 
 
0.008 
 
 
1.63 (1.14-2.34) 
 
 
0.008 
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Table 6.5 The relationship between combined cytoplasmic and nuclear STAT3 expression 
and local and systemic environment characteristics of patients undergoing elective, 
potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data analysed using χ2 analysis for linear trend. 
 
  Nuclear STAT3/ Nuclear pSTAT3 
Tumour microenvironment 
(n when data missing) 
Both low 
n=100 (%) 
One high 
n=74 (%) 
Both high 
n=22 (%) 
P 
Klintrup-Makinen 
grade 
 
Weak 
Strong 
 
35 (35) 
65 (65) 
 
24 (32) 
50 (68) 
 
6 (27) 
16 (73) 
0.486 
Tumour stroma 
percentage  
(195) 
 
Low 
High 
 
81 (81) 
19 (19) 
 
51 (69) 
23 (31) 
 
14 (67) 
7 (33) 
0.056 
CD3+ margin density 
(184) 
 
Low 
High 
 
45 (48) 
48 (52) 
 
40 (58) 
29 (42) 
 
16 (73) 
6 (27) 
0.033 
CD3+ cancer cell nest 
density  
(192) 
 
Low 
High 
 
58 (60) 
39 (40) 
 
47 (64) 
26 (26) 
 
20 (91) 
2 (9) 
0.017 
CD8+ margin density 
(184) 
 
Low 
High 
 
53 (56) 
42 (44) 
 
40 (60) 
27 (40) 
 
15 (68) 
7 (32) 
0.295 
CD8+ cancer cell nest 
density  
(190) 
 
Low 
High 
 
67 (69) 
30 (31) 
 
51 (72) 
20 (28) 
 
19 (86) 
3 (14) 
0.153 
CD45R0+ margin 
density  
(186) 
 
Low 
High 
 
44 (46) 
52 (54) 
 
37 (54) 
31 (46) 
 
15 (68) 
7 (32) 
0.051 
CD45R0+ cancer cell 
density  
(192) 
 
Low 
High 
 
66 (67) 
32 (33) 
 
47 (65) 
25 (35) 
 
22 (100) 
0 (0) 
0.030 
FOXP3+ margin 
density  
(186) 
 
Low 
High 
 
55 (57) 
42 (43) 
 
35 (51) 
33 (49) 
 
14 (67) 
7 (33) 
0.747 
FOXP3+ cancer cell 
nest density  
(188) 
 
Low 
High 
 
48 (50) 
49 (50) 
 
32 (46) 
38 (54) 
 
11 (52) 
10 (48) 
0.964 
Modified Glasgow 
Prognostic Score 
 
0 
1 
2 
 
62 (62) 
29 (29) 
9 (9) 
 
44 (59) 
22 (30) 
8 (11) 
 
13 (59) 
6 (27) 
3 (14) 
0.576 
Neutrophil:lymphocyte 
ratio  
(195) 
 
≤5 
>5 
 
79 (80) 
20 (20) 
 
59 (80) 
15 (20) 
 
17 (77) 
5 (23) 
0.837 
Neutrophil:platelet 
score  
(176) 
 
0 
1 
2 
 
65 (73) 
18 (21) 
5 (6) 
 
51 (76) 
16 (24) 
0 (0) 
 
16 (76) 
3 (14) 
2 (10) 
0.746 
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Table 6.6 The relationship between combined cytoplasmic and nuclear STAT3 expression, clinicopathological characteristics and cancer-specific 
survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
  
Cancer-specific survival 
Clinicopathological characteristics Univariate analysis P Multivariate 
analysis 
P 
Age (<65/ 65-74/ >75) 1.00 (0.73-1.37) 0.986 - - 
Sex (Female/ male) 1.43 (0.84-2.44) 0.188 - - 
Adjuvant therapy (No/ yes) 1.43 (0.83-2.47) 0.196 - - 
Tumour site (Colon/ rectum) 0.99 (0.57-1.74) 0.983 - - 
TNM stage (I /II /III) 2.16 (1.35-3.48) 0.001 - 0.228 
Tumour differentiation (Mod-well/ poor) 1.18 (0.51-2.75) 0.700 - - 
Venous invasion (No/ yes) 3.35 (1.97-5.70) <0.001 2.82 (1.58-5.04) <0.001 
Margin involvement (No/ yes) 2.82 (1.12-7.09) 0.028 - 0.282 
Peritoneal involvement (No/ yes) 2.45 (1.45-4.13) 0.001 - 0.103 
Tumour perforation (No/ yes) 4.34 (1.04-18.11) 0.044 - 0.106 
Modified Glasgow Prognostic Score (0/ 1/ 2) 1.43 (0.99-2.08) 0.057 1.79 (1.18-2.70) 0.006 
NPS (0/ 1/ 2) 1.72 (1.13-2.62) 0.012 - 0.098 
NLR (<5/ >5) 1.13 (0.60-2.13) 0.715 - - 
Mismatch repair status (Competent/ deficient) 1.37 (0.69-2.71) 0.370 - - 
Klintrup-Makinen grade (High/ low) 2.33 (1.20-4.49) 0.012 2.23 (1.04-4.81) 0.040 
Tumour stroma percentage (Low/ high) 2.52 (1.48-4.30) 0.001 2.75 (1.55-4.89) 0.001 
Nuclear STAT3/ nuclear pSTAT3 (Both low/ one high/ both high) 1.63 (1.14-2.34) 0.008 1.39 (0.94-2.06) 0.102 
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7 Staging the tumour and staging the host: evaluation of a 
novel tumour microenvironment-based prognostic score in 
patients with primary operable colorectal cancer  
7.1 Introduction 
In Chapter 4, H&E-based assessment of the tumour-associated stroma, using TSP, was 
shown to have prognostic value independent of the clinicopathological characteristics of 
patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
without neoadjuvant therapy.  Furthermore, assessment of TSP held prognostic value 
independent of other components of the tumour microenvironment, and in particular the 
generalised inflammatory cell infiltrate as measured using the KM grade. 
Despite appearing to hold independent prognostic value, combined assessment of the 
tumour-associated stroma (using TSP) and tumour inflammatory cell infiltrate (using KM 
grade), and subsequently the interaction and combined impact on survival of patients with 
primary operable colorectal cancer, has not previously been examined.  This presents the 
opportunity to develop a tumour microenvironment-based score which may provide 
prognostic information complimentary to current clinicopathological assessment.  
Therefore, the aim of the present study was to examine the combined prognostic value of 
KM grade and TSP, and to evaluate a novel, tumour microenvironment-based prognostic 
score in patients with stage I-III colorectal cancer undergoing elective, potentially curative 
resection. 
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7.2 Patients and Methods 
Clinicopathological characteristics 
Patients who had undergone elective, potentially curative  resection of stage I-III colorectal 
adenocarcinoma without neoadjuvant therapy were identified from a prospectively 
collected and maintained database of elective and emergency colorectal cancer resections 
performed in a single surgical unit at GRI .  Inclusion and exclusion criteria and 
clinicopathological staging has previously been described in Chapter 4.  Determination of 
MMR status, as previously described in Chapter 5, was performed for a subset of patients 
who were concurrently included in a previously constructed TMA.   
Multi-disciplinary team review, indications for adjuvant chemotherapy and routine follow-
up of patients following surgery has previously been described in Chapter 2.  Date and 
cause of death was crosschecked with the cancer registration system and the Registrar 
General (Scotland).  Death records were complete until 15th March 2013 that served as the 
censor date.  Cancer-specific survival was measured from the date of surgery until the date 
of death from colorectal cancer. 
Assessment of the tumour microenvironment 
Using archived H&E-stained sections of the deepest point of invasion, the generalised 
inflammatory cell infiltrate was assessed using KM grade and the tumour-associated 
stroma was assessed using TSP as previously described in Chapter 4.  Briefly, KM grade 
was classified as low grade or high grade and TSP was classified as low (≤50%) or high 
(>50%). 
Statistical analysis 
The relationship between clinicopathological and tumour microenvironment characteristics 
and survival was examined using univariate Cox proportional hazards regression to 
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calculate HRs and 95% CIs.  Variables with P-value <0.1 on univariate regression analysis 
were examined in a multivariable model using a backwards conditional method.  The 
relationship between a tumour microenvironment-based score and survival was further 
examined using Kaplan-Meier log-rank analysis, with five-year survival presented as 
percentage surviving (SE).  The relationship between the tumour microenvironment score 
and other clinicopathological characteristics was examined using the χ2 test for linear 
trend.  A P-value <0.05 was considered statistically significant.  All statistical analyses 
were performed using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).  The West of 
Scotland Research Ethics Committee approved the study.
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7.3 Results 
A total of 307 patients who underwent elective resection for stage I-III colorectal cancer 
were included.  Clinicopathological characteristics are summarised in Table 7.1.  Two 
thirds of patients were older than 65 at time of surgery with a similar number of males and 
females.  The majority of patients (71%) underwent colonic resection, with pathological 
confirmation of lymph node negative (stage I/II) disease in approximately two thirds of 
patients.  Overall, 82 patients (27%) received adjuvant chemotherapy; 59 patients (52%) 
with lymph node positive (stage III) disease received adjuvant chemotherapy compared to 
23 patients (12%) with lymph node negative (stage I/II) colorectal cancer.  Mismatch 
repair status was available for 208 patients, with MMR deficient colorectal cancer 
identified in 33 patients (16%). A low KM grade and high TSP were identified in 66% and 
25% of patients respectively. 	
The median follow-up of survivors was 126 months (range 59-194 months), with 95 
cancer-specific deaths and 86 non-cancer deaths.  Five-year cancer specific survival was 
75% overall, 85% in patients with stage I/II disease and 58% in patients with stage III 
disease. The relationship between clinicopathological and tumour microenvironment 
characteristics and cancer-specific survival is shown in Table 7.1.  On univariate analysis, 
advancing age (P<0.05), T stage (P<0.01), N stage, venous invasion (both P<0.001), 
margin involvement (P<0.05), peritoneal involvement (P=0.001), low KM grade and high 
TSP (both P=0.001) were all associated with reduced survival.  Mismatch repair deficiency 
showed a trend towards increased survival (P=0.082).  On multivariate survival analysis, 
the presence of venous invasion (P=0.001), a low KM grade (P<0.05) and a high TSP 
(P<0.01) were independently associated with poorer cancer-specific survival, whereas 
advanced age and increasing N stage showed a trend towards poorer survival (P=0.052 and 
P=0.061 respectively).	
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The prognostic value of KM grade and TSP was further examined (Table 7.2).  Five-year 
cancer-specific survival of patients was stratified from 90% to 68% by KM grade, and 
from 80% to 62% by TSP.  A cumulative prognostic score based on these characteristics of 
the tumour microenvironment was subsequently derived.  As the univariate HRs and 95% 
CIs for low KM grade and high TSP overlapped, the presence of each characteristic scored 
one point, thus stratifying patients into four possible groups.  Patients with a high KM 
grade and low TSP comprised 27% of the study population and had a five-year survival of 
89%; conversely patients with a low KM grade and high TSP comprised 19% of the group, 
with a four-fold increased risk of cancer-death and five-year survival of 51%.  The 
presence of a low KM grade and low TSP was identified in almost half of the patients 
studied and was associated with an intermediate five-year survival of 75% and two-fold 
increased risk of cancer-death compared to those patients with high KM grade and low 
TSP.  Only 6% of patients had a high KM grade with a high TSP; this group of patients 
had an identical five-year survival to patients with a high KM grade and low TSP. 
As a high TSP was not associated with poorer cancer-specific survival in patients with a 
high KM grade, the cumulative prognostic score was modified to include all patients with a 
high KM grade in the good prognostic group, irrespective of TSP assessment.  This 
modified prognostic score, termed the Glasgow Microenvironment Score (GMS), stratified 
patients with primary operable colorectal cancer into three distinct prognostic groups 
(Figure 7.1, Table 7.2): a good prognostic group (GMS=0 with a high KM grade and either 
high or low TSP) with five-year survival of 89%, an intermediate prognostic group 
(GMS=1 with a low KM grade and low TSP) with an almost two-fold increased risk of 
cancer death and five-year survival of 75%, and a poor prognostic group (GMS=3 with a 
low KM grade and high TSP) with a four-fold increased risk of death and five-year 
survival of 51%.  Furthermore, on multivariate analysis (Table 7.3), GMS was associated 
with a two-fold increased risk of cancer-death (HR 1.93, 95% CI 1.36-2.74, P<0.001), 
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independent of N stage (P<0.05) and venous invasion (P=0.001).  Examples of the 
microenvironment typical of GMS 0 and GMS 2 are displayed in Figure 7.2. 
The clinical utility of the GMS was further explored in relation to lymph node 
involvement, venous invasion, MMR status and use of adjuvant therapy (Table 7.4).  The 
GMS stratified survival of patients with both lymph node negative (stage I/II) and positive 
(stage III) disease (P=0.036 and P=0.002, respectively).  Using the combination of lymph 
node involvement and GMS, five-year cancer-specific survival ranged from 92% (stage I/II 
and GMS=0) to 37% (stage III and GMS=2).  Furthermore, patients with stage III disease 
and GMS=0 had five-year survival superior to that of patients with stage I/II disease and 
GMS=2 (81% versus 69%).  The GMS was similarly able to provide further prognostic 
information alongside venous invasion and MMR status; the combination of venous 
invasion and GMS stratified five-year survival from 93% (venous invasion absent and 
GMS=0) to 27% (venous invasion present and GMS=2), whereas using the combination of 
MMR status and GMS, five-year survival ranged from 100% (MMR deficient and 
GMS=0) to 37% (MMR competent and GMS=2).  In addition, when patients were 
stratified by use of adjuvant therapy, GMS was predictive of survival independent of 
adjuvant therapy use (both P=0.002) 
The relationship between GMS and clinicopathological characteristics was subsequently 
examined (Table 7.5).  Increasing GMS was associated with use of adjuvant chemotherapy 
(P<0.05), increasing TNM stage, T stage (both P≤0.001), N stage (P<0.01), venous 
invasion (P<0.05), margin and peritoneal involvement (P<0.01).  The GMS was not 
associated with age, sex, tumour site, differentiation, MMR status or the presence of 
tumour perforation.
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7.4 Discussion 
The present study, for the first time, examines the clinical utility of combined assessment 
of the tumour inflammatory cell infiltrate and tumour stroma, utilising the KM grade and 
TSP respectively, in patients with primary operable colorectal cancer.  A simple, 
cumulative prognostic score based on the assessment and interaction of these 
characteristics using routine histopathological specimens and termed the Glasgow 
Microenvironment Score (GMS), was able to provide improved risk stratification.  
Utilising this score, it was possible to identify a group of patients with lymph node 
negative disease with five-year survival comparable to patients with lymph node 
involvement.  Conversely, it was also possible to identify patients with stage III disease 
and five-year survival of over 80%.  Similarly, the GMS was able to stratify patient 
survival independent of venous invasion and MMR status.  Such a simple, routinely 
available score can be readily evaluated and validated.  If this proves to be the case, then 
the GMS may help better inform decisions regarding the need for adjuvant therapy and 
surveillance for otherwise “low risk” patients, or avoid unnecessary treatment for those 
previously deemed “high risk” on the basis of standard pathological staging. 
The results of the present study also have implications regarding our understanding of the 
nature of the tumour microenvironment.  As survival of patients with a strong KM grade 
did not differ with TSP, it could be inferred that the presence of a strong, conspicuous 
inflammatory infiltrate represents the host’s normal anti-tumour response.  Furthermore, 
few patients had a high TSP in the presence of a strong inflammatory cell infiltrate.  As 
such, it may be loss of this coordinated immune response that facilitates disease 
progression, allowing tumour stroma formation that in turn facilitates growth and invasion.  
Therefore, future work must not only consider the intrinsic properties of the tumour cell 
itself, but also the components of the tumour microenvironment. 
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The results of the present study are limited by the small number of patients with stage I 
disease (21 patients), and as such it was not possible to examine the clinical utility of the 
GMS in this subgroup of patients separately.  Given that earlier, node negative disease is 
likely to predominate with the introduction of screening (496), this would be an important 
area for further research.  In addition, although the GMS stratified survival independent of 
MMR status, no other prognostic molecular markers were examined.  To date however, 
few of these markers have been recommended for use in routine clinical practice, and as 
such their clinical utility in the management of patients with primary operable colorectal 
cancer is yet to be realised (497).  Finally, the results of the present study remain to be 
validated.  Separation of the study cohort into a training and validation set would have 
allowed for internal validation, however such an approach may have lacked sufficient 
statistical power for exploratory subgroup analysis.  Furthermore, external validation 
would still be required before the GMS could be incorporated into routine pathological 
reporting.  Given that the GMS utilises routine H&E-stained pathological specimens, this 
will facilitate external validation.  Indeed, assessment of the GMS may be readily 
automated (464, 498), further facilitating validation and the implementation of such 
measures into routine clinical practice.   
In summary, the present study demonstrates the clinical utility of a novel cumulative 
prognostic score based on the tumour inflammatory cell infiltrate and tumour stroma in 
patients with primary operable colorectal cancer.  This score, termed the Glasgow 
Microenvironment Score, has much to commend it since it is simple and routinely 
available. 
 
.
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Figure 7.1 The relationship between the Glasgow Microenvironment Score and cancer-
specific survival of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer (log-rank P<0.001) 
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Figure 7.2 The Glasgow Microenvironment Score in patients with colorectal cancer (x200 
magnification). (A) displays a high Klintrup-Mäkinen grade and low tumour stroma 
percentage(Glasgow Microenvironment Score 0), and  (B), displays a low Klintrup-
Mäkinen grade and high tumour stroma percentage (Glasgow Microenvironment Score 2)
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Table 7.1 The relationship between clinicopathological characteristics and cancer-specific survival of patients undergoing elective, potentially curative 
resection of stage I-III colorectal cancer 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
  Cancer-specific survival 
Clinicopathological characteristics n (%) Univariate analysis P Multivariate analysis P 
Age (<65/ 65-74/ >75) 106 (35)/ 106 (35) / 95 (31) 1.36 (1.05-1.75) 0.018 - 0.052 
Sex (Female/ male) 151 (49) / 156 (51) 0.92 (0.61-1.37) 0.667 - - 
Adjuvant therapy (No/ yes) 225 (73) / 82 (27) 1.26 (0.82-1.95) 0.289 - - 
Tumour site (Colon/ rectum) 218 (71) / 89 (29) 1.02 (0.65-1.59) 0.947 - - 
TNM stage (I /II /III) 21 (7) / 173 (56) / 113 (37) - - - - 
T stage (1-2/ 3/ 4) 29 (9) / 196 (64) / 82 (27) 1.51 (1.12-2.05) 0.007 - 0.680 
N stage (0/ 1/ 2) 194 (63) / 90 (29) / 23 (7) 1.96 (1.48-2.58) <0.001 - 0.061 
Tumour differentiation (Mod-well/ poor) 270 (88) / 37 (12) 1.60 (0.91-2.83) 0.104 - - 
Venous invasion (No/ yes) 203 (66) / 104 (34) 2.31 (1.54-3.47) <0.001 2.41 (1.43-4.07) 0.001 
Margin involvement (No/ yes) 289 (94) / 18 (6) 2.42 (1.22-4.82) 0.012 - 0.432 
Peritoneal involvement (No/ yes) 229 (75) / 78 (25) 2.02 (1.33-3.06) 0.001 - 0.249 
Tumour perforation (No/ yes) 300 (98) / 7 (2) 2.47 (0.777-7.84) 0.126 - - 
Mismatch repair status (Competent/ deficient) (208) 175 (84) / 33 (16) 0.47 (0.21-1.10) 0.082 - 0.352 
Klintrup-Mäkinen grade (High grade/ low grade) 103 (34) / 204 (66) 2.42 (1.47-4.01) 0.001 2.02 (1.11-3.70) 0.021 
Tumour stroma percentage (≤50%/ >50%) 231 (75) / 76 (25) 2.05 (1.35-3.12) 0.001 2.13 (1.27-3.58) 0.004 
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Table 7.2 The relationship between Klintrup-Mäkinen grade, tumour stroma percentage and cancer-specific survival of patients undergoing elective, 
potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate univariate hazard ratios and 95% confidence intervals. CSS – cancer-specific 
survival, SE – standard error, HR – hazard ratio, 95% CI – 95% confidence interval,  
Table 7.2 displays the relationship between KM grade and TSP, and scores based upon these characteristics, on cancer-specific survival of patients 
undergoing elective resection of stage I-III colorectal cancer as measured by five-year survival and hazard ratios and 95% confidence intervals. The 
combination of KM grade and TSP provided greater prognostic value than either characteristic alone.
Clinicopathological characteristics N 5-year CSS % (SE)  Univariate HR (95% CI) P 
Klintrup-Mäkinen grade 
KM high grade 
KM low grade 
 
103 
204 
 
90 (3) 
68 (3) 
 
1 
2.42 (1.47-4.01) 
 
 
0.001 
Tumour stroma percentage 
TSP low 
TSP high 
 
231 
76 
 
80 (3) 
62 (6) 
 
1 
2.05 (1.35-3.12) 
 
 
0.001 
Combined Klintrup-Mäkinen grade/ tumour stroma percentage 
KM high grade/ TSP low 
KM high grade/ TSP high 
KM low grade/ TSP low 
KM low grade/ TSP high 
 
84 
19 
147 
57 
 
89 (4) 
89 (7) 
75 (4) 
51 (7) 
 
1 
1.23 (0.41-3.71) 
2.00 (1.12-3.58) 
4.25 (2.28-7.92) 
 
- 
0.715 
0.020 
<0.001 
Glasgow Microenvironment Score 
0 (KM high grade) 
1 (KM low grade/ TSP low) 
2 (KM low grade/ TSP high) 
 
103 
147 
57 
 
89 (3) 
75 (4) 
51 (7) 
 
1 
1.92 (1.13-3.28) 
4.08 (2.29-7.27) 
 
- 
0.017 
<0.001 
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Table 7.3 The relationship between the Glasgow Microenvironment Score, clinicopathological characteristics and cancer-specific survival of patients 
undergoing elective, potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
.
 Cancer-specific survival 
Clinicopathological characteristics Univariate analysis P Multivariate analysis P 
Age (<65/ 65-74/ >75) 1.36 (1.05-1.75) 0.018 - 0.068 
Sex (Female/ male) 0.92 (0.61-1.37) 0.667 - - 
Adjuvant therapy (No/ yes) 1.26 (0.82-1.95) 0.289 - - 
Tumour site (Colon/ rectum) 1.02 (0.65-1.59) 0.947 - - 
TNM stage (I /II /III) - - - - 
T stage (1-2/ 3/ 4) 1.51 (1.12-2.05) 0.007 - 0.685 
N stage (0/ 1/ 2) 1.96 (1.48-2.58) <0.001 1.45 (1.02-2.06) 0.040 
Tumour differentiation (Mod-well/ poor) 1.60 (0.91-2.83) 0.104 - - 
Venous invasion (No/ yes) 2.31 (1.54-3.47) <0.001 2.39 (1.42-4.01) 0.001 
Margin involvement (No/ yes) 2.42 (1.22-4.82) 0.012 - 0.429 
Peritoneal involvement (No/ yes) 2.02 (1.33-3.06) 0.001 - 0.230 
Tumour perforation (No/ yes) 2.47 (0.777-7.84) 0.126 - - 
Mismatch repair status (Competent/ deficient) (208) 0.47 (0.21-1.10) 0.082 - 0.296 
Glasgow Microenvironment Score (0/ 1/ 2) 2.03 (1.52-2.71) <0.001 1.93 (1.36-2.74) <0.001 
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Table 7.4 The relationship between the Glasgow Microenvironment Score, lymph node status, venous invasion, adjuvant chemotherapy and mismatch 
repair status and cancer-specific survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
Log-rank P-value provided for the differential prognostic value of GMS in stratifying cancer-specific survival within each subgroup (rows). CSS – 
cancer-specific survival, SE – standard error.
      Glasgow Microenvironment Score  
 All patients     0 1 2 P 
 N 5-yr CSS %  
(SE) 
    N 5-yr CSS %  
(SE) 
N 5-yr CSS %  
(SE) 
N 5-yr CSS %  
(SE) 
 
Lymph node status 
Negative (Stage I/II) 173 86 (3)     70  92 (3) 99  84 (4) 25 69 (10) 0.036 
Positive (Stage III) 113  58 (5)     33 81 (7) 48 55 (7) 32  37 (9) 0.002 
Venous invasion 
Absent 203 82 (3)     74 93 (3) 98 77 (4) 31 70 (8) 0.025 
Present 104 62 (5)     29 78 (8) 49 70 (7) 26 27 (9) <0.001 
Adjuvant treatment 
No adjuvant therapy 225 76 (3)     79 90 (3) 112 73 (4) 34 58 (9) 0.002 
Adjuvant therapy 82 72 (5)     24 87 (7) 35 81 (7) 23 43 (10) 0.002 
All patients (n=307) 307 75 (3)     103  89 (3) 147 75 (4) 57  51 (7) <0.001 
MMR status 
MMR deficient 33 84 (7)     13 100 (0) 15 67 (12) 5 - <0.001 
MMR competent 175 71 (4)     59 84 (5) 81 76 (5) 35 37 (9) 0.094 
All patients  (n=208) 208 73 (3)     72 87 (4) 96 75 (5) 40 45 (8) <0.001 
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Table 7.5 The relationship between Glasgow Microenvironment Score and 
clinicopathological characteristics of patients undergoing elective, potentially curative 
resection of stage I-III colorectal cancer 
 
Data analysed using χ2 analysis for linear trend. 
  GMS 0 GMS 1 GMS 2  
 
Clinicopathological Characteristics n=103 (%) n=147 (%) n=57 (%) P 
Host characteristics      
Age  
<65 
65-74 
>75 
 
36 (35)a 
39 (38) 
28 (27) 
 
47 (32) 
50 (34) 
50 (34) 
 
23 (40) 
17 (30) 
17 (30) 
 
0.972 
Sex  
Female 
Male 
 
51 (50) 
52 (51) 
 
77 (52) 
70 (48) 
 
23 (40) 
34 (60) 
0.386 
Adjuvant therapy  
No 
Yes  
 
79 (77) 
24 (23) 
 
112 (76) 
35 (24) 
 
34 (60) 
23 (40) 
0.040 
Tumour characteristics      
Tumour site  
Colon 
Rectum 
 
74 (72) 
29 (28) 
 
104 (71) 
43 (29) 
 
40 (70) 
17 (30) 
0.812 
T stage   
1-2 
3 
4 
 
19 (18) 
63 (61) 
21 (20) 
 
9 (6) 
105 (71) 
33 (22) 
 
1 (2) 
28 (49) 
28 (49) 
<0.001 
N stage  
0 
1 
2 
 
70 (68) 
29 (28) 
4 (4) 
 
99 (67) 
36 (25) 
12 (8) 
 
25 (44) 
25 (44) 
7 (12) 
0.004 
TNM stage  
I 
II 
III 
 
12 (12) 
58 (56) 
33 (32) 
 
8 (5) 
91 (62) 
48 (33) 
 
1 (2) 
24 (42) 
32 (56) 
0.001 
Tumour differentiation  
Mod/well 
Poor 
 
90 (87) 
13 (13) 
 
131 (89) 
16 (11) 
 
49 (86) 
8 (14) 
0.893 
Venous invasion  
No 
Yes 
 
74 (72) 
29 (28) 
 
98 (67) 
49 (33) 
 
31 (54) 
26 (46) 
0.032 
Margin involvement  
No 
Yes 
 
101 (98) 
2 (2) 
 
139 (95) 
8 (5) 
 
49 (86) 
8 (14) 
0.003 
Peritoneal involvement  
No 
Yes 
 
83 (81) 
20 (19) 
 
113 (77) 
34 (23) 
 
33 (58) 
24 (42) 
0.004 
Tumour perforation  
No 
Yes 
 
101 (98) 
2 (2) 
 
143 (97) 
4 (3) 
 
56 (98) 
1 (2) 
0.979 
Mismatch repair status (n=208)  
Competent 
Deficient 
 
59 (82) 
13 (18) 
 
81 (84) 
15 (16) 
 
35 (88) 
5 (13) 
0.441 
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8 Tumour invasiveness as a determinant of the local and 
systemic environment and the basis of staging systems based 
on these characteristics in primary operable colorectal 
cancer  
8.1 Introduction 
For patients without overt systemic metastatic disease, prognosis and the need for adjuvant 
chemotherapy is primarily determined by the depth of invasion of the primary tumour (T 
stage) as well as the presence of regional lymph node metastases (N stage).  However, the 
use of the TNM staging system remains problematical, since increasing disease stage does 
not necessarily reflect a stepwise increase in the risk of recurrence or death.  For example, 
the survival of patients with Stage IIIa (T1/2, N1) colon cancer is superior to that of 
patients with stage IIb (T4, N0) disease (162).  Given the failings of TNM criteria, there 
has been increasing effort to refine colorectal cancer staging using both pathological and 
molecular characterisation, particularly in the context of stage II and stage III disease (204, 
432, 499).  The local and systemic environment, as examined in previous Chapters, 
similarly reflects a promising approach. 
The presence of adverse local and systemic characteristics is associated with increasing 
tumour invasiveness as determined by T stage.  For example, in Chapter 2, the presence of 
an elevated systemic inflammatory response as measured by mGPS was shown to be 
associated with advancing T stage; only 2% of patients with T1 disease had a mGPS=2 
compared to 41% of patients with T4 disease (P<0.001).  Similarly, in Chapter 4, 
increasing T stage was associated with an increase in the proportion of patients with a high 
TSP (P=0.027).  Furthermore, previous studies have shown that the density of both the 
generalised and adaptive T-lymphocytic inflammatory cell infiltrate degrades with 
increasing T stage (243, 433, 500). 
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Given the routine reporting of tumour invasiveness as measured by T stage, it would be of 
interest to examine the prognostic value of such measures of the local and systemic 
environment in comparison to present TNM-based staging.  As such, the aim of the present 
study was to examine the interrelationships between T stage, components of the local and 
systemic environment, and survival of patients undergoing potentially curative resection of 
primary operable colorectal cancer. 
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8.2 Patients and Methods 
Clinicopathological characteristics 
Patients who had undergone elective, potentially curative resection of stage I-III colorectal 
adenocarcinoma without neoadjuvant therapy were identified from a prospectively 
collected and maintained database of all elective and emergency colorectal cancer 
resections performed in a single surgical unit at GRI.  Inclusion and exclusion criteria, 
clinicopathological staging and the multi-disciplinary team process has previously been 
described in Chapter 4.  Mismatch repair status was determined as described in Chapter 5. 
Routine follow-up of patients following surgery has previously been described in Chapter 
2.  Date and cause of death was crosschecked with the cancer registration system and the 
Registrar General (Scotland).  Death records were complete until 31st March 2014 that 
served as the censor date.  Cancer-specific survival was measured from the date of surgery 
until the date of death from colorectal cancer. 
Assessment of the tumour microenvironment 
Using archived H&E sections of the deepest point of invasion, the generalised 
inflammatory cell infiltrate was assessed using KM grade and the tumour-associated 
stroma was assessed using TSP as previously described in Chapter 4.  The KM grade was 
classified as low grade or high grade and TSP was classified as low (≤50%) or high 
(>50%).  The GMS was calculated as described in Chapter 7.  Tumour necrosis was graded 
as low (absent or <10% of tumour area) or high (>10% of tumour area) as previously 
decribed (235). 
The adaptive T-lymphocytic infiltrate, as measured by mature (CD3+) and cytotoxic 
(CD8+) T-lymphocyte density within the invasive margin and cancer cell nests was 
examined as described in Chapter 4.  Briefly, the density of CD3+ and CD8+ T-
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lymphocytes within each compartment was graded as either high (moderate or high) or low 
(weak or absent).  The Immunoscore, a prognostic score based on the density of mature 
and cytotoxic T-lymphocytes within the invasive margin and cancer cell nests (501), was 
subsequently calculated.  The Immunoscore ranged from Im0 (low density of both cell 
types in both regions) to Im4 (high density of both cell types in both regions).  For the 
purposes of statistical analysis, patients were stratified into three prognostic groups: Im0/1 
(low density), Im2/3 (moderate density) and Im4 (high density).  
Assessment of systemic inflammatory responses 
The mGPS was calculated as previously described in Chapter 2, and the NLR was 
calculated as described in Chapter 5.  
Statistical analysis 
The relationship between T stage and characteristics of the local and systemic environment 
was examined using the c2 test for linear trend. Their relationship with cancer-specific 
survival was examined using Kaplan-Meier log-rank analysis and was measured as 
percentage surviving at five years (SE)  A P-value£0.05 was considered statistically 
significant.  All statistical analyses were performed using SPSS version 22.0 for Mac (IBM 
SPSS, IL, USA). 
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8.3 Results 
A total of 331 patients were included in the final analysis.  The clinicopathological 
characteristics of this cohort have previously been described in Table 4.1.  Two thirds of 
patients were 65 or older at time of surgery and 52% were male.  Thirty percent of patients 
underwent resection of rectal cancer.  Eighty-two patients (25%) received adjuvant 
therapy; 1 patient with stage I disease, 22 with stage II and 59 with stage III received 
adjuvant therapy.  The majority of patients had a tumour breaching through muscularis 
propria, with 208 patients with T3 and 90 patients with a T4 tumour.  Of the remaining 
patients, eight had a T1 tumour and 25 had a T2 tumour.  Examples of T1, T3 and T4 
tumours are displayed in Figure 8.1. 
The relationship between T stage and clinicopathological characteristics is displayed in 
Table 8.1.  Advancing T stage was associated with a colonic primary (P<0.001), advancing 
N stage (P<0.01), margin involvement and venous invasion (both P<0.001), and poor 
differentiation (P<0.05).  In addition, advancing T stage was associated with adjuvant 
chemotherapy (P<0.05) but not age or sex.  Mismatch repair status was available for 209 
patients; MMR status was not associated with advancing T stage. 
The relationship between T stage and components of the local and systemic environment 
was subsequently examined (Table 8.2).  Advancing T stage was associated with high 
grade necrosis, an infiltrative invasive margin, low KM grade (all P£0.001) and high TSP 
(P<0.01).  Furthermore, increasing T stage was associated with lower Immunoscore 
(P<0.05) and the presence of elevated systemic inflammatory responses as measured by 
both mGPS and NLR (both P<0.05).  Certain characteristics appeared to become more 
prevalent earlier than others; for example, there was a proportionally greater increase in the 
number of patients with high grade necrosis, an infiltrative margin and low KM grade 
observed in the increase from T2 to T3, whereas the proportion of patients with high TSP 
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and elevated systemic inflammatory responses, showed a greater increase between T3 to 
T4 (Figure 8.2). 
The interrelationships between components of the local and systemic environment was 
subsequently examined (Table 8.4); tumour necrosis was inversely associated with TSP 
and the Immunoscore and positively associated with the mGPS and NLR; an infiltrative 
margin was associated with necrosis and TSP; KM grade was positively associated with 
Immunoscore and inversely associated with TSP and NLR.  Finally, mGPS and NLR were 
significantly associated. 
The relationship between characteristics of the local and systemic environment and five-
year cancer-specific survival was examined (Table 8.4).  The median follow-up of 
survivors was 134 months (interquartile range 108-170 months) with 96 cancer deaths and 
105 non-cancer deaths.  Five-year cancer-specific survival of the whole cohort was 77%.  
N stage, character of the margin, KM grade, TSP, Immunoscore and mGPS all stratified 
five-year survival (all P<0.001).  The GMS effectively stratified survival at five years from 
90% to 53% (P<0.001).  Tumour necrosis and the NLR did not stratify survival.  
Furthermore, MMR status was not statistically associated with survival.	
To examine how such assessment may be utilised alongside T stage, subsequent survival 
analysis was performed in patients with T3 tumours.  N stage, character of the margin, KM 
grade, TSP, GMS, Immunoscore and the mGPS all stratified five-year survival.  
Furthermore, NLR showed a trend towards an association with survival.  In patients with 
T3 tumours, the GMS, the Immunoscore and mGPS had similar if not greater prognostic 
utility than N stage (Figure 8.3); the absolute difference in survival at five-years observed 
with N stage was 24%, whereas the absolute difference with GMS, Immunoscore and 
mGPS was 35%, 30% and 24% respectively.
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8.4 Discussion 
The results of the present study confirm the relationship between tumour invasion and the 
presence of adverse characteristics within both the local and systemic environment.  
Furthermore, how assessment of such characteristics provides an alternative staging system 
to the current TNM-based assessment has been examined. 
Advancing T stage was shown to correlate significantly with the presence of an 
increasingly tumour-supportive microenvironment as evidenced by loss of host immune 
responses, expansion of the tumour-associated stroma and the presence of an infiltrative 
margin.  It was of interest that the progression of each of these characteristics appeared to 
occur in a stepwise manner, with the proportion of some appearing to increase at an earlier 
T stage than others.  For example, attenuation of the generalised local inflammatory cell 
infiltrate appeared to occur at a relatively early stage, with a strong KM grade present in 
67% of patients with T2 tumours compared to only 32% of patients with T3 tumours.  
Conversely, the presence of an infiltrative margin and expansion of the tumour-associated 
stroma appeared to occur at a later stage, with a clear stepwise change evident between T3 
and T4 tumours.  
Although the present results are based on observational data, they potentially inform our 
understanding of the nature of the tumour microenvironment and its development in 
patients with colorectal cancer.  Loss of the anti-tumour immune response, or ‘immune 
escape’ may be the potential precipitant allowing sustained tumour growth and invasion 
(226, 260), with other adverse tumour microenvironment characteristics occurring further 
downstream in the presence of “pro-tumour” local and systemic immune responses (398).  
Certainly, it is recognised that the immune microenvironment evolves in tandem with stage 
progression, favouring the development of a more pro-tumour “immunome” as T stage 
increases (500).  As this progresses and anti-tumour immunity is degraded and 
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subsequently replaced by pro-tumour inflammatory responses, it may allow the 
development of further adverse tumour microenvironment characteristics, such as 
recruitment and activation of the tumour stroma and tumour-associated fibroblasts (502), 
and tumour cell dedifferentiation and budding (503, 504).  In the present study, this would 
explain the relatively late increase in TSP and presence of an infiltrative margin. 
Assessment of characteristics of the local and systemic environment determined survival, 
even after controlling for T stage.  In addition, assessment of the GMS and the 
Immunoscore each respectively stratified survival of patients greater than nodal status.  
This is consistent with previous work whereby assessment of the tumour 
microenvironment, and in particular the immune response, may yield greater prognostic 
value than TNM stage itself confers (260).  Much like the GMS stratifies prognosis greater 
than either of its determinants alone, it would be of interest to examine the clinical utility 
of assessment of the tumour microenvironment in its entirety; indeed it would be expected 
that combined assessment of the immune response, tumour-associated fibroblasts, and the 
tumour itself (as assessed by tumour budding) would synergistically stratify survival 
greater than each individual component (255, 505). 
In addition to MMR status, numerous other molecular characteristics have been confirmed 
to hold prognostic value in patients with colorectal cancer (492, 499).  Despite this, such 
techniques are not uniformly employed in routine clinical practice and remain costly.  
Therefore, it was of interest that in the present study assessment of the local and systemic 
environment was of greater prognostic value than MMR status.  The present results further 
support those of Chapter 5, whereby assessment of systemic and local inflammatory 
profiles were shown to hold prognostic value independent of MMR status.  Similarly, 
previous work suggests that assessment of the local environment, and in particular the 
inflammatory cell infiltrate, may predict survival independent of more extensive molecular 
characterisation (200, 201, 430).  The relatively simple methodologies employed in the 
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present study, and their reliance on routine pathological specimens, would make them 
attractive candidates not only for widespread clinical use, but also for retrospective 
application to previously recruited clinical trials.  Indeed, the relative prognostic value of 
comprehensive assessment of the local and systemic environment compared to 
comprehensive molecular characterisation remains to be fully determined.  Furthermore, 
whether individual molecular subtypes express a phenotypical local and systemic 
environment would be of considerable interest. 
Although tumour necrosis was strongly associated with increasing T stage consistent with 
previous reports (235, 506), it was not a determinant of prognosis.  As the tumour grows in 
size, the number of tumour cells increases rapidly to a point where its supporting 
vasculature can no longer sustain tissue oxygen tensions and intratumoural hypoxia 
becomes more prevalent, resulting in unprogrammed cell death and necrosis (507).  
However, the development of tumour necrosis is multifactorial, and may be influenced by 
oncogenic pathway activation (506), the local immune response (235), and, as observed in 
Chapter 4, the presence of a protective expanded tumour-associated stroma.  As such, any 
prognostic value could potentially be attributed to these numerous upstream phenomena 
rather than the presence of necrosis itself. 
Although informative, it is clear that TNM staging is suboptimal, particularly given the 
lack of a stepwise increase in risk with increasing disease stage (162).  Current staging, and 
therefore prognosis and treatment, is heavily weighted towards the presence of lymph node 
metastases.  However, subsequent revisions of the TNM staging system have introduced 
significant changes to pathological definitions, particularly with respect to nodal stage and 
often with little supporting evidence (160).  Indeed, such changes have led to concern 
regarding potential “upstaging of patients” without any significant implications for 
prognosis (408, 409).  Given that the criteria for T stage remains relatively standardised 
and largely unchanged since first described by Dukes (154), it presents an attractive and 
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logical foundation to base disease staging upon. Several proposed schemes have utilised T 
stage as an important determinant of disease stage in combination with other factors, such 
as venous invasion, and with less reliance on the presence of nodal involvement as a 
defining factor for high-risk disease (432, 508, 509).  Although the present study was 
largely limited to patients with T3 disease, it displays how assessment of the tumour local 
and systemic environment may be utilised in the routine staging of patients with primary 
operable colorectal cancer.  However further studies, particularly encompassing patients 
with T1/2 disease are required to examine both the nature of the microenvironment as well 
as the clinical utility of such assessments across all disease stages. 
The present study is limited by the small number of patients with early stage disease.  
Indeed, relatively few patients with T1/T2 tumours were included, and as such it was not 
possible to examine the prognostic value of the above measures in this patient group.  
Given the increasing predominance of this patient group with the advent of screening 
programmes (496), this would be of considerable interest.  Furthermore, tumour budding 
was not examined in this cohort.  Although strongly associated with the configuration of 
the infiltrative margin (510), the presence of budding is phenotypical of epithelial-
mesenchymal transitioning.  Given its increasing interest as an independent predictor of 
poor survival (511), it would be of interest to examine its prognostic utility relative to other 
components of the local and systemic environment. 
In conclusion, the present study confirms the relationship between tumour invasiveness, as 
assessed by T stage, and the presence of adverse local and systemic environment 
characteristics, and shows how such characteristics may be utilised to guide prognosis to a 
greater extent than current TNM-based staging of patients with primary operable colorectal 
cancer. 
.
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Figure 8.1 Colorectal cancer T stage (x100 magnification). (A) shows an example of a T1 tumour with invasion into submucosa. (B) shows an example 
of a T3 tumour with invasion through muscularis propria into surround serosal tissue without breach of peritoneum. (C) shows an example of a T4 
tumour with invasion onto peritoneal surface
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Figure 8.2 The relationship between T stage and adverse characteristics within the local 
and systemic environment of patients undergoing elective, potentially curative resection of 
stage I-III colorectal cancer. (A) tumour microenvironment characteristics, and (B) 
systemic environment characteristics, The y-axis denotes the percentage of patient within 
each T stage with each adverse characteristic 
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Figure 8.3 The relationship between pathological and local and systemic environment 
characteristics and cancer-specific survival of patients undergoing elective, potentially 
curative resection of T3 colorectal cancer. (A) N stage (P=0.031), (B) Glasgow 
Microenvironment Score (P<0.001), (C) Immunoscore (P=0.001), and (D) modified 
Glasgow Prognostic Score (P=0.004). All P-values calculated using log-rank analysis
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Table 8.1 The relationship between tumour invasiveness (T stage) and clinicopathological 
characteristics of patients undergoing elective, primary resection of T1-T4 colorectal 
cancer 
Data analysed using χ2 analysis for linear trend. 
  T1 T2 T3 T4  
Clinicopathological 
characteristics 
(n when data missing) 
n=8 
(%) 
n=25 
(%) 
n=208 
(%) 
n=90 
(%) 
P 
Host characteristics      
Age  
<65 
65-74 
>75 
 
1 (13) 
5 (62) 
2 (25) 
 
9 (36) 
8 (32) 
8 (32) 
 
69 (33) 
70 (34) 
69 (33) 
 
33 (37) 
27 (30) 
30 (33) 
0.713 
Sex  
Female 
Male 
 
5 (62) 
3 (38) 
 
16 (64) 
9 (36) 
 
93 (45) 
115 (55) 
 
46 (51) 
44 (49) 
0.533 
Adjuvant 
therapy  
(330) 
 
No 
Yes 
 
6 (75) 
2 (25) 
 
23 (92) 
2 (8) 
 
159 (76) 
49 (24) 
 
60 (67) 
29 (33) 
0.030 
Tumour characteristics      
Tumour site  
Colon 
Rectum 
 
2 (25) 
6 (75) 
 
12 (48) 
13 (52) 
 
145 (70) 
63 (30) 
 
73 (81) 
17 (19) 
<0.001 
N stage  
0 
1 
2 
 
5 (62) 
3 (38) 
0 (0) 
 
20 (80) 
4 (16) 
1 (4) 
 
139 (67) 
56 (27) 
13 (6) 
 
45 (50) 
32 (36) 
13 (14) 
0.002 
Tumour 
differentiation 
 
Well/ mod 
Poor 
 
7 (87) 
1 (13) 
 
24 (96) 
1 (4) 
 
189 (91) 
19 (9) 
 
72 (80) 
18 (20) 
0.016 
Margin 
involvement 
 
Absent 
Present 
 
8 (100) 
0 (0) 
 
25 
(100) 
0 (0) 
 
205 (99) 
3 (1) 
 
72 (80) 
18 (20) 
<0.001 
Venous 
invasion 
 
Absent 
Present 
 
8 (100) 
0 (0) 
 
23 (92) 
2 (8) 
 
140 (67) 
68 (33) 
 
45 (50) 
45 (50) 
<0.001 
Mismatch 
repair status 
(209) 
 
Competent 
Deficient 
 
7 (87) 
1 (13) 
 
15 (88) 
2 (12) 
 
110 (87) 
17 (13) 
 
44 (77) 
13 (23) 
0.161 
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Table 8.2 The relationship between tumour invasiveness (T stage), and the local and 
systemic environment of patients undergoing elective, primary resection of T1-T4 
colorectal cancer 
Data analysed using χ2 analysis for linear trend. 
 
 T1 
(%) 
T2 (%) T3 (%) T4 (%)  
Tumour microenvironment 
(n when data missing) 
n=8 
(%) 
n=25 
(%) 
n=208 
(%) 
n=90 
(%) 
P 
Necrosis  
(297) 
 
Absent 
Present 
 
7 (87) 
1 (13) 
 
19 (90) 
2 (10) 
 
106 (56) 
82 (44) 
 
37 (46) 
43 (54) 
<0.001 
Invasive margin 
(312) 
 
Expansile 
Infiltrative 
 
7 (87) 
1 (13) 
 
18 (82) 
4 (18) 
 
119 (60) 
78 (40) 
 
34 (40) 
51 (60) 
<0.001 
Klintrup-Mäkinen 
grade (307) 
 
Strong 
Weak 
 
5 (62) 
3 (38) 
 
14 (67) 
7 (33) 
 
63 (32) 
133 (68) 
 
21 (26) 
61 (74) 
0.001 
Tumour stroma 
percentage  
(331) 
 
Low 
High 
 
7 (87) 
1 (13) 
 
19 (76) 
6 (24) 
 
168 (81) 
40 (19) 
 
56 (62) 
34 (38) 
0.006 
Immunoscore 
(226) 
 
0-1 
2-3 
4 
 
2 (29) 
2 (29) 
3 (42) 
 
8 (42) 
7 (37) 
4 (21) 
 
68 (49) 
54 (39) 
17 (12) 
 
37 (61) 
17 (28) 
7 (12) 
0.016 
Systemic environment 
(n when data missing) 
     
Modified Glasgow 
Prognostic Score  
(330) 
 
0 
1 
2 
 
6 (75) 
2 (25) 
0 (0) 
 
16 (64) 
8 (32) 
1 (4) 
 
127 (61) 
51 (25) 
30 (14) 
 
45 (51) 
29 (33) 
15 (17) 
0.031 
Neutrophil: 
lymphocyte ratio 
(225) 
 
≤5 
>5 
 
6 (86) 
1 (14) 
 
17 (85) 
3 (15) 
 
115 (82) 
25 (18) 
 
39 (67) 
19 (33) 
0.033 
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Table 8.3 The interrelationship between tumour microenvironment and systemic 
environment characteristics of patients undergoing elective, primary resection of T1-T4 
colorectal cancer 
 
 
 
 
 
 
 
 
Displayed values are P-values calculated using c2 test for linear trend between variables.   
+ positive correlation, - inverse correlation 
 
 Necrosis Invasive 
margin 
KM 
grade 
TSP Immunoscore mGPS 
Invasive 
margin 
0.774 - - - - - 
KM grade 
 
0.142 <0.001- - - - - 
TSP 0.001- <0.001+ 0.069- - - - 
Immunoscore 0.014- 0.185 <0.001+ 0.569 - - 
mGPS <0.001+ 0.593 0.465 0.177 0.189 - 
NLR 0.021+ 0.298 0.076- 0.558 0.562 <0.001+ 
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Table 8.4 The relationship between T stage, clinicopathological and local and systemic 
environment characteristics and five-year cancer-specific survival of patients undergoing 
elective, primary resection of T1-T4 colorectal cancer 
Log-rank P-value provided for the prognostic value of individual characteristics. CSS – 
cancer-specific survival, SE – standard error. 
.
 All (T1-T4) T3 disease 
N 5-yr 
CSS % 
(SE) 
P N 5-yr 
CSS % 
(SE) 
P 
All  331 77 (2) - 208 82 (3) - 
N stage  
N0 
N1 
N2 
 
209 
95 
27 
 
86 (2) 
64 (5) 
46 (10) 
<0.001 
 
 
139 
56 
13 
 
88 (3) 
70 (6) 
64 (14) 
0.031 
 
 
Mismatch repair 
status 
 
Deficient 
Competent 
 
33 
176 
 
88 (6) 
73 (3) 
0.100  
17 
110 
 
94 (6) 
79 (4) 
0.206 
Necrosis  
Absent 
Present 
 
169 
128 
 
80 (3) 
72 (4) 
0.130  
106 
82 
 
84 (4) 
77 (5) 
0.404 
Invasive Margin  
Expansile 
Infiltrative 
 
178 
134 
 
82 (3) 
69 (4) 
<0.001  
119 
78 
 
85 (3) 
75 (5) 
0.004 
Klintrup-Mäkinen 
grade 
 
Strong 
Weak 
 
103 
204 
 
90 (3) 
70 (3) 
<0.001  
63 
133 
 
93 (3) 
76 (4) 
0.001 
Tumour stroma 
percentage 
 
Low 
High 
 
250 
81 
 
81 (3) 
64 (6) 
<0.001  
168 
40 
 
84 (3) 
71 (7) 
0.018 
Glasgow 
Microenvironment 
Score 
 
0 
1 
2 
 
103 
147 
57 
 
90 (3) 
77 (4) 
53 (7) 
<0.001  
63 
105 
28 
 
93 (3) 
81 (4) 
58 (10) 
<0.001 
Immunoscore  
4 
2-3 
0-1 
 
31 
80 
115 
 
96 (3) 
87 (4) 
62 (5) 
<0.001  
17 
54 
68 
 
100 (0) 
87 (5) 
70 (6) 
0.001 
Modified Glasgow 
Prognostic Score 
 
0 
1 
2 
 
294 
90 
46 
 
83 (3) 
72 (5) 
57 (8) 
<0.001  
127 
51 
30 
 
86 (3) 
82 (6) 
62 (9) 
0.004 
Neutrophil: 
Lymphocyte Ratio 
 
≤5 
>5 
 
177 
48 
 
79 (3) 
73 (7) 
0.362  
115 
25 
 
84 (3) 
74 (9) 
0.091 
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9 Comparison of the prognostic value of measures of the 
tumour inflammatory cell infiltrate and tumour-associated 
stroma in patients with primary operable colorectal cancer 
9.1 Introduction 
Although semi-quantitative assessment of the generalised inflammatory cell infiltrate, such 
as that offered by the KM grade, has been validated as a stage-independent prognostic 
characteristic (248, 249), the prognostic value of immunohistochemistry-based assessments 
of immune cell type and location within the tumour microenvironment is of interest (232, 
501).  Initially describing the density of cytotoxic (CD8+) and memory (CD45R0+) T-
lymphocytes within the tumour microenvironment, the Immunoscore has recently been 
refined to reflect a cumulative score based on the density of the overall mature CD3+ T-
lymphocyte population in addition to the CD8+ T-lymphocyte population at the invasive 
margin and within the tumour core, and has been validated as a prognostic marker with 
superior prognostic ability when compared to TNM staging in colorectal cancer (260, 501, 
512).  However, whether the Immunoscore, with all the inherent complexities of 
immunohistochemistry, is superior to the KM grade remains to be determined. 
In Chapter 7, a novel, cumulative tumour microenvironment-based score, comprised of 
KM grade and TSP, was shown to stratify survival greater than either measure alone in 
patients undergoing elective, potentially curative resection of primary operable colorectal 
cancer.  Using this prognostic score termed the Glasgow Microenvironment Score (GMS) 
it was possible to further stratify five-year cancer-specific survival of those patients with a 
weak local inflammatory cell infiltrate from 75% to 51%.  Indeed, the GMS has much to 
commend it, given its reliance on routinely available pathological specimens and rapid, 
reproducible, semi-quantitative histopathological assessments.  However, whether 
inclusion of a potentially more detailed measure of the inflammatory cell infiltrate, such as 
the Immunoscore, may alter the prognostic value of the GMS and the tumour-associated 
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stroma in particular is not clear. Therefore, the present study had two aims: first, to 
compare the prognostic value of assessment of the inflammatory cell infiltrate using the 
Klintrup-Mäkinen grade and the Immunoscore, and second, to examine the clinical utility 
of combined assessment of the inflammatory cell infiltrate and TSP. 
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9.2 Patients and Methods 
Clinicopathological characteristics 
Patients were identified from a prospectively collected and maintained database of elective 
and emergency colorectal cancer resections performed in a single surgical unit at GRI.  For 
the purposes of the present chapter, patients who had undergone emergency or elective, 
potentially curative resection of stage I-III colorectal adenocarcinoma without neoadjuvant 
therapy were included.  Other inclusion and exclusion criteria, clinicopathological staging, 
multi-disciplinary team review and follow-up protocols has previously been described in 
Chapter 2 and 4.  Assessment of MMR status was performed as described in Chapter 5. 
Date and cause of death was crosschecked with the cancer registration system and the 
Registrar General (Scotland).  Death records were complete until 31st March 2014 that 
served as the censor date.  Cancer-specific survival was measured from the date of surgery 
until the date of death from recurrent or metastatic colorectal cancer. 
Assessment of the tumour microenvironment 
The KM grade and TSP were both assessed using routine H&E-stained sections of the 
deepest point of tumour invasion as previously described in Chapter 4.  The KM grade was 
categorised as low grade or high grade, and TSP was categorised as low (≤50%) or high 
(>50%). 
Full sections of the invasive margin were stained for mature T-lymphocytes (CD3+) and 
cytotoxic (CD8+) T-lymphocytes as previously described in Chapter 4.  The Immunoscore 
was calculated as described in Chapter 8.  Briefly, the density of CD3+ and CD8+ T-cells 
within the invasive margin and tumour centre were separately semi-quantitatively graded 
as high or low; and the Immunoscore was calculated from the number of regions with a 
high CD3+ and CD8+ cell density, giving five potential groups (Im0, Im1, Im2, Im3, Im4), 
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ranging from all regions low density (Im0) to all regions high density (Im4).  An example 
of different CD3+ T-lymphocyte densities within different tumour microenvironment 
regions is displayed in Figure 9.1. 
Statistical analysis 
The relationship between components of the tumour microenvironment and cancer-specific 
survival was examined using Kaplan-Meier log-rank analysis, with five-year survival 
presented as percentage surviving (SE).  The relationship between components of the 
tumour microenvironment, clinicopathological characteristics and survival was examined 
using multivariate Cox proportional hazards regression to calculate HRs and 95% CIs.  
Variables with a P-value ≤0.05 on univariate regression analysis were entered into a 
multivariate model using a backward conditional method.  All statistical analyses were 
performed using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).  A P-value ≤0.05 was 
considered statistically significant.  
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9.3 Results 
The study population was comprised of 246 patients undergoing potentially curative 
resection of stage I-III colorectal cancer.  Clinicopathological characteristics are displayed 
in Table 9.1.  Approximately two thirds of patients were 65 years of age or older at time of 
surgery and 52% were male.  Fifteen patients (6%) underwent emergency resection, and 
just over two thirds of patients underwent resection of colon cancer.  Histopathological 
reporting confirmed stage I, stage II and stage III disease in 7%, 52% and 41% of patients 
respectively.  Mismatch repair status was available for 205 patients; 30 patients (15%) had 
mismatch repair deficient colorectal cancer.  
The median follow-up of survivors was 145 months (range 87-206 months) with 76 
colorectal cancer-related deaths and 76 non-cancer deaths.  Five-year survival was 74% for 
cancer-specific survival and 63% for overall survival.  In total, 71 patients (29%) received 
adjuvant chemotherapy; one patient with stage I (6%) disease, 19 patients with stage II 
disease (15%), and 51 patients with stage III disease (51%) received adjuvant 
chemotherapy.  
The relationship between the local inflammatory cell infiltrate and cancer-
specific survival 
The relationship between measures of the local inflammatory cell infiltrate and cancer-
specific survival is displayed in Figure 9.2 and Table 9.2.  A low KM grade was associated 
with poorer five-year survival (66% vs. 88%; P=0.002).  When stratified by tumour site, 
low KM grade was associated with poorer survival of patients with colon cancer (P=0.018) 
and showed a trend towards poorer survival of patients with rectal cancer (P=0.068).  
When stratified by TNM stage, low KM grade showed a trend towards poorer survival of 
patients with node negative (stage I/II) disease (P=0.053) and node positive (stage III) 
disease (P=0.057).  Finally, low KM grade was associated with poorer survival of both 
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patients who received and did not receive adjuvant therapy (P=0.046 and P=0.028 
respectively). 
The relationship between Immunoscore and cancer-specific survival is displayed in Figure 
9.2 and Table 9.2.  Five-year cancer-specific survival ranged from 93% for patients with 
Im4 to 61% for patients with Im0 (P<0.001).  The survival of patients with Im0 and Im1, 
or Im2 and Im3 did not differ significantly (P=0.788 and P=0.599, respectively).  As such, 
for further statistical analysis, the Immunoscore was refined to stratify patients in to three 
prognostic groups: Im4, with five-year survival of 93%; Im2/3, with five-year survival of 
84%; and Im0/1, five-year survival of 61% (P<0.001).  When stratified by tumour site, a 
low Immunoscore was associated with poorer survival of patients with both colon and 
rectal cancer (P=0.003 and P=0.001 respectively).  When stratified by TNM stage, low 
Immunoscore was associated with poorer survival of patients with stage I/II disease 
(P=0.002) and stage III disease (P=0.011).  Finally, low Immunoscore was associated with 
poorer survival of patients who did not receive adjuvant chemotherapy (P<0.001) and 
showed a trend towards poorer survival in patients who did receive adjuvant therapy 
(P=0.059). 
Klintrup-Mäkinen grade was strongly associated with the Immunoscore (P<0.001; Figure 
9.3).  Comparison between the prognostic value of the KM grade and Immunoscore was 
subsequently performed (Table 9.3).  The Immunoscore was able to further stratify the 
survival of patients with both a low and high KM grade; the survival of patients with a low 
KM grade ranged from 90% (Im4) to 60% (Im0/1) (P=0.015), whereas the survival of 
patients with a high KM grade ranged from 94% (Im4) to 71% (Im0/1) (P=0.010).  In 
contrast, KM grade did not further significantly stratify the Immunoscore. 
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The relationship between tumour stroma percentage, the tumour 
inflammatory cell infiltrate and cancer-specific survival 
The prognostic value of combined assessment of the inflammatory cell infiltrate and TSP 
was subsequently examined (Table 9.4).  Tumour stroma percentage significantly stratified 
the survival of patients from 80% (low TSP) to 57% (high TSP) (P=0.001).  In 
combination with assessment of the inflammatory cell infiltrate, TSP significantly 
stratified survival of those with a weak infiltrate but not those with a strong infiltrate.  In 
particular, TSP significantly stratified survival of patients with a low KM grade from 75% 
to 47% (P<0.001), whereas in patients with a high KM grade, survival of patients with a 
low TSP was comparable to that of patients with a high TSP (P=0.485).  In combination 
with the Immunoscore, the effect of TSP on survival decreased as the Immunoscore 
increased; TSP stratified the survival of patients with Im0/1 from 71% to 38% (P<0.001) 
and patients with Im2/3 from 87% to 77% (P=0.069), but not patients with Im4 (P=0.545) 
(Figure 9.4).  Conversely, assessment of the inflammatory cell infiltrate was able to stratify 
survival of patients with both a high and low TSP; KM grade stratified patients with a low 
TSP from 88% to 75% (P=0.081) and patients with a high TSP from 87% to 47% 
(P=0.034), whereas Immunoscore stratified survival of patients with a low TSP from 92% 
to 71% (P=0.002) and patients with a high TSP from 100% to 38% (P=0.004). 
The relationship between Klintrup-Mäkinen grade, Immunoscore, tumour 
stroma percentage, clinicopathological characteristics and cancer-specific 
survival 
On univariate survival analysis (Table 9.5), emergency presentation, T stage, mGPS (both 
P<0.05), N stage, venous invasion, margin involvement and peritoneal involvement (all 
P≤0.001) were associated with cancer-specific survival.  The KM grade (P=0.003), 
Immunoscore and TSP were all associated with survival (both P<0.001).	
On multivariate analysis, after controlling for age, sex, tumour site and adjuvant therapy 
and considering all variables significant on univariate analysis (Model 1), the 
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Immunoscore and TSP (both P<0.01), but not the KM grade, were associated with survival 
independent of venous invasion (P=0.001) and mGPS (P<0.05).  When the Immunoscore 
was removed from the multivariable model (Model 2), KM grade (P<0.05) and TSP 
(P<0.01) remained associated with survival independent of venous invasion (P=0.001) and 
mGPS (P<0.01). 
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9.4 Discussion 
In the present study, an immunohistochemistry-based assessment of the inflammatory cell 
infiltrate was superior to that of H&E-based assessment in predicting outcome of patients 
undergoing potentially curative resection of stage I-III colorectal cancer.  Furthermore, the 
combination of assessment of the inflammatory cell infiltrate, using either KM grade or 
Immunoscore, and the tumour-associated stroma, using TSP, provided additional 
prognostic information. 
The present study compared the prognostic utility of two validated measures of the tumour 
inflammatory cell infiltrate – the KM grade and the Immunoscore (248, 501).  Although 
both were associated with cancer-specific survival, the Immunoscore, an 
immunohistochemistry-based assessment of CD3+ and CD8+ T-lymphocyte density, was 
able to stratify survival of patients to a greater degree than KM grade, an H&E-based 
assessment of the generalised inflammatory cell infiltrate.  In particular, the Immunoscore 
was able to stratify survival of patients with both a low and high KM grade; indeed, 
survival of patients with a low KM grade but high Immunoscore was comparable to that of 
patients with a high KM grade. 
The relative difference in the prognostic value of both measures of the inflammatory cell 
infiltrate may be explained by the components of the immune response that each measures. 
Whereas KM grade provides a measure of the overall, generalised inflammatory cell 
infiltrate, the Immunoscore measures the host adaptive T-lymphocytic response to cancer.  
Indeed, although an increase in KM grade is associated with an increase in the density of 
tumour-infiltrating T-lymphocytes (233, 433, 452), it is also associated with an increase in 
the density of the innate immune infiltrate, and in particular neutrophils and macrophages 
(233, 452).  In the present study, within the group of patients with a high KM grade, the 
number of patients with a low (Im0/1, n=19) or high (Im4, n=21) Immunoscore (as a 
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measure of adaptive immunity) was similar, whereas of those patients with a low KM 
grade, a small number had a high Immunoscore.  Therefore the KM grade may not always 
represent the same entity.  However, although the importance of host adaptive anti-tumour 
immune responses is recognised, it is now appreciated that myeloid-derived cells, such as 
neutrophils and macrophages, play an important functional role in promoting tumour 
progression (513).  Indeed, it remains to be determined whether immunohistochemistry-
based assessment of the innate immune infiltrate may increase the clinical and prognostic 
utility of measuring the inflammatory cell infiltrate in patients with colorectal cancer. 
It was of interest in the present cohort that TSP, an assessment of the tumour-associated 
stroma, was associated with survival independent of either measure of the inflammatory 
cell infiltrate, and that combined assessment provided greater prognostic value.  For 
example, it was possible to stratify five-year survival from 92% (Im4, low TSP) to 38% 
(Im0/1, high TSP).  Furthermore, although the relationship between TSP and survival was 
strongest in patients with a poor inflammatory cell infiltrate, both the number of patients 
with a high TSP, and its prognostic value, decreased as the density of the inflammatory 
infiltrate increased.  Although it has previously been suggested that the presence of a 
tumour-associated stroma precludes effective infiltration of the tumour microenvironment 
by an anti-tumour immune response (443), the present results are consistent with those of 
Chapter 4 and 7, and may favour the alternative hypothesis that loss of the adaptive 
immune infiltrate predisposes to the development of a pro-tumour stromal compartment, 
potentially mediated by the residual innate immune infiltrate (502). 
Consistent with the GMS proposed in Chapter 7, the present results suggest that a similar 
scheme may be applied to the combination of the Immunoscore and TSP and may have 
even greater clinical utility.  Indeed, such a combination may optimise risk prediction in 
patients undergoing colorectal cancer resection by identifying both those with an excellent 
prognosis (Im4; five-year cancer-specific survival of 93%), and those with an extremely 
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poor prognosis who may benefit from adjuvant therapy (Im0/1, high TSP; five-year 
cancer-specific survival of 38%).  
In the present study, it was of interest that both the systemic inflammatory response as 
measured by mGPS, and the local inflammatory cell infiltrate as measured by either KM 
grade or the Immunoscore had independent prognostic value on multivariate analysis.  It is 
likely that these measures reflect different aspects of the same underlying process, and 
therefore it would be of interest to compare the local and systemic inflammatory responses 
and how they may be combined to form a prognostic score. Indeed, Turner and colleagues 
have recently combined measures of the local and systemic inflammatory response to give 
better risk stratification in patients with node negative colorectal cancer (514).  However, 
the rationale of their approach that combined the NLR and assessment of the chronic 
inflammatory cell density was not clear, since different cell types were assessed locally and 
systemically.  Indeed, only approximately 20% of patients had an elevated NLR and a low 
chronic inflammatory cell density, and therefore this score does not capture the same 
entity.  Similarly, combinations of other systemic and local inflammatory measures, such 
as the mGPS and KM grade or Immunoscore, will have such limitations. Moreover, the 
numbers of patients included in the present analysis limits the value of such analysis and 
therefore was not formally examined.  
The present analysis is perhaps limited by its use of manual, semi-quantitative assessment 
of the inflammatory cell infiltrate as opposed to automated assessment as has been 
recommended for routine assessment of the Immunoscore (501).  However, the manual 
techniques employed showed excellent inter-operator agreement (249, 433) and manual 
assessment of the inflammatory cell infiltrate has been shown to correlate strongly with 
automated assessment (445, 464).  Furthermore, manual assessment of 
immunohistochemical staining may allow for greater discrimination of non-specific, 
background staining and provide superior prognostic value compared to automated 
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assessment (445).   Furthermore, meaningful statistical analysis was precluded by the small 
number of patients in particular subgroups, such as those with stage II disease and high-
risk pathological characteristics, or patients with stage I disease.  Finally, the results of the 
present study, and in particular the prognostic utility of combined assessment of the 
inflammatory cell infiltrate and tumour-associated stroma, remain to be validated in an 
independent patient cohort from an independent centre. 
In conclusion, the present results suggest that the prognostic value of an 
immunohistochemistry-based assessment of the inflammatory cell infiltrate is superior to 
H&E-based assessment in patients undergoing potentially curative resection of stage I-III 
colorectal cancer.  Furthermore, TSP improves the prediction of survival by either measure 
of the inflammatory cell infiltrate. 
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Figure 9.1 Examples of CD3+ T-lymphocyte staining in patients with colorectal cancer (x200 magnification). (A) displays low density, whereas (B) 
displays a high density at the invasive margin. (C) displays a high stromal density and (D) displays a high intraepithelial/ cancer cell nest density of 
CD3+T-lymphocytes
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Introduc)on:+
The&host&immune&response&is&
important&in&the&preven=on&of&
tumour&progression&in&solid&organ&
cancers&but&is&not&u=lised&in&clinical&
prac=ce.&The&aim&was&to&evaluate&
the&clinical&u=lity&of&the&local&
inﬂammatory&response&in&pa=ents&
with&colorectal&cancer.&
&
Conclusion+
A&coordinated&adap=ve&immune&response&is&an&important&
factor&in&predic=ng&outcome&in&pa=ents&with&colorectal&
cancer.&By&comparing&diﬀerent&methodologies&we&have&
provided&a&founda=on&on&which&to&develop&a&standardised&
approach&for&assessing&tumour&inﬂammatory&cell&inﬁltrate.&
Results+
A&strong&inﬁltra=on&of&tumour&inﬁltra=ng&lymphoctyes&
(TIL’s)&was&associated&with&improved&cancer&speciﬁc&
survival.&When&speciﬁc&TLcell&subtypes&were&considered,&
CD3+&was&the&strongest&predictor&of&survival&at&both&the&
invasive&margin&(CD3+&IM)&and&tumour&stroma&(CD3+&ST)&
while&CD8+&was&the&strongest&predictor&in&the&cancer&cell&
nests&(CD8+&CCN).&Inﬁltra=on&of&TIL’s&was&associated&with&
early&tumour&stage,&an&expanding&growth&paSern&and&
lower&levels&of&venous&invasion&but&not&inﬂuenced&by&
host&characteris=cs&or&systemic&inﬂamma=on.&The&Galon&
Immune&Score&and&the&KlintrupLMakinen&grade&were&
strongly&related&to&individual&TLcell&inﬁltra=on&and&all&
three&methods&exhibited&similar&survival&rela=onships&in&
both&nodeLposi=ve&and&nodeLnega=ve&disease.&
&
Methods:&
365&pa=ents&with&primary&operable&
colorectal&cancer&were&included.&
The&local&inﬂammatory&response&
was&assessed&using&three&diﬀerent&
methods;&(1)&individual&immune&
cells&(CD3+,&CD8+,&CD45R0+,&
FOXP3+);&(2)&a&composite&
immunohistochemistryLbased&score&
(Galon&Immune&Score);&(3)&a&
histopathological&assessment&
(KlintrupLMakinen&grade).&
Rela=onships&with&tumour&and&host&
characteris=cs&were&established&
and&the&prognos=c&value&of&each&
method&compared.&&
&
!
 
! Univariate! Multivariate!
Immune!Score! HR! 95%!CI! p*! HR! 95%!CI! p*!
!
Colorectal)cancer)(stage)I/III))
CD3+!IM! 0.51! (0.40,!0.64)! <0.001! 0.72! (0.52,!0.99)! 0.045!
CD3+!ST! 0.54! (0.43,!0.67)! <0.001! ! ! 0.07!
CD8+!CCN! 0.53! (0.42,!0.66)! <0.001! 0.58! (0.44,!0.77)! <0.001!
K:M!grade! 0.54! (0.43,!0.68)! <0.001! ! ! 0.20!
Galon!Immune!Score! 0.72! (0.63,!0.82)! <0.001! ! ! 0.18!
!
Colorectal)cancer)(stage)I/II))
CD3+!IM! 0.52! (0.35,!0.77)! 0.001! ! ! 0.35!
CD3+!ST! 0.44! (0.30,!0.63)! <0.001! 0.61! (0.39,!0.93)! 0.020!
CD8+!CCN! 0.49! (0.38,!0.70)! <0.001! 0.56! (0.36,!0.86)! 0.009!
K:M!grade! 0.56! (0.39,!0.79)! 0.001! ! ! 0.41!
Galon!Immune!Score! 0.74! (0.60,!0.90)! 0.003! ! ! 0.45!
!
Colon)cancer)
CD3+!IM! 0.56! (0.41,!0.74)! <0.001! 0.61! (0.39,!0.96)! 0.031!
CD3+!ST! 0.57! (0.43,!0.76)! <0.001! ! ! 0.07!
CD8+!CCN! 0.53! (0.41,!0.70)! <0.001! 0.55! (0.39,!0.79)! 0.001!
K:M!grade! 0.58! (0.42,!0.74)! <0.001! ! ! 0.15!
Galon!Immune!Score! 0.75! (0.64,!0.88)! <0.001! ! ! 0.08!
!
Rectal)cancer)
CD3+!IM! 0.43! (0.28,!0.64)! <0.001! ! ! 0.22!
CD3+!ST! 0.45! (0.30,!0.67)! <0.001! 0.57! (0.35,!0.94)! 0.027!
CD8+!CCN! 0.51! (0.35,!0.76)! 0.001! 0.45! (0.26,!0.78)! 0.005!
K:M!grade! 0.52! (0.35,!0.76)! 0.001! ! ! 0.49!
Galon!Immune!Score! 0.68! (0.54,!0.85)! 0.001! ! ! 0.40!
!
*Cox!proportional!hazards!regression!
 
Table&3.&&Contingency&table&analysis&demonstrating&the&inter6relationships&between&T6cell&subtypes,&K6M&grade&and&the&Galon&
Immune&Score&in&colorectal&tumours.&
!
CD3+! CD45R0+! CD8+! FOXP3+!
Margin! Stroma! CC!nests! Margin! Stroma! CC!nests! Margin! Stroma! CC!nests! Margin! Stroma! CC!nests!
CD3+! Margin! & & & & & & & & & & & &
! Stroma! <0.001& & & & & & & & & & & &
! CC!nests! <0.001& <0.001& & & & & & & & & & &
CD45R0+! Margin! <0.001& <0.001& <0.001& & & & & & & & & &
! Stroma! <0.001& <0.001& <0.001& <0.001& & & & & & & & &
! CC!nests! <0.001& <0.001& <0.001& <0.001& <0.001& & & & & & & &
CD8+! Margin! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& & & & & & &
! Stroma! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& & & & & &
! CC!nests! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& & & & &
FOXP3+! Margin! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& & & &
! Stroma! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& & &
! CC!nests! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& 0.001& <0.001& <0.001& <0.001& &
! &
K<M!grade! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001&
Galon!Immune!Score! <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001& <0.001&
&
!
p&values&represent&chi&square&tests&for&linear&trend&with&all&relationships&positive&unless&stated&
                                    
 
Number!exposed!to!risk!
CD3+&IM&(strong)& 35& 34& 33& 32& 31& 30& 27& 24& 12&
CD3+&IM&(mod)& 95& 90& 86& 82& 72& 69& 62& 55& 26&
CD3+&IM&(weak)& 146& 130& 116& 100& 87& 81& 71& 60& 29&
CD3+&IM&(absent)& 39& 35& 26& 20& 16& 14& 13& 12& 6&
&
&
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Figure&2.&Kaplan@Meier&survival&curves&demonstrating&the&cancer&specific&survival&of&patients&with&primary&
operable&colorectal&cancer&according&to&the&application&of&proposed&immune&scores.&Clockwise&from&top&left;&
CD+&IM,&CD8+&CCN,&K@M&grade&and&the&Galon&Immune&Score.&&
 
Number!exposed!to!risk!
CD8+&CCN&(strong)& 37& 36& 34& 34& 32& 31& 29& 27& 13&
CD8+&CCN&(mod)& 60& 57& 55& 53& 48& 46& 41& 37& 18&
CD8+&CCN&(weak)& 122& 113& 99& 87& 76& 73& 65& 57& 27&
CD8+&CCN&(absent)& 106& 93& 80& 65& 55& 47& 41& 34& 16&
Number!exposed!to!risk!
K@M&grade&(strong)& 28& 28& 28& 27& 27& 26& 23& 22& 11&
K@M&grade&(mod)& 86& 82& 75& 68& 62& 59& 55& 50& 24&
K@M&grade&(weak)& 158& 150& 133& 118& 102& 94& 85& 71& 34&
K@M&grade&(absent)& 72& 65& 55& 44& 38& 32& 27& 23& 10&
Number!exposed!to!risk!
Galon&(4)&–&Hi& 58& 57& 56& 55& 50& 49& 45& 40& 18&
Galon&(3)&–&Hi& 53& 51& 46& 44& 39& 38& 35& 32& 15&
Galon&(1@2)&–&Hi&& 105& 94& 87& 76& 64& 59& 52& 45& 22&
Galon&(0)&–&Hi&& 90& 80& 66& 53& 48& 41& 35& 31& 15&
p<0.001 
K-M grade (absent) 
K-M grade (strong) 
K-M grade (moderate) 
K-M grade (weak) 
(4) - Hi 
(3) - Hi 
(1-2) - Hi 
(0) - Hi 
p<0.001 
p<0.001 p<0.001 
CD3+ IM (strong) 
CD3+ IM  (moderate) 
CD3+  IM (weak) 
CD3+ IM (absent) 
CD8+ CCN (strong) 
CD8+ CCN (moderate) 
CD8+ CCN (weak) 
CD8+ CCN (absent) 
Table&4.&&The&relationships&between&T2cell&infiltration&and&cancer&specific&survival&in&patients&
with&primary&operable&colorectal&cancer&(Model&1;&TIL’s&in&the&invasive&margin,&Model&2;&TIL’s&in&
the&tumour&stroma,&Model&3;&TIL’s&in&the&cancer&cell&nests).&&
&
&
&
! ! ! Univariate! Multivariate!
Location! Type! Density! HR! 95%!CI! p*!! HR! 95%!CI! p*!!!
&&
&Invasive(margin(
Margin& CD3+& Absent/weak/mod/strong& 0.51& (0.40,&0.64)& <0.001& 0.49& (0.38,&0.63)& <0.001&
Margin& CD45R0+& Absent/weak/mod/strong& 0.62& (0.50,&0.77)& <0.001& & & 0.45&
Margin& CD8+& Absent/weak/mod/strong& 0.53& (0.42,&0.66)& <0.001& & & 0.61&
Margin& FOXP3+& Absent/weak/mod/strong& 0.66& (0.51,&0.84)& 0.001& & & 0.18&
&
&Tumour(stroma(
Stroma& CD3+& Absent/weak/mod/strong& 0.54& (0.43,&0.67)& <0.001& 0.58& (0.46,&0.75)& <0.001&
Stroma& CD45R0+& Absent/weak/mod/strong& 0.64& (0.51,&0.82)& <0.001& & & 0.94&
Stroma& CD8+& Absent/weak/mod/strong& 0.70& (0.55,&0.88)& 0.002& & & 0.79&
Stroma& FOXP3+& Absent/weak/mod& 0.67& (0.53,&0.84)& 0.001& & & 0.06&
&
Cancer(cell(nests(
CC&nests& CD3+& Absent/weak/mod/strong& 0.54& (0.44,&0.67)& <0.001& 0.73& (0.55,&0.97)& 0.030&
CC&nests& CD45R0+& Absent/weak/mod/strong& 0.64& (0.51,&0.79)& <0.001& & & 0.61&
CC&nests& CD8+& Absent/weak/mod/strong& 0.53& (0.42,&0.66)& <0.001& 0.68& (0.50,&0.90)& 0.008&
CC&nests& FOXP3+& Absent/weak& 0.52& (0.36,&0.75)& 0.001& & & 0.08&
&
*&Cox&proportional&hazards&regression&
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Figure+1.&Examples&of&stained&sec=ons&
demonstra=ng&diﬀerent&paSerns&of&TLcell&
inﬁltra=on&in&the&microenvironment&of&
colorectal&tumours.&Absence&of&TLcell&
inﬁltra=on&(Panel&A);&Strong&inﬁltra=on&of&
CD3+&cells&at&the&invasive&margin&(Panel&B);&
Strong&inﬁltra=on&of&CD3+&cells&in&the&
tumour&stroma&with&rela=ve&‘sparing’&of&the&
cancer&cell&nests&(Panel&C);&and&strong&
inﬁltra=on&of&CD8+&cells&in&the&cancer&cell&
nests (Panel&D).&
T bl +1. The&interLrela=onship &between TLcell&subtypes,&KLM&grade&and&
the&Galon&Immune&Score&in&colorectal&tumours.&
Table+2.++The&rela=onships&between&TLcell&
inﬁltra=on&and&cancer&speciﬁc&survival&in&
pa=ents&with&primary&operable&colorectal&
cancer&(Model&1;&TIL’s&in&the&invasive&
margin,&Model&2;&TIL’s&in&the&tumour&
stroma,&Model&3;&TIL’s&in&the&cancer&cell&
nests).&&
Figure+2.&KaplanLMeier&survival&curves&demonstra=ng&the&cancer&speciﬁc&survival&of&
pa=ents&with&primary&operable&colorectal&cancer&according&to&the&applica=on&of&
proposed&immune&scores.&Clockwise&from&top&lee;&CD+&IM,&CD8+&CCN,&KLM&grade&
and&the&Galon&Immune&Score.&&
Table+4.&Comparison&of&the&
prognos=c&value&of&diﬀerent&methods&
of&assessing&the&local&inﬂammatory&
response&in&pa=ents&with&primary&
operable&colorectal&cancer&(Model&1;&
stage&ILIII&colorectal&cancer,&Model&2;&
stage&ILII&colorectal&cancer,&Model&3;&
colon&cancer,&Model&4;&rectal&cancer).&&
&&
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Figure 9.2 The relationship between the local inflammatory cell infiltrate and cancer-
specific survival of patients undergoing potentially curative resection of stage I-III 
colorectal cancer. (A) Klintrup-Mäkinen grade (P=0.002), (B) Immunoscore (P<0.001), 
and (C) Immunoscore groups (P<0.001). All P-values calculated using log-rank analysis 
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Figure 9.3 The relationship between Klintrup-Mäkinen grade and Immunoscore in patients 
undergoing potentially curative resection of stage I-III colorectal cancer (χ2 analysis for 
linear trend P<0.001) 
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Figure 9.4 The relationship between Immunoscore, tumour stroma percentage and cancer-
specific survival of patients undergoing potentially curative resection of stage I-III 
colorectal cancer. (A) Im0/1 (P<0.001), (B) Im2/3 (P=0.069), and (C) Im4 (P=0.545). All 
P-values calculated using log-rank analysis 
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Table 9.1 Clinicopathological characteristics of patients undergoing potentially curative 
resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   All 
Clinicopathological Characteristics 
(n when data missing) 
 n=246 (%) 
Host characteristics    
Age  
<65 
65-74 
>75 
  
82 (33) 
84 (34) 
80 (33) 
Sex  
Female 
Male 
  
117 (48) 
129 (52) 
Modified Glasgow Prognostic Score   
0 
1 
2 
  
138 (56) 
80 (33) 
28 (11) 
Presentation  
Elective 
Emergency 
  
231 (94) 
15 (6) 
Adjuvant therapy  
No 
Yes  
  
175 (51) 
71 (29) 
Tumour  characteristics    
Tumour site  
Colon 
Rectum 
  
169 (69) 
77 (31) 
TNM stage  
I 
II 
III 
 
 
 
18 (7) 
128 (52) 
100 (41) 
T stage   
1-2 
3 
4 
  
26 (11) 
152 (62) 
68 (28) 
N stage  
0 
1 
2 
  
146 (59) 
77 (31) 
23 (9) 
Lymph nodes examined  
<12 
≥12 
 
 
 
 
159 (65) 
87 (35) 
Tumour differentiation  
Mod/well 
Poor 
  
216 (88) 
30 (12) 
Venous invasion  
No 
Yes 
  
158 (64) 
88 (36) 
Margin involvement  
No 
Yes 
  
230 (94) 
16 (7) 
Peritoneal involvement  
No 
Yes 
  
178 (72) 
68 (28) 
Tumour perforation  
No 
Yes 
  
238 (97) 
8 (3) 
Mismatch repair status  
(205) 
 
Competent 
Deficient 
  
175 (85) 
30 (15) 
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Table 9.2 Comparison between measures of the local inflammatory cell infiltrate, tumour stroma percentage and cancer-specific survival of patients 
undergoing potentially curative resection of stage I-III colorectal cancer 
 
Log-rank P-value provided for the prognostic value of KM grade and Immunoscore within each column group. CSS – cancer-specific survival, SE –
standard error. 
 
 Tumour site  TNM stage  Adjuvant therapy 
 All patients Colon Rectum  TNM I/ II TNM III  No Yes 
 N 5-yr 
CSS % 
(SE) 
N 5-yr 
CSS % 
(SE) 
N 5-yr 
CSS % 
(SE) 
 N 5-yr 
CSS % 
(SE) 
N 5-yr 
CSS % 
(SE) 
 N 5-yr 
CSS % 
(SE) 
N 5-yr 
CSS % 
(SE) 
Klintrup-Mäkinen 
grade 
                
Low grade 161 66 (4)  111 65% (5) 50 69% (7)  89 77% (5)  72 53% (6)  110 69% (5) 51 61% (7) 
High grade 85 88 (4) 
0.002 
58 88% (4) 
0.018 
27 88% (6) 
0.068 
 57 93% (4) 
0.053 
28 78% (8) 
0.057 
 65 87% (4) 
0.028 
20 89% (7) 
0.046 
                 
Immunoscore                 
Im0/1 127 61 (4) 87 63% (5)  40 58% (8)   69 72% (6) 58 49% (7)  91 62% (5)  36 59% (8) 
Im2/3 87 84 (4) 60 81% (5) 27 92% (5)  54 92% (4) 33 72% (8)  60 89% (4) 27 74% (8) 
Im4 32 93 (5) 
<0.001 
22 90% (7) 
0.003 
10 100% (0) 
0.001 
 23 95% (5) 
0.002 
9 88% (12) 
0.011 
 24 91% (6) 
<0.001 
8 100% (0) 
0.059 
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Table 9.3 The relationship between Klintrup-Mäkinen grade, Immunoscore and cancer-specific survival of patients undergoing potentially curative 
resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
Log-rank P-value provided for the prognostic value for KM grade within each Immunoscore group (row) and for Immunoscore within each KM group 
(column). CSS – cancer-specific survival, SE –standard error. 
 
 
 
 All 
(Low and high KM grade) 
    Low 
Klintrup-Mäkinen grade 
 High 
Klintrup-Mäkinen grade 
Immunoscore N 5-yr CSS % (SE)     N 5-yr CSS % (SE)  N 5-yr CSS % (SE) 
Im0/1 127 61% (4)     108 60% (5)  19 71% (11) 0.598 
Im2/3 87 84% (4)     42 77% (7)  45 91% (4) 0.279 
Im4 32 93% (5) <0.001     11 90% (9) 0.015  21 94% (5) 0.645/0.010 
All (Im0-4) 246 74% (3)     161 66% (4)   85 88% (4) 0.002 
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Table 9.4 Comparison of the combined prognostic value of different measures of the local inflammatory cell infiltrate and tumour stroma percentage in 
patients undergoing potentially curative resection of stage I-III colorectal cancer 
 
Log-rank P-value provided for the prognostic value of KM grade and Immunoscore within each TSP group (row) and TSP within each KM grade and 
Immunoscore group (column). CSS – cancer-specific survival, SE –standard error. 
Table 9.4 displays the relationship between measures of the local inflammatory cell infiltrate (KM grade and Immunoscore), TSP and five-year cancer-
specific survival of patients undergoing elective resection of stage I-III colorectal cancer. The TSP provided further prognostic stratification of patients 
with a low density inflammatory cell infiltrate but not a high density inflammatory cell infiltrate as measured by both KM grade and Immunoscore. 
Conversely, the inflammatory cell infiltrate was able to further stratify survival or patients with both a low and high TSP. 
 
 Klintrup-Mäkinen grade  Immunoscore 
 All  Low grade  High grade   All  Im0/1  Im2/3  Im4 
TSP N 5-yr CSS 
% (SE) 
 N 5-yr CSS 
% (SE) 
 N 5-yr CSS 
% (SE) 
 N 5-yr CSS 
% (SE) 
 N 5-yr CSS 
% (SE) 
 N 5-yr CSS 
% (SE) 
 N 5-yr CSS 
% (SE) 
High 67 57% (6)  50 47% (7)  17 87% (9) 0.081  67 57% (6) b  37 38% (8)  24 77% (9)  6 100% (0) 
0.002 
Low  179 80% (3) 
<0.001 
 111 75% (4) 
<0.001 
 68 88% (4) 
0.034/0.485 
 179 80% (3) 
<0.001 
 90 71% (5) 
<0.001 
 63 87% (4) 
0.069 
 26 92% (5) 
0.004/0.545 
All  246 74% (3)  161 66% (4)   85 88% (4)   246 74% (3)  127 61% (4) c   87 84% (4)  32 93% (5)  
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Table 9.5 The relationship between Klintrup-Mäkinen grade, Immunoscore, tumour stroma percentage, clinicopathological characteristics and cancer-
specific survival of patients undergoing potentially curative resection of stage I-III colorectal cancer 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis to calculate two models; Model 1 using all variable significant on univariate analysis, and Model 2, excluding Immunoscore and 
using KM grade only. 
 Cancer-specific survival 
 Univariate HR  
(95% CI) 
P Multivariate HR  
(95%CI) (Model 1) 
P Multivariate HR  
(95% CI) (Model 2) 
P 
Age (<65/ 65-74/ >75) 1.18 (0.90-1.57) 0.237 - 0.444 - 0.091 
Sex (female/ male) 0.93 (0.59-1.46) 0.762 - 0.065 - 0.308 
Presentation (elective/ emergency) 2.22 (1.06-4.62) 0.034 - 0.724 - 0.369 
Adjuvant therapy (no/ yes) 1.40 (0.88-2.24) 0.160 - 0.988 - 0.505 
mGPS (0/ 1/ 2) 1.50 (1.10-2.05) 0.010 1.52 (1.09-2.11) 0.013 1.61 (1.16-2.24) 0.005 
Tumour site (colon/ rectum) 0.82 (0.49-1.36) 0.433 - 0.479 - 0.316 
T stage (1-2/ 3/ 4) 1.49 (1.07-2.07) 0.017 - 0.704 - 0.981 
N stage (0/ 1/ 2) 1.78 (1.32-2.41) <0.001 - 0.148 - 0.066 
Lymph nodes examined (>12/ <12) 1.38 (0.87-2.17) 0.171 - - - - 
Differentiation (mod-well/ poor) 1.40 (0.72-2.72) 0.322 - - - - 
Venous invasion (no/ yes) 2.95 (1.87-4.66) <0.001 2.20 (1.37-3.54) 0.001 2.35 (1.45-3.80) 0.001 
Margin involvement (no/ yes) 3.15 (1.56-6.33) 0.001 - 0.067 - 0.096 
Peritoneal involvement (no/ yes) 2.19 (1.38-3.46) 0.001 - 0.225 - 0.125 
Tumour perforation (no/ yes) 2.52 (0.92-6.93) 0.072 - - - 0.060 
MMR status (competent/ deficient) 0.42 (0.17-1.05) 0.064 - - - - 
Tumour stroma percentage (low/ high) 2.46 (1.56-3.89) <0.001 2.36 (1.44-3.84) 0.001 2.05 (1.28-3.30) 0.003 
Klintrup-Mäkinen grade (weak/ strong) 0.44 (0.25-0.76) 0.003 - 0.469 0.50 (0.29-0.87) 0.015 
Immunoscore (Im0-1/ Im2-3/ Im4) 0.66 (0.56-0.80) <0.001 0.43 (0.28-0.66) <0.001   
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10 The relationship between pre-operative aspirin and statin 
use and systemic inflammatory responses of patients 
undergoing potentially curative resection of colorectal cancer 
10.1 Introduction 
In addition to identifying patients at increased risk of recurrence following potentially 
curative resection of colorectal cancer, assessment of systemic inflammatory responses 
may also guide the use of adjuvant systemic therapies.  Although an elevated mGPS 
suggested a lack of response to 5-FU-based chemotherapy in Chapters 2 and 3, it may 
however predict increased response to other, novel therapies, and in particular those 
targeting tumour-associated inflammatory responses.  For example, recent clinical trial 
data has identified an elevated mGPS as a biomarker of response to ruxolitinib, a JAK 
inhibitor, in patients with metastatic pancreatic cancer (491). 
Two potential therapeutic agents that may target tumour-associated inflammation in 
patients with colorectal cancer are aspirin and statins.  There has been considerable interest 
regarding the role of aspirin in the chemoprevention of colorectal neoplasia (70, 277, 515-
519), as well as as an adjunctive therapy following a diagnosis of colorectal cancer (279, 
296, 520, 521).  Similarly, regular statin use may have both chemopreventive and 
secondary prevention benefits in patients with colorectal cancer (522-524). 
It is likely that the anti-neoplastic effects of both aspirin and statins reflect the pleiotropic 
nature of these drugs, however, both are recognised as having intrinsic anti-inflammatory 
properties.  Indeed, pro-inflammatory and immune pathways and mediators, such as 
tumour COX-2 expression (521), human leukocyte antigen-1 (HLA-1) (525), and the 
phosphatidylinositol 3-kinase (PI3K) pathway (208, 521, 526), have all been suggested as 
potential therapeutic targets mediating the effects of aspirin in patients with cancer. 
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In a previous cohort study, elevated levels of serum sTNFR-1, but not C-reactive protein 
(CRP), predicted increased effect of long-term aspirin therapy in reducing colorectal 
cancer risk (64), whereas a further cohort study suggested that aspirin may prevent 
longitudinal incremental increases in serum CRP.  However, this did not appear to account 
for its chemotherapeutic benefit in reducing the risk of subsequent colorectal adenomata 
(332).  The relationship between aspirin and statin use and systemic inflammatory 
responses in patients with established colorectal cancer however remains to be determined.  
As such, the aim of the present study was to examine the relationship between routine use 
of aspirin and statins and systemic inflammatory responses in patients undergoing 
potentially curative resection of colorectal cancer. 
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10.2 Patients and Methods 
Patients were identified from a prospectively collected database of colorectal cancer 
resections performed since January 1997 in a single surgical unit in Glasgow Royal 
Infirmary.  For the purposes of the present study, patients who had undergone elective or 
emergency resection of stage I-III colorectal adenocarcinoma with curative intent from 
January 2010 to July 2014, and for whom pre-operative prescribing data was available, 
were included.  Resection was deemed curative on the basis of pre-operative computed 
tomography and intraoperative findings.  Patients who underwent local resection, resection 
with palliative intent or for whom pre-operative prescription data was not available, were 
excluded.  Clinicopathological staging was performed using TNM 5th edition, and MDT 
review, provision of adjuvant chemotherapy and routine follow-up were performed as 
previously described in Chapter 2.  The pre-operative systemic inflammatory response was 
measured using the mGPS and NPS as previously described in Chapters 2 and 5 
respectively. 
Electronic patient case notes were reviewed for pre-operative use of aspirin and statins.  
Primary care referral letters were the primary source of prescribing data.  Pre-operative 
anaesthetic assessment documents and medical clerk-in documents completed on 
admission to hospital were used if referral letters did not include the appropriate 
information.  For the purposes of the present study, patients who were prescribed aspirin or 
statins at the time of surgery were considered as aspirin or statin users.  Patient 
comorbidity using ASA Physical Status grade, smoking status and body mass index (BMI) 
was all obtained from pre-operative anaesthetic assessments.  
Date and cause of death was crosschecked with the cancer registration system and the 
Registrar General (Scotland).  Death records were complete until 30th May 2015 that 
served as the censor date.  Cancer-specific survival was measured from the date of surgery 
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until the date of death from recurrent or metastatic colorectal cancer, and overall survival 
until date of death from any cause. 
Statistical analysis 
The relationship between clinicopathological characteristics and aspirin and statin use was 
examined using the χ2 method for linear trend for categorical variables.  A P-value ≤0.05 
was considered statistically significant.  Binary logistic regression was used to examine the 
relationship between aspirin and statin use, clinicopathological characteristics and the 
presence of a systemic inflammatory response, as characterised by mGPS≥1, by 
calculating ORs and 95% CIs.  Variables with P- value ≤0.1 on univariate analysis were 
entered into a multivariate model using a backwards conditional method.  The relationship 
between aspirin use and survival was examined using Kaplan-Meier log-rank analysis.  
Survival was displayed as percentage surviving to three years (SE).  All analyses were 
performed using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).  The West of Scotland 
Research Ethics Committee approved the study. 
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10.3 Results 
Four hundred and forty-six patients undergoing potentially curative resection of stage I-III 
colorectal cancer were included.  Demographics of the study population are displayed in 
Table 10.1 and Table 10.2.  Approximately two thirds of patients were 65 or older at time 
of resection and 57% were male.  Ten percent of patients underwent emergency resection 
and 14% underwent neoadjuvant chemoradiotherapy prior to surgery.  One third of patients 
underwent resection of rectal cancer.  Pathological staging confirmed stage I disease in 103 
(23%) patients, stage II disease in 173 (39%) patients and stage III disease in 160 (36%) 
patients.  Of the 60 patients who received neoadjuvant therapy, 10 had evidence of 
pathological complete response.  A quarter of patients had an elevated mGPS and 16% had 
an elevated NPS prior to surgery. Twenty-seven percent of patients were prescribed aspirin 
and 42% were prescribed a statin at the time of diagnosis.  All patients were prescribed 
once daily low-dose aspirin (75mg) and a number of different statin types and doses were 
prescribed. 
The relationship between aspirin and statin use and clinicopathological 
characteristics 
Aspirin and statin use was strongly associated, with 100 patients receiving both 
medications (P<0.001, Table 10.3).  The relationship between aspirin and statin use and 
clinical characteristics is displayed in Table 10.1.  Aspirin use was associated with older 
age at diagnosis (P=0.001), male sex (P<0.05), higher ASA grade (P<0.001), higher BMI 
(P<0.05) and showed a trend towards higher prevalence of ever smoking (P=0.052).  
Furthermore, aspirin use was significantly inversely associated with the presence of a 
systemic inflammatory response as measured by mGPS (mGPS=0 84% vs. 71%, P=0.007) 
but not the NPS (P=0.746).  Statin use was associated with older age, higher ASA grade 
(both P<0.001) and elevated BMI (P<0.01) and showed a relationship to less frequent use 
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of neoadjuvant therapy (P<0.01).  No relationship between statin use and either mGPS or 
NPS was observed.   
The relationship between aspirin and statin use and pathological characteristics is 
displayed in Table 10.2.  Aspirin use was not associated with pathological characteristics 
of the tumour.  Statin use was inversely associated with the presence of margin 
involvement (P<0.05) but showed no other association with pathological characteristics. 
When analysis was restricted to patients undergoing elective resection without neoadjuvant 
therapy, aspirin use remained associated with the presence of a systemic inflammatory 
response as measured by mGPS (P=0.019) but not the NPS.  Statin use was not associated 
with either the mGPS or NPS.  
The relationship between aspirin and statin use and the pre-operative systemic 
inflammatory response in patients undergoing potentially curative resection of 
colorectal cancer 
The relationship between aspirin and statin use, host and tumour characteristics and the 
presence of a pre-operative systemic inflammatory response was subsequently examined 
using binary logistic regression (Table 10.4).  For the purposes of analysis, the presence of 
a systemic inflammatory response was defined as mGPS≥1.  On univariate analysis, 
emergency presentation (OR 8.36, P<0.001), advancing T stage (OR 3.13, P<0.001), 
advancing N stage (OR 1.32, P=0.066), poor differentiation (OR 3.09, P=0.001), margin 
involvement (OR 4.31, P=0.001), peritoneal involvement (OR 4.37, P<0.001) and tumour 
perforation (OR 9.35, P=0.007) were associated with the presence of an elevated mGPS, 
whereas elevated BMI (OR 0.68, P<0.01), neoadjuvant therapy (OR 0.48, P=0.054), rectal 
primary (OR 0.37, P<0.001) and aspirin use (OR 0.47, P=0.007) were inversely associated 
with the mGPS.  Statin use was not associated with the mGPS on univariate analysis.  On 
multivariate analysis, aspirin use was associated with a lower mGPS (OR 0.38, P=0.005), 
independent of emergency presentation (OR 4.00, P=0.001), rectal primary (OR 0.58, 
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P=0.091), T stage (OR 1.9, P<0.001), differentiation (OR 2.06, P=0.069) and margin 
involvement (OR 3.28, P=0.033). 	
When analysis was restricted to patients undergoing elective resection without neoadjuvant 
therapy (Table 10.5), advancing age (P=0.066), BMI, T stage, differentiation, margin 
involvement, peritoneal involvement (all P<0.01) and aspirin use (P<0.05) were associated 
with mGPS on univariate analysis.  On multivariate binary logistic regression, BMI (OR 
0.66, P<0.05), T stage (OR 2.45, P<0.001) and aspirin use (OR 0.41, P<0.05) were 
independently associated with the presence of a systemic inflammatory response as 
measured by mGPS. 
The relationship between aspirin use and survival of patients undergoing 
potentially curative resection of colorectal cancer 
The relationship between pre-operative aspirin use, systemic inflammatory responses and 
three-year cancer-specific and overall survival following elective resection of colorectal 
cancer without prior neoadjuvant therapy was subsequently examined.  Three patients who 
were lost to follow-up and three patients who died within 30 days of surgery were 
excluded from survival analysis.  The median follow-up of survivors was 33 months 
(interquartile range 21-44 months) with 30 cancer-associated deaths and 14 non-cancer 
deaths.  Aspirin use was associated with poorer three-year cancer-specific survival (93% 
(2) vs. 85% (4), P=0.043) and was associated with poorer three-year overall survival (92% 
(2) vs. 75% (5), P=0.001).  When stratified by pre-operative mGPS (Figure 10.1), in 
patients with mGPS=0, aspirin use was associated with reduced cancer-specific survival 
(95% (2) vs. 87% (5), P=0.032) and overall survival (94% (2) vs. 75% (6), P<0.001).  In 
patients with mGPS≥1, aspirin use showed a non-significant trend towards reduced cancer-
specific (88% (4) vs. 71% (14), P=0.333) and overall survival (83% (5) vs. 71% (14), 
P=0.540). 
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To control for the interrelationship between aspirin use and patient comorbidity, 
subsequent analysis was performed on patients with ASA grade I/II.  Aspirin use was not 
associated with cancer-specific survival (95% (2) vs. 91% (6), P=0.481), but was 
associated with reduced overall survival (94% (2) vs. 83% (7), P=0.05).  When stratified 
by the systemic inflammatory response, in patients with mGPS=0, aspirin use was not 
associated with cancer-specific survival (96% (2) vs. 90% (7), P=0.160) but was associated 
with reduced overall survival (96% (2) vs. 80% (8), P=0.004).  The number of patients 
with mGPS≥1 who were prescribed aspirin (n=5) precluded meaningful statistical analysis, 
however there were no cancer-associated or non-cancer deaths in this group within three 
years of surgery, compared to three cancer-associated deaths in patients with mGPS≥1who 
were not prescribed aspirin (n=36).
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10.4 Discussion 
Although not associated with the pathological characteristics of the tumour, patients 
prescribed regular low-dose aspirin prior to potentially curative resection of stage I-III 
colorectal cancer were less likely to have elevated systemic inflammatory responses than 
those not prescribed aspirin.  The results of the present study suggest that the protective 
effects of aspirin in patients with colorectal cancer may, at least in part, be mediated by 
attenuation of aberrant, tumour-associated host inflammatory responses. 
In the present study, all patients prescribed aspirin received low-dose treatment (75mg) 
which, similar to statins, is primarily utilised for primary and secondary prevention of 
cardiovascular disease.  Reflective of this, patients prescribed aspirin and statins were more 
likely to have a higher ASA grade at time of surgery and were more likely to be older.  
Given that both a high burden of comorbidity and advanced age have previously been 
associated with the presence of an elevated mGPS in patients with colorectal cancer (392), 
the present results, whereby aspirin use was associated with a low mGPS even after 
controlling for these factors, are intriguing.  Indeed, given that patients prescribed these 
drugs would be expected to be systemically inflamed due to underlying co-morbidities, the 
absolute reduction of 13% in the proportion of patients with an elevated mGPS may under-
estimate the true anti-inflammatory effect of aspirin in patients with colorectal cancer. 
Of interest however, the ASA grade was not associated with the pre-operative systemic 
inflammatory response in the present analysis as might be expected.  This may reflect the 
subjective nature of assessment of the ASA grade (527).  Indeed, although the ASA grade 
may be a reliable indicator of in-hospital risk (528, 529), it does not fully evaluate patient 
co-morbid status (530).  As such, further studies considering the burden of co-morbid 
disease should utilise more rigorous, objective measures, such as the Lee Cardiac Risk 
Index (392). 
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Increased adiposity and an elevated BMI have previously been identified as risk factors for 
elevated systemic inflammatory responses as evidenced by serum CRP (417, 531).  In the 
present analysis however, elevated BMI was not associated with the systemic 
inflammatory response, with patients with a low BMI more likely to have an elevated CRP 
and mGPS; 62% of patients in the low BMI group had a mGPS≥1 compared to only 18% 
of patients in the high BMI group.  This may reflect the underlying nature of the systemic 
inflammatory response in patients with cancer.  It is now accepted that elevated systemic 
inflammatory responses are an integral component of the cancer cachexia syndrome (399), 
and may not only drive but be driven by weight loss and myopenia (482).  Furthermore, the 
present study may be underpowered to find any significant relationship between an 
elevated BMI and a clinically significant elevation of serum CRP>10mg/L; indeed, Visser 
and colleagues, utilising data from the Third National Health and Nutrition Examination 
Survey, required a cohort of over 16 000 patients to identify an approximately two-fold 
increase in the prevalence of a CRP>10mg/L in obese compared to non-obese individuals 
(417). 
In the present analysis, aspirin use was not associated with pathological characteristics of 
the tumour, such as TNM stage and the presence of venous invasion.  This is contradictory 
to previous studies utilising cancer registry data and community prescription registration 
data, where the use of aspirin in the year prior to diagnosis was associated with smaller 
primary tumour size and reduced likelihood of metastatic disease in patients with 
colorectal and lung cancer (532, 533).  However, these previous studies included patients 
with metastatic disease whereas the present analysis included only patients with stage I-III 
colorectal cancer.  Furthermore, the methods of statistical analysis employed differ; the 
present study examined for an overall trend between aspirin use and T stage, N stage and 
TNM stage, whereas Jonsson et al and Pawitan et al utilised multinomial logistic 
regression to calculate the risk of a higher tumour stage compared to the lowest possible 
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stage.  Utilising this method in the present cohort, the odds ratio of a T4 versus a T1 
tumour comparing aspirin users to non-users is 0.51 (95% CI 0.24–1.11, P=0.088), similar 
in magnitude to the studies by Jonsson and Pawitan (OR 0.66 and OR 0.70 respectively). 
The mechanisms responsible for the anti-neoplastic effects of aspirin in patients with 
cancer and colorectal cancer in particular remain to be fully defined, however the results of 
the present analysis further support the hypothesis that these may be in part mediated by 
the host inflammatory response.  Aspirin may affect tumour biology and subsequent host 
inflammatory responses through inhibition of the pro-inflammatory COX-2 enzyme; 
alongside reducing the incidence of COX-2 expressing tumours (315), previous studies 
have suggested a survival benefit for aspirin commenced following a diagnosis of 
colorectal cancer only in patients with COX-2 expressing tumours (296). 
Despite evidence supporting a role for COX-2 inhibition, aspirin used at the low doses 
documented in the present study and many of the previous studies confirming a survival 
benefit does not irreversibly inhibit tissue COX-2 activity due to its short half-life, and as 
such other putative mechanisms have been suggested (534).  One potential candidate 
downstream of COX-2 activity is inactivation of the P13K pathway, which is constitutively 
activated in patients with mutated PIK3CA.  Analysis of data from the Nurses’ Health 
Study and Health Professionals Follow-up Study (208), and post-hoc molecular analysis of 
data from the VICTOR randomised controlled trial (526) both support the presence of 
PIK3CA mutation as a predictive biomarker for adjuvant aspirin therapy.  Furthermore, 
both pre-clinical data (535, 536) and analysis of STAT3-associated SNPs in patients with 
breast cancer (537) have suggested a potential role of the JAK/STAT3 pathway in 
mediating the anti-tumour effects of aspirin.  
In addition to a direct effect on the tumour cell, irreversible inhibition of platelet function 
may also mediate the anti-tumour effects of low dose aspirin.  Platelet function is enhanced 
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in patients with colorectal cancer (319); furthermore, platelets aggregate with circulating 
tumour cells to facilitate dissemination of micrometastases (538), and may mediate the 
process of EMT through activation of the NF-ĸB pathway (525).  Indeed, Reimers and 
colleagues hypothesised that such activity may explain the relationship between aspirin 
and increased survival in patients with tumours which express HLA-1, a necessary 
prerequisite for tumour cell-platelet signalling (525).  Similarly, platelet activation may 
also activate STAT3 through IL-6 transignalling, which again is attenuated by inhibition of 
platelet function (539, 540).  Indeed, given that the above putative mechanisms primarily 
rely on inactivation of signal transduction pathway, the presently observed associations 
with acute phase proteins but not cellular components of the systemic inflammatory 
response, such as platelet count, is not surprising.  
The present analysis found no consistent relationship between statin use and either tumour 
pathological characteristics or components of the systemic inflammatory response.  The 
evidence supporting the chemotherapeutic effects of statins is more conflicting.  Whereas a 
previous non-randomised controlled study found that pre-operative simvastatin use 
decreased serum IL-6 concentrations in patients with colorectal cancer (358), a further 
cohort study of patients undergoing chemoradiotherapy for oesophageal and rectal cancer 
found no such relationship (359).  The results of such cohort-based studies, however, may 
be confounded by other variables which have not been controlled for, such as prescribing 
of other medications with potential chemotherapeutic benefit (518, 541).  In the present 
analysis, for example, statin and aspirin use were strongly associated.  Furthermore, the 
type of statin used may also influence chemotherapeutic benefit; whereas in the present 
study all statin types were considered, previous studies have suggested that only lipophilic 
statins, which may easily cross the cell membrane, are associated with increased survival 
in patients with colorectal cancer (524, 542). 
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Despite being associated with a lower mGPS, aspirin use was not associated with improved 
survival and in fact appeared to be associated with poorer cancer-specific and overall 
survival at three years.  These results must be interpreted with caution due to the lack of 
long-term follow-up, the limited number of observed events, and the small number of 
patients with an elevated mGPS and pre-diagnosis aspirin use, however this may reflect the 
underlying indication for receiving aspirin; most if not all patients will have received 
aspirin for secondary prevention of cardiovascular disease rather than for its 
chemotherapeutic effects.  As such any effect on survival will be confounded by the 
presence of co-morbidities. 
Although aspirin use is associated with reduced incidence of colorectal cancer, an 
increasing body of evidence suggests that it is potentially aspirin use commenced after, and 
not prior to diagnosis, which is associated with improved survival of patients with 
colorectal cancer (521).  Indeed, although the results of the present analysis suggest that 
pre-diagnosis aspirin use may attenuate or prevent elevated host systemic inflammatory 
responses, it is not known whether this translates into a long-term improvement in survival.  
Furthermore, whether the presence of an elevated systemic inflammatory response may be 
a reliable biomarker of response to adjuvant aspirin therapy remains to be seen, and may be 
answered by subgroup analysis of the presently recruiting ASCOLT and Add-Aspirin 
Trials (303, 543). 
The present study is limited by the methodology employed to identify aspirin and statin 
users.  Both duration of use and compliance with prescribed medications were not taken 
into consideration and may confound results.  However, the abolishment of prescription 
charges in Scotland in 2011 means that prescription cost is unlikely to be a barrier to long-
term medication.  Furthermore, such factors would likely result in an under-estimation of 
the effects of aspirin and statins on host inflammatory responses.  An additional limitation 
of the present study is that over the counter use of aspirin and other NSAIDs was not taken 
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into consideration.  However, previous data has shown that over 90% of aspirin use is from 
prescribed use (544), and reporting of prescribed NSAID use in the present cohort was low 
(<8%), suggesting that this is unlikely to be a confounding factor. 
In conclusion, the present results suggest that the anti-neoplastic effects of aspirin may be 
mediated in part through attenuation of host inflammatory responses.  These results 
provide a rationale for future clinical trials examining the effects of aspirin therapy in 
patients with colorectal cancer and elevated systemic inflammatory responses. 
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Figure 10.1 The relationship between aspirin use, modified Glasgow Prognostic Score and 
survival of patients undergoing elective, potentially curative resection of stage I-III 
colorectal cancer without neoadjuvant therapy. (A) mGPS=0 and cancer-specific survival 
(P=0.032), (B) mGPS=0 and overall survival (P<0.001), (C) mGPS≥1 and cancer-specific 
survival (P=0.333), and (D) mGPS≥1 and overall survival (P=0.540). All P-values 
calculated using log-rank analysis 
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Table 10.1 The relationship between aspirin and statin use and clinical characteristics of patients undergoing potentially curative resection of stage I-III 
colorectal cancer 
  All  Aspirin use   Statin use  
Clinical characteristics 
(n when data missing) 
 (n=446) (%)  No aspirin (n=326) (%) Aspirin (n=120) (%) P  No statin (n=259) (%) Statin (n=187) (%) P 
Age  
<65 
65-74 
>74 
  
158 (35) 
170 (38) 
118 (27) 
  
135 (41)  
110 (34)  
81 (25) 
 
23 (19)  
60 (50) 
37 (31) 
0.001   
114 (44) 
92 (35) 
53 (21) 
 
44 (24) 
78 (41) 
65 (35) 
<0.001 
Sex  
Female 
Male 
  
191 (43) 
255 (57) 
  
151 (46) 
175 (54) 
 
40 (33) 
80 (67) 
0.014   
119 (46) 
140 (54) 
 
72 (39) 
115 (61) 
0.117 
ASA grade 
(436) 
 
I-II 
III-IV 
  
280 (64) 
156 (36) 
  
234 (73) 
86 (27) 
 
46 (40)  
70 (60) 
<0.001   
195 (77) 
59 (23) 
 
85 (47) 
97 (53) 
<0.001 
BMI 
(415) 
 
<18.5 
18.5-24.9 
25-29.9 
>30 
  
13 (3) 
131 (32) 
128 (31) 
143 (34) 
  
12 (4) 
102 (33) 
91 (30) 
100 (33) 
 
1 (1) 
29 (26) 
37 (34) 
43 (39) 
0.049   
9 (4) 
88 (37) 
69 (29) 
72 (30) 
 
4 (2) 
43 (24) 
59 (33) 
71 (40) 
0.004 
Smoking status 
(436)  
 
Never 
Ex 
Current 
  
208 (48) 
167 (38) 
61 (14) 
  
164 (51) 
110 (35) 
44 (14) 
 
44 (37) 
57 (48) 
17 (14) 
0.052   
132 (52) 
85 (33) 
38 (15) 
 
76 (42) 
82 (45) 
23 (13) 
0.272 
Presentation 
 
 
 
Elective 
Emergency 
  
402 (90) 
44 (10) 
  
292 (90) 
34 (10) 
 
110 (92) 
10 (8) 
0.511   
233 (90) 
26 (10) 
 
169 (90) 
18 (10) 
0.885 
Neoadjuvant therapy   
No 
Yes 
  
386 (86) 
60 (14) 
  
284 (87) 
42 (13) 
 
102 (85) 
18 (15) 
0.562   
214 (83) 
45 (17) 
 
172 (92) 
15 (8) 
0.004 
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Table 10.1 (continued) The relationship between aspirin and statin use and clinical characteristics of patients undergoing potentially curative resection of 
stage I-III colorectal cancer 
Data analysed using χ2 analysis for linear trend. 
 
 
  All  Aspirin use   Statin use  
Clinical characteristics 
(n when data missing) 
 (n=446) (%)  No aspirin (n=326) (%) Aspirin (n=120) (%) P  No statin (n=259) (%) Statin (n=187) (%) P 
mGPS 
(435) 
 
0 
1 
2 
  
326 (75) 
40 (9) 
69  (16) 
  
226 (71) 
32 (10) 
58 (18) 
 
100 (84) 
8 (7) 
11 (9) 
0.007   
184 (73) 
25 (10) 
42 (17) 
 
142 (77) 
15 (8) 
27 (15) 
0.415 
NPS 
(438) 
 
0 
1 
2 
  
366 (84) 
57 (13) 
15 (3) 
  
265 (83) 
45 (14) 
10 (3) 
 
101 (86) 
12 (10) 
5 (4) 
0.746   
213 (84) 
34 (13) 
7 (3) 
 
153 (83) 
23 (13) 
8 (4) 
0.619 
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Table 10.2 The relationship between aspirin and statin use and tumour characteristics of patients undergoing potentially curative resection of stage I-III 
colorectal cancer 
 
 
  All  Aspirin use   Statin use  
Tumour characteristics 
(n when data missing) 
 (n=446) (%)  No aspirin (n=326) (%) Aspirin (n=120) (%) P  No statin (n=259) (%) Statin (n=187) (%) P 
Tumour site  
Colon 
Rectum 
  
301 (67) 
145 (33) 
  
224 (69) 
102 (31) 
 
77 (64) 
43 (36) 
0.364   
167 (64) 
92 (36) 
 
134 (72) 
43 (28) 
0.111 
Stage  
PCR 
I 
II 
III 
  
10 (2) 
103 (23) 
173 (39) 
160 (36) 
  
8 (3) 
74 (23) 
126 (39) 
118 (36) 
 
2 (2) 
29 (24) 
47 (39) 
42 (35) 
0.901   
8 (3) 
57 (22) 
101 (39) 
93 (36) 
 
2 (1) 
46 (25) 
72 (38) 
67 (36) 
0.862 
T stage   
0 
1 
2 
3 
4 
  
10 (2) 
60 (13) 
61 (14) 
223 (50) 
92 (21) 
  
8 (3) 
41 (13) 
48 (15) 
155 (47) 
74 (23) 
 
2 (2) 
19 (16) 
13 (11) 
68 (56) 
18 (15) 
0.459   
8 (3) 
32 (12) 
39 (15) 
123 (48) 
57 (22) 
 
2 (1) 
28 (15) 
22 (12) 
100 (53) 
35 (18) 
0.932 
N stage  
0 
1 
2 
  
286 (64) 
107 (24) 
53 (12) 
  
208 (64) 
81 (25) 
37 (11) 
 
78 (65) 
26 (22) 
16 (13) 
0.916   
166 (64) 
61 (24) 
32 (12) 
 
120 (64) 
46 (25) 
21 (11) 
0.858 
Less than 12 nodes 
examined  
 
 
No 
Yes 
  
362 (81) 
84 (19) 
  
262 (80) 
64 (20) 
 
100 (83) 
20 (17) 
0.478   
204 (79) 
55 (21) 
 
158 (84) 
29 (16) 
0.127 
Differentiation 
(432) 
 
Mod-well 
Poor 
  
390 (90) 
42 (10) 
  
283 (90) 
32 (10) 
 
107 (91) 
10 (9) 
0.616   
224 (90) 
25 (10) 
 
166 (91) 
17 (9) 
0.795 
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Table 10.2 (continued) The relationship between aspirin and statin use and pathological characteristics of patients undergoing potentially curative 
resection of stage I-III colorectal cancer 
 
Data analysed using χ2 analysis for linear trend. 
 
 
 
  All  Aspirin use   Statin use  
Tumour characteristics 
(n when data missing) 
 (n=446) (%)  No aspirin (n=326) (%) Aspirin (n=120) (%) P  No statin (n=259) (%) Statin (n=187) (%) P 
Venous invasion  
Absent 
Present 
  
177 (40) 
269 (60) 
  
123 (308) 
203 (62) 
 
54 (45) 
66 (55) 
0.164   
95 (37) 
164 (63) 
 
82 (44) 
105 (56) 
0.127 
Margin involvement   
Absent 
Present 
  
425 (95) 
21 (5) 
  
310 (95) 
16 (5) 
 
115 (96) 
5 (4) 
0.743   
242 (93) 
17 (7) 
 
183 (98) 
4 (2) 
0.030 
Peritoneal 
involvement 
 
Absent 
Present 
  
365 (92) 
81 (18) 
  
261 (80) 
65 (20) 
 
104 (87) 
16 (13) 
0.109   
211 (81) 
48 (19) 
 
154 (82) 
33 (18) 
0.811 
Tumour perforation   
Absent 
Present 
  
438 (98) 
8 (2) 
  
321 (98) 
5 (2) 
 
117 (97) 
3 (3) 
0.496   
255 (98) 
4 (2) 
 
183 (98) 
4 (2) 
0.641 
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Table 10.3 The relationship between aspirin and statin use in patients undergoing 
potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
  Aspirin 
n (%) 
 Statin 
n (%)  
All patients  120  187 
Aspirin 
No 
Yes 
  
- 
- 
  
87 (47) 
100 (53) 
Statin 
No 
Yes 
  
20 (17) 
100 (83) 
  
- 
- 
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Table 10.4 Determinants of the pre-operative modified Glasgow Prognostic Score of patients undergoing potentially curative resection of stage I-III 
colorectal cancer 
Data analysed using binary logistic regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
  mGPS=0 mGPS≥1  Univariate OR (95% 
CI) 
P  Multivariate OR (95% 
CI) 
P 
Age (<65/ 65-74/ >74)  114 / 132 / 80 39 / 33/ 38  1.17 (0.89-1.54) 0.272  - - 
Sex (female/ male)  141 / 185 47 / 63  1.02 (0.66-1.58) 0.924  - - 
ASA grade (I-II/ III-IV)  207 / 68 117 / 38  0.99 (0.63-1.56) 0.961  - - 
BMI (<18.5/18.5-24.9/25-29.9/>30)  5 / 94 / 99 / 113 8 / 35 / 26 / 25  0.68 (0.52-0.88) 0.004  - 0.190 
Smoking status (never/ ever)  157 / 164 45 / 60  1.28 (0.82-1.99) 0.281  - - 
Presentation (elective/ emergency)  312 / 14 80  / 30  8.36 (4.23-16.50) <0.001  4.00 (1.74-9.20) 0.001 
Neoadjuvant therapy (no/ yes)  275 / 51 101 / 9  0.48 (0.23-1.01) 0.054  - 0.821 
Tumour site (colon/ rectum)  203 / 123 90 / 20  0.37 (0.22-0.63) <0.001  0.58 (0.31-1.09) 0.091 
T stage (0/ 1/ 2/ 3/ 4)  10 / 51 / 57 / 166 / 
42 
0 / 5 / 2 / 54 / 
49 
 3.13 (2.23-4.40) <0.001  1.93 (1.36-2.75) <0.001 
N stage (0/ 1/ 2)   212 / 82 / 32 66 / 23 / 21  1.32 (0.98-1.77) 0.066  - 0.131 
Less than 12 nodes (no/ yes)  263 / 63 92 / 18  0.82 (0.46-1.45) 0.490  - - 
Differentiation (mod-well/ poor)  292 / 21 90 / 20  3.09 (1.60-5.96) 0.001  2.06 (0.95-4.50) 0.069 
Venous invasion (absent/ present)  135 / 191 38 / 72  1.34 (0.85-2.10) 0.204  - - 
Margin involvement (absent/ 
present)  
 317 / 9 98 / 12  4.31 (1.77-10.54) 0.001  3.28 (1.10-9.76) 0.033 
Peritoneal involvement (absent/ 
present) 
 287 / 39 69 / 41  4.37 (2.62-7.29) <0.001  - 0.130 
Tumour perforation (absent/ 
present) 
 324 / 2 104 / 6  9.35 (1.86-47.01) 0.007  - 0.238 
Aspirin (no/ yes)  226 / 100 91 / 19  0.47 (0.27-0.82) 0.007  0.38 (0.20-0.75) 0.005 
Statin (no/ yes)  184 / 142 68 / 42  0.80 (0.51-1.25) 0.324  - - 
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Table 10.5 Determinants of the pre-operative modified Glasgow Prognostic Score of patients undergoing elective, potentially curative resection of stage 
I-III colorectal cancer without neoadjuvant therapy 
  Univariate OR (95% CI) P  Multivariate OR (95% CI) P 
Age (<65/ 65-74/ >74)  1.38 (0.99-1.94) 0.066  - 0.436 
Sex (female/ male)  1.19 (0.70-2.03) 0.522  - - 
ASA grade (I-II/ III-IV)  1.20 (0.86-1.67) 0.295  - - 
BMI (<18.5/ 18.5-24.9/ 25-29.9/ >30)  0.60 (0.44-0.82) 0.002  0.66 (0.47-0.92) 0.013 
Smoking status (never/ ever)  1.56 (0.91-2.66) 0.103  - - 
Tumour site (colon/ rectum)  0.60 (0.31-1.16) 0.129  - - 
T stage (1/ 2/ 3/ 4)  2.87 (1.93-4.28) <0.001  2.45 (1.62-3.71) <0.001 
N stage (0/ 1/ 2)  1.11 (0.76-1.63) 0.590  - - 
Less than 12 nodes (no/ yes)  0.74 (0.36-1.50) 0.400  - - 
Differentiation (mod-well/ poor)  3.57 (1.61-7.92) 0.002  - 0.109 
Venous invasion (absent/ present)  0.98 (0.57-1.66) 0.925  - - 
Margin involvement (absent/ present)   7.94 (1.93-32.59) 0.004  - 0.188 
Peritoneal involvement (absent/ present)  3.21 (1.72-6.00) <0.001  - 0.230 
Tumour perforation (absent/ present)  - 0.999  - - 
Aspirin (no/ yes)  0.42 (0.21-0.83) 0.013  0.41 (0.19-0.89) 0.025 
Statin (no/ yes)  0.68 (0.40-1.16) 0.156  - - 
Data analysed using binary logistic regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
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11 Pre-operative, colonoscopic-based assessment of the tumour 
microenvironment in patients with colorectal cancer 
11.1 Introduction 
In addition to guiding the prognosis of patients with colorectal cancer, assessment of the 
tumour microenvironment may also be of value in predicting response to treatment.  The 
presence of a high density lymphocytic infiltrate, for example, has been shown to predict 
increased response to neoadjuvant chemoradiotherapy (512, 545-547).  Similarly, 
treatment effect of anti-angiogenic and other biological agents may also be influenced by 
the composition of the tumour microenvironment (490, 548).   
Furthermore, the tumour microenvironment itself is an attractive therapeutic target, with 
increasing evidence suggesting that radiotherapy, anti-angiogenic therapies and other novel 
agents may influence its composition and architecture (490, 549, 550).  Furthermore, anti-
inflammatory agents, such as NSAIDs (326) and H2RAs (366) have been shown to 
promote infiltration of the tumour microenvironment by activated lymphocytes. 
It is clear that pre-operative assessment of the tumour microenvironment could inform 
decision-making regarding neoadjuvant therapy prior to surgical resection.  For example, 
identifying patients with an unfavourable tumour microenvironment (i.e. low density 
inflammatory cell infiltrate and expanded tumour-associated stroma) could potentially 
avoid the administration of standard chemoradiotherapy regimes where it is unlikely to be 
of benefit, and instead allow for administration of therapies targeting the tumour 
microenvironment itself. 
One of the inherent difficulties with characterisation of the tumour microenvironment is 
the reliance on tumour specimens obtained following surgical resection, therefore limiting 
clinical utility in the neoadjuvant setting.  Accordingly, several groups have attempted to 
characterise the tumour microenvironment of patients with colorectal cancer utilising pre-
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operative colonoscopic biopsies, primarily with the aim of predicting response to 
neoadjuvant chemoradiotherapy (512, 545-547).  However, interpretation and subsequent 
reporting of biopsy specimens depends on a number of factors, including quality and 
quantity of tissue obtained, tissue fixation and availability of surplus blocks and slides for 
additional testing (551, 552).  Furthermore, given that radiotherapy induces significant 
histologic reactions and architectural restructuring, it is not clear from these observational 
studies how closely biopsy-based assessment truly reflects the tumour microenvironment.  
Two studies included patients proceeding directly to surgery for rectal cancer; whereas one 
study (n=31) found that biopsy assessment of the inflammatory cell infiltrate correlated 
with full section analysis (546), another study (n=54) found that the density of CD8+ T-
lymphocytes in full sections was significantly higher than that in preoperative biopsies, 
suggesting that intratumoural heterogeneity may preclude biopsy-based assessment (547).  
Additionally, although biopsy-based assessment of the tumour-associated stroma in 
patients with oesophageal cancer has previously been shown to be feasible (553), no study 
to date has assessed the use of colonoscopic biopsies as a means of pre-operatively 
assessing TSP in patients with colorectal cancer.   
Given the above, the aim of the present study was to examine the feasibility and prognostic 
utility of pre-operative colonoscopic biopsy-based assessment of the inflammatory cell 
infiltrate and tumour-associated stroma in patients undergoing potentially curative 
resection of colorectal cancer without neoadjuvant therapy. 
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11.2 Patients and Methods 
Clinicopathological characteristics 
Patients were identified from a prospectively collected database of elective and emergency 
colorectal cancer resections performed since January 1997 in a single surgical unit in 
Glasgow Royal Infirmary.  Patients who had undergone assessment of the tumour 
microenvironment as described in Chapter 4, and for whom corresponding pre-operative 
colonoscopic biopsies were available, were included.  Only patients with documented 
invasive adenocarcinoma present on pre-operative biopsies were included, whereas those 
with dysplastic changes only were excluded.  Indications for adjuvant chemotherapy, MDT 
review and routine follow-up of patients following surgery has previously been described 
in Chapter 2.  Date and cause of death was crosschecked with the cancer registration 
system and the Registrar General (Scotland).  Death records were complete until 15th 
March 2013 that served as the censor date.  Cancer-specific survival was measured from 
the date of surgery until the date of death from colorectal cancer. 
 Biopsy specimens 
Archived, paraffin-embedded, colonoscopic biopsy specimens and corresponding H&E-
stained sections matched to the primary tumour were retrieved for each patient.  Due to the 
limited quantity of tissue available, only CD3+ T-lymphocytes were assessed in biopsy 
specimens.  Sections (2.5µm  thick) were cut and mounted on silanised slides before 
being dewaxed in xylene and rehydrated through graded alcohols.  An autostainer 
(ThermoFisher Autostainer 480s) was used to perform staining.  Antigen retrieval was 
carried out in a PT module (ThermoFisher) using ThermoFisher retrieve solution pH9.  
Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 5 minutes 
before rinsing with TBS. Primary antibody (CD3+; ThermoFisher RM-9107-S) was applied 
(1:300 dilution) and incubated for 20 minutes at room temperature before rinsing again 
with TBS.  The signal was amplified and visualised using the ThermoFisher Quanto kit 
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and diaminobenzidine colour developer before counterstaining with haematoxylin for three 
minutes.  Sections were then washed in running tap water for one minute and dipped in 
acid-alcohol for five seconds before washing again.  Finally, sections were dipped in 
Scott’s tap water for one minute before rinsing again and dehydrating using graded 
alcohols and xylene.  Cover slips were applied with DPX. 
Both H&E and CD3+-stained colonoscopic biopsies and surgically resected specimens 
were converted to digital format using a Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, Milton Keynes, UK) at x20 optical magnification.  Subsequent visualisation 
and automated image analysis was performed using Slidepath Digital Image Hub, version 
4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK). 
Manual assessment of the tumour microenvironment 
Full section assessment 
Full H&E-stained sections of the deepest point of invasion obtained following surgical 
resection were used to examine the local inflammatory cell infiltrate and tumour-associated 
stroma. The TSP was assessed as described in Chapter 4 and categorised as low (≤50%) or 
high (>50%).  Sections stained for CD3+ mature T-lymphocytes were used for assessment 
of the inflammatory infiltrate as described in Chapter 4, and categorised as high and low.  
 Biopsy assessment 
The density of CD3+ T-lymphocytes in colonoscopic biopsies was examined using manual, 
semi-quantitative assessment.  At x10 magnification, the intratumoural density of CD3+ T-
lymphocytes throughout the biopsy specimen was graded as low (absent or weak) or high 
(moderate or strong).  T-lymphocytes present within dysplastic and normal mucosa were 
not considered to be intratumoural lymphocytes and therefore excluded from analysis.  An 
example of colonoscopic biopsy staining is shown in Figure 11.1. 
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Assessment of the tumour-associated stroma using H&E-stained colonoscopic biopsies 
was performed using TSP.  At x10 magnification, the proportion of intratumoural stroma 
was graded as low (≤50%) or high (>50%).  Where possible, assessment was performed in 
areas of the biopsy specimen where tumour cells were present circumferentially around the 
tumour-associated stroma, with mucinous deposits, necrosis and dysplastic or normal 
mucosa all excluded from the area of analysis.  Similar to the technique previously 
described by Mesker and colleagues for assessment of oesophageal biopsies, stromal 
fragments without any cancer cells were excluded from analysis (553). 
All assessments were performed by an investigator blinded to clinicopathological and 
outcome data.  To ensure consistency of scoring, a proportion of biopsies were double-
scored for biopsy T-lymphocyte density (n=28) and TSP (n=30) by a blinded co-
investigator (CSDR).  The intra-class correlation co-efficient (ICC) was calculated, to 
assess inter-observer variability, with an ICC 0.40-0.75 considered ‘fair to good’ (554).  
Automated assessment of the tumour inflammatory cell infiltrate 
Automated assessment of intratumoural CD3+ T-lymphocyte density using both full 
sections and colonoscopic biopsies was performed using the Tissue Image Analysis, 
version 2.0 plugin for Slidepath (Slidepath, Leica Biosystems, Milton Keynes, UK).  To 
ensure only intratumoural T-lymphocytes were analysed in surgically resected specimens, 
sections were annotated; at x10 magnification, three 1mm2 rectangles were drawn using 
the ‘Draw rectangle’ tool to include regions felt to be most representative of the tumour 
microenvironment.  Using these annotated regions, ‘Tissue IA Optimiser’ was selected and 
‘Measure stained cells algorithm’ was chosen.  The algorithm provides a range of values 
to describe the number of positive cells in the region of interest.  For the purposes of the 
present study, the “cellular H-score of nuclear staining” (H-score) was recorded for each 
annotated area and the average H-score calculated for each specimen.  A similar method 
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was used to calculate T-lymphocyte density of colonoscopic biopsies. Due to the area of 
biopsy material available for analysis for each specimen however, only one 1mm2 
rectangle was drawn per section.  An example of automated assessment of colonoscopic 
biopsy T-lymphocyte density is shown in Figure 11.1. 
Statistical analysis 
Receiver operating characteristic (ROC) curves and the area under the curve (AUC) was 
used to identify the optimal cut-off point for the H-score as a predictor of high T-
lymphocyte density within the tumour microenvironment of surgically resected specimens.  
The relationship between categorical variables was examined using the χ2 method for 
linear trend and continuous variables using Mann-Whitney U test.  Cancer-specific 
survival was displayed as percentage surviving at five years (SE).  The relationship 
between clinicopathological characteristics and cancer-specific survival was examined 
using Kaplan-Meier log-rank analysis and multivariate Cox proportional hazards 
regression to calculate HRs and 95% CIs.  Variables with a P-value ≤0.1 on univariate 
regression analysis were entered into a multivariate model using a backward conditional 
method.  All statistical analyses were performed using SPSS version 22.0 for Mac (IBM 
SPSS, IL, USA).  A P-value ≤0.05 was considered statistically significant. 
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11.3 Results 
One hundred and twenty patients were included in the analysis.  Clinicopathological 
characteristics are displayed in Table 11.1.  Almost two thirds of patients were 65 years of 
age or older at time of surgery and 53% were male.  Eighty-two (68%) patients had a colon 
cancer.  Six patients (5%) had stage I disease, whereas 55 (46%) and 59 (49%) had stage II 
and stage III disease respectively.  Thirty-seven (31%) patients received adjuvant therapy.  
Using manual assessment of surgically resected full sections, a high T-lymphocyte density 
within the invasive margin, tumour stroma and cancer cell nests was identified in 45%, 
55% and 33% patients of patients respectively.  A high TSP was identified in 27 (23%) 
patients. 
Biopsy-based, manual assessment of the tumour microenvironment 
Semi-quantitative, manual assessment of colonoscopic biopsy T-lymphocyte density was 
performed.  The interobserver ICC was 0.585 (P=0.014) indicating fair-to-good 
concordance.  Fifty-five patients (46%) had a high density of T-lymphocytes.  Biopsy T-
lymphocyte density was strongly associated with T-lymphocyte density at the invasive 
margin (P=0.006) and within the cancer cell nests (P=0.046) of full section specimens, but 
not within the cancer stroma (P=0.313; Table 11.2).   
Assessment of TSP using colonoscopic biopsies was performed.  The interobserver ICC 
was 0.745 (P<0.001), indicating good concordance.  Sixty-five patients (54%) had a high 
TSP.  Biopsy TSP was associated with full section TSP (P=0.001; Table 11.2).   
Biopsy-based, automated assessment of the tumour microenvironment 
To confirm that automated assessment of T-lymphocyte density correlated with manual 
assessment, automated assessment was first performed on surgically resected, full section 
specimens.  The median H-score was 22 (range 2-94, interquartile range (IQR) 13-38).  
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The H-score of patients with a high T-lymphocyte density at the invasive margin, within 
the cancer stroma and the cancer cell nests was significantly higher than those with a low 
T-lymphocyte density (all P<0.001, Table 11.3); the AUC for full section H-score 
predicting a high T-lymphocyte density was >0.78 (P<0.001) for each location within the 
tumour microenvironment (Figure 11.2, Table 11.3).  This analysis confirmed that 
automated assessment of T-lymphocyte density within surgically resected specimens using 
the Tissue Image Analysis plugin was comparable to manual, semi-quantitative assessment 
as previously described. 
Automated assessment of colonoscopic biopsy T-lymphocyte density was subsequently 
performed.  Although generally higher, colonoscopic biopsy H-score correlated with full 
section H-score (r=0.329, P<0.001).  The median H-score was 58 (range 1-140, IQR 33-
83).  The biopsy H-score of patients with a high density of T-lymphocytes at the invasive 
margin, within the cancer stroma and the cancer cell nests as assessed manually using full 
sections was significantly higher than those with a low T-lymphocyte density (all P<0.05, 
Table 11.4).  The AUC for biopsy H-score predicting a high T-lymphocyte density was 
0.651, 0.677 and 0.622 for the invasive margin, cancer stroma and cancer cell nests 
respectively, with an optimal cut-off point for each of 57 (Figure 11.3, Table 11.4). 
Give the above, the median biopsy H-score was subsequently used to stratify patients into 
those with a high biopsy T-lymphocyte density (H-score>57) and those with a low biopsy 
T-lymphocyte density (h-score≤57).  Using this threshold (Table 11.5), biopsy H-score was 
associated with a high density of T-lymphocytes within surgically resected specimens at 
the invasive margin (P<0.01) and cancer stroma (P<0.001) and showed a trend towards an 
association with the density within cancer cell nests (P=0.060). 
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The relationship between colonoscopic biopsy-based assessment of the tumour 
microenvironment and survival 
The relationship between colonoscopic biopsy-based assessment of the tumour 
microenvironment and cancer-specific survival was examined (Figure 11.4).  The median 
follow-up of survivors was 136 months (interquartile range 115-161 months) with 34 
cancer-associated deaths.  Manual assessment of colonoscopic biopsy T-lymphocyte 
density showed a trend towards an association with cancer-specific survival (P=0.120); 
five-year survival of patients with a high density was 85% (5) compared to 72% (6) for 
patients with a low density.  Automated assessment of biopsy T-lymphocyte density was 
associated with survival (P=0.007); five-year survival of patients with a high density was 
88% (4) compared to 68% (6) for patients with a low T-lymphocyte density.  Assessment 
of biopsy TSP was associated with cancer-specific survival (P=0.005); five-year survival 
of patients with a low TSP was 84% (4) compared to 68% (7) for patient with a high TSP. 
On univariate Cox regression survival analysis (Table 11.6), manual assessment of biopsy 
T-lymphocyte density showed a trend towards an association with cancer-specific survival 
(HR 0.58, 95%CI 0.291.17, P=0.125).  Automated assessment of biopsy T-lymphocyte 
density was significantly associated with survival (HR 0.39, 95%CI 019-0.80, P=0.010), as 
was assessment of biopsy TSP (HR 2.56, 95%CI 1.30-5.04, P=0.007).  On multivariate 
survival analysis, automated biopsy T-lymphocyte density (P<0.05) and biopsy TSP 
(P<0.01) were associated with cancer-specific survival independent of TNM stage, venous 
invasion (both P<0.05) and margin involvement (P=0.058). 
As automated assessment of biopsy T-lymphocyte density and biopsy TSP were 
independently associated with survival, the prognostic value of a biopsy-derived Glasgow 
Microenvironment Score (biopsy GMS) was examined (Figure 11.5).  The biopsy GMS 
was derived as follows: patients with a high automated T-lymphocyte density were given a 
score of 0, patients with a low automated T-lymphocyte density and low TSP were given a 
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score of 1, and patients with a low automated T-lymphocyte density and high TSP were 
given a score of 2.  The biopsy GMS stratified cancer-specific survival of patients 
(P<0.001); patients with biopsy GMS=0 (n=62) had five-year survival of 88% (4), whereas 
patients with a biopsy GMS=1 (n=38) and 2 (n=20) had five-year survival of 76% (7) and 
49% (12) respectively.  In this cohort, this was similar to the conventional GMS (GMS=0 
89% (5), GMS=1 79% (6), GMS=2 50% (13), P=0.029) and a derived GMS using T-
lymphocyte density at the invasive margin and TSP (89% (4), 74% (6) and 49% (14), 
P=0.019).
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11.4 Discussion 
The results of the present study suggest that pre-operative assessment of the tumour 
microenvironment is feasible utilising colonoscopic biopsies.  Furthermore, such biopsy-
based assessments appear to have prognostic value in addition to standard, TNM-based 
clinicopathological staging.  Introduction of pre-operative assessment of the tumour 
microenvironment may have significant impact not only on staging of patients with 
colorectal cancer, but also the provision of neoadjuvant therapy, particularly aimed at 
targeting the tumour microenvironment. 
Manual, semi-quantitative assessment of biopsy T-lymphocyte density and TSP predicted 
both T-lymphocyte density and TSP within surgically resected specimens.  The techniques 
employed were adapted from those previously described for assessment of full sections of 
tumours incorporating the invasive margin at the deepest point of invasion.  Given that 
biopsy specimens are obtained from the luminal margin of the tumour rather than the 
invasive margin, this further supports previous work suggesting that lymphocyte density is 
consistent across different regions of the tumour microenvironment (433).  Indeed, this 
would further advocate the use of biopsy-derived specimens for assessment of the tumour 
microenvironment when full surgically resected specimens are not available, such as in 
patients with overt metastatic disease at presentation. 
In keeping with previous work in oesophageal cancer (553), there was excellent inter-
observer agreement with respect to biopsy TSP.  However, manual assessment of biopsy 
T-lymphocyte density appeared to show greater inter-operator variability, albeit still with 
‘fair-to-good’ agreement as measured by ICC.  This may reflect the inherent difficulties of 
assessment of colonoscopic biopsies which vary not only in size and quality of tissue, but 
also abundance of tumour tissue present (551).  Whereas the only criteria for biopsies to be 
included in the present analysis was the presence of invasive malignancy, more rigorous 
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criteria may result in more accurate assessment with improved inter-observer agreement.  
For example, Courrech Staal and colleagues reported that stringent selection criteria for 
biopsy sections (at least 20% of invasive malignancy present in the biopsy and at least six 
fragments present) increased concordance with full section analysis for mutational analysis 
(553).  Furthermore, standardisation of scoring techniques to ensure agreement between 
investigators should be addressed to ensure consistency of scoring prior to further study. 
Digital pathology has been advocated as an important development in the field of routine 
gastrointestinal pathology reporting (555, 556).  The use of automated systems, as in the 
present study, can increase the objectivity and reproducibility of quantitative-based 
assessment (445, 464, 557).  Therefore, it is not surprising that automated assessment of 
biopsies had greater discriminatory value than manual assessment with respect to 
predicting both the T-lymphocyte density of surgically resected specimens and prognosis.  
Such systems, however, have been criticised with respect to differentiating between 
tumour and non-tumour tissue as well as discriminating between true and background 
staining (445, 557).  To allow for these limitations in the present study, all sections were 
marked with an appropriate region of interest.  Although not allowing for full automation 
of the process, this did however ensure that only tumour-containing regions and those with 
appropriate staining were considered for analysis therefore reducing the possibility of 
software or algorithm-based error. 
In addition to allowing for pre-operative assessment of the tumour microenvironment, 
biopsy-based assessment was shown to have prognostic value independent of TNM 
staging.  Using the combination of biopsy TSP and T-lymphocyte density alone, it was 
possible to stratify five-year survival from 88% to 49%.  This is strikingly similar to the 
prognostic value of full section analysis of the tumour microenvironment using the 
conventional GMS or a derived GMS utilising T-lymphocyte density.  Although it is not 
expected that biopsy-based assessment of the tumour microenvironment will replace full 
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section analysis following potentially curative surgery, it may however have a role in the 
treatment of patients not undergoing surgical resection.  For example, it would be of 
considerable interest to investigate whether biopsy assessment of the tumour 
microenvironment may stratify survival of patients with metastatic colorectal cancer, and 
how this may subsequently impact upon therapeutic options. 
The present study is limited by its lack of an automated assessment of the tumour-
associated stroma.  As such it was not possible to fully automate assessment of the tumour 
microenvironment as measured using biopsies or surgically resected specimens.  This was 
not performed as automated digital pathology systems may not always differentiate 
between tumour and non-tumour tissue on H&E-stained sections (557).  Given that the 
tumour-associated stroma is predominantly comprised of mesenchymal myofibroblasts, 
immunohistochemistry staining for an associated protein, such as a-smooth muscle actin 
(558), may facilitate future attempt at automation.  Furthermore, modern digital pathology 
systems can be readily ‘educated’ to differentiate between different tumour compartments.  
In addition, prospective validation of the above described biopsy-based assessments of the 
tumour microenvironment are required before they can be routinely adopted in clinical and 
research practice. 
In conclusion, the results of the present study suggest that assessment and staging of the 
tumour microenvironment of patients undergoing resection of colorectal cancer is feasible 
using colonoscopic biopsies.  This will allow for appropriate stratification of patients 
entering clinical trials targeting the colorectal cancer tumour microenvironment.
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Figure 11.1 Assessment of T-lymphocyte density using colonoscopic biopsies of patients 
undergoing elective, potentially curative resection of stage I-III colorectal cancer without 
neoadjuvant therapy. (A) biopsy specimen stained for CD3+ T-lymphocytes at x20 
magnification. (B) the same specimen, typical of a high T-lymphocyte density, at x100 
magnification, and (C) the same specimen analysed using automated assessment with’ 
Tissue IA Optimiser’ and ‘Measure stained cells algorithm’ in Tissue Image Analysis 
plugin for Slidepath at x100 magnification.  Orange and red staining signifies CD3+ T-
lymphocytes, whereas blue and purple staining signifies non-stained cells 
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Figure 11.2 Receiver operator characteristic curves comparing automated assessment of T-
lymphocyte density within different regions of surgically resected specimens from patients 
undergoing elective, potentially curative resection of stage I-III colorectal cancer without 
neoadjuvant therapy. (A) invasive margin (AUC 0.787, P<0.001), (B) tumour stroma 
(AUC 0.879, P<0.001), and (C) tumour cancer cell nests (AUC 0.794, P<0.001) 
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Figure 11.3 Receiver operator characteristic curves comparing automated assessment of 
colonoscopic biopsy T-lymphocyte density and manual assessment of T-lymphocyte 
density within different regions of surgically resected specimens from patients undergoing 
elective, potentially curative resection of stage I-III colorectal cancer without neoadjuvant 
therapy. (A) invasive margin (AUC 0.651, P=0.005), (B) tumour stroma (AUC 0.677, 
P=0.001), and (C) tumour cancer cell nests (AUC 0.622, P=0.030) 
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Figure 11.4 The relationship between colonoscopic biopsy-based assessment of the 
tumour microenvironment and cancer-specific survival of patients undergoing potentially 
curative resection of stage I-III colorectal cancer without neoadjuvant therapy. (A) manual 
assessment of T-lymphocyte density (P=0.120), (B) automated assessment of T-
lymphocyte density (P=0.007), and (C) tumour stroma percentage (P=0.005). All P-values 
calculated using log-rank analysis 
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Figure 11.5 The relationship between biopsy derived and full section assessment of the 
Glasgow Microenvironment Score and cancer-specific survival of patients undergoing 
potentially curative resection of stage I-III colorectal cancer without neoadjuvant therapy. 
(A) biopsy Glasgow Microenvironment Score (P<0.001), (B) conventional Glasgow 
Microenvironment Score (P=0.029), and (C) T-lymphocyte-derived Glasgow 
Microenvironment Score (P=0.019). All P-values calculated using log-rank analysis 
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Table 11.1 Clinicopathological characteristics of patients undergoing elective, potentially 
curative resection of stage I-III colorectal cancer without neoadjuvant therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   All 
Clinicopathological Characteristics  n=120 (%) 
Host  characteristics    
Age  
<65 
65-74 
>75 
  
44 (36) 
38 (32) 
38 (32) 
Sex  
Female 
Male 
  
56 (47) 
64 (53) 
Adjuvant therapy  
No 
Yes  
  
83 (69) 
37 (31) 
Tumour  characteristics    
Tumour site  
Colon 
Rectum 
  
82 (68) 
38 (32) 
T stage   
1/2 
3 
4 
  
12 (10) 
75 (62) 
33 (28) 
N stage  
0 
1 
2 
  
61 (51) 
46 (38) 
13 (11) 
TNM stage  
I 
II 
III 
 
 
 
6 (5) 
55 (46) 
59 (49) 
Tumour differentiation  
Mod/well 
Poor 
  
115 (96) 
5 (4) 
Venous invasion  
No 
Yes 
  
80 (67) 
40 (33) 
Margin involvement  
No 
Yes 
  
113 (94) 
7 (6) 
Peritoneal involvement  
No 
Yes 
  
87 (72) 
33 (28) 
Tumour perforation  
No 
Yes 
  
117 (97) 
3 (3) 
CD3+ invasive margin density  
Low 
High 
  
65 (55) 
54 (45) 
CD3+ stromal density  
Low 
High 
  
54 (45) 
66 (55) 
CD3+ cancer cell nest density  
Low 
High 
  
81 (67) 
39 (33) 
Tumour stroma percentage  
Low 
High 
  
93 (77) 
27 (23) 
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Table 11.2 The relationship between colonoscopic biopsy and full section manual 
assessment of the tumour microenvironment of patients undergoing elective, potentially 
curative resection of stage I-III colorectal cancer without neoadjuvant therapy 
Data analysed using χ2 analysis for linear trend. 
Table 11.2 displays the relationship between manual assessment of biopsy T-lymphocyte 
density and TSP and full section manual assessment of T-lymphocyte density and TSP. 
Biopsy assessment of T-lymphocyte density was associated with density within the 
invasive margin and cancer cell nests of full sections (both P<0.05) but not within the 
stroma. Biopsy TSP was associated with full section TSP (P=0.001). 
   Colonoscopic biopsy 
   T-lymphocyte density 
Surgically resected specimen  Low (n=65) 
(%) 
 High (n=55) 
(%) 
 P 
Invasive margin T-lymphocyte 
density 
 
Low 
High 
  
43 (66) 
22 (34) 
  
22 (41) 
32 (59) 
 0.006 
Stromal T-lymphocyte density  
Low 
High 
  
32 (49) 
33 (51) 
  
22 (40) 
33 (60) 
 0.313 
Cancer cell nest T-lymphocyte 
density 
 
Low 
High 
  
49 (75) 
16 (25) 
  
32 (58) 
23 (42) 
 0.046 
   Tumour stroma percentage 
   Low (n=55) 
(%) 
 High (n=65) 
(%) 
 P 
Tumour stroma percentage  
Low 
High 
  
66 (87) 
10 (13) 
  
27 (61) 
17 (39) 
 0.001 
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Table 11.3 The relationship between automated and manual assessment of T-lymphocyte density in surgically resected specimens of patients undergoing 
elective, potentially curative resection of stage I-III colorectal cancer without neoadjuvant therapy 
 
 
 
 
 
 
 
Continuous data analysed using Mann-Whitney U test. Area under the curve calculated using receiver-operator character curves. IQR – inter-quartile 
range, 95% CI – 95% confidence interval. 
Table 11.3displays the relationship between automated and manual assessment of T-lymphocyte density within full sections to ensure that both methods 
are comparable. Automated assessment of T-lymphocyte density was associated with manual assessment of density within the invasive margin, cancer 
cell nests and stroma of full sections (all P<0.001). 
 
   Automated assessment 
Manual assessment  Median h-score (IQR)  P  Area under the curve (95% CI)  
Invasive margin T-lymphocyte 
density 
 
Low 
High 
  
16 (11-25) 
33 (22-52) 
 <0.001  0.787 (0.704-0.869)  
Stromal T-lymphocyte density  
Low 
High 
  
13 (10-19) 
34 (23-51) 
 <0.001  0.879 (0.820-0.938)  
Cancer cell nest T-lymphocyte 
density 
 
Low 
High 
  
17 (11-28) 
38 (23-63) 
 <0.001  0.794 (0.710-0.878)  
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Table 11.4 The relationship between automated assessment of the tumour inflammatory cell infiltrate using colonoscopic biopsies and manual 
assessment of the inflammatory cell infiltrate using surgically resected specimens of patients undergoing elective, potentially curative resection of stage I-
III colorectal cancer without neoadjuvant therapy 
 
 
 
 
 
 
 
Continuous data analysed using Mann-Whitney U test. Area under the curve calculated using receiver-operator character curves. IQR – inter-quartile 
range, 95% CI – 95% confidence interval. 
Table 11.4 displays the relationship between automated assessment of biopsy T-lymphocyte density and manual assessment within full sections. 
Automated assessment of biopsy T-lymphocyte density was associated with manual assessment of density within the invasive margin, cancer cell nests 
and stroma of full sections (all P<0.05). 
   Automated assessment 
Manual assessment  Median H-score (IQR)  P  Area under the curve (95% CI)  
Invasive margin CD3+ density  
Low 
High 
  
48 (23-78) 
65 (40-93) 
 0.005  0.651 (0.553-0.749)  
Stromal CD3+ density  
Low 
High 
  
39 (23-74) 
64 (45-93) 
 0.001  0.677 (0.578-0.776)  
Cancer cell nest CD3+ density  
Low 
High 
  
52 (31-78) 
66 (39-93) 
 0.030  0.622 (0.516-0.728)  
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Table 11.5 The relationship between automated assessment of T-lymphocyte density in 
colonoscopic biopsies and manual assessment of T-lymphocyte density in surgically 
resected specimens of patients undergoing elective, potentially curative resection of stage 
I-III colorectal cancer without neoadjuvant therapy  
  
Data analysed using χ2 analysis for linear trend. 
 
 
 
 
   Colonoscopic biopsy 
Automated assessment 
Surgically resected specimen 
Manual assessment 
 Low (n=58) 
(%) 
 High (n=62) 
(%) 
 P 
Invasive margin T-lymphocyte density  
Low 
High 
  
40 (69) 
18 (31) 
  
25 (41) 
36 (59) 
 0.002 
Stromal T-lymphocyte density  
Low 
High 
  
36 (62) 
22 (38) 
  
19 (29) 
44 (71) 
 <0.001 
Cancer cell nest T-lymphocyte density  
Low 
High 
  
44 (76) 
14 (24) 
  
37 (60) 
25 (40) 
 0.060 
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Table 11.6 The relationship between colonoscopic biopsy-derived assessment of the tumour microenvironment, clinicopathological characteristics and 
cancer-specific survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer without neoadjuvant therapy 
 
 
 
 
 
 
 
Data analysed using Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Backwards conditional method used for 
multivariate analysis. 
 
 
 Cancer-specific survival 
Clinicopathological characteristics  Univariate analysis P  Multivariate analysis P 
Age (<65/ 65-74/ >75)  1.16 (0.77-1.75) 0.488  - - 
Sex (Female/ male)  1.30 (0.66-2.59) 0.442  - - 
Adjuvant therapy (No/ yes)  1.29 (0.64-2.61) 0.480  - - 
Tumour site (Colon/ rectum)  1.66 (0.83-3.33) 0.150  - - 
TNM stage (I/ II/ III)  2.64 (1.33-5.24) 0.005  2.42 (1.19-4.94) 0.015 
Tumour differentiation (Mod-well/ poor)  1.53 (0.37-6.37) 0.562  - - 
Venous invasion (No/ yes)  3.32 (1.67-6.61) 0.001  2.24 (1.09-4.63) 0.029 
Margin involvement (No/ yes)  3.86 (1.34-11.10) 0.012  2.93 (0.97-8.91) 0.058 
Peritoneal involvement (No/ yes)  1.76 (0.88-3.51) 0.112  - - 
Tumour perforation (No/ yes)  1.79 (0.27-14.48) 0.505  - - 
Manual biopsy T-lymphocyte density (Low/ high)  0.58 (0.29-1.17) 0.125  - - 
Automated biopsy T-lymphocyte density (Low/ high)  0.39 (0.19-0.80) 0.010  0.44 (0.21-0.92) 0.030 
Biopsy tumour stroma percentage (Low/ high)  2.56 (1.30-5.04) 0.007  2.88 (1.44-5.75) 0.003 
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12 Conclusions 
At the beginning of this period of research, it was clear that the present TNM-based staging 
of patients with colorectal cancer is suboptimal.  Although staging and need for adjuvant 
therapy are primarily based on the presence of lymph node metastases, a significant 
proportion of patients with lymph node negative disease may subsequently die prematurely 
from their disease.  Conversely, a proportion of patients with lymph node positive disease 
have survival comparable to those with earlier stage disease.  A number of pathological 
and molecular characteristics identifying patients at high risk have been defined, however 
there remains a need to identify other factors which may aid in risk stratification and 
decision making regarding treatment.  One approach is to consider the local and systemic 
environment, encompassing both host inflammatory responses and the tumour 
microenvironment.  In addition to identifying patients at high risk of recurrence, the host 
inflammatory response to cancer provides an attractive therapeutic target.  Indeed, 
conventional anti-inflammatory drugs, such as aspirin and NSAIDs, have been associated 
with improved outcomes in patients with colorectal cancer, potentially through modulation 
of tumour-associated inflammation (Chapter 1). 
In spite of a significant body of work supporting the role of tumour-associated 
inflammation as being integral to disease progression and an important determinant of 
outcome, several questions remained.  First, how measures of the systemic inflammatory 
response, such as the mGPS may be utilised alongside present TNM-based staging, and 
how this may be applied across different populations from distinct geographical regions, 
was unclear.  Similarly, how more comprehensive assessment of the tumour 
microenvironment, encompassing not only the tumour inflammatory cell infiltrate but also 
the tumour-associated stroma, may be used to determine prognosis was not known.  
Furthermore, the underlying tumour-based characteristics which may determine these local 
and systemic responses remained to be fully investigated.  Finally, it was not clear whether 
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the anti-neoplastic effects of commonly prescribed drugs such as aspirin and statins is in 
part mediated by favourable effects on host inflammatory responses. 
This thesis started with a comparison of the relative prognostic value of assessment of the 
pre-operative systemic inflammatory response and TNM-based staging in patients 
undergoing potentially curative resection of stage I-III colorectal cancer (Chapter 2).  The 
mGPS, one of the most widely reported systemic inflammatory scores in patients with 
cancer, was utilised.  It was shown that the mGPS held prognostic value independent of 
TNM staging and other pathological characteristics associated with high risk disease.  
Furthermore, in patients with stage III colon cancer, the presence of a systemic 
inflammatory response appeared to abrogate any survival benefit from adjuvant 5-FU-
based chemotherapy.  Although patients with colorectal cancer and systemic inflammation 
are at increased risk of recurrence and death, the results of this Chapter would suggest that 
novel therapeutic agents, most likely targeting the inflammatory response, rather than 
conventional chemotherapy may be needed in this specific patient group.  Further work in 
this field should be performed to investigate the relationship between systemic 
inflammation and response to adjuvant chemotherapy as well as anti-inflammatory drugs, 
potentially by retrospective analysis of clinical trial data. 
In Chapter 3, it was shown that systemic inflammatory profiles differ between populations 
from distinct geographical locations; in the present case, populations of patients with 
colorectal cancer from the West of Scotland and Japan.  Although associated with similar 
patient and tumour characteristics in both populations, even after controlling for these 
factors patients from Scotland were more likely to be systemically inflamed.  The 
underlying reason why distinct populations may differ in their inflammatory profile is 
unclear, however it was hypothesised that this may be attributable to uncontrolled factors, 
such as comorbidity and obesity.  However, the mGPS showed prognostic value in both 
populations.  Indeed, given its differing prevalence across populations, it is clear that 
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measures of the systemic inflammatory response should be reported routinely, particularly 
in the context of outcome data.  The present results could be confirmed retrospectively 
utilising international clinical trial data.  Furthermore, studies of the relationship between 
systemic inflammation and cancer outcome could be performed in regions with large 
migrant populations to ascertain if the differences observed are indeed secondary to host or 
environmental factors. 
In Chapter 4 the relationship between the tumour-associated stroma, other components of 
the tumour microenvironment, such as tumour necrosis and the local inflammatory cell 
infiltrate, and survival was examined.  Using the TSP, an H&E-based assessment of the 
extent of stromal infiltration, it was found that a high proportion of stroma was associated 
with adverse tumour characteristics, such as advanced T stage, an infiltrative invasive 
margin, and loss of the tumour-infiltrating inflammatory cell infiltrate.  Of interest, an 
expanded stroma was inversely associated with the presence of tumour necrosis, 
suggesting a pertinent role in protecting against hypoxia.  Despite such associations, a high 
TSP remained independently associated with reduced survival of patients with colorectal 
cancer, validating previous work by Mesker and colleagues.  Taken together, these results 
further confirm the stroma as an important contributor towards a tumour-supporting 
microenvironment and as a potential therapeutic target.  Future work could refine the 
prognostic value of the tumour-associated stroma by examining such characteristics as 
stromal and collagen maturity in addition to TSP.  Furthermore, chemotherapeutics which 
target the stroma or overcome the stroma as a barrier to effective tumour cell targeting, 
have been utilised in other tumour types.  On such example is nab-paclitaxel in patients 
with pancreatic ductal adenocarcinoma (559).  Whether a similar approach may translate in 
to an effective treatment strategy in patients with colorectal cancer and a high TSP would 
be of interest.  
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In Chapter 5, the role of MMR deficiency as a determinant of host local and systemic 
inflammatory responses was examined.  Although the present results confirmed the 
relationship between MMR deficiency and the presence of a conspicuous inflammatory 
cell infiltrate, it was observed, for the first time, that patients with MMR deficient 
colorectal cancer had elevated systemic inflammatory responses as measured by the mGPS 
and the NPS.  Although paradoxical, given the opposing prognostic effects of MMR 
deficiency and elevated systemic inflammatory responses, the present results could be 
explained by a number of potential mechanisms.  As immune checkpoint activation is 
recognised to counterbalance the anti-tumour immune infiltrate in MMR deficient tumours, 
one potential hypothesis is that the systemic inflammatory response may represent a 
common upstream precursor of both phenomena, for example, the JAK/STAT3 pathway. 
The results of Chapter 5 also confirm the prognostic value of local and systemic 
inflammatory responses independent of MMR/ MSI status. Indeed, they provide further 
rationale for the assessment of inflammatory responses in addition to MMR/ MSI status in 
patients with colorectal cancer.  In keeping with this, the prognostic value of the local 
inflammatory cell infiltrate independent of MSI status has recently been confirmed in a 
large population-based case-control study of over 2000 patients (560).  The relationship 
between MMR status, systemic inflammatory responses and outcome however await 
confirmation in a larger population than that presently studied.  Furthermore, whether local 
and systemic inflammatory responses remain prognostic independent of more 
comprehensive genetic and molecular characterisation remains to be determined. 
In Chapter 6, the relationship between the IL-6/JAK/STAT3 signal transduction pathway, 
local and systemic inflammatory responses and outcome of patients with colorectal cancer 
was examined.  Activation, as measured by tumour cell STAT3 expression, was associated 
with adverse inflammatory responses.  Despite STAT3 expression being associated with 
reduced survival on univariate analysis, it was not independent of pathological 
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characteristics nor local and systemic inflammatory responses.  It is likely that the local 
and systemic environment is defined by a number of pathways, with JAK/STAT3 
activation being just one mechanism by which the tumour deregulates host inflammatory 
responses.  Indeed, although the JAK/STAT3 pathway may be one potential therapeutic 
target, future work is needed to investigate and compare other pro-inflammatory pathways, 
such as NF-ĸB.  Furthermore, whether assessment of inflammatory responses, and in 
particular the mGPS, may identify patients likely to benefit from inhibitors of JAK/STAT3 
and other inflammatory pathways, remains to be investigated. 
Given the independent prognostic value of the tumour-associated stroma and inflammatory 
cell infiltrate, Chapter 7 aimed to investigate the clinical utility of their combined 
assessment.  The prognostic value of the stroma was subordinate to the local inflammatory 
cell infiltrate, however combined assessment stratified survival greater than either measure 
alone.  A combined score based on these characteristics, termed the Glasgow 
Microenvironment Score, was simple to perform and relied on routine specimens with no 
additional costs.  Therefore, it can be readily validated by independent groups.  Although 
observational only, the results also give further potential insight into the natural history of 
the tumour microenvironment; it would appear that it is loss of the anti-tumour immune 
response which is the early initiator of a supportive tumour microenvironment, with 
tumour stroma expansion occurring at a later point.  Although speculative, this hypothesis 
may be readily examined in larger clinical cohort studies encompassing patients with early 
stage disease. 
The definition of T stage has remained relatively stable since initially being described by 
Dukes.  As such, Chapter 8 aimed to examine how increasing T stage, as a marker of 
tumour invasiveness, related to both the local and systemic environment.  As would be 
expected, as tumour invasiveness increased, the tumour microenvironment became more 
supportive, with loss of the inflammatory cell infiltrate as measured by both Immunoscore 
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and KM grade, an increase in TSP and the presence of an infiltrative invasive margin.  
Furthermore, systemic inflammatory responses increased with increasing T stage.  Of 
interest however, the development of these characteristics appeared to follow a stepwise 
pattern, with loss of the immune infiltrate occurring at an earlier T stage and development 
of a high TSP, infiltrative margin and an elevated systemic inflammatory response 
occurring later.  Furthermore, the GMS, Immunoscore and mGPS, appeared to have similar 
if not greater prognostic value compared to lymph node status when examined in the 
context of patients with T3 disease.  Although only providing a cross-sectional view of the 
relationship between tumour invasiveness and such characteristics, these results further 
support the hypothesis that loss of the local inflammatory cell infiltrate is an important 
initiating step in the development of a tumour-favouring environment at both the local and 
systemic level.  In addition, they support the routine assessment of both local and systemic 
inflammatory responses in patients with colorectal cancer.  It is clear however that further 
work is required in this area, particularly in earlier stage disease to confirm the prognostic 
value of assessment of the local and systemic environment. 
Chapter 9 aimed to examine the clinical utility of two differing approaches to assessment 
of the local inflammatory cell infiltrate, namely the KM grade and Immunoscore.  It was 
found that the Immunoscore stratified survival to a greater extent than KM grade; indeed, it 
was possible to stratify survival of patients with both a low and high KM grade using the 
Immunoscore.  From these findings it was hypothesised that in those patients with a 
discordance between measures of the generalised and T-lymphocytic infiltrate (i.e. high 
KM grade but low Immunoscore), the peritumoural inflammatory infiltrate represented 
other components of the host cellular immune response, most likely innate immune cells 
such as neutrophils and macrophages, with an adverse effect on outcome.  It was of interest 
however, that the TSP was able to stratify survival of patients with both a low 
Immunoscore and KM grade.  Indeed, this would further support the routine assessment of 
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TSP in addition to the local inflammatory cell infiltrate in patients with colorectal cancer.  
The results of this Chapter further support the efforts of a recent international 
collaborative, which has validated the Immunoscore as a stage-independent prognostic 
factor in patients with colorectal cancer (561).  It is clear however that further work is 
required to validate assessment of the TSP as an additional prognostic factor, particularly 
in combination with assessment of the inflammatory cell infiltrate. 
Although aspirin and statins are reported to have a potential anti-inflammatory effect in 
patients with cancer, it is not clear how their routine use at time of diagnosis affects 
markers of the systemic inflammatory response.  In Chapter 10, it was found that pre-
operative use of low-dose aspirin, but not statins, was associated with a lower pre-
operative mGPS in patients undergoing resection of colorectal cancer, suggesting a 
beneficial effect on the systemic inflammatory response in patients with colorectal cancer.  
Survival data was immature, however aspirin users appeared to have poorer survival than 
non-aspirin users.  This is likely to reflect the underlying reason for aspirin use in this 
cohort, as all patients received aspirin for cardiovascular risk modification.  However, the 
relationship between aspirin use and a lower mGPS was surprising, as comorbidity burden 
is associated with elevated systemic inflammatory responses.  Indeed, the true anti-
inflammatory effect of aspirin in patients with colorectal cancer may be underestimated in 
this cohort.  Further studies are required to examine the relationship between aspirin and 
NSAID use, systemic inflammatory responses and outcome of patients with colorectal 
cancer.  This could be performed in the context of currently recruiting trials of adjuvant 
aspirin therapy.  Furthermore, investigation of the relationship between aspirin and 
NSAIDs and characteristics of the tumour microenvironment are required.  Retrospective 
assessment of the tumour microenvironment in archived tumour tissue from the cohort 
studied in this Chapter would be a logical starting point for ongoing work in this field. 
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Finally, in Chapter 11, the feasibility of pre-operative assessment of the tumour 
microenvironment, using colonoscopic biopsy specimens, was examined.  It was found that 
both the tumour inflammatory cell infiltrate, as measured by T-lymphocyte density, and the 
TSP could be measured using biopsy specimens.  Furthermore, the reliability of the former 
was improved by use of automated digital pathology.  A biopsy GMS derived from these 
measures was independently associated with survival.  Although it would not be expected 
that biopsy-based assessment would replace more comprehensive assessment using 
surgically resected specimens, these results do raise two interesting concepts for further 
investigation.  Firstly, it would allow for assessment of the primary tumour 
microenvironment in patients with metastatic disease or those who are not candidates for 
curative resection.  Secondly, it would potentially allow for pre-operative staging of the 
tumour microenvironment, therefore creating a window of opportunity for neoadjuvant 
therapy directed at the tumour microenvironment.  Indeed, whether aspirin and NSAIDs, or 
other novel therapeutic agents such as JAK/STAT3 inhibitors may be of use in this setting 
would be of considerable interest. 
In summary, the present thesis suggests that the local and systemic environment create a 
supportive environment which promotes continued tumour growth and dissemination to the 
detriment of the patient.  In addition to determining prognosis of patients with colorectal 
cancer, measurement of these characteristics may yield potential therapeutic targets.  The 
above work confirms that assessment of the systemic inflammatory response, using 
routinely available prognostic scores such as the mGPS, complements TNM staging to 
identify patients with otherwise “low risk” disease at high risk of recurrence.  Conversely, 
it is also possible to “downstage” patients deemed high risk based on lymph node 
involvement alone.  Furthermore, the mGPS appears to be applicable internationally, 
further supporting its routine reporting.  A similar approach may be taken with respect to 
the tumour microenvironment, with combined assessment of both the tumour inflammatory 
  353 
cell infiltrate and tumour-associated stroma having greater prognostic value than either 
measure alone.  Although the GMS described herein provides an attractive concept 
because of its reliance on routine specimens and relative simplicity, it may well be that 
more refined measures of the local inflammatory response, such as the Immunoscore, 
provide a more reliable measure of host anti-tumour immunity.  However, there remains a 
need to examine other components of the tumour microenvironment, such as tumour cell 
budding and innate immune cell infiltration, as potential adjuncts to a comprehensive 
tumour microenvironment-based score and as potential therapeutic targets. Such work may 
increase our insights into the development of the tumour microenvironment. 
The work presented in this thesis suggest that several factors, pertaining to not only the 
host but also the tumour, may determine characteristics of the local and systemic 
environment (Figure 12.1).  Indeed, although some of these factors, such as MMR status, 
may be tumour cell-intrinsic and therefor non-modifiable, targeting intracellular signalling 
pathways presents one potential therapeutic option which may be further investigated.  
However, the work presented herein suggests that the local and systemic environment are 
shaped by a number of different pathways, and it may be that the predominant pathways 
differ between patients.  Indeed, whether JAK/STAT3 is the optimal target or whether 
other pathways may have greater impact on cancer-association inflammation and survival 
remains to be determined.  Further work, exploring the molecular characteristics associated 
with each of the phenotypic features examined in this thesis will hopefully identify 
potential druggable targets which may be utilised in future clinical practice.  Irrespective, 
the work presented suggests that pre-operative assessment at the local and systemic level is 
feasible in this patient group prior to resection; this may aid in the identification of suitable 
candidates for enrolment in clinical trials targeting such targets and the local and systemic 
environment in general. 
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Figure 12.1 The relationship between the local and systemic environment, host factors, 
signal transduction pathway activation and genomic instability and tumour initiation and 
progression 
 
In summary, this thesis has aimed to address the two hypotheses stated in Chapter 1.8.  The 
work presented supports the role of the local and systemic environment, encompassing the 
tumour microenvironment and systemic inflammatory responses, as potential adjuncts in 
the staging of patients undergoing potentially curative resection of stage I-III colorectal 
cancer.  Furthermore, a number of tumour and host factors determine the local and 
systemic environment.  Although some may be tumour-cell intrinsic and therefore non-
modifiable, others, including inflammatory signal transduction pathways, may provide 
attractive therapeutic targets which may reduce risk of recurrence and increase survival of 
patients with colorectal cancer.  
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14 Appendices 
Appendix 1 
STAT3 antibody-9132 (Cell Signalling) Immunohistochemistry  
(Performed in Institute of Cancer Sciences) 
 
Buffer -  Citrate Buffer 
0.1M Citric acid (1.92g in 100ml dH2O) 
0.1M Na citrate (14.7g in 500ml dH2O) 
1.8ml citric acid, 8.2ml Na citrate, 90ml dH2O; pH to 6.0 
 
Dewax and rehydrate: 
Dewax the slides:  2 x 3 mins in Xylene 
Rehydrate:  2 x 3 mins 100% alcohol  
2 mins 90% alcohol 
2 mins 70% alcohol 
Rinse in Water 
 
Antigen Retrieval: 
Add the slides to water bath at 96oC for 20 minutes   
Cool for 20 mins then wash in running water 
Transfer to a staining dish with water (slides can be stored like this)  
Treat with 3% H2O2 (13ml H2O2 in 387ml water) for 10 mins on a stirrer  
Rinse for 1min with running H2O 
 
Staining: 
Ring sections with DAKO pen to create a barrier 
Blocking solution: add 100µl of casein per 0.9 ml of TBS- buffer  (200uL per slide) 
Cover the section with blocking solution and incubate for 20 minutes at room temp 
Blot serum from sections 
Incubate in primary antibody overnight at 4oC , with 200uL per slide (dilution: 1:100) 
Wash 5 mins in TBSx2 
Envision for 30 mins (200uL per slide) 
Wash 5 mins in TBSx2 
Make DAB substrate (DAKO) 1:50, 3ml of substrate buffer to 60ul of DAB chromagen. 
Add as much as possible per slide. Incubate until colour develops (2-10 mins) 
Wash in water 10 mins 
 
Counterstain: 
Stain in haematoxylin for 60 seconds 
Rinse in running tap water 
1 dip in acid alcohol 
Blue with scots tap water substitute (45 sec) 
Rinse in running tap water 
 
Dehydrate and mount: 
1 min 70% alcohol 
1 min 90% alcohol 
2 x 1 min 100% alcohol 
2 x 1 min xylene 
Mount in DPX
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Appendix 2 
pSTAT3Tyr705 antibody-9131 (Cell Signalling) Immunohistochemistry 
(Performed in Institute of Cancer Sciences) 
 
Buffer -  Tris-EDTA Buffer pH 8 (1000mL distilled water) 
0.37g Sodium EDTA 
0.55g Tris in 
 
Dewax and rehydrate: 
Dewax the slides:  2 x 3 mins in Xylene 
Rehydrate:  2 x 3 mins 100% alcohol  
2 mins 90% alcohol 
2 mins 70% alcohol 
Rinse in Water 
 
Antigen Retrieval: 
Microwave on full power for 13.5 mins to warm the solution, no lid, no rubber   
Add the slides and lid and microwave on full power for ~2-3 mins to bring to pressure  
Microwave for 5 mins under pressure 
CAREFULLY remove weight to allow steam to escape, and remove lid 
Cool for 20 mins 
Wash in running water 
Transfer to a staining dish with water (slides can be stored like this)  
Treat with 0.3% H2O2 (13ml H2O2 in 387ml water) for 10 mins on a stirrer  
Rinse for 1min with running H2O 
 
Staining: 
Ring sections with DAKO pen to create a barrier 
Blocking solution: add 50µl of horse serum per 0.95 ml of TBS- buffer  (200uL per slide) 
Cover the section with blocking solution and incubate for 20 minutes at room temp 
Blot serum from sections 
Incubate in primary antibody overnight at 4oC, with 200uL per slide (dilution: 1:50) 
Wash 5 mins in TBSx2 
Envision for 30 mins (200uL per slide) 
Wash 5 mins in TBSx2 
Make DAB substrate (DAKO) 1:50, 3ml of substrate buffer to 60ul of DAB chromagen. 
Add as much as possible per slide. Incubate until colour develops (2-10 mins) 
Wash in water 10 mins 
 
Counterstain: 
Stain in haematoxylin for 60 seconds 
Rinse in running tap water 
1 dip in acid alcohol 
Blue with scots tap water substitute (45 sec) 
Rinse in running tap water 
 
Dehydrate and mount: 
1 min 70% alcohol 
1 min 90% alcohol 
2 x 1 min 100% alcohol 
2 x 1 min xylene 
Mount in DPX
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Appendix 3 
CD3 antibody 9107-S (Thermo RM) Immunohistochemistry  
(Performed in University Department of Pathology using ThermoFisher Autostainer 480s) 
 
 
Dewax and rehydrate: 
Dewax the slides:  2 x 3 mins in Xylene 
Rehydrate:  2 x 3 mins 100% alcohol  
2 mins 90% alcohol 
2 mins 70% alcohol 
Rinse in Water 
 
Antigen Retrieval: 
Thermofisher PT Module using Thermofisher Retrieve pH9 solution 
Wash in running water 
Transfer to a staining dish with water (slides can be stored like this)  
Treat with 0.3% H2O2 (13ml H2O2 in 387ml water) for 5 mins then rinse with TBS buffer 
UV protein block for 5 mins then rinse with TBS buffer 
 
Staining: 
Ring sections with DAKO pen to create a barrier 
Incubate in primary antibody overnight at room temperature, with 200uL per slide 
(dilution: 1:300) 
Wash with TBS buffer thoroughly 
Quanto Amplifier for 10 mins then rinse with TBS buffer 
Quanto Polymer for 10 mins then rinse with TBS buffer 
DAB Quanto Substrate for 5 mins then rinse with water 
 
Counterstain: 
Stain in haematoxylin for 3 minutes 
Rinse in running tap water 
1 dip in acid alcohol 
Rinse in running tap water 
Blue with scots tap water substitute (45 sec) 
Rinse in running tap water 
 
Dehydrate and mount: 
1 min 95% alcohol 
1 min 100% alcohol 
3 x 5 min xylene 
Mount in DPX
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Appendix 4 
MMR Protein (Dako UK Ltd) Immunohistochemistry 
(Performed in University Department of Pathology using ThermoFisher Autostainer 480s) 
 
Antibodies Product code  Concentration 
MLH1  M3640   1:100 
MSH6  M3646   1:100 
MSH2  M3639   1:50  
PMS2  M3647   1:50 
 
Dewax and rehydrate: 
Dewax the slides:  2 x 3 mins in Xylene 
Rehydrate:  2 x 3 mins 100% alcohol  
2 mins 90% alcohol 
2 mins 70% alcohol 
Rinse in Water 
 
Antigen Retrieval: 
Thermofisher PT Module using Thermofisher Retrieve pH9 solution 
Heated to 96oC for 20 mins then coole 
Wash in running water 
Transfer to a staining dish with water (slides can be stored like this)  
Treat with 0.3% H2O2 (13ml H2O2 in 387ml water) for 5 mins then rinse with TBS buffer 
UV protein block for 5 mins then rinse with TBS buffer 
 
Staining: 
Ring sections with DAKO pen to create a barrier 
Incubate in primary antibody for 20 mins at room temperature, with 200uL per slide  
Wash with TBS buffer thoroughly 
Quanto Amplifier for 10 mins then rinse with TBS buffer 
Quanto Polymer for 10 mins then rinse with TBS buffer 
DAB Quanto Substrate for 5 mins then rinse with water 
 
Counterstain: 
Stain in haematoxylin for 3 minutes 
Rinse in running tap water 
1 dip in acid alcohol 
Rinse in running tap water 
Blue with scots tap water substitute (45 sec) 
Rinse in running tap water 
 
Dehydrate and mount: 
1 min 95% alcohol 
1 min 100% alcohol 
3 x 5 min xylene 
Mount in DPX
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Appendix 5 
‘Tissue IA Optimiser Measured cells algorithm’ Slidepath, (Leica Biosystems) 
Algorithm Preferences Measure Stained 
Cells Default 
Preference 
0=Âµm, 1=mm, 2=pixels 0 
Segment Tissue from Background by Intensity 220 
0=Nuclei are similar, >=1, Nuclei increasingly diverse 
(darkest to lightest) 
2 
0=Strong Nuclear Counterstaining, 2=Weak Nuclear 
Counterstaining 
2 
Values in units 37 
Eliminate nuclei with area outside this range (specified in 
units squared) 
0 
Eliminate nuclei with density outside this range 0 
Eliminate nuclei with nuclear area density outside this range 
(specified in units squared) 
0 
Eliminate cells with area outside this range (specified in units 
squared) 
0 
Values in units 100 
Above this value pixels are identified as negative 220 
Eliminate nuclei with a % below this value 10 
Identify nuclei having strong/moderate/weak staining 
intensity 
99 
Above this value pixels are identified as negative 220 
Eliminate areas with a % below this value 75 
Identify areas having strong/moderate/weak staining 
intensity 
160 
Above this value pixels are identified as negative 220 
Eliminate areas with a % below this value 75 
Identify areas having strong/median/weak staining intensity 160 
0 = Include All Cells, 1 = Include only Positive Cells, 2 = 
Include only Negative Cells 
0 
0 = Include All Cells, 1 = Include only Positive Cells, 2 = 
Include only Negative Cells 
0 
0 = Include All Cells, 1 = Include only Positive Cells, 2 = 
Include only Negative Cells 
0 
Default Calibration 1 
Nuclear Counterstain deconvolution-
Haematoxylin 
Nuclear Marker deconvolution-DAB 
 
